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Abstract 
Post surgical adhesions (PSAs) are an inevitable outcome of surgery and their presence 
leads to pathogeneses and significant economic impact. 
The studies within this thesis utilised standard and reproducible abrasion models, in 
rabbits, pigs and rats, to investigate the formation and maturation of PSAs with strict 
quantitative analyses. These studies have shown that the development of PSAs is a series 
of complex, multi-factorial processes. PSA development can be classified into two 
stages: (i) PSA modelling occurring up to/including 16 hours post injury characterised by 
the inflammatory response and fibrin deposition and maturation; and (ii) PSA 
remodelling occurring from 16 hours onwards and characterised by tissue repair, 
collagen deposition and maturation and chemical mediation by TGF-P. 
Treatment with VivostatTm System Derived (novel) Fibrin Sealant significantly reduced 
the formation of PSAs with mean PSA reduction of 80% for the rabbit uterine hom 
abrasion model, from 3 separate studies; 83% for the pig stomach/colon/caecurn abrasion 
model, from 2 separate studies; 80% for the rat caecum abrasion model. This is 
significantly better than other fibrin sealants investigated in this thesis. 
PSA prevention with novel fibrin sealant demonstrated a similar pattern to PSA 
development, with two stages of development evident: (i) tissue generation modelling 
occurring up to/including 16 hours post injury characterised by the inflammatory 
response and fibrin deposition and maturation; and (ii) tissue generation remodelling 
occurring from 16 hours onwards and characterised by tissue repair, collagen deposition 
and maturation and chemical mediation by TGF-P. However the extent and subsequent 
time taken for these changes to occur was significantly reduced. 
The prevention of PSAs and alterations of wound healing by novel fibrin sealant is most 
probably due to the sealant acting as a haemostat, as well as a physical barrier. Thus 
preventing fibrinous and subsequent fibrous PSA formation. 
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Introduction Chapter 1 
1.0 Introduction 
1.1 Post Surgical Adhesions (PSAs) 
Adhesions are linkages which join together organs which would normally be separate and 
freely moveable. Their presence causes an upset in normal physiology resulting in 
potential morbidity and mortality. They are highly differentiated tissues, consisting of 
connective tissue proteins and cellular elements, with exact composition varying 
throughout their development. Dependent upon their developmental stage, adhesions can 
be defined as: 
i. fibrinous - primary transient adhesions, consisting 'primarily of fibrin, together with 
cellular components 
I fibrous - secondary permanent adhesions, consisting primarily of vascular collagen, 
with scattering of cells. 
Adhesions are also defined according to their origin. They are generally classified as: 
L inherited or congenital adhesions - these are present from birth. There are two 
schools of thought as to the origin of these adhesions: 
a. anomalies due to the failure of the gut to rotate and descend or other 
developmental anomalies 
b. pre-natal inflammatory conditions within the peritoneal cavity 
I acquired adhesions - these may be further divided into: 
a. inflammatory adhesions - resulting from inflammatory conditions such as pelvic 
inflammatory disease, endometriosis, acute cholecystitis, acute diverticulitis and 
peritonitis 
b. post surgical adhesions (PSAs). 
1.1.1 History 
Causes of adhesions and associated problems have varied over the last two centuries and 
so in turn has the clinical interest in them. Until the advent of reliable and safe 
anaesthesia and aseptic surgical techniques, surgical procedures were risky and rare, and 
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hence so were surgically associated sequelae. Consequently only inflammatory and 
congenital adhesions were discovered, usually limited to unusual findings at post mortem 
(Hodgkin, 1836). However by the end of the last century surgical treatments for 
pathogeneses were becoming more common and were soon followed by reports of PSAs 
usually fatal (Bryant, 1872; Battle 1883). Since this time reports of and interest in PSAs 
have gone hand in hand with the increased use of surgical procedures. 
Although surgical techniques have been maximised over many decades to increase their 
efficiency and effectiveness and decrease associated problems it is doubtful that surgical 
sequelae will ever be totally eradicated. The formation of adhesions, following many 
types of surgical procedures is almost inevitable and presents major problems for both 
surgeons and patients alike. PSAs are associated with morbidity and potential mortality, 
resulting, in some cases, in: failed surgical therapy; the need for re-operation or 
conservative treatment; complication of further surgical procedures; increased workload; 
and a large economic burden in today's climate of limited resources (DiZerega, 1994; 
DeCherney & DiZerega, 1997; Holmdahl & Risberg, 1997). 
1.1.2 Associated Pathogeneses 
It is agreed that the main problems arising from PSAs in the peritoneum are intestinal 
obstruction, infertility, pain, and complications with/leading to re-operation within the 
peritoneal cavity. However since any invasive surgical procedure has the potential to 
induce PSA formation, reports of PSAs ensuing from pericardial (Youmans et a1,1968; 
Cliff et al, 1973; Milgalter et al., 1985; Mitchell el aL, 1994), pleural (Youmans et al., 
1968; Kaiser et al., 1979) and orthopaedic (Bucknall & Ellis, 1984; Gelberman & 
Manske, 1985; Hagberg et aL, 1991; Frykman et al., 1993) practices are also common. 
Understandably, pericardial adhesions have great significance due to the unique function 
of the heart and the increased number of cardiac surgical therapies carried out in a 
society where heart disease is a major cause of morbidity and mortality in adults. 
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1.1.3 Incidence 
Incidence of the different types of adhesions have shown variation over the last century, 
corresponding with the trend of surgical treatment for disease. Information regarding the 
incidence of adhesions has been limited to post mortem reports, observations made 
during surgical procedures and in more recent years "second look" studies, usually 
laparoscopic in nature (Bulletti et al., 1996; Fernandez el al., 1996; Edelstam et al, 
1998). 
1.1.3.1 Overall 
An autopsy study carried out in 1973 by Weibel and MaJno found the incidence of 
adhesions to be 44.5% from 752 subjects (336 women and 416 men). Their data was 
comparable to the 44.9% adhesion incidence reported by Benzer et at, (1963) and 
greater than the 31.1% found by Diebold in 1930. Weibel and MaJno (1973) 
hypothesised that the increase in incidence seen between 1930 and 1960/1970's 
corresponded to increased surgical practice over this period. 
1.1.3.2 Adhesion Types 
In 1952 Nemir el al., determined the cause of adhesions causing bowel obstruction 
(adhesional obstruction) to be post surgical in 79% of cases and congenital in the 
remaining 21%. Similar results were found by Perry et aL, (1955) with PSAs accounting 
for 79.4%, inflammatory adhesions 17.8% and congenital adhesions 2.8% of adhesional 
bowel obstructions. A status quo appears to have occurred from the 1950's to 1970's, 
with Weibel and Majno's study in 1973 reporting that of adhesions found, 67% were 
post surgical and 28% inflammatory/congenital in nature. 
However in 1990 Menzies and Ellis reported the incidence of adhesions following major 
abdominal surgery to be 93%, with 9.6% occurrence for inflammatory adhesions and 
0.9% for congenital adhesions. Hence over the past twenty years there is a pattern flor 
increased incidence of PSAs, with a decline in inflammatory/congenital adhesions. This 
has also been reported by Duron et al., (1993), who also demonstrated a 93% presence 
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of PSAs following abdominal surgery. 
This pattern for increased PSAs and decreased spontaneous adhesions has occurred in 
developed countries only. A study on adhesional obstruction in Nigeria by'Chiedozi et 
al., (1980) reported there was almost equal division between post-traumatic and post- 
inflammatory adhesions (54.3% and 45.7% respectively). This pattern can be accounted 
for by the lower number of laparotornies performed in developing countries compared to 
the western world and also to the relatively high incidences of typhoid, infectious 
hepatitis and other causes of primary peritoneal inflammation in the African patient 
population. 
interestingly there also appears to be a correlation between the type of adhesion and 
location within the abdominal cavity (Perry et al., 1955): adhesion involving the small 
and large bowel (mixed) and large bowel only were predominantly inflammatory 
(30.5%), then congenital (22.3%) and only a small portion post operative (6.8%). 
However the small bowel is much more susceptible to post surgical adhesional 
obstruction (88.4% of cases) compared to large (8.0%) and mixed (3.6%) obstructions. 
1.1.3.3 Previous Operation(s) 
Weibel and MaJno (1973) showed that the incidence of adhesions was dependent upon 
the type of previous operation, with incidence increasing after minor (5 1 %), major (72%) 
and multiple (93%) operations respectively. In contrast Luijendijk el at, (1996) found no 
difference between one minor and major operation however the number of adhesions was 
significantly lower in patients with a history of one operation compared to multiple 
operations. In addition the number of adhesions was significantly greater in patients with 
previous PSAs and those with surgical complications, such as abscesses, haematomas 
and intestinal leakages (Luijendijk et al., 1996). 
1.1.3.4 Age 
Several studies have detailed the effect of patient age on the occurrence of adhesions. 
4 
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Weibel and Majno noted that spontaneous adhesions occurred more frequently after the 
age of 60, although age did not exert an effect on the incidence of PSAs. Studies by Ray 
et al., (1993; 1998) detailing hospitalisation rates for adhesiolysis both show a bimodal 
distribution with age, with highest rates seen in adults between 26 and 50 years old, 
followed by adults 65 years and older in the 1988 study and reversal of these two groups 
in 1994. However it should be remembered that studies by Ray et al, (1993; 1998) only 
provide details on problematic adhesions rather than adhesions per se. 
1.1.3.5 Sex 
Weibel and Majno (1973) demonstrated that women have approximately 4% more PSAS 
and spontaneous adhesions compared to men. This observation is supported by the 
adhesiolysis hospitalisation rate studies by Ray el al., (1993; 1998) who reported rates 
six and four times greater for women compared to men respectively. 
1.1.3.6 Obesity and Height 
The development of PSAs is greater in short and obese patients, both women and men 
(although less pronounced in men) compared to obese patients of average height or taller 
or thin patients (Weibel and Majno, 1973). This study also recorded that obese women 
had greater incidences of spontaneous adhesions compared to thin women, however this 
observation may be better attributed to sex as obesity showed no effect on the incidence 
of spontaneous adhesions in men. 
1.1.3.7 Adhesional Intestinal Obstruction 
Postoperative bowel obstruction is a relatively rare but serious surgical complication. 
The incidence of early postoperative bowel obstruction (adhesional obstruction) has been 
reported to be 0.5% (Menzies & Ellis, 1990) and 0.69% (Stewart el aI, 1987) of 
laparotomy cases, with this figure rising to 1% within one year of surgery (Menzies & 
Ellis, 1990). Higher incidences of adhesional bowel obstruction following laparotomy 
have been reported in neonates (2.2% (Festen, 1982) and 8.3% (Wilkins & Spitz, 
1986)). The higher figures demonstrated in neonatal surgery is probably due the need for 
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increased precision, greater difficulty and hence increased operating time, with this 
hypothesis supported by more traumatic neonatal surgical procedures carrying a greater 
risk of adhesional obstruction development (Wilkins & Spitz, 1986). However the risk of 
developing small bowel obstruction has been shown to be not significantly higher in 
, 
neonates compared to infants and older children (Festen, 1982). 
in the western world, strangulated hernias were the most common causative factor for 
bowel obstruction during the first half of this century, however since the 1950s adhesions 
have become the primary cause (Table 1.1). 
Author(s) Publication Survcy Country % Causing Bowd Obstruction 
Ycar Ycar(s) Adhcsions Hcmias 
Souttar 1925 1920-1925 Britain 11.2 46.0 
Vick 1932 1925-1930 Britain 7.3 47.4 
Ncrnir et al., 1952 1940-1950 USA 39.7 25.1 
Pcrry et al., 1955 1942-1953 USA 31.0 10.2 
Playforth et d, 1970 USA 54.0 23.0 
Stcwardson et aL, 1978 1967-1976 USA 66.0 24.0 
Bizcr et al., 1981 1968-1978 USA 74.0 8.1 
Mcnzics & Ellis 1990 1984-1987 Britain 51.0 
Strickcr et al, 1994 19884991 USA 59.0 6.0 
Table 1.1: Percentages of bowel obstructions caused by adhesions and strangulated hcmias in 
the western world. 
The pattern demonstrated is hardly surprising considering how surgical practices have 
changed throughout this century, with increased number of surgical procedures and early 
elective treatment of hernias contributing. The effect of abdominal surgery on bowel 
obstructions is also highlighted by data from less developed countries, who perform 
laparotomies to a much lesser extent (Table 1.2) and reflect the pattern seen during the 
first half of this century in the western world. 
6 
Introduction Chapter 1 
Author(s) Publication Survey Country % Causing Bowel Obstruction 
Year Year(s) Adhesions Hernias 
McAdam 1961 1958-1960 Uganda 4.0 74.8 
Cole 1965 1957-1962 Nigeria 10.6 37.6 
Brooks & Bulter 1966 1952-1963 Jamaica 23.2 25.0 
Chiedozi et aL, 1980 1 
1973-1978 Nigeria 
1 
10.8 65.0 
Table 1.2: Percentages of bowel obstructions caused by adhesions and strangulated hernias in 
the developing countries. 
The small bowel is one of the most predominant areas for the formation of adhesions. 
Distribution of PSAs has been shown to involve the omentum (68%), small bowel 
(67%), abdominal wall (45%), colon (41%), liver (34%), female reproductive ofgans 
(23%), stomach (20%), retroperitoneum (14%) and spleen' (9%) (Luijendijk et al., 
1996). The high involvement incidence of PSAs associated with the small bowel have 
also been reported by Perry el al., (1955) (88.4%) and Menzies (1992)(60-70%). This 
predilection is probably associated with the location of the small bowel in the peritoneal 
cavity, both with regard to operative techniques and laparotomy wound. 
Perry et al, (1955) reported that operations on the large bowel, appendectomies and 
intestinal obstruction were the most common preceding surgical procedures. This was 
confirmed by Menzies & Ellis (1990) who found that of the previous operations 
performed 25% concerned the colon and rectum, 15% were appendectomies, 14% 
gynaecological operation and 9% total colectomies. Since these are some of the most 
common surgical interventions performed, problems of PSAs are magnified in a "catch 
22" situation. 
Development of post operative adhesional bowel obstruction can occur many years 
following surgery. Menzies & Ellis (1990) demonstrated that 21% of obstruction 
occurred within one month of surgery, 18% from I month to I year, 21% between I and 
5 years, 6% from 5 to 10 years and 21% after 10 years of the surgical procedure. Similar 
results have been reported by many authors, for example Stricker et al, (1994) found the 
median period of time from previous operation to intestinal obstruction to be two years, 
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whilst Brightwell et al, (1977) found that half of patients developed bowel obstruction 
within 4 months. However it is well known that the clinical manifestation of bowel 
obstruction may occur many years following the original surgical procedure (Brightwell 
et, al., 1977; Bevan, 1984; Stricker et al., 1994). 
Overall mortality rates related to adhesional bowel obstruction have been reported 
between 3% (Stewardson ef al., 1978) to 17.8% for early postoperative small bowel 
obstruction (Stewart et al., 1987) (Table 1.3) However they can range between 0 and 
37% depending upon the type of adhesion, patient age, surgical complications, duration 
prior to treatment and the type of treatment. 
Author(s) Year Country Mortality Rate (%) 
Vicks 1932 Britain 32.9 
Ncmir 1952 USA 7.5 
Pcrry et aL, 1955 USA 6.0 
Stcwardson et aL, 1978 USA 3.0 
Bcvan 1984 Britain 6.7 
Stcwart et aL, 1987 USA 17.8 
McAdam 1961 Uganda 12.5 
Cole 1965 Nigcria -13.0 
Table 1.3: Mortality rates for adhesional bowel obstruction. 
I Following diagnosis, type and timing of treatment for intestinal obstruction still remains a 
delicate matter. Conservative treatment appears to give an advantage in both morbidity 
and mortality when effective (Perry et at, 1955), avoiding surgical consequences such as 
the formation of further adhesions. However non surgical intervention can be 
disadvantageous if it proves to be ineffective. The longer the obstruction remains the 
greater the chance of associated pathogeneses, such as intraperitoneal abscesses, 
strangulation, gangrene and perforation, which is related to increased mortality (Perry et 
al., 1995; Ellis, 1997). 
Even with effective treatment the risk of adhesion reoccurrence is still present. Many 
experimental studies have stated high incidences of adhesion reoccurrence following 
division of existing adhesions (79% Menzies & Ellis, 1989; 100% Gervin et al., 1973). 
Clinically the probability of adhesion reformation has been stated as 12.5% (Bizer et aL, 
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1986) for conservative treatment and from 13 to 32% following surgical division (Bizer 
et al., 1986; Brightwell NL et al., 1977). 
1.1.3.8 Gynaecological Problems 
Previous gynaecological pathology has been shown to play a significant role in 
adhesional bowel obstruction. Stricker et al., (1994) found that 48% of patients with 
intestinal obstruction had previous gynaecological or obstetric problems or associated 
surgery respectively, with hysterectomy being the most common previous operation. Due 
to this association gynaecologists manage more than 20% of all female patients with 
intestinal obstruction. 
Adhesions are a significant causative agent of female infertility, with 15 - 20% attributed 
to adhesion presence (Soules et al., 1982; Hull et al., 1985). A study by Rapkin (1986) 
found that 39% of infertile patients exhibited pelvic adhesions as the only abnormal 
finding. In addition many studies have demonstrated an inverse relationship between 
pregnancy rate and pelvic adhesions, (Rock el at, 1978; Caspi et al, 1979; Caspi & 
Halperin, 198 1). The importance of the effect of adhesions on gynaecological conditions 
is demonstrated by the fact that the female reproductive system was the primary site of 
adhesiolysis procedures, accounting for 47% of all adhesiolysis hospitalisations (Ray et 
al., 1998). 
Chronic pelvic pain is one of the most common gynaecological complaints, yet its actual 
pathology still remains undefined and perplexing. It is believed by many that there is an 
association between pelvic pain and adhesions, associated with previous surgery or 
pelvic inflammatory disease. Kersch et al., (1984) demonstrated that adhesions were the 
most common pathology associated with abnormal pelvic organs and chronic pain, 
however not all pelvic adhesions caused pain. They hypothesised that the difference 
between painful and pain-free pelvic adhesions was dependent upon their restriction on 
organ mobility and expansion, however they state that this structural mechanical 
explanation is not the whole answer. However, Rapkin (1986) questions whether pelvic 
adhesions do in fact play such an important role in the pathogenesis of chronic pelvic 
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pain. 
1.1.3.9 Laparotomy verses Laparoscopy 
During the last decade there has been a trend for increased use of laparoscopy for 
appropriate abdominal procedures. This endoscopic procedure carries the obvious 
benefits of a less invasive technique, with a smaller incision wound, potentially reduced 
operative time, reduced recovery time and hence reduced patient care cost. 
Although laparoscopy does induce PSA formation there have been many reports of 
reduced incidences compared to the open method of laparotomy, as long as meticulous 
surgical standards are employed (Luciano, 1990; Moore el al., 1995; Bulletti et aL, 
1996; Reissman et al., 1996; Tittel el al., 1996; Tulandi, 1997; Chen el aL, 1998). 
However reports by Filmar et al., (1987) and Ellis (1997) are contradictory, stating that 
laparoscopy and laparotomy carry the same risk of inducing intra-abdominal adhesions. 
Support for these studies come from Ray et al., (1998) who reported that the increased 
use of laparoscopy between 1988 and 1994 does not appear to be associated with a 
reduction in adhesiolysis hospitalisation rate, 
The use of laparoscopy for surgical procedures will undoubtedly continue to become 
more popular due to increased patient comfort and decreased cost and workload to 
hospital staff However the benefits of this technique with regard to PSA reduction is 
debatable. 
1.1.4 Benefits 
it is generally agreed that the formation of adhesions following an inflammatory or 
surgical insult is almost inevitable. Hence the formation of adhesions following tissue 
injury is a normal natural phenomena and it could be argued that adhesions are therefore 
beneficial. 
The formation of a fibrin coat over injured tissue has obvious protective effects to the 
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underlying exposed tissue. However it has also been suggested that adhesions themselves 
are advantageous. Ellis (1962) hypothesised that the formation of adhesions was to 
provide damaged/ischaemic tissue with blood supply, calling adhesions "Vascular grafts", 
preventing necrosis, gangrene or perforation. Similar views have been stated by 
Myllarniemi & Karppinen (1968) who quoted that if adhesion formation is prevented 
recovery may be hampered, creating conditions favouring infection and leading to 
complications such as gangrene and necrosis. In an early study by Deaver, (1923) 
limiting of infection by adhesion formation Cwalling-off' process) was reported, with 
adhesions also providing fine strands and ladders along which phagocytic cells could 
travel to the source of infection in order to combat it. , 
Support for the hypothesis that PSAs are valuable comes from: 
i. ischaemia promoting adhesion development (Ellis, 1962; Myllarniemi & Karppinen, 
1968; Dunn & Mohler, 1990) 
ii. rapid angiogenesis associated with adhesions (Myllarniemi & Karppinen, 1968) 
iii. venous obstruction inducing adhesion formation (Belzer, 1967). 
However healing of defects which do not induce adhesion formation are not associated 
with pathogenic conditions. Hence it appears that although benign adhesions provide 
adhered tissues with some benefits (protection of underlying tissues from mechanical 
damage and vascular supply) their potential pathogeneses far outweigh their advantages, 
a view which is held world wide by most surgeons. 
1.1.5 Economic/Workload Impact 
In addition to pathogenesis, PSAs impose a significant economic and workload burden in 
today's climate of limited resources. 
In 1988 in the United States there were 281,982 hospitalisations during which 
adhesiolysis was performed, resulting in an estimated $1,179.9 million in expenditures, 
excluding outpatient care or the cost of failed surgical therapy due to adhesion 
development (Ray el al., 1993). A follow up study by Ray el al., (1998) reported a 
similar number (303,836) of hospitalisations for adhesiolysis in 1994, with an 
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estimated cost of $1.3 billion. Although hospitalisation rates were relatively constant 
between 1988 and 1994, comparative costs decreased between 1988 and 1994. This was 
related to a decrease in the average length of hospitalisation, a result of managed health 
care and less invasive adhesiolysis techniques (Ray et al., 1998). Although adhesiolysis 
only accounted for approximately 1% of all hospitalisations (Ray et al, 1998) they are a 
substantial drain on resources. 
Since adhesions are now the most common cause of bowel obstruction in the western 
world (Nemir et al., 1952; Perry et al., 1955; Playforth et al, 1970; Stewardson et al, 
1978; Bizer et al, 198 1; Menzies & Ellis, 1990; Stricker et al., 1994) the economic and 
workload impact is self evident. A survey by Scott-Coombes et al., (1993) showed that, 
in the United Kingdom, approximately 3600-4800 laparotomies per year are performed 
for adhesional bowel obstruction, with 8400 to 9600 admissions and an average hospital 
stay in excess of 15 days (McEntree et al., 1987). In addition an average of 3600 
laparotomies per year for non-adhesion related diseases are complicated by the presence 
of adhesions. 
Similar statistics have been found in other parts of Europe. Holmdahl & Risberg (1997) 
reported an overall incidence of laparotomy for adhesional bowel obstruction to be 4%, 
with again twice as many admissions. This equates to 1900 laparotomies performed each 
year for this type of bowel obstruction, with an estimated cost of US$4.1 million. If the 
statistics included pain, dysfunction and infertility then an estimated US$11 million per 
year was spent on treatment of adhesion-related pathogeneses. 
1.1.6 Formation 
1.1.6.1 Peritoneal Mesothelium 
The main functions of the peritoneum are to: 
i. Allow friction free movement of abdominal organs 
ii. "Wall off 'infection within the abdominal cavity 
Hi. Act as a reservoir of fat (omentum) 
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These functions of the peritoneum are related to its structure. 
The surface of the peritoneum is a single layer of loosely connected, flat, highly 
differentiated mesothelial cells., which possess a varying number of microvilli on their free 
surface. Due to the mesothelial cells being very poorly interconnected, the peritoneal 
surface is very delicate and susceptible to damage. Hence very minimal mobilisation or 
damage to the peritoneum causes uplifting of many mesothelial cells, leaving the surface 
denuded. Mesothelial cells rest on a basement membrane, which in turn rests on loose 
connective tissue. Connective tissue consists of collagen and reticular fibres and cellular 
elements - fibroblasts, lymphocytes, macrophages, adipocytes, plasma cells and mast cells 
(Johnson & Whitting, 1962; Baradi & Hope, 1964; Eskeland, 1966; Drollette & 
Badaway, 1992; DiZerega, 1997). 
Pleural and pericardial membranes are the only other membranes with a similar 
composition, and healing and adhesion development associated with these membranes 
probably progresses in a similar manner to the peritoneum. 
1.1.6.2 Peritoneal Fluid 
This extracellular fluid, which bathes the organs of the peritoneum, is a plasma exudate 
and has a similar composition: 
i. Plasma proteins, including large amounts of fibrinogen (DiZerega, 1997); and 
ii. Cellular elements - macrophages, monocytes, lymphocytes, eosinophils, mast cells 
but no mesothelial cells (Eskeland, 1966.1; Eskeland, 1966.2; Raftery, 19731). 
Peritoneal fluid has been shown to undergo both volumetric and component changes in 
response to surgery: 
i. Increased volume and plasma protein components (DiZerega, 1997). 
ii. Increased cell numbers 
9 Shimanuki el al., (1986) demonstrated that 6 hours after abrasion of the 
peritoneum, peritoneal fluid comprised of 87.5% polymorphonuclear cells, 
with Eskeland (Eskeland, 1966.1; Eskeland., 1966.2) observing that 
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polymorphonuclear granulocytes were present during the first three days 
following injury. 
o3 days following abrasion total cell number in peritoneal fluid increased with 
large mononuclear cells making up 97.6% (Shimanuki el at, 1986). 
o Reabrasion was followed by less leukocytes in the peritoneal fluid compared 
to the initial abrasion, however the percentage of macrophages was higher 24 
hours following reabrasion (Shimanuki et al., 1986). 
1.1.6.3 Adhesion Free Healing 
Interest in the healing of wounds has been considered ever since the advent of medicine. 
For many years the healing of all wounds was considered to be similar, for example, 
peritoneal wounds were thought to heal in the same manner as skin wounds, with 
gradual re7epithelisation from the wound boundary. However, in the early decades of this 
century, theories contradicting this hypothesis were purposed by Hertzler (1919) and 
Lewis (1923) who both suggested that re-epithelisation of peritoneal wounds occurred 
from subjacent tissues/cells. Although nowadays there are contradictory ideas concerning 
the origin of new mesothelial cells, it is agreed that mesothelial wounds (peritoneal, 
pleural and pericardial cavities) do differ in their healing mechanisms compared to skin 
and other defects. 
The two main observations of interest regarding the healing of peritoneal wounds are: 
L The rapidity of healing of peritoneal wounds, Vith a continuous layer of cells 
covering the wound surface within 8 days following injury (Ryan et aL, 1973; 
Johnson & Whitting, 1962; Ellis et al., 1965; Hubbard et al., 1967; Raftery, 19731; 
Eskeland, 1966.1; Eskeland, 1966.2) 
Healing of small and large defects occurs within the same time period (Ellis el aL, 
1965; Eskeland, 1966.1; Eskeland, 1966.2; Hubbard et al., 1967). 
Macroscopic Appearance 
In the first 2 days following injury peritoneal wounds appear to have a glistening but 
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uneven haemorrhagic surface (Williams, 1955; Ellis el al., 1965; Eskeland, 1966.1; 
Hubbard el al., 1967), and by 3 to 4 days the wound surface is still red, velvety 
(Eskeland, 1966.1) and glistening (Williams, 1955). The difference between the wound 
surface and the surrounding peritoneum progressively decreases over time, with the 
wound surface becoming gradually more pale, smooth and shiny (Eskeland, 1966.1; 
Hubbard el al., 1967). By 8 days the whole wound surface is smooth and glistening 
though still slightly more red than the surrounding peritoneum and at 14 days only a 
shallow depression of greyish white colour indicates the location of the wound 
(Eskeland, 1966.1). 
1.1.6.3.2 Structural Changes 
Overall there is agreement as to the structural changes which occur during adhesion-free 
healing of peritoneal wounds. Fibrin formation at the site of injury occurs rapidly (Figure 
1.1) with fibrin strands present at I hour following injury (Eskeland, 1966; Eskeland, 
1966). Fibrin strands form networks covering the wound surface during the first 2 to 3 
days, after which fibrin absorption is initiated (Johnson & Whitting, 1962; Raftery, 
1973. E). By 4 days post injury there is little or no fibrin in the wound exudate (Eskeland, 
1966.1; Raftery, 19731; Raftery, 19731). Collagen fibres are observed at 5 days (Ryan 
el al., 1973; Raftery, 19731), with thick collagen bundles seen in the base of the wound 
at 8 days and a thin layer of fibrous tissue covered by a continuous layer of mesotheliurn 
occupying the site of the original defect (Raftery, 1973. L). Little further change is seen 
thereafter, although the fibrous tissue appears to contract and reduce the size of the scar 
considerably (Ellis et al., 1965)(Figure 1.2). 
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Figure 1.2: Structural changes occurring during adhesion-free wound healing. 
In addition to connective tissue formation, the development of new blood vessels is 
essential for successful wound healing. Angiogenesis is a complex process involving the 
interplay between vascular and non vascular cells, soluble mediators and extracellular 
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matrix components. The process is the result of a cascade of overlapping steps: (i) 
degradation of basement membrane, (ii) migration of endothelial cells, (iii) proliferation 
of endothelial cells, and (iv) capillary tube formation and maturation. Macrophages play 
important roles in angiogenesis, through the release of both positive and negative 
chemical regulators (Appendix I Table 1.1) but mast cells, neutrophils and lymphocytes 
have also been implicated. Angiogenesis begins during the inflammatory stages of wound 
healing and new blood vessel formation has been demonstrated in peritoneal wounds 
afler 4 to 6 days (Johnson & Whitting, 1962). 
1.1.6.3.3 Cellular Involvement 
Cellular actions and interactions play essential roles in normal and pathological wound 
healing (Appendix I Table 1.2). Cellular involvement can be classified as having three 
main stages: (i) haemostasis; (ii) inflammatory response; (iii) tissue repair. These will be 
discussed in turn. 
(i) Haemostasis 
Immediately following tissue injury, platelets (and some blood cells) exude from the 
damaged tissue. These platelets adhere to exposed collagen present at the wound site, 
and secrete granules containing serotonin, adrenaline, adenosine diphosphate (ADP) and 
several clotting factors. Serotonin and adrenaline cause blood vessels to contract, ADP 
results in the platelets becoming more adherent, leading to the formation of a platelet 
plug, and the clotting factors result in the formation of a fibrin clot. Hence the process of 
haemostasis is achieved (Figure 1.3). 
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(ii) Inflammatory Response 
It is universally accepted that the inflammatory process plays an important role in both 
adhesion-free healing and adhesion formation. Inflammation is a localised protective 
response initiated by injury, with the aim of destroying, diluting or walling-off both the 
source of injury and the injured tissue. This complex process involves many biochemical, 
cellular and physiological processes, with the main characteristics shown in Figure 1.4. 
involvement of inflammatory cells during the complete healing process of peritoneal 
wounds has been demonstrated by several studies, with inflammatory cells seen in healing 
wounds from as little as I hour to at least 10 days post injury. 
fNJLJPY 
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smooth muscle small vessels 
Increase in blood flow Increase in Escape of oderna fluid into Leukocyte 
in arterioles, hydrostatic pressure extravascular compartment migration 
capillaries and venules in small vessels - including plasma proteins 
Figure 1.4 : Main characteristics of the inflammatory response. 
Eskeland (1966.1; 1966.2) sampled healing tissues at I and 4 hours post injury, and 
found cells, predominantly macrophages with occasional mast cells, entangled within 
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fibrin strands. By 12 hours, numerous cells were present within the fibrin strands, with 
polymorphonuclear leukocytes (PMNLs) the predominant cell type but many 
macrophages, a few eosinophils and mast cells were also seen (Raftery, 1973. E). Red 
blood cells, together with nucleated cells (macrophages, monocytes, polymorphs, 
eosinophils, lymphocytes and mast cells) have also been found in the fibrinous exudate at 
12 to 24 hours (Ellis et at, 1965; Raftery, 1973. L). 
After 24 hours underlying tissue still shows signs of damage and oedema. Neutrophils, 
eosinophils (Johnson & Whitting, 1962; Hubbard el al., 1967; Ryan el al., 1973; Raftery, 
1973. E), lymphocytes, histiocytes (Hubbard et al., 1967) and macrophages (Johnson & 
Whitting, 1962; Hubbard et al, 1967; Raftery, 19731; Raftery, 1973. E) have all been 
demonstrated. However Ryan et al., (1973) reported macrophages to be absent at this 
stage. 
However studies often detail contradictory results for the involvement of inflammatory 
cells at day 3. This may be a function of the type of injury inflicted. Ryan et al., (1973) 
reported that underlying tissue contained polymorphs and macrophages, whereas 
Raftery's studies (Raftery, 19731; Raftery, 1973. E) state that polymorphs, lymphocytes, 
eosinophils and mast cells were no longer present, with the only inflammatory cells 
remaining being macrophages. The same findings were presented by Hubbard el al., 
(1967) and this view is supported by Eskeland (1966.1) who showed that a large number 
of closely packed macrophages were seen in the superficial parts, often contrasting 
sharply with the relatively small number of cells in deeper parts. 
At 4 days cellular involvement is still marked, with reports of large numbers of cells 
present, evenly distributed throughout the wound (Eskeland, 1966.1) and considerable 
proliferative activity in undifferentiated mesenchymal. cells, macrophages and cells 
forming new blood vessels in the wound floor (Johnson & Whitting, 1962). Ryan el at, 
(1973) reported the presence of the same cell types as day 3, with the addition of 
underlying smooth muscle showing signs of microfilament regeneration (Ryan el aI, 
1973). A decrease in inflammatory cells occurred thereafter and by 7 and 10 days 
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following injury, underlying tissue showed only scattered macrophages (Raftery, 1973. E) 
(Figure 1.5). 
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Figure 1.5: Cellular involvement during adhesion-free wound healing. 
(iii) Tissue Repair 
The final cellular process of wound healing is tissue repair, involving both surface and 
deeper areas of the wound. There is general agreement for the healing of underlying 
tissues. Young fibroblasts have been seen in the base of the wound as early as 2 days 
post injury (Ellis ef al, 1965) (Figure 1.5). At 4 days fibroblast proliferation has been 
observed (Johnson & Whitting, 1962; Raftery, 1973. L), with fibroblasts alignment 
parallel to the wound surface seen by 5 days (Raftery, 19731; Raftery, 1973, E). This 
increase in fibroblast number and alignment corresponds with the presence of collagen 
observed at 5 days following injury (Raftery, 1973. L; Ryan el al., 1973). Fibroblasts 
have been demonstrated at 10 days following injury (Raftery, 1973. E), although Ellis et 
aL, (1965) reported that fibroblasts are replaced by histiocytes at 7 days. In addition, 
smooth muscle regeneration has been demonstrated as early as 4 days post injury and is 
reported as being completed by 7 days (Ryan el aL, 1973). 
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The question of cellular regeneration of the covering mesothelial layer on the wound 
surface is much more contentious (Table 1.4). There are four main theories for the origin 
of new mesothelial cells: 
Mesothelial cells,, either implanted from contact with peritoneum (Johnson & 
Whitting, 1962) or by proliferation and/or migration from adjacent, non-injured 
peritoneum (Robbin el al., 1949; Eskeland, 1966.1 (small defects) Hubbard el aL, 
1967 (minor role); Johnson & Whitting, 1962) 
II. Monocytes/macrophages differentiation into mesothelial cells (Johnson & Whitting, 
1962; Eskeland, 1966.1; Eskeland, 1966.2; Ryan et al., 1973 (mononuclear cells)) 
111. Fibroblast differentiation into mesothelial cells (Ellis et aL, 1965; Raftery, 1973. L; 
Raftery, 1973. E) 
IV. Mesenchymal cell differentiation into mesothelial cells (Hubbard et al., 1967; 
Raftery, 1973. E; Raftery, 1973. E (via fibroblasts)) 
Cell Type Author's 
Support Against 
Mcsothclial cell Robbin et aL, 1949 Eskcland, 1966.1 
Johnson & Whitting, 1962 Eskcland, 1966.2 
Eskeland, 1966.1 Raftcry, 1973. E 
Hubbard et aL, 1967 
Monocytc/macrophagc Johnson & Whitting, 1961 Raftcry, 19731 
Eskcland, 1966.1 Raftcry, 1973. E 
Eskcland, 1966.2 
Ryan et aL, 1973 
Fibroblast Ellis et aL, 1965 
Raftcry, 1973. L 
Raftcry, 1973. E 
Mcscnchymal ccll Hubbard et aL, 1967 
1 Raftcry, 1973. E 
Table 1.4: Possible origins for mesothclial ccils. 
The contradictory evidence for the origin of mesothelial cells is hard to interpret, but it is 
possible that there are several origins for regenerated mesothelium, with the pathway 
chosen dependent upon the injury type and peritoneal conditions. Several studies have 
listed different origins of new mesothelial cells in order of preference (Johnson & 
Whitting, 1962; Eskeland, 1966.1; Raftery, 1973. E) which support this hypothesis. 
Contributing factors to these contradictory theories include the diverse experimental 
models used, use of static time points to interpret a continuous rapidly changing process, 
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and the lack of clear cell identification. 
Chapter I 
Although different theories exist regarding the origin of new mesothelial cells, there is 
general agreement in the timing of the formation of new mesothelium on the surface of 
peritoneal defects. Within the first 24 hours following injury cells appear on the surface 
of the defect (Johnson & Whitting, 1962; Eskeland, 1966.1; Ryan et al., 1973), with Ellis 
et al., (1965) demonstrating approximately 50% of the surface covered with cells at this 
time. By 2 days the number of surface cells has greatly increased with most of the surface 
covered (Johnson & V&tting, 1962; Ellis et al., 1965; Raftery, 1973. E). A continuous 
layer of surface cells has been demonstrated in as little as 3 days following injury 
(Johnson & Whitting, 1962; Ellis et aL, 1965), with cellular attachments seen at 4 days 
(Ryan et al., 1973). By 7 to 8 days post injury all studies report that a continuous cell 
layer is present, attached to a basement membrane (Raftery, 1973. E) and by 10 to 14 
days the new mesothelium is indistinguishable from the normal, adjacent peritoneum 
(Ellis et al., 1965; Eskeland, 1966.1) . 
1.1.6.4 Biochemical Modulation 
Little research has investigated peritoneal healing and adhesion formation at the 
molecular level. Since such events are a complex sequences of cellular actions and 
structural changes, considerable molecular control must be present. It has been estimated 
that well over 100 substances are involved in the regulation of peritoneal healing (Table 
with the main sources being: (i) local tissue cells, and/or (ii) peritoneal fluid 
(Chegini, 1997). Although wound healing involves the interplay of many cell types with 
capabilities of secreting various cytokines and growth factors, macrophages have been 
identified in many studies as the most important source of molecular substances. 
Growth Factors Cytokines 
Transforming growth factors a and P Interleukins 
Epidermal growth factor Tumour necrosis factor-a 
Fibroblast growth factor Granulocyte macrophage colony stimulating factor 
Platelet derived growth factor Monocyte colony stimulating factor 
Insulin-like growth factor 
Heparin binding epidermal growth factor 
Table 1.5: Main growth factors and cytoldnes involved in wound healing. 
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Rong et al., (1997) investigated the levels of tumour necrosis factor-P, (TNF-PI), 
granulocyte macrophage colony stimulating factor (GM-CSF), interieukin-lp (IL-IP), 
tumour necrosis factor-cc (TNF-cc) and interferon-y (IFN-y) in peritoneal fluid following 
surgery and found levels to be maximally elevated in the first five to seven days, which 
corresponds with inflammatory and tissue repair responses. A similar study was carried 
out by Ford et al., (1989) in which significantly higher levels of IL-1 and 6, TNF and 
monocyte colony stimulating factor (M-CSF) were detected in wound fluid and it is 
hypothesised that these cytokines were secreted at the site of injury to interact and 
promote tissue remodelling. Decrease in levels of these cyiokines was demonstrated by 
the 13'hday following wounding, which may be a result of a regulatory process of the 
healed wound. 
It is clearly evident that wound healing is under biochemical regulation. Chegini (1997) 
stated that, for successful healing to occur, molecular control needs to be optimised, 
precise and synchronised. When inhibition, interruption or excess expression occurs, 
healing is either impaired (non-healing) or excessive (adhesion formation). 
1.1.6.5 PSA Formation 
Considering the pathogeneses of PSAs it is not surprising that much research has been 
directed toward this field. However in this area of medicine there has been much 
"armchair reasoning rather than experimental studies or accurate clinical observation" 
(Ellis, 1971), with a trend to prematurely leap into the development and trials of 
potential PSA preventative agents. Hence, even though reports of PSA have been around 
for over a century, many questions concerning the aetiology of PSAs still remain. It is 
only logical that prevention of PSAs can only be optimised when PSAs are fully 
understood, a view which is also held by many authors in this field (Ellis, 1971; Pijlman 
ef al., 1994). 
The overall formation of PSAs is in general agreement. In the middle of this century it 
was demonstrated by Thrompke & Siegner (1955) that injury or inflammation lead to the 
outpouring of fibrin and an adhesion is formed within 3 hours. This fibrinous or 
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primary adhesion has two possible outcomes. (i) it undergoes fibrinolysis and is absorbed 
within a few days (Jackson, 1958), or (ii) it becomes organised by the ingrowth of 
capillaries and collagen formation and becomes an established fibrous adhesion (Figure 
1.6). 
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Figure 1.6: Overview of PSA fonnation. 
1.1.6.5.1 Structural Changes 
A comprehensive light and electron microscopy study carried out by Milligan & Raftery 
(1974) showed the dynamics of fibrin and collagen within PSAs to follow a similar 
pattern to adhesion-free peritoneal healing. At I day post injury the adhesion consisted of 
a fibrin matrix, which remained unchanged for the first 3 days, after which most fibrin 
had been removed. Sparse and fibnllar collagen was first seen at 3 days after which it 
became the predominant structural protein. By 5 days collagen formation was well 
advanced, with collagen fibres laying in discrete bundles by 7 days post injury and further 
maturation until the end of the 2 month study (Figure 1.7). The formation of new blood 
vessels was observed from 3 days onwards. 
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Cellular Involvement 
Chapter I 
As with structural development of PSAs, cellular involvement follows a similar pattern to 
adhesion-free peritoneal. healing, that is, haemostasis, inflammatory response and tissue 
repair/modelling. 
The study by Milligan & Raftery (1974) details cellular activity during PSA formation, 
with support from Schade & Williamson (1968). At I day cells present in the fibrin 
matrix were macrophages and eosinophils, distorted extravasated R-BCs and necrotic 
cells, however PMNLs were the predominant cell type. By 2 days PMNL predominance 
was shared with macrophages, with lymphocytes and cosmophils also present. Reduction 
in the presence of PMNLs during the next 24 hours occurred leaving very few remaining 
by day 3, with macrophages predominant and many eosinophils present. From 4 to 7 
days macrophages and eosinophils were still present, in addition to increasing numbers of 
fibroblasts. From 14 days onwards relatively few cells remained, consisting mainly of 
elongated fibroblasts interspersed with collagen bundles and occasional macrophages 
(Figure 1.8). 
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Figure 1.8: Cellular involvement in PSA formation. 
1.1.6.6 PSA Formation versus Adhesion-Free Healing 
(7111plcr/ 
The search for causative factor(s) for the formation of PSAs has been ongoing since the 
first description of PSAs. Many hypotheses have been put forward, some with very little 
scientific basis, with inappropriate ideas exacerbating the problems of research into 
PSAs. For example at the beginning of this century it was generally accepted that open 
peritoneal defects lead to PSA formation, consequently suturing of such defects was 
advocated. However many subsequent studies have demonstrated that peritoneal defects 
can heal without adhesion development (Chandy & Rhoads, 1946; Johnson & Whitting, 
1962; Ellis el al., 1965; Eskeland, 1966.1; Gluckson, 1966; Raftery, 1973. L; McDonald 
ei al., 1988) and that suturing of such defects acted as a potent stimulator of PSAs due 
to the presence of foreign material and excess handling of viscera during the repair 
process. 
Since peritoneal defects have the potential to heal without adhesion formation it is 
somewhat surprising that PSAs involving peritoneal tissues are almost an inevitable 
outcome of surgical procedures. However, during surgery, there are many factors which 
have been identified as potential stimulators of PSAs (Table 1.6). 
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Category Potential Stimulators of PSAs Author's Offering Support 
Mechanical Trauma Myallarniemi & Karppinen, 1968 
Schade & Williamson, 1968 
IP physiological saline solution Chandy & Rhoads, 1946 
Exposure of viscera to air Deaver, 1923 
Cautery Deaver, 1923 
McDonald et aL, 1988 
Serosal Injury and Blood Ryan et aL, 1971 
Cliff et aL, 1973 
infection Deaver, 1923 
Holtz, 1984 
O'Leary & Coakley, 1992 
Ischaen-da Ellis, 1962 
Myallarnicmi & Karppincn, 1968 
Dunn & Mohler, 1990 
Vcnous Congestion Belzer, 1967 
Foreign Materials Sutures Deaver, 1923 
Hubbard et aL, 1967 
Connolly & Stephens, 1968 
Holtz, 1982 
McDonald et aL, 1988 
O'Leary & Coakley, 1992 
Staples McDonald et aL, 1988 
Powder from Surgical Gloves Chandy & Rhoads, 1946 
Jangelman & Ellis, 1973 
Endotoxins from Surgical Gloves Perio et aL, 1990 
Dry Gauze Connolly & Stephens, 1968 
Reduction in Buckman et aL, 1976 
Fibrinolytic Activity 
Raftery, 1981 
Menzies& Ellis, 1989 
Vipond et aL, 1990 
Table 1.6: Potential stimulators of PSAs. 
Potential stimulators of PSAs can be divided into 5 main groups: 
i. Mechanical trauma - denuding of peritoneal surfaces can occur as a result of very 
mild injuries (for example, drying for 5 minutes or wetting with isotonic saline 
solution for 30 minutes (Ryan et al., 1971)) due to the intricate structure of covering 
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mesothelial cells. However it is generally agreed that such defects will heal 
successfully although perhaps not optimally, if left to heal naturally vvithout the 
interference of other agents. 
Infection - the potential of infection to stimulate adhesion formation has long been 
recognised. PSA development in this situation has preventative effects in limiting 
infection topographically in the peritoneal cavity (Deaver, 1923). Holtz (1984) 
highlighted the fact that the actual mechanisms by which infection induces adhesion 
formation are not clearly understood but probably include the numerous substances 
released by bacteria, including enzymes, which may damage tissue and induce the 
inflammatory response and substances which limit blood flow. 
iii. Ischaernia - the importance of ischaemia in PSA formation was first elucidated by 
Ellis (1962), with later studies supporting his hypothesis (Belzer, 1967; Myallarniemi 
& Karppinen, 1968; Dunn & Mohler, 1990). Ellis (1962) stated that factors which 
are associated with PSAs, such as tissue damage, removal and suturing, can be 
classified as tissue ischaemia, and that this, and not serosal damage, is the important 
factor in PSA development. 
iv. Foreign materials - many extraneous materials commonly associated with open 
wound surgery have been implicated in PSA formation. The actual pathways in which 
such materials induce PSAs are not fully understood, but probably involve ischaemia 
and/or inflammatory pathways. 
v. Reduction in fibrinolytic activity - many fibrinous PSAs have the potential to undergo 
lysis in the first week following surgery (Jackson, 1958), a phenomena well known 
by surgeons. Fibrin clots/fibrinous adhesions are removed by a fibrinolytic system, 
which degrades fibrin and fibrinogen to soluble products (Figure 1.9). 
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Many studies have demonstrated that natural fibrinolytic activity is effected by trauma, 
with a sustained decrease in activity up to 2 days post surgery. Ryan ef al., (1973) 
demonstrated that fibrinolysis was absent at 4 to 24 hours post surgery, with similar 
results found by Scott-Coombs el aL, (1995) in which plasminogen activating activity 
(PAA) was absent at 24 and 48 hours. Raftery (1981) stated that fibrinolytic activity, 
although reduced, was not maximally depressed at the time of operation with further 
depression in the first 24 hours post-operative. Following the absence of fibrinolytic 
ability in the first couple of post operative days, an increase in activity has been 
demonstrated (Ryan el al., 1973), with levels remaining elevated for 2 to 3 weeks and 
returning to normal thereafter. 
Buckman el at, (1976) demonstrated that the time which it took for PAA activity to 
return to normal following injury was dependent upon the type of injury, with abrasion 
returning to normal first, followed by crushing and then ischaemia. This study 
hypothesised that major stimuli to intraperitoneal adhesion formation exert their effect on 
peritoneal fibrinolysis for several days, explaining the failure of short-term therapy to 
prevent PSAs. Support for this hypothesis comes from Raftery (198 1) who demonstrated 
that significant depression of fibrinolytic activity occurred in response to peritoneal 
grafting, diathermy and peritoneal ischaemia. 
Gervin el al., (1973) showed that the relationship of adhesion production to reduction in 
fibrinolytic activity was highly significant, with 50% or more reduction in fibrinolytic 
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activity associated with massive adhesions. This study also demonstrated that fibrinolytic 
activity is present in all gastrointestinal serosa, with the greatest activity found in the 
mid-distal ileum and proximal colon, areas which are at greatest risk of PSAs formation 
(Gervin et al., 1973). 
The actual reduction in fibrinolytic activity in response to trauma is though to be a result 
of: 
Reduced tissue plasminogen activator (tPA) concentration (the principal 
physiological PA in peritoneal tissue) (Holmdahl, 1997), and 
ii. Increased concentration of plasminogen activator inhibitor I (PAI-1) and 
plasminogen activator inhibitor 2 (PAI-2) (Vipond ef al., 1990; Scott-Coombs et al, 
1995). 
1.1.7 Conclusions 
It is evident that the development of PSAs is dynamic and complex, involving 
interactions of many biological systems. However even though reports of PSAs have 
been around for many centuries, with their importance to both patients and medical 
personnel well established, many fundamental questions concerning the aetiology of 
pSAs still remain. It is only logical that prevention of PSAs can only be optimised when 
the formation and maturation of PSAs is fully understood, a view which is also held by 
this and many authors in this field (Ellis, 1971; Pijlman et al., 1994). 
1.2 Post Surgical Adhesion Preventative Strategies 
1.2.1 HistOrY 
Treatment of PSAs has been attempted, with varying success, since the mid-late 19"' 
century, with early practices of adhesion division by surgery still remaining today. 
Naturally adhesiolysis (surgical lysis of adhesions) leads to immediate relief from PSA 
pathogenesis, with this practice essential for such conditions as bowel obstructions. 
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However there are two main problems with this technique- 
i. A second surgical procedure is required, associated with additional patient 
discomfort, the possibility of further PSA formation (even with laparoscopic lysis) 
and additional economic and time expenditure 
ii. Adhesion reformation rate - clinically problematic adhesions have been reported to 
reoccur in 32% of cases (Brightwell el aL, 1977), although overall adhesion 
reformation rate is probably much higher and closer to experimental reformation 
rates of 80-100% (Menzies & Ellis, 1989, Gervin el aL, 1973). 
As with any medical condition, prevention is a much better alternative to treatment. In a 
comprehensive review of PSA prophylaxis, Boys (1942) identified five areas in which to 
develop measures against PSA formation (Figure 1.10). As recognised by Boys (1942) it 
is fibrinous/transient adhesions which need to be targeted, as once fibroblasts have 
started laying down collagen (from 3 days post operative) then only drastic measures, 
such as adhesiolysis and surgery, are going to be effective. 
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Figure 1-10: Potential PSA prevention strategies. 
(From Boys. 1942). 
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1.2.2 Surgical Procedure Alterations 
it is universally agreed that meticulous surgical technique is required to "limit" PSA 
formation. Such techniques includes: 
1. Strict asepsis 
2. Minimal, gentle tissue handling 
3. Proper haemostasis/removal of "free" blood 
4. Effective cautery/diathermy 
5. Avoidance of foreign material contamination 
6, Correct and essential only suturing 
7. Influencing position of PSA formation 
All of the above do not need expanding upon except the last. Many authors and surgeons 
agree that if PSAs are going to exist then influencing their site of formation will limit 
associated pathogenesis. Placement of the omentuin over injured tissue and/or peritoneal 
suture lines are common techniques directed at prevention of intestinal adhesions and aid 
re-entry into peritoneum respectively. Plication techniques, such as Noble plication, 
Childs-Phillips plication and modifications of the Baker tube insertion are techniques 
devised to prevent recurrent adhesional bowel obstruction (Menzies, 1992). Again these 
surgical techniques are aimed at controlling the site of adhesion formation/reformation so 
that the bowel maintains patency and obstruction is avoided. 
However it appears that suggested surgical precautions are not being optimised by 
surgeons, as highlighted in published surveys by Scott-Coombs el at, (1993) and 
Holmdahl & Risberg (1997) who independently investigated current practices employed 
by surgeons in Britain and Sweden respectively. 
it has long been recognised that starch from surgeons gloves acts as a potent stimulator 
of PSAs, however the use of such gloves is still widespread (Scott-Coombs el aI, 1993; 
Holmdahl & Risberg, 1997), with starch contamination during abdominal surgery 
common (Jangelman & Ellis, 1973; Holmdahl & Risberg, 1997). Only small amounts 
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of powder are required in the presence of peritoneal defect to form adhesions (Jangelman 
& Ellis, 1973) and hence the use of these gloves is potentially very hazardous. Although 
approximately half of the surgeons who use these gloves wash them prior to use (Scott- 
Coombs et at, 1993), washing techniques employed tended to be inadequate, with 
simple washing in water leaving about 10% of the original starch (Fraser, 1982) and 
causing clumping of particles which in turn hamper absorption and lead to granuloma 
and adhesion formation (Jangelman & Ellis, 1973; Scott-Coombs et at, 1993; Holmdahl 
& Risberg, 1997). Correct washing of gloves in povidone-iodine surgical scrub for one 
minute, followed by washing in running sterile water to remove 99.8 - 100% of starch 
(Fraser, 1982) was found to be utilised by only 2.6% of surgeons (Scott-Coombs et at, 
1993). However, even with effective washing procedures the risk of contamination via 
glove perforation still remains. 
Both studies also reported that the majority of surgeons suture the peritoneal layer, even 
through this process is unnecessary (Connolly & Stephens, 1968; Ellis & Heedle, 1977; 
O'Leary & Coakley, 1992), time consutning and induces PSAs. 
Full employment of TSA limiting surgical practicee' do not appear to be common place, 
with the development of avoidable PSAs occurring. Surgeons need to exploit these areas 
in order to lower PSA associated problems. For example, Holmdahl & Risberg (1997) 
estimated that the use of powder-free gloves alone could give a potential saving of US$3 
million/year. However even if all `TSA limiting techniques" were utilised, it is well 
recognised that PSAs will still develop. Hence for many years surgeons have sought 
additional prophylaxis to combat this pathogenesis. 
1.2.3 Potential PSA Preventative Agents 
There have been many studies investigating potential PSA preventative agents, ranging 
from foils of silver to fish bladders. Progression in finding an effective PSA preventative 
agent has been slow, with inadequate understanding of PSA development hindering the 
process. 
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An "ideal" PSA preventative agent would possess the following properties: 
non toxic 
non reactive/non immunogenic 
no/limited side effects 
effective 
remain in situ whilst required but ultimately biodegradable 
economically viable 
easy to use/time viable 
Chapter I 
In order to assess previously investigated potential PSA preventative agents (Appendix I 
Table 1.3), they have been grouped into categories according to their main mode of 
action, following the plan laid down by Boys (1942). However these are not definitive, 
with some potential agents having several modes of action and not all actions known. 
1.2.3.1 Prevention of Fibrin Coagulation 
Substances investigated with the potential to prevent the initial stage of PSA formation, 
fibrin deposition, include anticoagulants, such as sodium citrate, heparin, DicumorollO, 
and dextran. (Ellis, 1971; Ellis, 1982). 
Of these heparin has been the most extensively studied, with systemic or intraperitoneal 
administration being effective in preventing PSAs. However treatment with heparin 
carries serious risk of haemorrhage (Pijlman et aL, 1994), with associated deaths 
(Connolly & Smith, 1960; Ellis, 1971). For this reason the clinical use of heparin for PSA 
prevention was abandoned in the late 1940's (Connolly & Smith, 1960). 
1.2.3.2 Reduction of Inflammatory Response 
Corticosteroids inhibit: 
i. early inflammatory response - fibrin deposition (Pijlman el al, 1994). decrease 
vascular permeability alterations, stabilise lysosome membranes and inhibit synthesis 
and release of histamine and other mediating substances (Holtz, 1984) 
34 
Introduction Chapter I 
ii. later stages of wound healing - proliferation of capillaries and fibroblasts, deposition 
of collagen (Pijlman el at, 1994) although stimulates human fibroblast growth 
(Holtz, 1984). 
Most studies demonstrate that corticosteroid. efficacy in reducing PSAs is uncertain 
(Connolly & Smith, 1960; Menzies, 1992; DiZerega, 1994; Pijlman et al., 1994; Risberg, 
1997). Clinical use has also been limited by the associated side effects, namely delayed 
wound healing, immunosuppression, bone and muscle pain and psychiatric disturbances 
after completion of treatment (DiZerega, 1994; Pijlman et al., 1994; Risberg, 1997). 
Non-steroidal anti-inflammatory drugs (NSAIDs) change the metabolism of 
arachidonic acid by altering the cycloxygenase enzyme activities and formation of their 
end products, including prostaglandins and thromboxane, with arachidonic acid 
metabolites mediating many aspects of the inflammatory response (DiZerega, 1994). 
Several NSAIDs have been tried including ibuprofen, indomethacin, oxyphenbutazone, 
with conflicting results found with regard to PSA prevention (DiZerega, 1994; Pijlman el 
al., 1994) 
Histamine antagonists, for example, promethazine, have been used in con unction with 
corticosteroids, (Holtz, 1984; Pijlman et al., 1994) with results indicating that although 
this combination reduces the incidence of adhesions, it is associated with significant 
morbidity and mortality (Grosfel el aL, 1973). Promethazine is thought to uniquely limit 
the effects of histamine,, inhibit the increased vascular permeability induced by histamine 
and other factors, stabilise lysosomes and may inhibit fibroplasia (Holtz, 1984). No study 
has evaluated the use of this drug alone (Holtz, 1984; Pijlman et aL, 1994). 
other substances tried include calcium channel blockers, progesterone and colchicine. 
Calcium channel blockers, for example, nifedipine hydrochloride, have been shown to 
reduce the degree and incidence of PSAs (Menzies, 1992; Pijlman et al., 1994) probably 
due to an anti-inflammatory effect (Pijlman el al., 1994). Progesterone has also been 
reported to have anti-inflammatory and immunosuppressive properties, although PSA 
prevention studies have yielded inconclusive results (Pijlman et aL, 1994). Colchicine is 
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a known anti-inflammatory, largely utilised in the treatment of gouty arthritis. It inhibits 
the release of histamine-containing granules from mast cells, has anti-mitotic properties 
and has been demonstrated to reduce adhesion formation (Pijiman el al., 1994). 
1.2.3.3 Removal/Dissolution of Deposited Fibrin 
Many ribrinolytic agents have been investigated with regard to PSA prevention, for 
example, tissue-type plasminogen activator (tPA), streptokinase, streptodornase, single- 
chain urokinase,. actase and elastase with varying results (Ellis, 1971; Pijiman et al, 
1994; Risberg, 1997). All these agents carry the risk of impaired wound healing (Risberg, 
1997). The use of tPA has received a lot of interest with many studies reporting PSA 
reduction (Menzies & Ellis, 1989; Dunn and Mohler, 1993). tPA has several advantages 
over most other fibrinolytic agents due to it not being antigenic and has few, if any, 
general side effects (Pijlman et al., 1994). 
Other substances investigated include digestive and proteolytic enzymes. Digestive 
enzymes, for example, pepsin and trypsin, are rapidly neutralised by peritoneal exudates 
and hence their potential for preventing PSAs is very limited (Ellis, 1971). The 
proteolytic enzyme papain and later its derivatives (for example, Papase) attracted 
attention for possible PSA prevention in the first half of this century, however Boys 
(1942) demonstrated that this too is neutralised by peritoneal exudate and hence efficacy 
is unlikely. Hyaluronidase digests the connective tissue component hyaluronic acid and 
has shown some PSA reduction properties. 
Removal of fibrin deposits by peritoneal lavage with saline, dextran or hypertonic 
dextrose solutions has also been tried. However, these are rapidly absorbed by the 
peritoneum and are unlikely to prevent PSAs (Ellis, 1971). 
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1.2.3.4 Separation of Surfaces 
1.2.3.4.1 Physical Methods 
Two physical methods of separation are: 
1. distension of the peritoneal cavity (Boys, 1942; Ellis, 1982), and, 
2. early and increased peristalsis (Boys, 1942; Connolly & Stnith, 1960; Ellis, 
1982) 
Although these help prevent contact of peritoneal surfaces they are generally impractical, 
and consequently have stimulated little clinical interest. 
1.2.3.4.2 Solutions 
Two types of solutions have been used in an effort to prevent PSAS: 
1. large quantities of isotonic solutions, or, 
2. smaller quantities of hypertonic solutions (which has the potential to form 
enough transudate) 
Solutions investigated include normal saline, lactate Ringer's solution, hydroxyethyl 
starch, gelatine, silicone, povidone-iodine/polyvinylpyffolidine, phosphate buffered saline 
(PBS) and dextran (Ellis, 1971; Menzies, 1992; DiZerega, 1994), usually administered as 
an instillate at the end of the surgical procedure (DiZerega, 1994). Although 
hydroflotation is effective in the early stages of wound healing, solutions tend to be 
absorbed before the completion of peritoneal healing, hence their preventative effects 
against PSA formation is dubious. 
The most extensively studied solution is dextran, a water soluble polysaccharide, as a 
hypertonic solution, originally employed as a plasma expander. Low molecular weight 
dextran yielded insignificant results for PSA prevention and an unenthusiastic response 
from clinicians. However high molecular weight (HMW) dextran (mainly 32% dextran 
70), although it too has produced mixed results in experimental and clinical studies, has 
attracted more interest. Nowadays HXff dextran is the most commonly used substance 
employed to separate mesothelial surfaces (Pijlman et al., 1994), although it has not 
gained regulatory approval for adhesion prevention (Risberg, 1997). It is thought to have 
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multiple mechanisms of action (Pijlman et at, 1994; Risberg, 1997): 
* hydroflotation and siliconisation to separate peritoneal surfaces 
9 dilution to diminish local fibrin concentration 
" preservation of local plasminogen activators 
" interference with polymorphonuclear neutrophil expression of adhesion 
molecules 
" fibrin alterations, making it more susceptible to degradation 
Dextran is associated with some common side effects, including anaphylactic shock, 
allergic reactions, transient weight gain, ascites, oedema of the vulva or leg, pleural 
effusion, coagulopathy, fluid imbalance secondary to intraperitoneal osmotic load, 
impaired haemostasis, infection and transient liver disturbances reported (Holtz, 1984; 
DiZerega, 1994; Pijlman el al, 1994; Risberg, 1997). 
1.2.3.4.3 Physical Barriers 
Placement of a physical barrier between injured peritoneal surfaces prevents contact of 
such surfaces and thus has the potential to prevent PSA formation. Types of barriers 
investigated can be classified as either natural or artificial, with further division into non- 
absorbable and absorbable. 
Natural Barriers 
The introduction of natural., theoretically absorbable membranes was seen in the 1930's 
(Boys, 1942). Since then many natural barriers have been investigated with the aim of 
preventing PSAs, including amniotic membrane, omentum, ox peritoneum, beef allantoic 
membrane, fish bladder and mesothelial grafts (Boys, 1942; Connolly & Smith, 1960; 
Ellis, 1982; Pijlman el al., 1994). However such barriers usually promote PSA formation 
rather than prevent it (Pijiman el al., 1994). 
Artificial, Non-Absorbable Barriers 
Artificial, non-absorbable barriers were introduced in the first half of this century with 
many materials investigated, including foils of silver and other metals and sheets of silk 
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and rubber (Boys, 1942; Ellis, 1982). Unsurprisingly instead of preventing adhesions, 
these materials promoted adhesion formation, probably primarily by the foreign material 
pathway. 
Nowadays there is only one main non-absorbable material used for potential PSA 
prevention, Gore-Tex Surgical Membrane (W. L. Gore & Associates, Flagstaff, AZ, 
USA). This is an expanded polytetrafluoroethylene 0.1mm. thick sheet, used as a 
substitute for the pericardium (DiZerega, 1994). It has small pores (:! ý I gm) which retard 
cellular penetration and are thought to contribute to the lack of tissue adherence 
(DiZerega, 1994). Properties important to its potential PSA preventing ability include 
(DiZerega, 1994; Risberg, 1997) that it is non-biodegradable, non-thrombogenic, non- 
reactive/ non-immunogenic, with poor tissue adherence and easy handling at laparotomy. 
However, due to its poor tissue adherence Gore-Tex surgical membrane needs to be 
anchored in place, usually via sutures, hence remains as a permanent foreign material 
(DiZerega, 1994; Risberg, 1997). With regard to its PSA prevention power, conflicting 
reports have been made, however most clinical studies have recorded PSA prevention 
t 
(DiZerega, 1994; Pijlman et al., 1994). 
Artificial, Absorbable Barriers 
Oxidised Regenerated Cellulose (ORC) is a rayon patch which has been treated with 
nitrogen tetraoxide. Characteristics include that it is non-reactive, persists during the 
critical stages of re-epithelialisation then undergoes absorption and has antibacterial 
properties. 
The two main ORC barriers investigated for PSA prevention are: 
1. Surgicel@ (Johnson & Johnson Medical Inc., Arlington, TX, USA) an absorbable 
material used as haemostat. Once in vivo it is converted into gelatinous mass and 
absorbed within a few days. Studies have shown that Surgicelo both increase and 
prevent PSAs (DiZerega, 1994; Pijlman et al., 1994). 
2. InterceedO (Johnson & Johnson Medical Inc., Arlington, TX, USA) is similar to 
SurgicelO, although has a longer residence time (DiZerega, 1994). it undergoes 
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hydrolysis into a gelatinous "cocooe within 8 hours (DeCherney & Dizerega, 1997), 
breaking down macroscopically within 3 to 10 days and rnicroscopically within 28 
days (DeCherney & DiZerega, 1997; Risberg, 1997). In order to optimise the use of 
InterceedO, intraperitoneal irrigants and excess peritoneal fluid need to be removed 
and adequate haemostasis achieved (DeCherney & DiZerega, 1997) to ensure it 
maintains its position within the peritoneum without the use of sutures. The efficacy 
of InterceedO has been shown to vary (DiZerega, 1994; Pijlman et at, 1994; 
DeChemey & DiZerega, 1997) however its acceptance has been constrained by its 
decreased efficacy in the presence of blood or excess peritoneal fluid (Risberg, 1997) 
and although it is used in a wide variety of general surgical procedures in some 
countries,, but not in the United States as it is not FDA approved. 
Seprafilmlrm (Genzyme Corporation, Cambridge, MA, USA) is a hyaluronic acid- 
carboxymethy1cellulose (HA-CMC) polymer, which is non-toxic, non-immunogenic, 
biodegradable and biocompatible (Risberg, 1997). Once in vivo, SeprafilmrM turns into a 
hydrophilic gel within one day and forms a protective tissue coat for up to 7 days. The 
HA component is cleared from the body in 28 days, although the rate of CMC clearance 
is less clear (DeCherney & DiZerega, 1997; Risberg, 1997). Studies have shown that 
SeprafilmTm reduces PSA formation (DeCherney & DiZerega, 1997) and has gained 
regulatory approval in many European countries and North America (FDA approval) for 
PSA reduction. SeprafilmTm does not require suturing to remain in place and is effective 
in the presence of blood (Risberg, 1997), however care needs to taken with its 
application. It must be kept dry (excess fluid aspirated), handled gently with dry 
instruments and/or gloves and contact with tissues surfaces avoided until the application 
site reached. If incorrect contact occurs, standard irrigation solution is used to dislodge 
the membrane (DeCherney & DiZerega, 1997). 
Other barriers assessed include hyaluronic acid (HA) which forms a viscous solution 
which appears to coat peritoneal surfaces and has had some success in reducing PSAs 
(Pijlman et at, 1994). 
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Fibrin sealants: The use of fibrinogen as a haemostat has attracted attention for over a 
century, although it was not until the 1940's that its use as a tissue adhesive was 
introduced (Sierra, 1993). The early concept of fibrin glue, however, failed to flourish 
due to lack of strength and low efficacy of the glue, which in turn was due to poor 
technology resulting in low fibrinogen concentrations (Adamyan el at, 1991 -, Sierra, 
1993). In the 1970's cryoprecipitation techniques were used to obtain elevated levels of 
fibrinogen and other plasma proteins, which were used in conjunction with bovine 
thrombin with some success for nerve anastomoses (Sierra, 1993). Since then the interest 
in fibrin glues or sealants has thrived and nowadays surgical applications for fibrin 
sealants primarily include haemostasis and tissue sealing but also anastomoses and 
wound healing (promoting normal wound healing and PSA prevention). 
Fibrin sealants are tissue adhesives derived from blood, which exploit the final stages of 
coagulation. They generally consist of two component solutions- 
* component 1: fibrinogen (human), together with factor XIII 
* component I thrombin (human or bovine), together with calcium chloride 
Nfixing of these during application causes the formation of the fibrin sealant (Figure 
1.11). The sealant adheres to many surfaces, for example, exposed collagen at wound 
sites, sealing them from the surrounding environment. The sealant will remain ill vivo for 
several days, aided by the addition of an anti-fibrinolytic agent (for example, aprotinin), 
after which it will be absorbed by enzymatic and phagocytic mechanisms. 
Component 2ý 1`11 MI %OGE 
THROMBIN 
Calciiiiii Fibrin 
iolls (loosely connected monomer) 
kiýtoj X111 1,1ýtol MILI 
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FIBRIN SEALANT 
Figure 1.11: Fibrin sealant genesis. 
(Adapted from Sierra, 1993). 
I Component 
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The most commonly used application system for fibrin sealants is the Duploject double 
syringe system. (Figure 1.12). The contents of the two syringes are released at the same 
time and mixed in the Y-piece of the syringe, where polymerisation is initiated, and in 
this way fibrin sealant can be directly applied to the site. 
Component 1 
(Fibrinogen, Factor XIII) 
Component 2 
(Thrombin. Calcium ions) 
FIBRIN 
SEALANT 
Figure 1.12: Duploject fibrin sealant application system. 
Commercially available fibrin sealants include TisseelO or Tissucol(P (Immuno AG, 
Vienna, Austria), BeriplastO (Behringwerke, Marburg, Germany) and BiocollID (Centre 
de Transfusion Sanguine de Lille, France) which utilise human pooled fibrinogen. 
Although these, like all blood products, are careftilly screened for viral contaminates, 
regulatory approval for clinical trials have only been gained in Europe, with the 
exception of TissucolO which has also been approved in Japan and recently the USA. 
1.2.3.5 Inhibition of Fibroblast Proliferation 
Substances which have been investigated to potentially prevent PSA formation which 
have fibroblast inhibitory effects include antihistamines (example: Histadylg), steroids, 
cytotoxic drugs (Ellis, 197 1; Ellis, 1982). 
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1.2.4 Conclusions 
Chapter I 
It is universally agreed that meticulous surgical technique can limit the formation of 
PSAs, reducing the risk of adhesion associated pathogeneses. Full implementation of 
these techniques needs to occur in general surgery to preclude the formation of 
preventable PSAs. 
Much time and resources have been directed to find an ideal PSA preventative agent due 
to the medical and economic problems associated with PSAs. Despite such efforts there 
is currently no commercially available PSA preventative agent. As pointed out by Ellis 
(1982) there is a typical pattern associated with these agents: initial enthusiasm leading to 
clinical cases/trials, followed by further investigations showing either no effect or 
increased PSA formation compared to controls, finally resulting in substance being 
abandoned. 
There are several contributing factors responsible for this: 
* lack of understanding of the physiological, biochemical and cellular mechanisms 
governing PSA formation 
premature trials resulting from observations rather than hard scientific research 
lack of uniformity in PSA assessment model - variation in animal species, adhesion 
stimulus, severity, site and treatment itself (drug dose, administration route) 
* qualitative assessment of PSAs and PSA prevention leading to potentially biased, non- 
standardised and non comparable results with other studies 
Until these problems are dealt with it is unlikely that a PSA preventative agent will be 
found. 
1.3 VivostatTm System Human Derived Fibrin Sealant 
1.3.1 Commercially Available Fibrin Sealants 
Although fibrin sealants represent one of the most promising surgical develops of the last 
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decade, with uses in haemostasis, tissue sealing and PSA prevention, there are still 
problems associated with this'therapy. Commercially available fibrin sealants are derived 
from pooled human plasma together with exogenous agents such as thrombin, Factor 
X111, calcium ions and in some sealants, anti-fibrinolytic agents such as aprotinin. As 
discussed in section 1.2.3.4.3, due to the use of pooled human fibrinogen many such 
products have failed to obtain FDA approval for use in the United States. However the 
risk of viral contamination from human fibrinogen is not the only clinical risk associated 
with these products. The use of bovine products, such as bovine thrombin and aprotinin 
have risks of bovine spongiform encephalopathy (BSE) and antigenic reactivity (Hughes 
& Westwood, 1994). 
in order to totally eliminate the potential risks of infection and antigenicity, two 
parameters need to be met: 
1. eradication of all donor derived viruses or infectious agents 
no exogenous proteins added 
Due to the difficulty of blood product licensing and FDA approval in the United States, 
the use of autologous fibrinogen in fibrin sealants has been investigated. Fibrinogen can 
be successfully obtained from blood by the process of cryoprecipitation. However this 
procedure has proved to be technically non-viable, due to the long preparation time and 
low yield. The elimination of exogenous proteins however has received less attention, 
due to their clinical acceptability, even though potential problems remain. 
1.3.2 Autologous, Human Derived Fibrin Sealant 
There are many references in the literature reporting the use of autologous fibrin 
sealants, however this definition is inaccurate. These sealants utilise autologous human 
fibrinogen, together with non-autologous proteins (thrombin, aprotinin), hence these 
sealants are better referred to as semi-autologous fibrin sealants (Cederholm-Williams, 
1994). At present there is no truly autologous fibrin sealant available commercially. 
In view of problems associated with currently available fibrin sealants, ConvaTec Ltd 
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(A Bristol-Myers Squibb Company) have successfully developed a novel, truly 
autologous, human derived fibrin sealant essentially free from foreign proteins. It uses 
the serine proteinase batroxobin, bound to biotin, to cleave autologous fibrinogen to 
form an acid soluble fibrin I polymer, which readily dissolves in acid and repolymerises 
on neutralisation. On increasing the pH in the presence of calcium ions the fibrin I 
solution polymerises and endogenous prothrombin is cleaved to thrombin. Fibrinopeptide 
B is cleaved from fibrin I to form fibrin 11. Thrombin also activates factor XIII, resulting 
in the formation of chemically stable fibrin 11 polymer (Edwardson el al., 1994). Avidin, 
immobilised to an inert support agarose, is added to the fibrin I solution, binding to the 
biotin-batroxobin and the resulting complex is removed via filtration (Bayer el al., 1994) 
(Figure 1.13). 
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Figure 1.13: VivostatTM system human derived fibrin sealant (novel fibrin sealant) formation 
(adapted from Edwardson el al., 1994). 
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From 120ml of whole blood, 4 to 6ml of highly concentrated (20±2mg/ml) VivostatTm 
system human derived fibrin sealant (novel fibrin sealant) is prepared, by automated 
procedures, within 30 minutes. This fibrin sealant is completely autologous, essentially 
free from exogenous proteins and free from potentially harmful or infectious agents. It 
has excellent stability for at least 16 days when stored at -201C (Hollingsbee DA & 
Edwardson, 1994). In vivo and in vitro fibrinolytic stabilises are similar to fibrin sealants 
which contain aprotinin, an anti-fibrinolytic protein (Cederholm-Williams, 1994). The 
preparation process is safe, reproducible, optimised and fully automated. It has been 
demonstrated to be effective for sealing air leaks, achieving haemostasis in low and high 
pressure systems, achieving microsurgical anastomosis and eliminating CSF fluid leakage 
(Edwardson et aL, 1994; Green et al., 1994). 
Unlike other fibrin sealants, batroxobin, a serine proteinase derived from snake venom is 
utilised to cleave fibrinogen and not thrombin. Clinical use of batroxobin is well 
documented, with over 10 years of clinical experience. It has a highly specific mode of 
action, cleaving only fibrinopeptide A from fibrinogen, which is particularly relevant to 
fibrin sealant kinetics., allowing greater control of sealant (fibrin II) formation. Unlike 
thrombin and other venom derived enzymes it does not activate platelets and retains its 
activity in the presence of heparin. Batroxobin poses no risk of infection and has a low 
intrinsic immunogenic potential. Hence batroxobin is a desirable, and potentially safe 
alternative to exogenous thrombin for use in fibrin sealants (Blomback el al., 1994). 
In the preparation of novel fibrin sealant, batroxobin is biotinylated, to facilitate its easy 
removal afler it has completed it's function. The addition of avidin, immobilised to 
agarose, results in the binding of biotin to avidin, which is the strongest non-covalent 
interaction between a ligand and protein known in nature. The resulting avidin- 
agarose: biotin-batroxobin complex is then removed via filtration. The use of biotin and 
avidin in this process is both: 
9 safe - both biotin and avidin have excellent safety profiles, with highly purified 
phannaceutical grades readily available and the avidin-agarose and biotin-batroxobin 
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formulations have been optimised to preserve activity, ensure stability and sterilised by 
gamma irradiation. 
9 effective - more than 99% of the biotin-batroxobin is removed within 5 minutes, with 
the formulation and yield of fibrin sealant unaffected (Bayer et al., 1994). 
Thus novel fibrin sealant overcomes problems which are associated with other fibrin 
sealants, namely infection and antigenicity. 
1.4 Thesis Objectives 
i. To obtain comprehensive quantitative data concerning physiological, structural, 
cellular and biochemical mechanisms during PSA development in a definitive 
experimental model. 
ii. To obtain comprehensive quantitative data concerning physiological, structural, 
cellular and biochemical mechanisms during PSA prevention with novel fibrin sealant 
in a definitive experimental model. 
iii. To identify modes of action in which novel fibrin sealant prevents PSAs. 
iv. To assess PSA prevention by novel fibrin sealant using: 
a. different preparation and application techniques 
b. different animal species 
c. different PSA induction sites 
d. non-autologous and autologous systems. 
v. To directly compare PSA prevention by novel fibrin sealant, Tissucolg and CRYO in 
a definitive experimental model. 
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2.0 Materials and Methods 
2.1 Home Office Regulatory Guidelines 
Scientific use of animals in the United Kingdom is carefully controlled by the UK Home 
Office, primarily through the enforcement of the Animal (Scientific Procedures) Act 
1986. This act regulates "any experimental or other scientific procedure applied to a 
protected animal which may have the effect of causing that animal pain, suffering, 
distress or lasting harm". 
The act is regulated though the issuing of licences, of which three are required for 
experimental work of this nature to be carried out: 
Certificate of Designation - controls establishments where work is performed, with 
standards ensuring animal health and well being 
I Project Licence - which determines the validity of the work and controls the level of 
severity which is acceptable 
iii. Personal Licence - issued to people carrying out work specified under a project 
licence and guarantees that people are competent in their ability to perform such 
work. 
Regulations of the Animal (Scientific Procedures) Act 1986 conform to the European 
Convention for the Protection of Vertebrate Animals Used for Experimental and Other 
Scientific Purposes (Strasbourg, Council of Europe) and achieve the standard of care 
required by the US Department of Health and Human Services' Guide for the Care and 
Use of Laboratory Animals. 
2.2 Animal Models 
Careful considerations need to be made when choosing an experimental model in which 
it is hoped data obtained will contribute to clinical understanding. These considerations 
can be grouped into four main categories: 
clinical relevance for fair and direct comparisons between experimental and clinical 
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work 
ii. an accepted model for good reception of the work by the scientific community 
iii. valid and accurate model 
iv. availability, housing and cost of the model. 
The majority of experimental procedures carried in the UK are on mammals,, due to their 
physiological similarities to humans, with the species chosen being the lowest on the 
phytogenetic scale which is likely to satisfy the aims of the study. 
2.2.1 Rabbit Uterine Horn Abrasion Model 
Rabbits are one of the most commonly used experimental models, with main breeds 
utilised being New Zealand White, Dutch and Half Lop, Their extensive use is due 
mainly to their ease of availability, housing and relatively low cost. 
Rabbit models have been used extensively for studies investigating PSAs, many making 
use of the uterine horns as experimental sites (for example, NeuvArth and Khalaf, 1975; 
Nishimura el al., 1983; Diamond et al, 1987; De Laco et al., 1994; Marana, et al., 1997; 
Rodgers et al., 1997; Takeuchi et al., 1997; De Laco et al., 1998). These studies have 
devised various methods for induction of PSAs. ranging from the introduction of foreign 
materials to mechanical injuries such as scalpel incisions and crushing injury, with many 
different potential PSA prevention agents tried, ranging from fibrin sealants (Takeuchi el 
al., 1997, De Laco et al, 1994) to anti-inflammatory peptides (Rodgers el al, 1997). 
As detailed in the introduction to this thesis, a scientific failing with previously conducted 
studies is their qualitative nature. All rabbit studies reported in this thesis employed a 
definitive experimental model and quantitative analytical procedures. The model used 
was a slightly modified version of a widely used experimental system for the testing of 
potential peritoneal PSA preventative agents and has-been optinýsed over several studies 
prior to these investigations. In summary a standard abrasion injury was inflicted on each 
uterine hom and ipsilateral peritoneal wall, which would naturally lie in juxtaposition. 
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The injured areas were then held apposed using positional sutures, placed outside the 
experimental site, with treated sites separated by a layer of fibrin sealant. Experimental 
sites were then left M vivo for the length of recovery time dictated by the study protocol. 
Due to the level of injury induced and in ured surfaces being apposed this rabbit uterine j 
hom abrasion model is a severe experimental PSA model, with a "worse case" scenario 
created. 
To ensure that injuries of consistent standard area could be induced,, templates, 25 mm. x 
3mm, designed to fit the uterine horn or peritoneal wall, were specially constructed. 
Abrasions were induced using a scraper with a standard depth (1.5mm) which fitted the 
exact area of the template. With the additional parameter of using a set number of 
scrapes for each injury site, injuries were maximally standardised within the limits of 
biological variation. 
Quantitative analysis was carried out for all studies with stereological techniques 
employed for this purpose due to their precise and unbiased nature (refer to section 
2.14). This becomes especially important when comparing control and treated cases, as 
without such rigid regulations governing analytic procedures biases can be easily 
introduced. 
Uterine horns were chosen as the experimental site, together with the peritoneal wall, 
due to their size, structure and location within the peritoneal cavity. Heavy handling of 
tissues has been shown to induce PSA formation (Boys, 1942; Connolly & Smith, 1960) 
and hence excessive tissue handling needed to be avoided. In addition, ex-breeding 
rabbits were also chosen for these investigations due to their large size facilitating 
appropriate procedures. 
2.2.2 Pig Colonic, Caecal and Stomach Abrasion Model 
Pigs are one of the usual experimental models chosen when a larger model is required. 
Significantly less published information is available detailing the use of porcine models 
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with regard to PSAs. This is most probably due to the increased cost of using large 
animals in experimental work, both with regard to housing and surgical procedures, and 
with smaller models being acceptable for most PSA work. 
Porcine models previously used to investigate PSAs (Fowler el al., 1994; Reissman el 
al., 1996; Christoforoni el al., 1996) demonstrate, unsurprisingly, that pigs form PSAs in 
response to injury or trauma by identical pathogenesis to humans. Some success has been 
shown with preventative agents although their absolute value has as yet to be 
substantiated due to the limited number of published studies. 
Using knowledge obtained through the use of the rabbit uterine horn abrasion model, the 
pig abrasion model was also optimised and standardised. As with the rabbit model, 
templates were specially constructed, 25mm. x 3mm, to fit tissue areas and were used in 
conjunction with a scraper of known depth, 1.5mm. A set number of scrapes for each 
injury site was again employed and therefore, the injury was maximally standardised 
within the limits of biological variation. Additional use of quantitative analytical 
procedures ensured unbiased and precise results. 
One of the main reasons that a pig model was chosen for these studies was due to its 
large size and more importantly the larger volume of blood which could be taken. This 
allowed for truly autologous novel fibrin sealant to be made and tested. That is blood 
was collected from an anaesthetised animal prior to the surgical procedure, novel fibrin 
sealant was produced from this blood and then used to treat abrasion injuries in that 
animal. 
2.3 Animal Husbandry 
2.3.1 New Zealand White Rabbits 
Female, New Zealand White, ex-breeding rabbits, approximately 3.5kg in weight were 
supplied from Goreside Rabbits, UK or from Harlan Rabbits, UK, approved Home 
Office sources. 
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Rabbits were admitted to the department at least one week prior to commencement of 
the study to allow re-acclimatisation and full clinical observation to be made. All animals 
were examined and monitored for disease or injury before being admitted to the study 
and randomised to one of the control or treatment groups. Animals were individually 
labelled and housed singly in racked cages with grid floors. The environment was 
monitored for humidity and temperature. Food and water were allowed ad libitum until 
18 hours prior to surgery, when food was withdrawn. 
2.3.2 White Landrace Cross Pigs 
Large white landrace cross pigs, 15-25kg in weight, used in these studies were obtained 
from Fulmer Place Farm, an approved Home Office source. All animals were brought in 
to the department at least one week prior to surgery for acclimatisation and clinical 
observations, with only healthy animals admitted to the study, randomly assigned to a 
control or treatment group. Animals were individually identified by an ear tag and housed 
singly in pens with sawdust bedding. The environment was monitored for humidity and 
temperature. Following standard procedures, food and water were allowed ad libitum 
until 18 hours prior to surgery, when food was withdrawn. 
2.4 Study Groups 
2.4.1 Rabbit 
2.4.1.1 Pathogenesis of PSAs 
Each experimental group consisted of 4 -animals, with each animal 
injured at two sites, 
giving 8 experimental sites per group. In order to gain an accurate picture of the 
dynamics of PSA development, tissues were sampled at specified time points following 
injury; 30 seconds, 1,3,5,10,30'minutes, 1,4,8,16 hours, 1,3,5,7,17,28 and 42 
days. 
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2.4.1.2 Prevention of PSAs with VivostatTm System Human Derived Fibrin Sealant 
In order to understand the mechanisms responsible for the reduction and/or prevention of 
PSAs using VivostatTm system human derived fibrin sealant (novel fibrin sealant) a 
similar study to that investigating pathogenesis of PSAs (control situation) -was 
performed. 
Surgical and analytical procedures were completed on the Pathogenesis of PSAs study 
before the novel fibrin sealant study was commenced. Analysis of control data revealed 
that tenacious PSAs were evident at I hour post injury and all subsequent time points. 
Hence experimental investigation of novel fibrin sealant treated groups was started at I 
hour, with further sampling at 4,8,16 hours, 1,3,5,7,14,28 and 42 days. Each sample 
time point consisted of 4 animals, two experimental sites per animals, hence 8 
experimental sites per group. 
2.4.1.3 Comparison of Preparation and Application Methods of VivostatTm System 
Human Derived Fibrin Sealant for PSA Prevention 
This study, consisting of 5 experimental groups, investigated various novel fibrin sealant 
application methods with regard to their efficiency to prevent or reduce PSAs. Animals, 
all 14 day recovery, were randomised to one of the following groups: 
Treatment Group ViVostatTM 
Application 
Method 
Number of 
Animals 
Number of 
Experimental Sites 
Control 7 13 
Device Prepared Novel Fibrin Sealant Spray 6 12 
Device Prepared Novel Fibrin Sealant UNES Gun 6 12 
Device Prepared Novel Fibrin Sealant 
Bench Prepared Novel Fibrin Sealant 
Needle 
UNES Gun 
6 
6 
12 
12 
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2.4.1.4 Comparison of VivostatTm System Human Derived Fibrin Sealant, 
Tissucol@ and CRYO for PSA Prevention 
Three groups compared different fibrin sealants for their PSA prevention or reduction 
capacities together with a control group. Animals, 14 day recovery, were randon-ýised to 
one of the following groups: 
Treatment Group Number of 
Animals I Experimental Sites- 
Control Control cases were taken from 
Application Comparison Study 
Device Prepared Novel 6 12 
Fibrin Sealant (Needle Application) 
TissucolS 6 
-4 Units Bovine Ibrombin 5 
- 500 Units Bovine Tbrombin 6 
CRYO 6 
-4 Units Bovine Tbrombin 6 
- 500 Units Bovine Tbrombin 6 
2.4.2 Pig 
2.4.2.1 Pathogenesis of PSAs and Prevention with VivostatTm System Human and 
Porcine Derived Fibrin Sealant in the Pig Abrasion Model - Pilot Study 
This study consisted of 3 experimental groups investigated PSA prevention or reduction 
using human blood derived and porcine blood derived novel fibrin sealant together with a 
control group in the pig abrasion model. Details of each group, all 7 day recoveries, were 
as follows: 
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Treatment Group Number of Injury Site Number of 
Animals Experimental Sites 
Control 3 Total: 9 
Stomach 3 
Colon 4 
Caecum 2 
Human derived 3 Total: 8 
novel fibrin sealant Stomach 2 
Colon 4 
Caecurn 2 
Porcine derived 2 Total: 5 
novel fibrin sealant Stomach I 
Colon 2 
Caecum 2 
Chapter 2 
Porcine novel fibrin sealant group contained one post operative mortality, where the 
cause of death was a strangulated hernia due to suture breakdown. 
2.4.2.2 Pathogenesis of PSAs and Prevention with VivostatTm System Human 
Derived Fibrin Sealant in the Pig Abrasion Model - Main Study 
The purpose of this study was to substantiate and expand on the results obtained from 
the pilot study. This main study consisted of control and human blood derived novel 
fibrin sealant treated groups, with animals recovered after 14 days. 
Treatment Group Number of 
Animals 
Injury Site Number of 
Experimental Sites 
Control 5 Total: 10 
Stomach 5 
Colon 5 
Novel fibrin sealant 6 Total: 12 
Stomach 6 
Colon 6 
One control animal was a post operative mortality due again to a strangulated hernia 
attributed to suture breakdown. 
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2.5 Surgical Procedure 
Surgical procedures for studies investigating pathogenesis of PSAs and prevention with 
novel fibrin sealant studies were carried out by Miss SA Ricketts and Dr PD Sibbons. 
For all other studies surgical procedures were carried out by Dr PD Sibbons. 
2.5.1 Rabbit 
Premedication was administrated with hypnorm (Fentanyl citrate 0.315mg/ml and 
fluanisone 10mg/ml. Supplied by Janssen Saunderton, I-Egh Wycombe, 
Buckinghamshire. ) (0.2ml/kg body weight intramuscular) to the right gluteous maximus 
muscle. 
Surgical anaesthesia was induced with hypnorm (0.3ml/kg body weight intramuscular) 
and diazepam. (5mg/ml diazepam. Supplied by Phoenix Pharmaceuticals Limited, 
Gloucester. ) (2. Smg/kg body weight intravenous). Full sterile operating procedures were 
observed. Particular attention was paid to the washing of surgical gloves in sterile water 
to remove all traces of particulate matter (starch, powder) which might, if transferred to 
the operative site, induce granuloma or adhesion formation. 
Fur was shaved from the surgical area and the area scrubbed with alcoholic chlorhexidine 
followed by iodine. Laparotomy was performed using cutting diathermy, by a single 
incision in the midline, from lower liver margin to the level of the iliac fossa, through skin 
and muscle to peritoneum, which was divided with scissors. Retraction was applied to 
laparotomy wound edges to allow access to uterine horns (Figure 2.1). 
Experimental areas were selected on the serosal surface of each uterine hom and 
corresponding internal ipsilateral surfaces of the peritoneum, which would naturally lie in 
juxtaposition with each other. A standard template, constructed specifically either for the 
uterine horn or peritoneal wall, was placed on the selected areas (Figures 2.2 and 2.3), 
and each area abraded with the sharp edge of a scraping tool (Figure 2.4). A standard 
number of 10 scrapes was used to caused homogeneous punctate bleeding but not so far 
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as to cause frank contiguous haernorrhage (Figures 2.5 and 2.6). Hence a standard, and 
reproducible injury was produced in each case. 
Single throws of Stannius positional suture (Ethibond 6/0 or similar) were placed 5mm 
outside each end of abraded areas (peritoneal wall and uterine horn) (Figure 2.7). These 
sutures passed only through the serosa of the peritoneum and corresponding uterine 
horn. For control groups, sutures were tightened to bring the two juxtapositional 
abraded areas together and maintain contact between the two areas. Timing was 
commenced from this point. For treated groups positional sutures were tightened to 
bring the two abraded areas close together but not in contact and fibrin sealant was then 
applied (refer to Chapters 4,6 and 7 for volumes) to abraded areas (Figure 2.8). Sutures 
were then drawn together to bring the two areas into contact, using as much tension as 
was needed to create reasonable contact but avoiding tight sutures. Timing commenced 
from this point. 
In groups which sampled up to 30 minutes post injury, rabbits were kept anaesthetised, 
in the supine position with the laparotomy incision held closed with tissue clamps. In 
groups which sampled from I hour post injury onwards, the laparotomy was closed and 
reopened after the relevant time period. 
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Figure 2.1: Laparotomy opening and retraction of wound edges to show location of uterine 
horns. 
Materials and Methods 
Figure 2.2: Uterine horn template on selected area of utcrinc horn. 
Figure 2.3: Peritoneal wall template on selected area of peritoneal wall. 
Figure 2.4: Scraping tool used to abrade tissues. 
Chapler 2 
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Figure 2.5: Standard and reproducible abrasion injury on a uterine horn 
loop, Aide 
Figure 2.6: Standard and reproducible abrasion injury on the peritoncal wall. 
Figure 2-7: Positional sutures placed outside the cxpcriniental site. 
Chapter -' 
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Figure 2.8: Fibrin sealant applied to injured surfaces. 
Chapler 2 
Laparotomy wound closure was in two layers: first with 2/0 plain catgut on atraumatic 
half round needle for the peritoneum and muscle layers, using transplant longflow, over- 
under, non-interrupted crossed sutures; and secondly with 2/0 Prolene or similar on half 
round cutting needle using interrupted mattress sutures for the skin. Immediately after 
closure of the wound, "Opsite" (Smith and Nephew Medical Limited, Hull) wound 
dressing was applied on and around the wound to create "second skin" barrier. 
Rabbits were allowed to recover from anaesthesia in a warm, quiet environment. Once 
fully recovered, rabbits were removed to normal accommodation and allowed food and 
water ad libitum. All rabbits were subsequently monitored for possible procedure 
associated sequelae, for example, wound infection, wound leakage, temperature 
elevation, diarrhoea, constipation, appetite decrease or immobility. 
2.5.2 Pig 
Pre-medication was administered using Ketamine (Ketalar-50mg/ml ketamine 
hydrochloride. Supplied by Parke-Davis, Pontypool, Gwent. ) (5mgs/Kg) plus Xylazine 
(Rompun 2%-Xylazine hydrochloride 23.32mg/ml (equivalent to 20mg/ml xylazine) and 
lmglml methyl 4-hydroxy-benzoate (preservative). Supplied by Bayer Plc-, Animal 
Health Business Group, Bury St. Edmunds, Suffolk. ) (Img/kg)) intramuscularly in the 
gluteous maximus muscle. At the operating suite, pigs were induced to and maintained at 
full anaesthesia with Halothane at 4% in oxygen and nitrous oxide delivered at 1.5 litres 
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per minute and 0.5 litres respectively per minute via mask to the snout. 
Once anaesthetised pigs were transferred to lay in the supine position on the operating 
table, where they were secured by soft tapes to each limb. A plastic ear tag bearing the 
unique pig identification number for the study was secured to one of the animals ears. 
For each pig, the surgical site was shaved and scrubbed with chlorhexidine in alcohol 
followed by swabbing twice with iodine in alcohol. Sterile operative procedures were 
adhered to from this point on. 
The animals were draped. Cutting diathermy and scissors were used to expose the spiral 
colon and the stomach through a midline laparotomy starting at the level of the distal 
xyphoid process of the sternum and extending distally 10 - 12cms. 
One area was selected on the lateral surface of the spiral colon or on the blunt end of the 
caecum and the medio-lateral serosal aspect of the stomach such that these areas each 
laid naturally against the ipsilateral peritoneal wall. Areas were then selected on the 
ipsilateral peritoneal wall. As with the rabbit uterine horn abrasion model, each selected 
area was abraded, using a template and scraper (Figures 2.9 and 2.10), a standardised 
number of 12 scrapes which caused homogeneous punctate bleeding but not so far as to 
cause frank contiguous haemorrhage was performed (Figures 2.11 and 2.12). 
A single throw suture (Ethibond 0.6 or similar) was placed at each end of the 
experimental site but outside of the abraded areas (Figure 2.13). These sutures passed 
only through the internal serosa of the peritoneum and then passed through the serosa at 
the respective ends of the apposed abraded areas on the stomach or colon. Sutures were 
tightened to bring the two apposed abraded areas close together but not in contact. For 
treated cases, human or porcine novel fibrin sealant was applied to the abraded areas 
(mean volume of 1.3ml per experimental site) (Figure 2.14), whereas no treatment was 
applied in control cases. Positional sutures were then tightened to bring the two abraded 
areas into close contact. 
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The laparotomy was closed in two layers, first with 2/0 Dexon Plus on an atraumatic half 
round needle for pefitoneum and muscle layers, second with 2/0 Prolene or similar on 
half round cutting needle for skin. The first suture layer was of "transplant" longflow, 
over-under, non-interrupted crossed sutures, the second layer was of interrupted cruciate 
mattress sutures. Immediately after closure of the skin wound, "Opsite" (Smith and 
Nephew Medical Limited, Hull) was sprayed on and around the wound to create "second 
skin" barrier. 
wow& 
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Figure 2.9- Selected area of caecum during abrasion using the template and scrapper. 
Figure 2.10: Peritoneal wall template in position prior to abrasion. 
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Figure 2.11: Standard and reproducible abrasion ii1jury on the caccurn. 
Figure 2.12: Standard and reproducible abrasion injury on the pentoneal wall. 
Figure 2.13: Positional sutures thrown outside the experimental site. 
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Figure 2.14: Novel fibrin sealant application to the experimental site. 
Chapler 2 
Pigs were allowed to recover from anaesthesia in a recovery area. Proprietary analgesics 
(Terngesic (Buprenorphine 0.3mg/ml as hydrochloride. Supplied by Reckitt & Coleman 
Products Ltd., Hull. ) (5mgs intramuscular)) were administered. Once fully recovered, 
animals were returned to normal accommodation with twice daily feeds and water ad 
libitum. For the pilot study, pigs were monitored and recovered for 7 days and for the 
main study for 14 days. 
2.6 Termination Procedure 
Animals were anaesthetised as for the surgical procedure. Laparotomy was reopened 
along the original incision, with experimental areas identified and macroscopic 
observations recorded and photographed. The abraded area of the peritoneum together 
with a border of unabraded tissue in excess of 5mm was resected. The associated uterine 
horn in the rabbit studies, attached to the peritoneum by positional sutures at both ends 
of the abraded area, was resected away from the omentum and remaining uterine horn. 
For the pig studies, the colon, caecum and stomach experimental sites, joined to the 
peritoneum by positional sutures at each end of the site, were resected. Euthanasia was 
achieved by high dose intravenous pentabarbitone (Expiral-Pentobarbitone sodium BP 
200mg/n-d. Supplied by Sanofi Animal Health Ltd., Watford, Hertfordshire. ) (150mg/kg 
body weight)). 
64 
Materials andAfethods Chapter 2 
Resected tissues were trimmed of excess adipose tissue, pinned flat on stiff card, to 
retain a standard, fifelike tissue positional relationship, and immersion fixed in 10% 
neutral buffered formal saline for at least 24 hours at room temperature. 
2.7 Blood and Peritoneal Fluid Sample Collection 
Blood and peritoneal fluid samples were collected at specific times throughout the 
surgical and termination procedures for studies investigating pathogenesis of PSAs and 
prevention with novel fibrin sealant. Blood samples were taken prior to the surgical 
procedure to act as intra-case controls (blood sample 1) and blood and peritoneal fluid 
samples were taken immediately following initial laparotomy (blood sample 2 and 
peritoneal fluid sample 1) and following the second (termination) laparotomy (blood 
sample 3 and peritoneal fluid sample 2). 
Blood samples were taken from a peripheral vein (external jugular or bracheo-cephalic 
vein), placed into labelled EDTA tubes and gently mixed to ensure complete 
anticoagulation. Wedge blood films were made, a sample taken for analysis by Coulter 
Counter with the remaining sample then centrifuged at 1000xg for 10 minutes to obtain 
plasma which was quick frozen and stored at -800C. 
Peritoneal fluid samples were taken either undiluted directly from the peritoneal cavity or 
via a 5ml saline wash when insufficient undiluted fluid was present (dilution to be 
subsequently calculated via a protein assay). Samples were treated in the same manner as 
blood, being placed into EDTA tubes, gently mixed and subsequently stored at -80T. 
2.8 Prevention of PSAs using Fibrin Sealants 
2.8.1 , VivostatTm System Human Derived Fibrin Sealant 
The VivostatTm system is a medical device for the peri-operative preparation and intra- 
operative application of a completely autologous human fibrin sealant that does not 
require the addition of exogenous thrombin. 
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The ViVoStatTM system incorporates four integral components: 
i. An automated processor unit -a compact, non-sterile, reusable, fully automated 
electro-mechanical device that controls and drives the biochemical process that is 
housed within the disposable preparation unit. The processor incorporates innovative 
technology that automatically separates fibrin from whole blood and prepares a sterile 
concentrated fibrin I solution. 
ii. A disposable preparation unit -a sterile, closed, single-use, disposable device with 
integral and auxiliary reagents, that collects the blood, houses the biochemical process 
and harvests the resultant fibrin. 
iii. An automated applicator unit -a compact, non-sterile, reusable, electro-mechanical 
device which houses the resultant fibrin and pHIO buffer cartridges and feeds the 
applicator set. 
iv. A disposable applicator set -a sterile, single-use, disposable surgical instrument 
incorporating a non-blocking, adjustable spray head. The "fibrin-pen" connects to the 
applicator unit using an ultra-thin, disposable tube. 
in addition to the preparation of human novel fibrin sealant autologous porcine novel 
fibrin sealant can be successfully prepared via tlýs automated system. 
2.8.1.1 Device Preparation 
The recovery of fibrin I from whole blood was performed in the fully automated 
microprocessor controlled device under sterile conditions in less than 30 minutes. The 
device incorporates in-line process controls that ensure reproducibility and includes a 
state-of-the-art surgical instrument for controlled application of the resulting autologous 
fibrin sealant. 
Freshly drawn anti coagulated whole blood (120ml plus l7tnI 4% trisodium citrate USP) 
is separated and the resulting plasma (60ml) reacted with biotin-batroxobin for 10 
minutes at 37C. The acid soluble fibrin I polymer produced is isolated by centrifugation 
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and dissolved in 3.5 - 5.2ml 0.2M sodium acetate buffer (pH4) containing calcium ions. 
The result is 4 to 6H of concentrated fibrin 1 (20 ± 2mg/ml) which is stable for several 
days at -20'C. Trace amounts of biotin-batroxobin are removed by addition of freeze- 
dried avidin covalently coupled to agarose, which hydrates the fibrin 1. Within 5 minutes 
the biotin-batroxobin: avidin-agarose complex is removed by filtration and the purified, 
concentrated fibrin I is transferred to the applicator device (Figure 1.13). 
2.8.1.2 Bench Preparation 
Freshly drawn venous blood was collected into two, 50ml centrifuge tubes, each 
containing 7ml 4% tri-sodium citrate buffer, to a final volume of 50H each. Tubes were 
gently rolled to ensure thorough mbdng and hence anticoagulation. Samples were 
centrifuged at 2000xg for 20 minutes to obtain plasma which was pooled and incubated 
at 370C for 30 minutes prior to preparation of fibrin monomer and kept at 370C 
throughout the procedure. 
The ViVoStatTM cartridge used in the automated device was carefully opened to release 
the biotinylated batroxobin powder, which was emptied into a glass scintillation vial and 
reconstituted with 0.3ml de-ionised water (equivalent to approximately IOOBU/ml). 
0.25ml of biotin-batroxobin solution (i. e. 25BU) was added to the 50H aliquot of 
plasma and mixed at 370C for 5 minutes. The sample was then centrifuged at 3500 rpm 
for 5 minutes for formation of the fibrin monomer pellet which was subsequently 
harvested using a wooden swab stick by quickly stirring the sample and gradually 
progressing down the tube. The monomer was then transferred to a new vial, with any 
residual plasma removed by squeezing it against the side of the vial. 3. OmI of 0.2M 
sodium acetate buffer at pH 4.0 containing 24mM calcium chloride was then added to 
dissolve the fibrin monomer by vortex mixing for approximately 2 to 3 minutes. The 
yield of final fibrin monomer volume was approximately 4 to 5H. 
The avidin agarose compartment of the VivostatTM cartridge was emptied directly into 
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the vial containing the fibrin monomer solution. The fibrin monomer was mixed at 370C 
for 5 minutes. The sample was then filtered through a 20prn pore filter to remove the 
avidin-agarose: biotin-batroxobin complex and the fibrin monomer filtrate was collected 
and was then ready for use. 
2.8.1.3 Application 
The applicator device allows co-delivery of the fibrin I solution with 0.75M 
carbonate/bicarbonate buffer (pHIO) in a ratio of 7: 1 which is optimal for polymerisation 
of the fibrin monomer. The neutral pH achieved and the presence of calcium ions causes 
the conversion of endogenous prothrombin to thrombin and the activation of endogenous 
factor XIII within the fibrin I solution. This polymerises fibrin I to fibrin II and enables 
covalent cross linking of the resultant sealant to occur within 3 minutes (Figure 1.13). 
Several applicator devices have been developed for the delivery of novel fibrin sealant, 
some of which have been utilised in these studies. Prevention of PSAs with novel fibrin 
sealant rabbit and pig studies used the VivostatTIII applicator 100 series (100[d) set at the 
mid density spray (26gYs). Whereas application comparison and fibrin sealant 
comparison studies used the Vivostat"I 300gl applicator. Further application 
modifications investigated in the application study are described in Chapter 6. 
All study products were supplied by ConvaTec Ltd (A Bristol-Myers Squibb Company). 
Fibrin I concentrations of the VivostatTm system derived fibrin sealants were determined 
by a turbidimetric assay by ConvaTec Ltd. This assay is a spectrophotometric method 
based on the selective precipitation of fibrin I using ammonium sulphate resulting in a 
suspension which can be measured turbidimetrically. 
2.8.2 Tissucol(D 
Tissucol@ (or Tisseel@, Immuno AG, Vienna, Austria) is a commercially available 
pooled-source two component fibrinogen glue consisting of human fibrinogen, bovine 
thrombin and aprotinin, and calcium chloride. This study investigated the use of Tissucol 
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0 using two bovine thrombin concentrations, 4 and 500 units. 
Tissucol@ was reconstituted with a bovine aprotinin solution at 37T whilst thrombin 
was reconstituted in a calcium chloride solution at 37*C. Delivery was achieved via a 
Duploject system (Figure 1.12 Introduction), with mixing of the Tissucol@ and thrombin 
solutions within the application system, resulting in the release of a fibrinogen glue. 
2.8.3 CRYO 
"CRYO" is the name given to fibrin sealants which utilise cryoprecipitation to obtain 
fibrinogen from donor blood rather than enzymatic methods. Traditionally they are 
autologous, in that they are prepared from a single blood donor, and hence avoid viral 
contamination problems. As with Tissucol@, exogenous bovine thrombin is required for 
fibrin I production, with 4 and 500 units thrombin used in the studies reported in this 
thesis. 
2.9 Tissue Macrotomy 
Once the resected experimental tissues had been fixed the total length of each 
experimental site was recorded, with one experimental site equal to abraded peritoneal 
wall together with apposed abraded uterine horn (rabbit studies) or apposed abraded 
colon, caecum or stomach (pig studies). Starting at an arbitrary point outside of the 
experimental site, the complete experimental site was cut transversely into slices of 
uniform thickness using a specially designed macrotome (Figures 2.15 and 2.16). Each 
slice was placed, with the same cut surface down, in a histology cassette and sequentially 
numbered. 
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Figure 2.15: Uniform random slicing of the experimental site. 
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Figure 2.16: Macrotome and macroscopic transverse tissue sections. 
2.10 Histology - Paraffin Wax 
Dependent on the study, either odd numbered tissue slices (Pathogenesis of PSAs and 
Prevention of PSAs with novel fibrin sealant studies) or all slices (all other studies) were 
processed to paraffin wax for microscopical descriptive and Cavalieri's analysis. Paraffin 
wax is used routinely for histological processing due the large number of tissue blocks 
which can be processed in a relatively short time, under minimum supervision, ease of 
sectioning and the comparatively cheap cost of paraffin wax (Bancroft and Stevens, 
1982). 
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2.10.1 Processing 
Chapter 2 
All tissues were processed to paraffin wax using a Tissue Tek@ VIP 2000 Tissue 
Processor (Bayer Diagnostic, Basingstoke, UK) according to standard procedures 
(Appendix 11). 
2.10.2 Embedding 
Processed tissues were embedded using a wax embedding centre (Shandon, Runcorn, 
UK). Care was taken during embedding to ensure that the orientation of the transverse 
tissue slices was maintained. 
2.10.3 Microtomy 
5pm sections were cut from each block using a rotary microtome (Reichert-Jung 2030), 
with each section consisting of a full transverse section of tissue. 
2.10.4 H&E Staining 
Sections for Cavalieri's analysis of tissue zone volumes were 'stained with haematoxylin 
and eosin using Shandon. Varistain 24-4 (Shandon, Runcom, UK) according to standard 
procedures (Appendix 11). 
2.10.5 Mallory's Phosphotungstic Acid Haematoxylin (PTAH) Staining of Wax 
Sections for Fibrin Detection 
Mallory's PTAH is routinely used for the detection of fibrin in wax sections. It is 
essentially made up of three components: haematoxylin, phosphotungstic acid and water, 
with the acid acting as the mordant to oxidise the haematoxylin to haernatein. The PTAH 
staining method used in this study is a slightly modified version of Mallory's original 
method. 
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Wax sections from pathogenesis of PSAs and prevention with novel fibrin sealant studies 
were stained with PTAH for fibrin detection. 
Slides were de-waxed in xylene, rehydrated in decreasing grades of industrial methylated 
spirit (IMS) and taken to tap water following standard procedures. Slides were 
sequentially placed in 0.5% potassium permanganate for 5 minutes, 2.5% Iron Alum for 
20 minutes and 1% Oxalic Acid for 3 minutes. Slides were then washed in distilled water 
before being placed in filtered naturally oxidised PTAH at room temperature overnight 
or at 60"C for 2 hours. All slides were then blotted using fibre-free papers, quickly 
dehydrated in increasing grades of IMS, cleared in xylene and mounted. 
Fibrin was stained blue and collagen orange red. In addition, muscle stained blue, elastin 
and reticulin orange brown, basement membranes orange, osteoid orange red and 
cartilage variable shades of red. 
2.10.6 Van Gieson Staining of Wax Sections for Collagen Detection 
Van Giesods stain is the simplest method for the detection of collagen in histological 
preparations. However it has the disadvantages of staining young collagen light pink 
instead of deep red as it does mature collagen and the tendency of the stain to fade, 
irrespective of the mounting medium used (Drury and Wallington, 1980). 
Procedure 
Wax sections from pathogenesis of PSAs and prevention with novel fibrin sealant studies 
were stained with Van Gieson for collagen detection. 
Slides were de-waxed in xylene, rehydrated in decreasing grades of IMS and washed in 
tap water following standard histological procedures. Slides were stained in Celestine 
Blue solution for 5 rninutes, then rinsed in distilled water. They were then placed in 
Cole's Haernatoxylin for 2 ri-ýinutes, washed in tap water and then differentiated in acid 
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alcohol for about 2 minutes. This was followed by washing slides well in tap water and 
then staining with Van Gieson solution for 6 minutes. Slides were then blotted using 
fibre-free papers and very quickly dehydrated through increasing grades of IMS, cleared 
in xylene and mounted. 
Results obtained showed collagen stained red and fibrin yellow. Additionally muscle, 
elastin, reticulin, cartilage and basement membranes stained yellow and osteoid red. 
2.11 Immunohistochemistry 
Immunohistochemistry has found a niche in cases were routine and special histological 
stains fail to provide the specificity required for diagnosis. This technique utilises 
antibodies for the detection of structures of interest. Hence immunohistochernistry 
provides a highly specific and specialised identification system, which can be v1sualised 
using standard light microscopy. 
Two antibodies are employed: 
i. primary antibody directed to detect the structures of interest (antigen); and 
ii. secondary antibody which is directed against the primary antibody and has an 
enzymatic component, which, when a substrate is added, acts a tracer. 
Several enzymes have been used as markers, however the most frequently used, and the 
one used in these studies, is horseradish peroxides (Figure 2.17). 
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Figure 2.17: Immunohistochernistry principle. 
A limiting factor for the use of immunohistochen-ýstry is the type of tissue fixation used. 
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Routinely histological specimens are fixed using neutral buffered formal saline, however 
this fixation technique introduces problems with regard to immunohistochemical 
detection. Although the actual molecular mechanisms occurring during tissue fixation by 
formaldehyde is not completely understood, it is generally agreed that there is a loss of 
antigenicity, primarily due to the masking of antigens present. In order to overcome this 
problem several antigen retrieval techniques have been developed which can be grouped 
as either heat treatment (microwave and pressure cooker) or enzymatic treatments which 
are generally proteolytic. 
In pathogenesis of PSAs and prevention with novel fibrin sealant studies, formalin fixed, 
paraffin wax embedded sections were analysed for fibrin and collagen using 
immunohistochemical methods. Antigen retrieval techniques were used for both 
detection systems, with proteolytic treatment used for fibrin detection and pressure 
cooker treatment used for collagen detection, as recommended by suppliers of the 
primary antibodies. 
Primary antibodies used were obtained from commercial sources (refer to sections 2.11.1 
and 2.11.2) and, as no antibodies directed against rabbits were available, anti-human 
antibodies were used. In order to validate these antibodies for the detection of rabbit 
fibrin and collagen, rabbit and human control tissues were used. 
2.11.1 Immunohistochemical Detection of Fibrin 
For the detection of fibrin in formalin fixed, paraffin wax embedded rabbit tissues an anti- 
human fibrin IgG1 (American Diagnostica Inc, Greenwich, USA. Supplied by Alpha 
Laboratories Ltd, Eastleigh, Hampshire, England) was assessed. This has been shown to 
detect fibrin in snap frozen human cardiac allografts (Faulk et al., 1992) and was the 
most appropriate fibrin specific monoclonal antibody available at the time of investigation 
with the potential to detect fibrin in formalin fixed, paraffin embedded tissues. 
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Sections were dewaxed in xylene, rehydrated through decreasing grades of IMS and 
taken to 37T distilled water. Slides were transferred to 0.1% protease (Type XXIV) 
solution (Sigma-Aldrich Company Ltd, Poole, England) at 370C for 5 to 10 minutes and 
then washed well in running tap water to stop protease activity. 
Slides were subsequently washed in phosphate buffered saline (PBS) (pH 7.3) for 10 
minutes. Endogenous peroxidase activity was blocked by incubating sections in freshly 
made 0.3% hydrogen peroxide in methanol for 20 minutes. Slides were then washed 
twice in distilled water for 5 minutes and twice in PBS for 5 minutes. 
To reduce non-specific background staining, sections were covered with normal horse 
serum (Vector Laboratories, Peterborough, England) (15pl normal horse serum in Iml 
PBS) for 20 minutes, then excess serum was removed by blotting with fibre-free paper. 
Slides were incubated with diluted monoclonal anti-human fibrin IgGI for I to 2 hours at 
room temperature. Slides were then washed twice in PBS for 5 minutes. This was 
followed by incubation with peroxidase labelled secondary antibody (Vector 
Laboratories, Peterborough, England) (15gl normal horse serum in Iml PBS plus 591 
biotinylated anti-mouse serum) for 30 minutes at room temperature. 
During the incubation period the Elite ABC (Vector Laboratories, Peterborough, 
England) was prepared. After the incubation period slides were twice washed in PBS for 
5 minutes and then incubated for 30 minutes with Elite ABC at room temperature. 
Slides were again washed twice in PBS for 5 minutes and then developed in 3,3 
Diaminobenzidine (DAB) (Vector Laboratories, Peterborough, England) for 5 minutes at 
room temperature. Slides were then washed twice in water for 5 minutes and counter 
stained with Cole's haematoxylin for I minute. Finally slides were washed in running tap 
water for 2 minutes, dehydrated through increasing grades of IMS, cleared with xylene 
and mounted. 
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2.11.2 immunohistochemical Detection of Collagen 
For the detection of collagen in formalin fixed, paraffin wax embedded rabbit PSA 
tissues a human (interstitial) collagen I, II, III clone MCI-HA monoclonal antibody 
(Monosan, Netherlands, supplied by: Bradshaw Biologicals Ltd, Loughborough, 
England) was assessed. This antibody was chosen primarily due to its ability to detect all 
interstitial collagens and its potential to detect collagen in formalin fixed, paraffin 
embedded tissues. 
Procedure 
Slides were dewaxed in xylene, rehydrated in decreasing grades of IMS and taken to 
distilled water following standard procedures. 1600ml of 0.01M sodium citrate buffer 
(pH 6.0) was brought to the boil in a pressure cooker, slides were placed into a metal 
staining rack and lowered into the pressure cooker, ensuring that slides were well 
immersed in citrate buffer. The lid was then locked and slides were heated for I minute 
once pressure had been achieved. The pressure cooker was then removed from the heat 
source, run under cold water until the pressure had dissipated. Slides were then removed 
and placed immediately into distilled water. 
Slides were washed in PBS for 5 minutes. Endogenous peroxidase activity was blocked 
by incubating slides with freshly made 1.5% hydrogen peroxide in methanol for 10 
minutes. Slides were then washed twice in distilled water and subsequently PBS for 5 
minutes. 
To reduce non-specific background staining slides were covered with normal horse 
serum (refer to section 2.11.1.1) for 20 minutes, with excess serum then blotted from the 
slides using fibre-free paper. 
Slides were incubated with a human (Interstitial) collagen 1,11,111 Clone MCI-HA 
monoclonal antibody for I to 2 hours at room temperature. Slides were then washed 
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twice in PBS for 5 tninutes, followed by incubation with peroxidase labelled secondary 
antibody (refer to section 2.11.1.1) for 30 minutes at room temperature. 
Elite ABC (refer to section 2.11.1.1) was prepared and, following incubation, slides were 
twice washed in PBS for 5 minutes and then incubated for 30 minutes with Elite ABC at 
room temperature. Slides were again twice washed with PBS for 5 minutes and then 
covered with DAB (refer to section 2.11.1.1) for 5 minutes at room temperature. 
They were washed twice in water for 5 rainutes each and counter stained with Cole's 
haematoxylin for I tninute. Finally slides were washed for 2 rninutes in running tap 
water, dehydrated through increasing grades of IMS, cleared in xylene and mounted. 
2.12 Histology - Resin Processing 
For pathogenesis of PSAs and prevention with novel fibrin sealant studies, quantitative 
analysis of several different cell types was performed using the stereological "optical 
brick" method for determining cell number density (refer to section 2.14.2). This 
required a relatively thick tissue section (25gm). Although paraffin wax is the routine 
embedding medium used in histological investigations, it needs to be removed during 
staining procedures. For thick sections (such as 25gm) removal of the embedding 
medium causes tissue collapse, hence for this analytical technique an embedding medium 
which remained during staining was required. 
Many resins, including glycol methylacrylate, do not need to be removed for adequate 
staining, hence tissue ultrastructure is maintained. However care needs to be taken with 
regard to the type of resin selected as some processing fluids used to prepare tissue for 
resin embedding cause shrinkage. Also some resins are unsuitable for thick sections due 
to their brittle nature. Glycol methylacrylate, as used in these studies, optimises 
sectioning of thicknesses of 25pm or greater with minimum tissue processing (Mayhew 
& Gundersen, 1996) 
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2.12.1 Tissue Sampling 
() 
A finger of tissue was taken from the centre of even numbered experimental slIces, 
comprising of the injury sites from both the peritoneal wall and uterine horn (FIgure 
2.18). For non-adhered tissues, injury sites on the peritoneal wall and uterine horn were 
aligned and a sample taken from the central portion of both. 
ril 
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Figure 2.18: Schematic representation of tissue finger taken for resin processing. 
Tissue fingers were placed into separate glass vials containing 10% neutral butfered 
ormal saline labelled with the relevant animal number and tissue slice number. 
2.12.2 Tissue Processing 
Technovit 7100 (Kulzer Histo-Technik-, supplied by TAAB Laboratories Equipment Ltd, 
Reading, England) is a cold-polymeri sing resin based on hydroxyethylinethacrylate. Tile 
main properties it possesses are even penetration and polymerisation through specimens, 
low temperature polymerisation (23-37'C), reproducible and reliable embedding and its 
suitability to remain present during routine staining procedures. 
There are 4 main stages of processing tissues to resin: 
Dehydration - via immersion in increasing grades of IMS 70%, 80% and 95% for 
approximately 12 hours each 
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ii. Pre-infiltration - achieved by mixing equal amounts of absolute IMS and base liquid 
Technovit 7100 and incubating tissues in the resulting solution at room temperature 
for approximately 12 hours 
iii. Infiltration - immersion of tissues in infiltration solution, consisting of Ig (I sachet) of 
hardener I dissolved in I 00ml of base liquid Technovit 7100 
iv, Polymerisation - Iml hardener 11 added and gently stirred into 15ml of infiltration 
solution in a disposable container. Tissues were then placed into the appropriately 
labelled moulds and positioned as required, with injured surfaces of the peritoneal wall 
and uterine hom in juxtaposition. The polymerisation solution was added to each 
mould slowly and gently so as to cause minimal disturbance to tissues. Racks were 
transferred to a hot plate (-35'C) to aid polymerisation of the solution and then 
transferred to an oven (-350C) to complete the polymerisation process. 
Once resin blocks were completely polymerised, stubs were mounted onto the back of 
each block (for clamping into the microtome) using Technovit 3400 (Kulzer Histo- 
Technik; supplied by TAAB Laboratories Equipment Ltd, Reading, England). 5ml of 
Technovit 3040 liquid was added to lOg of Technovit 3040 powder and stirred quickly 
but gently. A layer of the Technovit 3040, approximately 2mm, was applied to the back 
surface of each resin block and a stub pressed into the Technovit (Figure 2.19). 
Completed blocks were then left to polymerise completely, after which they were 
labelled and blocks were then removed from the moulds. 
St b 
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Figure 2.19: Embedding set-up for resin (Technovit 7100 and 3040), 
Mounting Medium 
(Tcchnovit 3040) 
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A 25prn section, containing a complete transverse section of tissue was cut from each 
block using a Mod. 1140 Autocut microtome (Reichert-Jung) and mounted onto a slide. 
To aid sectioning, the surface of the resin block was slightly moistened with water. Slides 
were left on a hot plate at 70-80'C for approximately 2 hours and subsequently 
transferred to an 37'C incubator overnight to ensure complete adherence of sections to 
slides. 
2.12.4 Giemsa Staining 
Giemsa, a Romanowsky stain, differentially stains cellular granules and makes subtle 
distinctions in staining shading. It is comprised of a mixture of eosin and methylene blue 
solutions and it is the binding between the dyes and tissue components and between the 
dyes themselves which is responsible for the differential staining of cellular components. 
Used in collaboration with a weak acetic acid solution, further differentiation can be 
achieved, especially for the detection of eosinophil granules. The alcoholic properties of 
Giemsa also aid the penetration of the stain through the 25[im resin sections. 
Procedure 
A modified version of Giemsa's technique was used. Slides were placed directly into 
o. oo% Giemsa solution at 56'C for 40 minutes and then quickly rinsed twice in distilled 
water. Slides were then differentiated in a very weak acetic acid solution (1: 10 000 acetic 
acid to distilled water) for 10 minutes, gently agitated throughout. They were then 
quickly rinsed twice in distilled water, blotted using fibre-free papers, thoroughly 
dehydrated by incubation at 37'C for 24 hours and mounted. 
2.13 Tissue Zones 
Microscopic analysis of transverse sections revealed several different, discernible tissue 
area components which could be analysed stereologically (Figure 2.20) These were 
defined and classified as follows: 
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i. PSA - any tissue, arising from the injury sites, which connected the two 
surfaces. 
ii. Tissue generation - regenerative tissue growth attached either to injury site but 
not connecting the two. 
iii. Damage zone - the area between the line of the original serosal surface and the 
limit of actual visual tissue damage. 
iv. Reaction zone - the area between the limit of actual tissue damage and the 
limit of tissue changes not amounting to frank damage but identifiable as 
changes from normal (colour, cellular infiltration). 
v. Peritoneal. cell concentration zone - areas of abnormal cellular concentrations, 
mainly neutrophils, eosinophilic cells, and macrophages within the pefitoneum. 
vi. Uterine horn haemorrhage - haemorrhage located in the villus structures on 
the lumenal surface of the uterine hom. 
vii. In treated cases, fibrin sealant remaining and fibrin sealant associated cell 
concentration/reaction was quantified. 
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Figure 2.20: Schematic representation showing tissue zones in the rabbit uterine horn model. 
Corresponding zones could be distinguished in the experimental sites 
(peritoneal wall to colon/caccum and stomach) in the pig abrasion model. 
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The benefits of quantitative compared to qualitative data are many, but in summary can 
be described as the difference between absolute and observational knowledge. This is 
especially important when comparing the effects of different treatments, for example, 
potential PSA preventative agents. Qualitative data has the potential to be biased and 
imprecise, hence interpretation of data can be difficult, particularly when comparing 
different potential PSA preventative agents assessed by different qualitative methods. 
These problems are eliminated by unbiased and precise quantitative analysis. 
The field of stereology is concerned with obtaining quantitative 3 dimensional 
histological information derived from measurements made on the 2 dimensional planer 
surfaces of tissue sections (Gundersen et al., 1988). In order for data generated to be 
accurate it needs to be: 
unbiased, that is without systematic deviation from the true value. For example, two 
separate investigations are made to estimate the same quantity (Figure 2.21). 
Investigation X is biased and the value obtained is not the true value whereas 
investigation Y is unbiased with the true value found. The difference between value X 
and Y is the magnitude of bias, easily identifiable in this example but not during 
experimental practices. 
: Value 
Figure 2.21: Effect of bias on quantitative analysis. 
(Taken from Howard and Reed. 1998). 
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ii, precise, that is having low measurement variability, with precision decreasing the 
number of measurements and hence time required to obtain data. 
Dual benefits of unbiased and precise estimates of structural quantities is supplied only 
by stereology and no other technique (Mayhew, 1991a). However for both of these 
requirements to be met a few specific demands need to be fulfilled (Gundersen el al. 
1988) during analysis. If these are not taken into account, inaccurate results will be 
obtained, the identification of which may be difficult. The very worse case of this is 
precision combined with bias as results are highly inaccurate but appear to be very good 
(Figure 2.22). 
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Figure 2.22: Importance of unbiased and precise measurements for obtaining accurate data 
(Modif icd from Howard and Reed, 1998). 
For precise and unbiased estimates to be calculated several criteria need to be met with 
regard to the sampling technique utilised: 
i. no assumptions should be made about geometry, orientation, size or spatial 
distribution of the objects to be measured. The only way to achieve this is to use a 
design based approach (Howard 1990). 
ii. random sampling must be employed, that is, "to present all parts of the specimen an 
equal chance of being selected for examination" (Stuart, 1976). It is impractical, when 
obtaining microscopic quantitative data, to analyse the whole object of interest, for 
example, to count all cells present within a PSA when the total number could be 
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millions of cells per millimetre of tissue. To circumvent this impracticality, discrete 
samples are taken from the object of interest in a uniform random manner. Using 
uniform random sampling decreases variance after analysis of a few samples and 
hence increases the precision of the estimate compared to a random random sampling 
technique. 
Stereological techniques utilised in these studies were Cavalieri's Principle for 
determination of absolute volumes and the Optical Disector for numerical density, both 
of which are desctibed below. 
2.14.1 Cavalieri's Principle 
The determination of the volume of an object can be easily achieved for most objects via 
measurements of height and specific gravity. However for the calculation of volumes 
within volumes, for example., calculation of the damage zone within peritoneal tissue, 
these techniques are redundant. A method was developed by an Italian mathematician, 
Cavalieri (1598 to 1647) (Gundersen et al., 1988) for simple and accurate calculation of 
absolute volume and permits the determination of volumes within volumes. Cavalieri 
showed that "the volume of an object may be estimated from parallel sections, a known 
distance apart, by summing up the areas of all cross sections and multiplying this by the 
distance apart of each slice". 
Practically this technique involves the random application of a grid of uniformly placed 
points over the surface of each slice from a uniform randomly sliced object and counting 
the number of points associated with slice surface. This information together with the 
area associated with each point and mean thickness of each slices is used to calculate the 
absolute volume of the object. 
Experimental tissues were unifom-dy random sliced throughout the length of each 
experimental site, with the mean slice thickness known (refer to sections 2.9 and 2.10 for 
rules to be observed). Previous studies have shown that efficient estimates may be 
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obtained even if as few as 5 or 6 slices per object are taken (Gundersen and Jensen, 
1987). All cases in the studies reported in this thesis were therefore sliced to produce at 
least this number of slices. From each slice a section was produced and was viewed at a 
known magnification, using a modified microfiche reader (Canon FR 100). A grid of 
uniformly and constantly spaced points was placed, at random, over the image of each 
section (Figure 2.23). 
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Figure 2.23: Schematic representation of uniform grid of points randomly applied over a 
transverse section. 
The number of points (P) lying within the boundary of the area of interest was counted 
for all sections of the experimental site. These were totalled to obtain the entire number 
of points associated with this area of interest (IP). This value together with the area 
associated with each test point (aP) and mean thickness of each slice (t ) was used to 
calculate the reference volume for each area of interest (Vref). - 
V,, f =I Pf . a( P, ýf 
). -t 
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2.14.2 Numerical Density 
For pathogenesis of PSAs and prevention with novel fibrin sealant studies numerical 
densities of basophilic cells, eosinophilic cells, macrophages, lymphocytes and fibroblasts 
within PSA and tissue generation zones for each experimental site were determined using 
the stereological method of the optical brick (Howard et at, 1985). 
Until the 1980's counting of particles in 3 dimensional space had been model based and 
required assumptions to be made about particle size, shape and spatial orientation 
(Mayhew, 1991 a). Such assumptions resulted in many number estimates being inaccurate 
and biased. For example, when sectioning tissue for histological analysis, larger particles 
have a greater chance of being transected compared to smaller particles, in addition 
smaller particles have more chance of being totally included within a section thickness 
and therefore not displaying a profile on the section surface. Cigar shaped particles have 
greater probabilities of being transected transversely or obliquely rather than 
longitudinally and a perimeter of irregular particles can be transected by more than one 
plane creating potential difficulty in deciding whether or not individual particles 
appearing on that plane belong to the same parent particle (Mayhew, 199 1 a). 
In 1980 Cruz-Orive proposed the use of a volume probe, which consisted of a stack of 
serial sections cut from a random starting point to count particles in 3-D. This system 
was independent of particle shape, size and orientation and hence eliminated the 
problems of previously used methods. This principle was further developed by Sterio 
(1984) who stated that "arbitrary particles of any size and shape are sampled with a 
uniform chance only with a3 dimensional probe". He described the 3-D probe as a 
disector, that is, an unbiased counting frame (UCF) and a pair of serial sections a known 
distance apart. This design based disector principle proposed by Sterio (1984) was a 
major contribution to precise and unbiased counting of particles within a volume. 
However the efficiency of counting particles by the taking of physically separated serial 
sections can be increased by the use of a single thick section and optically sectioning 
through that section (Howard and Reed, 1998). 
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The first practical adaptation of this counting technique was demonstrated by Howard el 
aL, (1985) who introduced the "optical brick". The basic principle is the 3-D probe, of a 
known volume, samples the tissue of interest in a random uniform manner. The optical 
brick has three exclusion planes and three acceptance planes which are used for counting 
the number of profiles (cell nuclei in this study) present within its volume (Fig 2.24). The 
numerical density can then be calculated from measurements therefrom. 
Figure 2.24: Optical brick. 
(Adapted from Ansari, 1997). 
The green spheres arc those which would be counted since they do not 
intersect the exclusion planes (red) whereas the red spheres would not be 
counted since they intersect the exclusion planes, 
Practically the "optical brick" used in these studies consisted of an UCF mounted on a 
monitor screen used in conjunction with a known reference depth of 15[tm. The unbiased 
counting frame consists of two exclusion and two guard lines used for the unbiased 
counting of profiles (Figure 2.25), with a counting rule which states "profiles of features 
which intersect the frame but do not intersect the exclusion edge (solid line) are sampled. 
Features intersecting the image boundary will be rejected, since they would inevitably 
bias the estimate" (Gundersen, 1977). 
87 
Materials and Ifelhods 
_. 
ýýCEPTANCE LINE 
Figure 2.25: Unbiased counting frame (UCF). 
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Resin sections were viewed under oil immersion (xIOO objective lens; NA 1.25), with 
colour images projected via a camera (Sanyo Colour CCD video camera, Model No: 
VCC 3900) onto a colour monitor (JVC, Model No- AV-20GB), with a final 
magnification of x1250. Initially the tissue zone to be analysed was located at low 
magnification and a starting point was randomly chosen outside of this zone (Figure 
2.26). It this way analysis commenced from a truly random starting point within the area 
of interest. 
Once the first sample point was found, the section was focused through until the first 
nucleus of a cell of interest (either at the top or bottom of the section) came into 
maximum focus. The microcator (Sylvac, Sylvac System), an instrument used for the 
measuring of stage movement, hence the reference depth, was then set to zero and 
counting commenced from this point. The section was focused through until the nucleus 
of a cell of interest came into maximum focus and that cell recorded provided it was 
within the reference depth of 15ýtm and conformed to UCF counting rules. This 
procedure was repeated until the whole of the reference depth was covered. 
Once that sample point was completed, the section was moved in a uniform manner by 
tessellating across the whole of the tissue, repeating the counting procedure (Figure 
2.26). 
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Figure 2.26: Uniform random sampling of PSA for numerical density estimation. 
Numerical densities were calculated as follows. 
i. Calculation of the optical brick volume used: 
Volume of OpticalBrick Area of UCF - Rýference Height 
Vj, Af h 
Calculation of the volume of tissue sampled- 
Volume of Tissue Sampled Volume of Optical Brick - Number of (ICFs Counted 
VTI. Vf NI, 
Numerical density is then derived using: 
Numerical Density = 
Numher of Pr(fillesCounted 
Volume qf Tissue Sampled 
0 
VrIss 
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Total number can then be determined using the numerical density and absolute volume 
determined using Cavalieri's principle. 
Total Number = Numerical Density - Rýference P Ohime 
NTOT N, VREF 
2.14.3 Length Density 
For studies investigating PSA development and prevention with novel fibrin sealant 
length density and subsequently total length of vessels (blood and lymphatic) within 
PSAs and tissue generation were calculated using stereological methods. 
The theory behind this methodology is that a 2-D probe, for example a histological 
section, hits an object in proportion to its length (Figure 2.27). Thus the number of 
intersects of the object per unit area of the section is related to the length of the object 
within the reference space. However section orientation can cause problems, with 
intersect number varying with differing section orientation. To avoid this problem and to 
ensure unbiased length estimation sections should be of uniform random orientation, 
which practically is the usual case (Howard, 1998). 
Figure 2.27: Intersection of a linear feature by a random planc/section 
(Taken from Howard, 1998). 
To estimate length density tissues are uniformly randomly sampled using UCFs. The 
number of points within UCFs are counted and used to calculate length density as 
follows. - 
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Length Density= 2- 
Numberof Points 
UCF Area 
Chapter 2 
Due to time limitations only preliminary analyses were performed. Two left hand side 
experimental sites were selected from each sample time point with 3 slides (LI, L5 and 
L9) analysed only. Approximately 15 samples were taken for each case with tissues 
sampled in an uniform random manner. Length density estimations and calculations were 
performed using a purpose designed digital stereology package (Kinetic Imaging, 
Liverpool, UK). Total length was subsequently calculated by multiplying length density 
by total volume (calculated by Cavalieri's method). 
Total Length = Length Density - Reference Volume 
2.14.4 Coefficient of Error 
To determine the precision of the quantitative counting methods used, the coefficient of 
error (CE) (Gundersen and Jensen, 1987; Matheron, 1965) was calculated for each 
technique using the following equations: 
i. CE for Volume 
V(31: (Pi - Pj) + 2: (Pi - Pj+J - 41: (Pi 'pi=2 ))/12 CE (v_f )=IP, 
where Pi is the number of points counted for the tissue area of interest 
ii. CE for Numerical Density 
Ep. LP Eq - EP 
where n is the number of sample points per area of interest, P is the total number of 
disectors falling in the area of interest and Q-is the total number of cells counted 
(Cochran 1977). 
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iii. CE for Total Number 
/'vrl/ tot) 
VCE2 CE2(Vre Ch(N (Nv) + 
2.14.5 Validation of Stereological Methodology 
Chapter 2 
Many scientists would like to see stereological techniques validated against previously 
used quantitative methods. There is an inherent problem with this since other quantitative 
assessments are potentially biased whereas stereological techniques known to be 
unbiased (Mayhew & Gundersen, 1996). However comparison with other 3-D 
techniques have shown that stereological methods yield accurate and biologically 
important data (Gundersen & Osterby, 1981; Rosen & Harry, 1990). This has lead to the 
increased use of stereological methods in biological sciences for quantitative estimations, 
for example, rat heart ventricle volume (Mattfedt, 1987), rabbit lung volume (Michel & 
Cruz-Orive, 1988), and total number of neurons in the human neocortex (Braendgaard et 
al., 1990) 
2.15 Full Blood Counts 
in order to identify any systemic cellular changes occurring during PSA development or 
prevention with novel fibrin sealant full and differential cell counts were performed. 
Routine human clinical full blood and differential cell counts have been performed by 
auto-analysers for many years due to the time intensive nature and potential inaccuracies 
of manual methods. The auto-analyser used was set up for human clinical investigations 
and hence potentially may produce inaccurate differential counts due to differences 
between human and rabbit blood cells which the auto-analyser was not configured to 
detect. Therefore to identify and eliminate incorrect results manual differential counts 
were performed in addition to auto-analysis. 
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2.15.1 Automated Counting 
A Coulter MaxM (Coulter Electronics) was used for automated full blood counts. A 200 
gm whole blood sample was aspirated by the analyser and separated into three parts for 
analysis: 
i. Red blood cell (RBC) and platelet number determination 
ii. White blood cell (WBQ number determination 
Cell counts were all determined by the Coulter Principle. In summary, as cells pass 
through an aperture, across which an electric current flows, they interfere with that 
current. This interference is monitored electronically as pulses, with the number of 
pulses proportional to the number of cells and the magnitude of the pulse 
proportional to the volume of the cell. 
2.15.2 Manual Differential Counting 
Wedge blood films were made and stained using a Hema-Tek 200 staining machine 
(Ames, Bayers Diagnostics), which employs a modified Wright's stain (Appendix II). 
This, like Giemsa, is a Romanowsky stain and differentially stains cellular granules due to 
the binding of eosin and methylene blue. 
Films were viewed under oil immersion with a final magnification of x 1000. Caution was 
taken with regard to areas of the film analysed, with single cell layers chosen and 
avoidance of the tail end of the film which will contain a concentration of large cells due 
to the spreading motion during the preparation of the smear. Areas were systematically 
sampled in a tessellation motion and with a minimum of 100 cells counted for each 
sample. 
2.16 Enzyme Linked Immunosorbent Assays (ELISAs) 
To investigate any systemic and local biochemical modulation of PSAs and prevention 
with novel fibrin sealant, ELISAs for TNF-a and TGF-p were performed on blood and 
peritoneal fluid samples taken during the pathogenesis of PSAs and novel fibrin sealant 
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studies. 
ELISAs employ antibodies to detect specific molecules and enzymes as sensitive and 
versatile amplification agents. In this way they provide an accurate detection system 
which is frequently utilised in medicine, for example, pregnancy tests. 
Most ELISAs are based on a standard system. A microtitre plate is coated with an 
antibody directed against the molecule of interest M. A standard or sample is then 
added, with the immobilised antibody capturing any molecules (M) present via an 
antibody-antigen reaction. The plate is then washed to remove any unbound substances 
and an antibody conjugated with an enzyme, directed against the molecule of interest 
(M) is added. This conjugated antibody binds via an antibody-antigen reaction to any 
bound molecule of interest (M). The plate is again washed to remove any unbound 
substances and a substrate is added to develop colour in proportion to the amount of 
conjugated antibody present and therefore the amount of molecule (M) present in the 
standard or sample. The colour reaction is stopped by acidification and the intensity of 
colour measured using a spectrophotometer, with sample concentrations of the molecule 
(M) determined from standard values (Figure 2.29). 
94 
Materials andAlethods 
ELISA plate 
%lollodolial 
m0m9 
Absorbance read 
Figure 2.28: ELISA system. 
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2.16.1 Tumour Necrosis Factor-a ELISA (Genzyme) 
Chapter 2 
(Genzyme Factor-Test-XTI Mouse TNF-(x ELISA kit Protocol Booklet) 
The Factor-Test-Xrm Mouse tumour necrosis factor-a (TNF-cc) ELISA kit (Genzyme 
immunobiologicals, Cambridge, USA) was assessed for the detection of TNF-cc in rabbit 
plasma and peritoneal fluid samples. It is a solid-phase ELISA employing the multiple 
antibody sandwich principle. The 96 well ELISA plate is pre-coated with monoclonal 
anti-mTNF-cc and on addition of standards or samples, any TNF-cc present is bound to 
the monoclonal antibody. 
After washing the plate to remove any unbound material, a peroxidase-conjugated 
polyclonal anti-mTNF-et (HRP-conjugate) is added, which binds to the bound TNF-Ct. 
The plate is washed again to remove any unbound material. A substrate solution is then 
added which initiates a peroxidase catalysed colour change that is subsequently stopped 
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by acidification. The absorbance measured at 450nm is proportional to the concentration 
of TNF-cc present in the standards or samples. 
A standard curve is obtained by plotting the concentration of mTNF-cc standards against 
their resulting absorbencies. The TNF-(x concentration in experimental samples are then 
determined using the standard curve. 
Validation 
As described above the TNF-a ELISA kit used is intended for the detection of mouse 
TNF-a. Since this study was concerned with the measurement of TNF-a in rabbit plasma 
and peritoneal fluid samples, validation of the kit for the detection of rabbit TNF-cc was 
required. 
For this purpose a rabbit TNF-cc control was necessary and since no rabbit TNF-cc is 
available commercially, a control was produced by in vitro methods. Two methods were 
assessed for the production of rabbit TNF-a in vitro both using whole blood, the first 
isolating blood monocytes, the primary source of TNF-a, the second, which avoided 
monocyte isolation, used the whole blood sample (Appendix II). 
Isolated monocytes or whole blood were cultured, together with lipopolysaccharide 
(LPS) solution, in 5% carbon dioxide at 37'C, to activate monocytes present t. 0 
synthesise and release TNF-cc. After the incubation period, the culture solution was 
collected, centrifuged to remove cellular or LPS components and the resulting solution 
containing any TNF-cc collected and stored at -800C. 
Both rabbit and rat samples were used for obtaining TNF-a controls to determine the 
validity and reproducibility of the TNF-cc production technique, since the ELISA kit used 
detects rat as well as mouse TNF-cc. 
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Procedure (Genzyme Factor-Test-XTM Mouse TNF-cc ELISA kit Protocol Booklet) 
ELISA kit and samples were to brought up to room temperature, whilst the wash buffer 
(detergent in buffer) was prepared (I wash buffer to 20 distilled water). TNF-a 
standards, 0.357 1407 560 and 2240pg/ml, were prepared by serial dilution of the 
supplied 8.96ng/ml TNF-(x standard with diluted wash buffer. 
All standards and samples were assayed in duplicate. 100pl of standard or sample was 
added to each well, with plasma samples diluted at least 1: 2 with diluted wash buffer. 
The plate was incubated for 2 hours ±5 minutes at 37 ±2 OC. All wells were then 
aspirated and washed thoroughly 4 times using diluted wash buffer. IOOPI of HRP- 
Conjugated anti-Mouse TNF-cc was subsequently added to each well and incubated for I 
hour ±5 minutes at 37 ±2 'C. 
Substrate solution was prepared by mixing equal volumes of Reagent A (0.001N 
hydrogen peroxide in buffered solution) and Reagent B (tetramethylbenzidine in 
methanol (<50%), DMSO (<2%) and glycerol (<15%)) no more than 15 minutes before 
use. Following incubation, wells were aspirated and washed thoroughly 4 times. 100til of 
prepared substrate solution was added to each well and incubated for 10 ±I minutes at 
room temperature. 100pl of stop solution (IM sulphuric acid) was added to each well 
and stirred to ensure thorough mixing and homogenous colour. The plate was then read 
within 30 n-ýinutes using a plate reader (Dynatech MR7000) at 450nm. 
TNF-a concentrations for samples were then calculated. All standards and sample 
absorbances were averaged and the blank reading (0 pg/ml TNF-a) was subtracted. A 
standard curve was plotted from the TNF-cc standard results, with an order I regression 
curve fit used to read TNF-cc concentrations for each sample. Dilution factors were taken 
into consideration in calculating absolute TNF-cc concentrations for each sample. 
2.16.2 Transforming Growth Factor-Ol ELISA (Genzyme) 
(Genzyme Predicta@ TGF-P, ELISA Kit Protocol Booklet) 
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The Genzyme Predicta(D Human Transforming Growth Factor-P, (TGF-P, ) ELISA Kit 
(Genzyme Immunobiologicals, Cambridge, USA) was assessed for the detection of rabbit 
TGF-P in collected plasma and peritoneal fluid samples. 
The kit contains a 96-well microtitre plate containing immobilised mouse monoclonal 
antibody to TGF-O,. For measurement of biologically active TGF-01, samples, standards 
and controls must be diluted and acidified., using hydrochloric acid (IN) for one hour. 
Following incubation, acidified samples and standards are neutralised to pH 7.0-7.4 with 
sodium hydroxide (IN), and are ready to be assayed or aliquotted and frozen until assay. 
Afler activation, standards ranging from 0.10 to 4.00ng/ml are prepared via serial 
dilution. However, final results of specimens must be calculated by multiplication by the 
appropriate dilution factor. 
A measured volume of activated sample, standard, or control is added to each test well 
and incubated to allow any TGF-01 present to be bound by antibodies on the microtitre 
plate. The wells are then washed and a direct-labelled BRP-conjugated polyclonal 
antibody to TGF-P, is added which binds to the TGF-P, bound during incubation. After 
washing, a substrate solution is added to the wells, producing a blue colour in the 
presence of peroxidase. The colour reaction is then stopped by the addition of acid which 
changes the blue colour to yellow. The intensity of the yellow colour is directly 
proportional to the amount of TGF-01 present in the sample, standard, or control. The 
absorbance of each well is read at 450mn and a standard curve is constructed to 
quantitate TGF-P, concentrations in the controls and samples. 
Validation 
The ELISA kit used for the Aetection of rabbit TGF-p is intended for the detection of 
human TGF-01, hence validation of the kit with regard to its detection of rabbit TGF-P 
was carried out. 
There is no commercially available rabbit TGF-p hence rabbit TGF-P controls were 
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produced in vitro (Appendix 11). Whole blood samples were taken from both rabbit and 
human subjects, with the human sample determining the validity and reproducibility of 
the TGF-0 preparation technique. Samples were centrifuged for separation of platelet 
rich plasma, with platelets being the primary source of TGF-P. This platelet rich plasma 
was further centrifuged to obtain a platelet concentrate, with a small volume of platelet 
poor plasma used to resuspend cells. Platelets were then cytolysed in order for stored 
TGF-0 to be released using a freeze (-80'C)/thaw cycle and the TGF-P rich substrate 
collected and either assayed immediately or stored (-80'C). 
Procedure (Genzyme Predicta@Human TGF-01 ELISA kit Protocol Booklet) 
All samples and the ELISA kit were allowed to reach room temperature before the assay 
was commenced. Appropriate volumes of wash buffer (concentrated detergent solution 
with 0.02% thimerosal as preservative) were prepared, using a 20 fold dilution of wash 
reagent to distilled water. 
Standard and sample were first diluted by adding 20pl of TGF-01 standard to 440gl of 
sample diluent (buffered solution with protein and <0.01% Proclin-300 as preservative) 
or by adding 10 [d of plasma sample to 450pl of sample diluent. Standards and samples 
were activated by addition of 20gl of IN hydrochloric acid, gently mixed and then 
incubated at 2-8"C for 60±2 minutes. Neutralisation then occurred by adding 20PI of IN 
sodium hydroxide and mixing. 
Serial dilutions of the activated TGF-01 stock standard (4ng/ml) with sample diluent 
resulted in TGF-01 standards of 0,0.10,0.26,0.64,1.60 and 4.00ng/ml. 
100pl of activated standard or sample was added to each well and incubated for 60±2 
minutes at 37±2 "C. Wells were then aspirated and washed well 5 times. 100ýd of anti- 
TGF-01 BRP-conjugate was then added to each well and incubated for 60±2 minutes at 
37±2 "C. Wells were again aspirated and washed 5 times. 
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100[d of substrate solution (tetramethylbenzidine (<2%) in solvent (<40%) and 0.03% 
hydrogen peroxide in buffered solution) was added to each well and allowed to incubate 
for 20±1 minutes at room temperature. 1001A of "stop" solution (acid solution (<2N)) 
was then added to each well, - which was stiffed and absorbance read at 450= within 
30 
minutes using a plate reader (Dynatech MR7000). 
To calculate the concentration of TGF-P, in each standard and sample, the mean was 
calculated from duplicate readings and the blank reading was subtracted. A standard 
curve was produced (regression order 1) and TGF-01 concentrations for each sample 
read off the standard curve. Multiplication by the dilution factor then resulted in the 
absolute TGF-P, concentration for each sample. 
2.16.3 TGF-01 ELISA (R& D Systems) 
(R&D Systems Quantikinem Human TGF-01 Immunoassay Protocol Booklet) 
The Quantikine Tm Human TGF-01 Immunoassay (R&D Systems, Abingdon, UK) 
employs the quantitative sandwich ELISA technique, and was used for analysis of plasma 
and peritoneal fluid sample for TGF-P, content. 
TGF-P soluble receptor Type II which binds TGF-P, has been pre-coated onto a 
microtitre plate. Standards and samples are pipetted into the wells and any TGF-PI 
present is bound by the immobilised receptor. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for TGF-Plis added to the 
wells to sandwich the TGF-01 bound during the first incubation. The soluble receptor 
binds TGF-01, TGF-PP and TGF-05 with similar affinities. The sensitivity of the 
immunoassay is provided by the polyclonal antibody which is specific for TGF-01. The 
soluble receptor also binds TGF-02but with an affinity at least 100 fold lower. Following 
a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to 
the wells and colour develops in proportion to the amount of TGF-P, bound in the initial 
step. The colour development is stopped by acidification and the intensity of the colour is 
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measured using a spectrophotometer. 
Validation 
The same technique was used as described in 2.16.2. 
Procedure (R&D Systems QuantikineTm Human TGF-01 Immunoassay Protocol 
Booklet) 
All samples and the ELISA kit were brought up to room temperature prior to initiation 
of the assay. 
Samples required activation before analysis. 100ýd of plasma was added to 100ýd 2.5N 
acetic acid/IOM urea solution, mixed well and incubated for 10 minutes at 25"C. 100pt 
of 2.7N sodium hydroxide/IM HEPES solution was then added and mixed well to stop 
the activation process. During the activation process samples underwent a3 fold 
dilution. Samples were then further diluted 4 fold with calibrator diluent RD6M (animal 
serum with preservative). Hence overall samples were diluted 12 fold. 
The appropriate amount of wash buffer (concentrated solution of buffered surfactant 
with preservative) was prepared in a 1: 25 fold dilution with distilled water. TGF-P 
standard was reconstituted by addition of 2ml of Calibrator Diluent RD6M to TGF-P 
standard vial. The resulting concentration of standard stock solution was 2000pg/mI. 
TGF-P standards, 0,31.2,62.5,125,250,500,1000 and 20OOpg/mI, were then prepared 
by serial dilution of the stock standard. 
All standards and samples were assayed in duplicate. 200111 of standard or sample was 
added to each well and incubated for 3 hours at 25T. After which each well was 
aspirated and washed thoroughly 3 times, 200pI of Conjugate was added to each well 
and incubated for 1.5 hours at 25*C. 
Substrate solution was prepared by mixing equal volumes of Substrate A (stabilised 
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hydrogen peroxide) and Substrate B (stabilised chromogen (tetramethylbenzidine)). 
Following the incubation period all wells were aspirated and washed thoroughly 3 times. 
Then 20OVI of prepared substrate solution was added to each well and incubated for 20 
minutes at 25"C. Finally 501d of stop solution (2N sulphuric acid) was added to each 
well and mixed well to ensure even colour distribution. Plates were read on a plate 
reader (Dynatech MR7000) plate reader at 450nm within 30 minutes. 
Calculation of TGF-P concentration for each sample was carried out using the TGF-P 
standard results. All standard and sample absorbance readings were averaged and the 
mean blank reading (0 pg/mI TGF-P ) subtracted from each reading. A standard curve 
was produced and samples values were read off the order I regression of the curve. 
Finally, dilution factors were used to calculate the actual TGF-P concentrations for each 
sample assayed. 
2.17 Statistical Analysis 
All data was collected into respective experimental groups, with mean, standard 
deviation, standard error of the mean and percentage coefficient of variation calculated 
using MS Excel 5.0. 
Statistical comparisons between experimental groups was performed using Student's t 
test. In cases where normality or equal variance failed, Mann Whitney Rank Sum test 
was used. All tests were performed using the computer package Sigma Stat 1.0. 
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3.0 Pathogenesis of PSAs 
3.1 Introduction 
Interest in post surgical adhesions (PSAs) has been prevalent since the advent of surgery. 
Their effects on patients health, economic and workload burdens have resulted in much 
research investigating potential PSA preventative agents, ranging from inabsorbable 
barriers to fibrinolytic agents (refer to Section 1.2). However despite much effort there 
currently is no commercially available PSA preventative agent. 
it has been hypothesised by both this and other authors that this lack of success is 
primarily attributed to many aspects of PSA development being undetermined. Although 
comprehensive qualitative studies investigating PSA formation were conducted in the 
1960-70's, little research in this area has occurred since with studies concentrating on 
potential anti-PSA agents. Hence there is a lack of quantitative knowledge available 
regarding the physiological and biochemical mechanisms governing PSA development. In 
order for potential PSA preventative agents to be optimised for successful PSA 
prevention further understanding of the mechanisms controlling PSA development is a 
necessity. 
The aims of this study were to: 
i. quantitatively define physiological, structural, cellular and biochemical mechanisms 
occurring during the development of PSAs using design based, unbiased, stereological 
techniques in an established experimental model 
ii. identify possible windows of pathogenesis where pharmaceutical intervention may be 
most effective. 
3.2 Materials and Methods 
A rabbit uterine horn abrasion model was used to induce peritoneal PSAs (surgical and 
teffnination procedures described in Chapter 2). Defined areas on the uterine hom and 
corresponding peritoneal wall were abraded using a standard template and scraper. These 
103 
Pathogenesis ofP&4s Chapter 3 
injured areas were held in juxtaposition via positional sutures located outside the 
experimental site and timing commenced from this point. Tissues were sampled at 30 
seconds, 1,3P 5,10 30 minutes 148 16 hours, 1,3,5,7,14,28 and 42 days 
following injury, Yýith each time point group consisting of 8 experimental sites. 
Resected tissues (experimental sites) were uniform randomly sliced transversely (refer to 
Section 2.9). Odd numbered slices were processed to paraffin wax for volumetric 
analysis (tissue zones and structural changes) and even numbered sections processed to 
resin, for number density analysis for cellular involvement (Chapter 2). 
No morbidity or mortalities were observed throughout this study. 
3.3 Macroscopical Analysis 
General PSAs associated with laparotomy were seen in all cases, that is, PSAs from the 
peritoneal suture line to underlying tissues, including the omentum, fat pad over the 
bladder and the bladder itself None of these PSAs interfered with any of the 
experimental sites. 
Within as little as 5 minutes following injury fibrin strands could be seen between the 
abraded surfaces of the uterine horn and peritoneal wall. By 30 minutes the two surfaces 
were adhered along their length in vivo with this trend continuing from there on (Figures 
3.1 and 3.2). The overall macroscopic incidence of PSAs in vivo from 10 minutes and 
onwards was 90%, with a detailed breakdown shown on Graph 3.1 (Appendix III Table 
3.1). 
Experimental tissues were carefully resected for microscopical analysis. Since 
experimental sites were 100% adhered by 10 minutes post injury, their macroscopic 
appearance throughout development showed little change (Figures 3.1 and 3.2). 
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Figure 3.1: Macroscopic PSA at 3 days post injury. 
Figure 3.2: Macroscopic PSA at 14 days post injur). 
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Graph 3.1: Mean macroscopic incidence of PSAs. 
Chapter 3 
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3.4 Volumetric Analysis of Tissue Zones 
It is universally recognised that PSA formation is a complex, multi-factorial process. In 
order to understand the basic physiological changes occurring during PSA development 
quantitative analysis of different tissue components was performed for all experimental 
sites. Hence physiological changes occurring in PSAs from 30 seconds to 42 days were 
investigated. 
Odd numbered uniform random slices from each experimental site were processed to 
paraffin wax and sections cut at 5pm. One section from each block was stained with 
haematoxylin and eosin and analysed using Cavalieri's Principal. Absolute volumes of 
PSA, peritoneal and uterine horn tissue generation and damage zones, peritoneal reaction 
and cell concentration zones and uterine horn haemorrhage (Figure 3.1) were calculated 
for each experimental site, with mean volumes subsequently determined for each 
experimental time point (refer to Chapter 2). 
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Figure 3.3: Schematic representation of tissue zones. 
3.4.1 Results 
Microscopically, PSAs were first evident I hour following injury and at all subsequent 
time points (Graph 3.2; Appendix III Table 3.2; Figure 3.4). Mean PSA volume 
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increased significantly (P<0.05) up to 16 hours following, with the most rapid increase 
occurring between 4 and 16 hours (Figure 3.5). Up to 7 days a trend for mean PSA 
volume to increase was observed, after which there was a trend to decrease, although not 
statistically significant (P>0.05) time point to time point (Appendix III Table 3.3). 
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Peritoneal tissue generation (PTG) was present at all sampling time points (Graph 3.3; 
Appendix III Table 3.2). From 30 seconds to I day post injury mean volume of PTG 
showed a gradual trend to increase. A significant increase (P<0.01) in mean volume was 
seen between I and 3 days. From 3 to 14 days a trend of slower increase in mean volume 
was observed (Figure 3.6), followed by a significant decrease (P<0.05) between 14 and 
28 days, with volume continuing to decrease but at a much slower rate at 42 days post 
injury (Appendix III Table 3.3). 
Uterine horn tissue generation (UTG) was first seen microscopically after I hour and at 
all time points from there on (Graph 3.3; Appendix III Table 3.2). An overall increase in 
mean volume was seen between I hour and 5 days. Significant increases (P<0.05) were 
seen between I and 4 hours and between 3 and 5 days (P<0.001) (Figure 3.7). From 5 
days post injury a trend to decrease was seen, with a significant decrease (P<0.01) seen 
between 7 and 14 days. After 14 days there was a trend for mean volume to increase, 
although this was not significant (P>0.05) from time point to time point (Appendix III 
Table 3.3). 
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Mean volume of total tissue generated (TTG) demonstrated a trend to increase up to 14 
days post injury with significant increases seen at 3 and 20 minutes, 8 and 16 hours, 3 
and 5 days (Graph 3.4; Appendix III Tables 3.2 and 3.3), Following the peak in mean 
volume a significant decrease is observed at 28 days, after which little change occurred. 
Mean volume for experimental sites for peritoneal damage was found to be fairly 
constant from 30 seconds to 3 days (Graph 3.5; Appendix III Table 3.2). From 3 to 5 
days there was a significant increase (P<0.01) in mean volume, followed by a gradual 
increase (non-significant) up to 14 days (Figure 3.6). Following this a sharp decline was 
observed although this was not statistically significant (P>0.05) time point to time point 
(Appendix III Table 3.3). 
Uterine horn damage showed an overall constant mean volume per injury site from 30 
seconds to 3 days (Graph 3.5; Appendix III Table 3.2). A significant increase (P<0.01) 
occurred between 3 and 5 days (Figure 3.7). Between 5 and 7 days a significant decrease 
(P>0.001) in mean volume was seen (Appendix III Table 3.3). From 7 days to the end of 
our study mean volume of uterine horn damage remained constant. 
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Graph 3.3: Mean tissue generation volumes 
together with SEMs and statistical differences. 
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Peritoneal reaction was evident at 30 seconds after injury (Graph 3.6; Appendix III Table 
3.2) and demonstrated a steady increase in mean volume up to 8 hours. From 8 to 16 
hours there was a significant increase (P<0.0001) in mean volume, then a significant 
decrease (P<0.001) from 16 hours to I day. This was followed by a significant increase 
(P<0.001) from 24 hours to 3 days with mean volume remaining constant between 3 and 
5 days. After 5 days there was a steady decrease in mean volume per time point group 
(Appendix III Table 3.3). 
Peritoneal cellular concentration was not present until 4 hours after injury, and levels 
seen up to I day were minimal (Graph 3.7; Appendix III Table 3.2). After 16 hours a 
III 
Pathogenesis of AUs Chapler 3 
significant increase (P<0.05) in mean volume was observed which peaked at 3 days. 
Following this was an equally sharp decrease, with non detectable levels seen from 14 
days onwards (Appendix III Table 3.3). 
Mean uterine horn haemorrhage was seen at the first sample time point of 30 seconds 
and remained until 3 days (Graph 3.8; Appendix III Table 3.2). Although there were 
many fluctuations during this time, the general trend was similar volumes from 30 
seconds to 3 minutes, followed by an increase at 5 minutes, with levels remaining 
elevated up to I day, after which a sharp decrease was seen. Significant changes 
(P>0.05) were seen between 8 and 16 hours, 16 hours and I day, I and 3 days and 3 and 
5 days (Appendix III Table 3.3). 
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Graph 3.6: Mean peritoneal reaction volumes 
together with SEMs and statistical differences. 
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Graph 3.8: Mean volumes of uterine horn haemorrhage 
together with SEMs and statistical differences. 
The overall coefficient of error was calculated to be 11.4%. 
3.4.2 Discussion 
( 7itipler 3 
The overall incidence of PSAs in this study was found to be 85% (microscopic) to 90% 
(macroscopic/in vivo). These are calculated from the first time point in which PSAs were 
present in the majority of cases, 8 hours and onwards for microscopic and 10 minutes 
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and onwards for macroscopic observations. These incidences are comparable to the 
recently reported clinical incidence of 93% for human post operative intraperitoneal 
adhesions (Menzies and Ellis, 1990; Duron et al., 1993). 
The injury used in this study was more than severe enough to have the potential to 
induce PSAs in all cases. It is hypothesised that all cases formed primary or fibrinous 
PSAs in response to the abrasion injury but subsequently some of these fibrinous PSAs 
underwent lysis, decreasing the incidence of PSAs for the whole of this study. Support 
for this comes from both observations made by surgeons and this study. Reports that 
PSAs formed during the early post-operative period spontaneously lyse are prevalent in 
the surgical community, with a similar situation seen during this study: 100% of cases 
from 8 hours to I day possessed PSAs and it was not until after this time that incidence 
decreased at some sample time points. Hence fibrinolysis of initial, fibrinous PSAs 
occurred in approximately 10-15% of the cases in this study, with this phenomena 
probably due to increased fibrinolytic capacity of those individual animals. 
Although experimental sites were adhered in vivo in as little as 10 Minutes following 
injury, it was not until I hour post injury that these fibrinous PSAs were tenacious 
enough to remain intact whilst until going tissue resection, slicing and processing. Hence 
the formation of fibrinous PSAs in response to mechanical injury is very rapid and 
quicker than previous estimates of 3 hours (Thrompke & Siegner, 1955). 
- From 4 to 16 hours post injury, maximal increases in PSAs volume were seen, hence a 
period of intense PSA infrastructural modelling occurred at this development stage. This 
is probably primarily due to laying down of fibrin and it would appear that the deposition 
of fibrin is a stimulator of further fibrin deposition. In addition to fibrin deposition we 
also know that during this time period the inflammatory response of wound healing is 
being established (Milligan & Raftery, 1974) with PMNL and macrophage involvement. 
These cells are known for their phagocytotic and chemotactic activity, releasing a wide 
variety of cytokines and growth factors. This cellular and biochemical activity maybe 
another stimulator for the deposition of further fibrin shown in this study as the increase 
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in mean PSA volume. 
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From 16 hours to 7 days there was a trend for mean volume of PSA to increase. Initially 
this trend is due to further fibrin deposition, however from 4 days onwards it is most 
probably due to collagen lay down by fibroblasts (Milligan & Raflery, 1974). In addition 
cellular infiltration and activity and angiogenesis will also exert an effect on PSA volume. 
Hence from 16 hours onwards PSA remodelling was occurring, with fibrinous PSAs 
transforming into established fibrous PSAs. From 7 days onwards a trend for mean PSA 
volume to decrease was seen. It is hypothesised that this is a result of contraction of 
collagen bundles (Ellis et al., 1965) and to some extent decreasing cellular presence 
(Milligan & Raflery, 1974). 
Considering PSA prevention, any therapeutic intervention should be directed at these 
first stages of PSA development, ideally at the time of surgery thus preventing PSA 
modelling. Failing this lysis of PSAs should be concentrated during the period of PSA 
modelling, that is the first 16 hours following injury. Any attempts at separation or lysis 
of PSAs after this time will be increasingly difficult and carry a higher risk of stimulating 
further PSAs by the action of adhesiolysis. 
PSAs, by definition, are not isolated entities and the effects of changes in adjacent and 
underlying tissues on the development of PSAs has been generally neglected by previous 
studies. Studies by Ellis (1962) and Belzer (1967) have demonstrated a relationship 
between damage and PSAs, with the results of this study supporting this, with a direct 
relationship between the volume of the original injury including tissue changes associated 
with the original injury and the volume of injury tissue generated from those damaged 
tissues (PSA and tissue generation). According to these results it is possible that n-dnor 
contusional injury, not readily seen as operative trauma, may have the potential to induce 
PSAs. This is in support of those authors who suggest that heavy handling of tissues 
during surgery results in PSA development (Connolly & Smith, 1960). 
The time scale for injury tissue generation was similar in both the peritoneal wall and the 
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uterine horn and it appears that injury tissue is the only volume change during the first 
few days of wound healing in this model. After an initial relatively slow injury tissue 
volume changes, there was a period of significant increase in the amount of tissue 
generated. For the peritoneum, this time was from day I to 14 post injury, after which 
time tissue generation decreased, whereas for the uterine horn, the increase in volume 
occurred from 3 to 5 days, and then decreased. This pattern showed a delay in the 
beginning of the most active phase of tissue generation, which was also seen with PSA 
development, although this was much shorter, up to 4 hours. This may show that access 
for PSAs to angiogenesis and other cellular tissue generation stimulators, from both 
injured tissues, constitutes more efficient tissue growth and therefore faster generation of 
PSAs when injury tissue connects peritoneal wall to uterine horn. 
The decrease in tissue generation observed in both peritoneum and uterine horn 
following the above mentioned peak in tissue generation activity could be due to: (i) 
fibrinolysis, but is more probably due to (ii) tissue generation from the injured surfaces 
becoming part of the PSA, (iii) phagocytosis of tissue generation, and (iv) contraction of 
collagen bundles within the tissue. 
The uterine hom produced less tissue generation at each of the time points investigated 
which has been a common feature of all previous studies in this laboratory. This is most 
probably due to the uterine hom sustaining a lower extent of underlying damage 
compared to the peritoneum during injuring. It is clear from the results of this and 
previous studies (Ellis, 1962; Belzer, 1967) that there is a relationship between the 
amount of damage suffered and volume of fibrotic tissue generated. However it is also 
possible that the peritoneum is capable of greater injury-induced reaction, compared to 
the uterine horn, in resp6nse to this type of injury. Support for this can be found in the 
fact that at 30 seconds following injury, oedema was detectable at the peritoneal injury 
site but it was not until I hour following injury that any external reaction was noted in 
the uterine horn. 
Although we have considered our classification of tissue generation to be PSA-like 
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material which is simply not adhered, there may be other differences. This may be 
supported by the different time scales in which they formed, and the significant decreases 
in the mean volume of tissue generation present for both the peritoneum and uterine 
horn, although no significant decrease was seen for PSA volume. A reason for the latter 
could be simple physical parameters if fibrinolysis is involved, with tissue generation 
could be more susceptible to attack due to the larger exposed surface area compared to 
PSA. Equally it is possible that tissue generation only supplied with vascular and cellular 
support from one injury site may take place at a significantly reduced rate compared to 
tissue supplied from both injury sites as with PSAs. 
For both peritoneum and uterine horn, similar changes were seen with regard to mean 
volume of damage: constant volumes up to 3 days representing the volume of tissue 
removed during the injury process, followed by a significant increase and then decrease. 
This follows the normal progression of wound healing. The abrasion injury process 
would not only have removed the serosa and some underlying tissue, but would also 
have damaged underlying and adjacent tissue. This in turn would lead to associated 
hypoxia and ischaernia and subsequently local tissue necrosis. For proper wound healing 
to occur, necrotic tissue needs to be removed and all debris cleared from the injury site 
by phagocytosis. It is this tissue clearance which results in increased damage volume. 
However once cleared tissue repair occurred and by 42 days, the mean volume of 
damage for both uterine horn and peritoneal wall was reduced to very minimal levels 
indicating a successful wound healing process to compensate for damaged/lost tissue. 
Clearance of necrotic tissue by phagocytotic cells is highlighted by the correlation 
between peritoneal cell concentration and peritoneal damage volumes. Following the 
peak in peritoneal cell concentration at 3 days post injury there was a peak in peritoneal 
damage at the next time point of 5 days. This suggests that between 3 and 5 days post 
injury there was very active phagocytic response which was highly effective at damaged 
tissue removal. Cellular concentrations observed additionally follows the pattern of 
cellular activity during PSA development. Milligan and Raftery (1974) reported intense 
cellular infiltration into damage tissue between I and 5 days after tissue injury which is 
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precisely what was seen in this study, with a peak in cellular concentration occurring at 3 
days. 
Peritoneal cellular concentration results also correspond with that for peritoneal reaction. 
If we assume that a significant portion of the reaction which we see microscopically is 
due to biochemical mediators, controlling inflammation and cell infiltration, then the peak 
seen in this biochemical reaction corresponds with that seen with cellular concentration. 
Our results indicate that chemotactic activity is occurring within adhered tissues. 
Reaction within the peritoneal wall seen at 42 days following injury was still relatively 
high, especially compared to that seen at the initiation of this study. Wound healing can 
take several months to be completed so this reaction was not surprising, however levels 
observed were higher than expected. This could be due to peak levels of reaction being 
so elevated that a significant amount of time is needed for reaction to subside. In this 
case, PSA formation must induce a large and sustained reactive tissue response. 
Although microscopically we could not distinguish an area of reaction on the uterine 
hom at the magnification used, haemorrhage was evident up to 3 days following injury. 
Due to the highly vascular nature of the uterine hom it is not surprising that this type of 
injury would induce a haemorrhagic reaction. The haemostatic state of the uterine horn 
was completely restored by 5 days following injury. 
Conclusions 
i. In vivo PSAs were present from 10 minutes following injury, although these initial 
linkages are relatively weak and tenuous, 
ii. Tenacious PSAs were present from I hour post injury. 
iii. PSA development can be classified into two distinct stages: 
* PSA modelling - occurring during the first 16 hours, in which maximum rate 
of PSA construction transpires. 
* PSA remodelling - from 16 hours onwards, in which primary fibrinous PSAs 
mature into established fibrous PSAs. 
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iv. An estimated 10 to 15% of fibrinous PSAs were broken down during the course of 
this study. 
v. There was a direct relationship between volume of damage (initial and subsequent) 
and the volume of injury tissue generated. 
vi. PSA development follows the normal pattern of wound healing. 
MURY 
fibrin exudate 
(PSA or tissue generation) 
inflammatory response 
(cellular and biochemical) 
tissue necrosis 
clearance of 
necrotic tissue 
TISSUE REPAIR 
vii. PSA prevention should ideally be initiated immediately post injury to prevent PSA 
modelling or alternatively during PSA modelling. 
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Figure 3.8-. Summary of physiological changes occurring during PSA development. 
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3.5 Volumetric Analysis of Fibrin and Collagen 
Fibrin and collagen are the main structural elements present in fibrinous and fibrous 
PSAs respectively. Milligan & Raftery (1974) demonstrated that up to 3 days post injury 
PSAs were constructed of a fibrin matrix, with a few collagen fibres first seen at 3 days. 
After 3 days this equilibrium was reversed with collagen being the predominant structural 
protein and fibrin nearly totally removed. By 5 days collagen formation was advanced 
with collagen bundles now present and further maturated seen from thereon. Hence 
fibrinous PSAs are seen up to andfincluding 3 days, after which they are transformed into 
fibrous PSAs. 
The aims of this study were to: 
i. substantiate the fibrinous and fibrous nature of PSA described previously by 
quantitatively investigating volumes of fibrin and collagen in developing, 
experimentally-induced PSAs and tissue generation 
ii. compare adhered and non adhered cases within the control group with regard to fibrin 
and collagen composition and determine structural differences. 
Odd numbered slices of all experimental sites were processed to paraffin wax with 59m 
sections cut from each block. Sections were stained with PTAH for fibrin detection 
and/or Van Gieson for collagen detection and analysed using Cavalieri's Principal for 
determining absolute volumes of fibrin and collagen (refer to Chapter 2). 
3.5.1 Results 
During the first 16 hours following injury, fibrin only was present in injury tissue (PSAs 
and tissue generation) and was predominant for the first 3 days (Graph 3.9; Appendix III 
Table 3.4; Figure 3.9). From I to 28 days percentage of fibrin present decreased, with 
significant decreases between I and 3 days (P>0.01), 3 and 5 days (P>0.0001) and 14 
and 28 days (P>0.05) (Appendix III Table 3.5). 
Collagen was first evident at I day following injury, although only accounting for 0.07% 
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(Graph 3.9; Appendix III Table 3.4). However, from this time point to 28 days mean 
percentage of collagen increased, with significant increases between I and 3 days 
(P>0.01), 3 and 5 days (P>0.0001) and 14 and 28 days (P>0.05) (Appendix III Table 
3.5). By 5 days collagen was the predominant structural protein present, with this trend 
maintained throughout the remainder of this study (Figure 3.10). 
Volume of fibrin increased from 1 to 8 hours., with a significant increase (P>0.01) 
between I and 4 hours and volumes remaining similar up to I day post injury (Graph 
3.10; Appendix III Tables 3.4 and 3.5). There was then a rapid and significant increase 
(P>0.01) between I and 3 days, at which time point volume of fibrin peaked. A dramatic 
decrease occurred from 3 to 5 days, followed by a steady decline with a significant 
decrease (P>0.05) from 14 to 28 days, at which time fibrin was absent. 
At I day collagen was present in very small volumes and demonstrated a minor but 
significant increase (P>0.01) in volume from 1 to 3 days (Graph 3.10; Appendix III 
Tables 3.4 and 3.5). From 3 to 14 days collagen volume increased rapidly with significant 
increases from I to 3 days (P>0.01) and 3 to 5 days (P>0.001). Maximum collagen 
volume was reached at 14 days and a si0ficant decrease (P>0.05) was seen from 14 to 
28 days, after which little change was seen. 
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Graph 3.9: Mean fibrin and collagen percentages 
together with SEMs and statistical differences. 
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Comparison of tissue zones demonstrated significant differences between tissue zones at 
two sample time points following injury (Graphs 3.11 and 3.12, Appendix III Table 3.6). 
At 3 days, significant differences were demonstrated between UTG and PSA (P<0.01) 
and UTG and PTG (P<O. 00 1), with UTG having greater mean percentage of fibrin/lower 
mean percentage of collagen. At 5 days post injury, significant differences were seen 
between PSA and PTG (P<0.05) and PSA and UTG (P<0.05), with PSA demonstrating 
greater mean percentage of fibrin/lower mean percentage of collagen. 
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Analysis of adhered and non-adhered cases revealed a trend for non-adhered cases to 
have lower mean fibrin volumes at 5 and 7 day time points compared to adhered cases. 
However significant differences (P<0.05) were only seen for mean total volume of 
collagen at 5 and 42 days post injury, with adhered cases demonstrating greater mean 
volumes compared to non-adhered cases (Graph 3.13, Appendix III Table 3.7). 
The mean coefficient of error for this study was 7.1%. 
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Graph 3.13: Mean collagen volumes for adhered and non-adhered cases 
together with SEMs and statistical differences. 
3.5.2 Discussion 
Fibrin was the predominant structural protein present from I hour to 3 days post injury 
after which it significantly decreased (P<0.001), with collagen dominant from 5 days to 
the end of the study. This correlates with the previous study by Milligan and Raftery 
(1974) which stated that fibrin was present until 4 days post injury with all remains 
removed thereafter, and collagen production began at 3 days. In addition data fits with 
Jackson (1958) who stated that transient PSAs are absorbed by fibrinolysis within 72 
hours following injury, hence, during this time, are fibrinous in nature. 
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PSAs and peritoneal and uterine hom tissue generation are fibrinous up to/including 3 
days post injury, after which there is a rapid conversion, with fibrous PSAs seen 
thereafter. This information is very important with regard to PSA prevention. Fibrinous 
PSAs have the potent to undergo lysis with minimal tissue injury or chance of stimulating 
further PSAs, these are therefore the types of PSAs which preventative agents should be 
targeted against. Lysis or separation of fibrous PSA will be significantly more traumatic, 
associated with potential tissue injury and subsequent stimulation of PSA formation. 
From 30 seconds to 30 minutes, tissue generated in response to injury consisted of blood 
cell clots on the surface of the peritoneal wall and uterine horn. It was not until I hour 
post injury that fibrin strands were observed together with blood cell clots and this 
corresponds with the first presence of tenacious PSAs (refer to Section 3.4). Little 
change was seen at 4 hours, however by 8 hours, fibrin strands had increased and they 
had formed meshworks. This increased structural strength corresponds with 100% ex 
vivo PSA presence (refer to Section 3.4) and highlights the importance of a fibrin 
framework for the development of PSAs. Cell involvement was seen together with fibrin 
up to 3 days and then was less predominant, corresponding with the domination of 
collagen at 5 days and onwards. Collagen production was first seen at I day post injury 
therefore between 16 hours and I day fibroblasts had entered injury tissue and begun 
production of collagen. Lay down of collagen was rapid between 3 and 14 days when 
peak collagen volume was seen. After this, collagen volume decreased due primarily to 
contraction of collagen bundles. 
During the course of this study, mean volumes of fibrin and collagen failed to reach the 
values determined for total tissue generation. Reasons for this are that, initially, some of 
the tissue identified as tissue generation will be liquid exudate released from the 
experimental site in response to injury. Further into development, cellular involvement 
will account for a large proportion of tissue generated, with blood and lymph vessels 
formed by angiogenesis also adding to tissue generation volume. 
During this study all cases sampled from 8 hours to I day possessed PSAs whereas 
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approximately 10-15% of cases sampled from 3 days onwards did not have PSAs 
present. It is hypothesised that these PSA-fi-ee cases did produce fibrinous PSA in 
response to injury and that these fibrinous PSAs were present up to I day post injury 
after which they were lysed. Hence natural fibrinolysis of fibrinous PSAs occurred 
between I and 3 days following injury which correlates with the time in which fibrin 
volume was decreasing and collagen production began in earnest. It would appear from 
the data, that this is the period in which fibrinous PSAs are most susceptible to 
lysis/division. 
Adhered control cases demonstrated a trend for greater mean percentages and volumes 
of fibrin at 5 and 7 days compared to non-adhered control cases at these sample time 
points. Since no significant differences were seen for total mean volumes of these tissue 
zones (Appendix III Tables 3.8 and 3.9) the mean fibrin volumes are true differences. 
This supports the hypothesis that non-adhered cases have greater fibrinolytic capacities 
compared to adhered cases. In addition, the physical factor of exposed surface area of 
fibrin available for fibrinolysis could play a role in this increased amount of fibrin present 
in adhered compared to non-adhered cases. 
These hypotheses are supported by comparison of fibrin and collagen composition in 
PSAs and tissue generation zones which revealed that fibrin tends to remain in PSAs for 
a longer time compared to tissue generation zones. In addition there is a trend for fibrin 
to remain present in UTG longer than PTG. Since these observations are taken from 
percentage comparisons, peritoneal and uterine horn tissue generation have a trend to 
have greater collagen composition compared to PSA. This is directly accountable to 
fibroblasts either being greater in number or a similar number laying down more collagen, 
with the former theory the most probable due to easier access to tissue generation zones. 
Analysis of numerical densities and total numbers of cells within tissue zones will clarify 
this matter. 
Conclusions 
i. PSAs and tissue generation are primarily composed of fibrin during the first 3 days 
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following injury and are termed fibrinous. 
ii. PSAs and tissue generation are primarily composed of collagen from 5 days onwards 
and are termed fibrous. 
iii. PSA prevention should be aimed at fibrinous PSAs rather than fibrous PSAs- 
iv. The composition of injury tissue varies throughout PSA development: 
9 Between 30 seconds to 30 minutes tissue was composed of blood cell clots 
produced during haemostasis 
From I to 4 hours fibrin strands were present resulting in the formation of 
tenacious PSAs 
9 From 8 hours to 3 days a fibrin meshwork was present, resulting in 100% 
incidence of PSAs 
From I day onwards collagen strands were present. These aligned in collagen 
bundles by 5 days when collagen was predominant leading to the formation of 
established fibrous PSAs. Contraction of collagen bundles occurred from 14 
days resulting in reduced volume. 
v. Approximately 10-15% of fibrinous PSAs were lysed during this study between 
and 3 days. This appears to be a susceptible time for fibrinous PSA lysis. 
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Figure 3.11: Summary of fibrin and collagen changes during PSA development. 
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3.6 Number Analysis of Cellular Components 
Due to the nature of PSAs there is high cellular content and activity throughout their 
formation and maturation. Milligan & Raftery (1974) demonstrated that PMNLs were 
the predominant cell type present in PSAs at I day following their induction, however 
macrophages and eosinophils were also present. By 2 days macrophages had become 
more established, sharing the predominance with PMNLs, with lymphocytes and 
eosinoPhils also present. During the next day numbers of PNINLs decreased with 
macrophages, followed by eosinophils, predominant. Fibroblasts increased in numbers 
from 4 to 7 days with numbers of macrophages and eosinophils decreasing. By 14 days 
and onwards cells were relatively sparse, with fibroblasts and occasional macrophages 
seen (refer to Section 1.1.6.5.2). 
Morphological differences exist between human and several mammalian species, with the 
main difference between rabbit (Appendix III Table 3.16) and human blood cells is that 
rabbit neutrophils contain granules which stain pink, that is eosinophilic granules, which 
are absent in human neutrophils. This difference has lead to confusion with cell 
identification of rabbit blood cells over the years. For the purpose of this study, granular 
cells which contained eosinophil granules were termed eosinophilic cells and those with 
only basophil granules termed basophilic cells. In addition monocytes and lymphocytes 
were counted. 
Although Milligan & Raftery (1974) detailed differences in cell presence through PSA 
development no study has quantified cellular presence. Thus aims of this study were to: 
i. quantify the numbers of basophilic cells, eosinophilic cells, macrophages, lymphocytes 
and fibroblasts present in PSA and peritoneal. and tissue generation from I hour to 42 
days following injury 
I identify cellular trends influencing PSA development. 
Even number slices obtained from uniform random slicing of experimental sites were 
processed to resin. A section was cut from each resin block at a thickness of 25[tm, 
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stained with a modified Giemsa stain and analysed using a stereological technique, the 
optical brick, for determining number density. Total numbers were then calculated from 
numbers densities and volumes (refer to Chapter 2). 
3.6.1 Results 
3.6.1.1 Number Densities 
3.6.1.1.1 Cell Predominance 
Number density predominance of cells investigated varied throughout PSA, PTG and 
UTG formation and development (Graph 3.14; Appendix III Table 3.10). From I to 4 
hours basophilic cells were the predominant cell type, followed by eosinophilic cells, 
macrophage, lymphocytes and fibroblasts respectively. There was a slight change seen 
between I and 4 hours with eosinophilic cells becoming the predominant cell type over 
basophilic cells. This pattern remained unchanged up to/including I day post injury, after 
which there was a significant shift in cell predominance's. From 3 days (5 days for PSAs) 
until the end of the study, fibroblasts were the predominant cell types followed by, in 
order of predominance, macrophages, basophilic cells, eosinophilic cells and 
lymphocytes. Hence inflammatory cells (eosinophilic cells, basophilic cells and 
macrophages) were predominant for the first day following injury after which tissue 
repair cells (fibroblasts and macrophages) were predominant (Figures 3.12 and 3.13). 
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3.6.1.1.2 Post Surgical Adhesions (PSAs) 
Number density for all cells analysed (total cells) within PSAs demonstrated an increase 
from 4 to 16 hours, peaking at 16 hours with a significant increase seen (P<0.01) from 8 
to 16 hours (Graph 3.15; Appendix III Table 3.10 and 3.11). From 16 hours to 3 days 
there was a slight trend to decrease followed by a significant increase (P<0.05) from 3 to 
5 days post injury. This second peak in number density at 5 days was transient with a 
significant decrease (P<0.01) from 5 to 7 days, with a trend for mean total cell density to 
decrease there after. 
Basophilic cell number density within PSAs showed an increase from 4 to 16 hours, 
peaking at 16 hours (Graph 3.15; Appendix III Table 3.10 and 3.11). Mean cell density 
then decreased until the end of the study, with a significant decrease (P<0.05) seen 
between 5 and 7 days. Eosinophilic cells demonstrated a similar trend to basophilic cells. 
From 4 hours onwards mean cell density increased to peak at 16 hours, with this increase 
significant (P<0.05) from 8 to 16 hours. From 16 hours to 42 days eosinophilic cell 
density decreased with a significant decrease (P<0.001) from I to 3 days (Graph 3.15; 
Appendix III Tables 3.10 and 3.11). 
Number density of macrophages and fibroblasts followed very similar trends throughout 
PSA development (Graph 3.15; Appendix III Tables 3.10 and 3.11). From 4 hours to I 
day there was little change, however, from I to 5 days there was an increase with 
number density peaking at 5 days post injury. This increase in mean density was 
significant for macrophages (P<0.01) from I to 3 days and for fibroblasts between I and 
3 days (P<0.01) and 3 to 5 days (P<0.001). After peaks at 5 days both macrophages and 
fibroblasts significantly decreased between 5 and 7 days (P<0.05 and P<0.01 
respectively) with macrophages showing a further decrease for the remainder of the 
study whereas fibroblast density remained relatively constant. 
There was little change in number density of lymphocytes throughout PSA development, 
however, mean density up to 3 days post injury showed a trend to be slightly greater than 
those after 3 days (Graph 3.15; Appendix III Tables 3.10 and 3.11). 
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3.6.1.1.3 Peritoneal Tissue Generation (PTG) 
Chapter 3 
Number density for total cells within PTG showed an increase from I to 16 hours, with 
significant increases (P<0.05) between I and 4 hours and 8 to 16 hours (Graph 3.16; 
Appendix III Tables 3.10 and 3.11 ). From 16 hours to I day there was a sharp decrease 
in total cell density followed by levels demonstrating a very slight trend to decrease until 
the completion of this study. 
Basophilic cell density within PTG remained unchanged from I to 8 hours post injury 
after which it increased to peak at 16 hours (Graph 3.16; Appendix III Tables 3.10 and 
3.11). Following this, density decreased steadily for the remainder of the study. 
Eosinophilic cells increased from the first sample time point of I hour to peak at 16 
hours, with a significant increase (P>0.001) between I and 4 hours. From 16 hours to 3 
days there was a sharp decrease in density, being significant from I to 3 days (P<0.001), 
with the trend to decrease continued there after (Graph 3.16; Appendix III Tables 3.10 
and 3.11). 
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Macrophage density were relatively constant for the first day of this study, with a 
significant increase (P<0.01) between I and 3 days (Graph 3.16; Appendix III Tables 
3.10 and 3.11). Mean density plateauxed from 3 to 7 days after which there was a 
significant decrease (P<0.05) from 7 to 14 days, with levels remaining at this minimal 
value for the rest of the study. The density of fibroblasts within PTG did not 
demonstrated any change until after I day when there were significant increases from I 
to 3 days (P<O. 0 1) and 3 to 5 days (P<O. 05) (Graph 3.16; Appendix III Tables 3.10 and 
3.11). From 5 days onwards mean density remained stable with a very slight decrease 
seen overall. Mean density of lymphocytes throughout PTG formation and development 
remained constant (Graph 3.15; Appendix III Tables 3.10 and 3.11). 
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Graph 3.16: Mean cell densities throughout PTG development 
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3.6.1.1.4 Uterine horn tissue generation (UTG) 
Total cell density within UTG showed an increase from I to 16 hours peaking at this 
time point (Graph 3.17; Appendix III Tables 3.10 and 3.11). From 16 hours to I day 
there was a significant decrease (P<0.01) in mean density which remained unchanged at 
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3 days. There was another increase between 3 and 5 days and a second peak in mean 
total cell density. From 5 to 7 days there was a decrease in mean density with little 
change there after. 
Basophilic cell density within UTG decreased significantly (P<0.05) from I to 4 hours 
. post 
injury (Graph 3.17; Appendix III Tables 3.10 and 3.11). Mean density showed a 
slight but gradual increase from 4 to 16 hours, with a slight peak at 16 hours. From 16 
hours to 3 days, levels decreased and little change was seen throughout the remainder of 
this study. Eosinophilic cells demonstrated a progressive trend to increase from I to 16 
hours, with a significant increase (P<0.001) in mean cell density between I and 4 hours. 
After peaking at 16 hours post injury, eosinophilic cell density decreased sharply until 5 
days, after which density were comparatively stable (Graph 3.17; Appendix III Tables 
3.10 and 3.11). 
Macrophage density varied little froml hour to I day, although a slight peak was evident 
at 16 hours. From I to 5 days there was a trend to increase, with a peak at 5 days and 
subsequently numbers decreasing until 42 days post injury (Graph 3.17; Appendix III 
Tables 3.10 and 3.11). Fibroblasts were at their minimal density from I hour to I day 
(Graph 3.17; Appendix III Tables 3.10 and 3.11). From I to 5 days there was a rapid 
increase in cell density, with a significant increase from I to 3 days (P<0.05). From 5 to 
7 days mean density decreased with consistent densities seen thereafter. As with PSA 
and PTG, lymphocyte density throughout UTG development demonstrated no significant 
changes (Graph 3.17; Appendix III Tables 3.10 and 3.11). 
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Chapler. 5 
T test analysis of number densities within PSA, PTG and UTG identified significant 
differences for basophilic cells, fibroblasts and cell totals. Number densities of fibroblasts 
and totals were significantly greater in PTG compared to PSA at 5 days (P<0.05) and 28 
days (P<0.01) following injury. However number densities were significantly greater 
(P<0.05) in UTG compared to PTG for the following: basophilic and total cells at I 
hours; total cells at 4 hours; fibroblasts at 16 hours; and fibroblasts and totals cells at 28 
days following injury. There were no significant differences for number densities between 
PSA and UTG at any time point (Appendix III Table 3.12). 
3.6.1.2 Total Numbers 
Cell Predominance 
Total numbers of basophilic cells, eosinophilic cells, macrophages, fibroblasts and 
lymphocytes within PSA, PTG and UTG for each case were calculated by multiplying 
number densities by the relevant volumes (determined using Cavalieri's Principal). Due 
to the determination of total numbers, total cell number predominances were the 
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same as those for number densities however there were minor differences with regard to 
cell percentages (Graph 3.18; Appendix III Table 3.13). 
PSA PTG 
100 
90 
80 
70 
c» 60 
50 
40 
30 
20 
10 
0 
0 (1) (A V) W (1) Ne !2 12 >ý 00A 0) U) U) ý !2 !2 !2>, 0 V) 'n w V) Q) >ý >ý >1 >ý >ý >1 0== :)- >ý >1 >1 >ý >1 >ý >ý >. >1 >. >ý >. MM 1: 0000MMMMM 0: 3: 3=3 
IS) is is 10000 000003 1000 330,333 M Lf) r- -M MM - T. TZ TZ -000 OD C14 M0 r- IT CO N- (n V) r- IT OD N It Co 0- (N IV IT 00 (D 
Time Elapsed Following Injury 
i Basophlic Cells ý Eossnophilic Cells 10111111111 Macrophages [ 
Fibroblasts ý Lymphocytes 
UTG 
ýee e...... Neeg >ýWww woo ýeee>, Wwm 03==m >ý >ý >1 >ý mm0===m >ý >1 >1 >ý >1 >ý 0 :3 :3=3 >ý >. >1 1: 00o0mmmmm00mmm 7: 000c) a(sisooo 0000ols mo 
- 
000 M MM -m TZ TZ 
IT 
Graph 3.18: Number total cell predominances in PSA- PTG and UTG. 
3.6.1.2.2 Post Surgical Adhesions (PSAs) 
Total numbers of all cells analysed (total cells) located within PSAS through their 
formation and maturation demonstrated a similar bi-phasic pattern as seen with number 
density. There was an increase in mean number from 4 to 16 hours, with a significant 
increase (P<0.001) between 8 and 16 hours. Little change was seen from 16 hours to 3 
days after which there was a rapid increase with mean numbers peaking at 5 days. From 
there on mean number of total cells decreased (Graph 3.19; Appendix III Tables 3.13 
and 3.14). 
Total numbers of basophilic cells in PSAs increased from 4 to 16 hours (Graph 3.19; 
Appendix III Tables 3.13 and 3.14). From 16 hours to 5 days mean number remained 
relatively constant with a decrease there after. Whereas eosinophilic cells demonstrated 
an increase from 4 to 16 hours, being significant (P<0.0001) from 8 to 16 hours. Little 
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change was seen from 16 hours to I day after which there was a decrease in mean 
numbers up until 28 days. This was significant (P<0.05) between I and 3 days and 
between 7 and 14 days. Mean numbers remained minimal from 28 to 42 days post injury 
(Graph 3.19; Appendix III Tables 3.13 and 3.14). 
Macrophage numbers within PSAs remained unchanged from 4 hours to I day (Graph 
3.19; Appendix III Tables 3.13 and 3.14). This was followed by a steady increase, 
significant (P<0.05) between 3 and 5 days, with mean numbers peaking at 5 days post 
injury and decreasing there after. Fibroblasts followed a similar pattern to macrophages. 
No significant change in mean number was seen within the first day however from I to 5 
days there was a rapid increase, with a significant increase (P<0.05) between 3 and 5 
days. After this 5 day peak levels decreased until the completion of the study (Graph 
3.19; Appendix III Tables 3.13 and 3.14). Lymphocytes showed little variation 
throughout the course of this study, with a slight peak seen at 16 hours post injury 
(Graph 3.19; Appendix III Tables 3.13 and 3.14). 
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3.6.1.2.3 Peritoneal Tissue Generation (PTG) 
Total numbers of cells within PTG increased from I to 16 hours, with significant 
increases (P<0.05) from I to 4 and 8 to 16 hours post injury (Graph 3.20; Appendix III 
Tables 3.13 and 3.14). There was a decrease from 16 hours to I day although this was 
not statistically significant (P>0.05). From I to 14 days mean total numbers of cells 
increased, a significant increase (P<0.05) between I and 3 days. Following the peak at 14 
days mean numbers rapidly decreased, with a significant decrease (P<0.01) between 14 
and 28 days. 
Numbers of basophilic cells increased from I hour to peak at 16 hours with a significant 
increase (P<0.05) seen between 8 and 16 hours. This was followed by comparatively 
constant number from 16 hours to 14 days, a decrease seen from there on (Graph 3.20; 
Appendix III Tables 3.13 and 3.14). Eosinophilic cells within PTG increased from I 
hour, a significant increase (P<0.05) between I and 4 hours, peaking at 16 hours post 
injury (Graph 3.20; Appendix III Tables 3.13 and 3.14). Mean numbers of eosinophilic 
cells then decreased to 3 days, with constant levels seen until the end of the study. 
Macrophage numbers showed little variation for the first day (Graph 3.20; Appendix III 
Tables 3.13 and 3.14). However from I day there was a steady increase, significant 
between I and 3 days (P<0.01) with numbers peaking at 7 days post injury and 
decreasing there after. Numbers of fibroblasts demonstrated similar trends to 
macrophages. From I hour to I day there were no significant changes, however from I 
to 14 days mean numbers increased with significant increases seen between I and 3 
(P<0.01) and 3 and 5 days (P<0.05). From 14 days onwards numbers of fibroblasts 
decreased, significantly (P<0.05) between 14 and 28 days (Graph 3.20; Appendix III 
Tables 3.13 and 3.14). Numbers of lymphocytes showed no significant trends throughout 
PTG formation and maturation (Graph 3.20; Appendix III Tables 3.13 and 3.14). 
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3.6.1.2.4 Uterine Horn Tissue Generation (UTG) 
Chapter 3 
Total numbers of cells analysed within UTG increased from I to 8 hours, with a 
significant increase (P<0.01) between I and 4 hours (Graph 3.21; Appendix III Tables 
3.13 and 3.14). Little change was seen between 8 hours and 3 days however a significant 
increase (P<0.01) was seen between 3 and 5 days, with numbers peaking at this point. A 
rapid decrease in total number was demonstrated between 5 and 14 days, being 
significant (P<0.01) from 7 to 14 days. A trend to increase was subsequently seen from 
14 days until the completion of this study. 
Basophilic cells demonstrated an increase in number from I to 8 hours (Graph 3.2 11 
Appendix III Tables 3.13 and 3.14). From 8 hours to 3 day little change was seen. 
However there was an increase from 3 to 5 days, levels remaining slightly elevated from 
5 to 7 days and then decreasing. Numbers of eosinophilic cells increased from I to 8 
hours, with a significant increase (P<0.001) between I and 4 hours. From 8 hours to 3 
days mean numbers decreased with little variation from 3 days post injury onwards 
(Graph 3.2 1; Appendix III Tables 3.13 and 3.14). 
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Numbers of macrophages and fibroblasts within UTG demonstrated very similar trends. 
From I hour to 3 days there were no major changes in mean total number. Significant 
increases were seen in both macrophage (P<0.05) and fibroblasts (P<0.01) from 3 days 
to peak at 5 days post injury. Mean numbers then decreased up to 14 days, with 
significant decreases (P<0.01) between 7 and 14 days. Macrophages then remained 
relatively constant for the rest of the study. Fibroblasts, however, showed a trend for 
numbers to increase from 14 to 42 days (Graph 3.21; Appendix III Tables 3.13 and 
3.14). Mean numbers of lymphocytes within UTG showed minimal levels through the 
course of this study, however slightly elevated numbers were seen from 5 to 7 days 
(Graph 3.21; Appendix III Tables 3.13 and 3.14). 
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Graph 3.21: Mean cell numbers throughout UTG development 
together with SEMs and statistical differences. 
During the course of this study significantly greater numbers of cells were located in 
PTG compared to PSA at the following times: macrophages at 8 hours (P<0.01); total 
cells at 7 days (P<0.05); and fibroblasts and total cells at 14 days (P<0.01). Greater 
numbers of cells were found in PSA compared to UTG at: 16 hours for basophilic cells 
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(P<0.05), eosinophilic cells (P<0.01) and total cells (P<0.01); I day for basophilic cells 
(P<0.01), eosinophilic cells (P<0.01), lymphocytes (P<0.05) and total cells (P<0.01); and 
at 3 days (P<0.05) for basophilic cells, macrophages and total cells. Finally greater 
numbers of cells were located in PTG compared to UTG at: I hour for basophilic cells 
(P<0.05), eosinophilic cells (P<0.01), macrophages (P<0.01) and totals (P<0.001); 4 
hours for basophilic cells (P<0.05), eosinophilic cells (P<0.01) and totals (P<0.05); I day 
(P<0.05) for basophilic, eosinophilic and total cells; 3,7 and 14 days for macrophages 
(P<0.05), fibroblasts (P<0.05) and total cells (P<0.01); and 28 days for macrophages 
(P<0.05) (Appendix III Table 3.15). 
The coefficient of error for number density counting was calculated to be 13%. 
3.6.2 Discussion 
Overall trends seen for cellular presence in developing PSAs and tissue generation were 
similar: From I hour to 1 day, inflammatory cells were the predominant cell types 
(eosinophilic cells, basophilic cells and macrophages respectively), however, from 3/5 
days onwards tissue repair cells were the predominant cells present (fibroblasts and 
macrophages). Hence the formation of PSAs and tissue generation has two distinct 
cellular cycles: (i) inflammatory response - predominant up to I day post injury; and (ii) 
tissue repair response - predominant from 3 days onwards, with a rapid conversion 
between these two cellular processes. 
The general trend in all tissue zones analysed for total cells present was an increase in 
mean number from I hour to 16 hours, with a peak at this point. This peak was due to a 
peak in eosinophilic and basophilic cells. This was followed by a decrease in mean 
number and subsequent increase to peak for a second time at 5 day post injury, due to a 
peak in fibroblast and macrophages. This in turn was followed by a decrease with mean 
numbers remaining consistent from 7 to 42 days. Hence during PSA and tissue 
generation development there are two distinct peaks in cellular presence: (i) 16 hours -a 
result of maximal presence of inflammatory cells (eosinophilic and basophilic cells); and 
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(ii) 5 days - due to maximal presence of tissue repair cells (fibroblasts and macrophages). 
It has previously been established that both adhesion free healing and PSA formation 
have the same basic cellular profiles: haemostasis followed by the inflammatory response 
and finally tissue repair (refer to Chapter 1 of this thesis). The results of this study 
conform to this theory and lend support for the 1974 study by Milligan & Raftery. They 
determined that during the first day of PSA development, PMNLs were the predominant 
cells with additional macrophages and eosinophils also present. At 2 days PMNL 
predominance was shared with macrophages, however, eosinophils and lymphocytes 
were also detected. Between 2 and 3 days numbers of PN4NLs decreased significantly 
with macrophages the most numerous cell with some eosinophils still present. From 4 to 
7 days macrophages and eosinophils still remained although there were ever increasing 
numbers of fibroblasts. By 14 days there were relatively few cells present, with those 
consisting of elongated fibroblasts and occasional macrophages. 
Differences seen with regard to PMNLs and eosinophil presence can largely be attributed 
to the animal species difference between this and Mlligan & Raftery's study (1974). 
Their study utilised a rat model, which has easily defined and identifiable neutrophils and 
eosinophils. Whereas, as discussed in the Section 3.7 of this thesis, rabbit subsets of 
polymorphonucellular cells are less defined. 
This study highlights that this transition between the inflammatory response and tissue 
repair with regard to cellular activity is very rapid and highly specific. Considering that 
the formation of PSAs is such a complex and multifactoral process such strict regulation 
is not surprising. For although PSA formation is sometimes regarded as "wound healing 
gone wrong", it is actually a well regulated, tightly controlled process. 
Following the induction of injury, haemostasis will be initiated instantaneously to limit 
blood loss and tissue damage. The final outcome of this process is blood vessel 
contraction, the fomation of a platelet plug and fortnation of a fibrin clot. Platelets 
entrapped within the platelet plug actively secrete chemical mediators which initiate the 
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inflammatory process, resulting in the escape of oedema fluid, including some plasma 
proteins and leukocyte raigration. 
Many different subsets of leukocytes are attracted to the chemotactic chemicals released 
at the injury site but their arrival is dependent upon their location within the body and 
their motility. Although leukocytes are primarily located within the circulatory system 
and within tissues, neutrophils (basophilic cells) have the advantages of being loosely 
adhered to vascular endothelium and are highly motile, with their migration accelerated 
by damage to blood vessels and inflammation. These are the first leukocytes present in 
any numbers at the site of injury as detailed in this and other studies. Eosinophils 
(eosinophilic cells) are the next cell type to arrive, with their predominance established 
very quickly (within 4 hours in this study). Both basophilic and eosinophilic cells possess 
similar characteristics) that is, they are capable of bacterial killing, phagocytosis and 
release of a whole host of cytokines and growth factors, eosinophils are also thought to 
possess anti-histamine properties which have been hypothesised as trying to limit the 
formation of PSAs (Milligan & Raftery, 1974) and be important in the organisation of 
wound healing. 
Following this period of intense inflammatory mediation many cytokines and growth 
factors are synthesised and released, which act as further attractants to cells. 
Mononuclear, leukocytes are present both in, blood as monocytes or in tissues as 
macrophages. The blood monocyte is well established as sluggishly motile hence its 
arrival at the site of injury is after basophilic and eosinophilic cells. Tissue macrophages 
actively kill bacteria and are highly phagocytotic - removing tissue debris and necrotic 
tissue from the injury site in order for proper wound healing to follow. Macrophages also 
release a wide variety of cytokines and growth factors, acting as potent stimulators 
enhancing trauma cell proliferation and angiogenesis. 
The final cell which is essential for wound healing and PSA formation is the fibroblast. 
Once present at the injury site, fibroblasts proliferate and synthesise collagen forming a 
protective layer over injured tissues and establishing fibrous PSAs. They release a variety 
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of chemical mediators and play a pivotal role in angiogenesis. By 5 to 7 days following 
injury, numbers of fibroblasts declined to a constant level, due to fibroblasts becoming 
trapped in the collagen matrix. 
Lymphocyte presence within PSAs or tissue generation throughout their development 
showed little change. Hence no case in this study developed any significant level of 
infection which would have required an immune reaction mounted against it. It is 
universally accepted that infection is a potent stimulator of PSAs however this did not 
play a factor in the formation of the PSAs within this study. 
Although both PSA and peritoneal and uterine horn tissue generation followed the same 
overall pattern with regard to cell predominances throughout their respective 
development, significant differences (P<0.05) were seen at several sample time points. At 
both 5 and 28 days there were greater number densities of fibroblasts and total cells 
within PSAs compared to PTG. This is thought to be a result of greater attraction of the 
fibroblasts into PSAs at 5 days, with their presence sustained for a longer length of time 
(demonstrated at 28 days). This could be due to fibroblast evacuation being more 
difficult within PSA tissue compared to PTG, or their greater numbers increasing 
evacuation time. 
No significant differences (P>0.05) were seen between PSA and UTG number densities. 
However, between PTG and UTG tissues there were differences (P<0.05) at 1,4 and 16 
hours and 28 days. It is most likely that greater number densities were seen within UTG 
compared to PTG due to greater vascularity of the uterine hom compared to the 
peritoneal wall, allowing quicker and increased access to damaged uterine horn tissue 
compared to damaged peritoneum tissue. 
Number totals within PSAs demonstrated peaks at 16 hours, a result of a peak in number 
densities of inflammatory cells and increase in PSA volume and a peak at 5 days, 
resulting from a peak in number density of tissue repair cells and PSA volume. The peak 
in inflammatory cells corresponds to lay down of fibrin, that is, PSA modelling and the 
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peak in tissue repair cells to maximum lay down of collagen, that is, PSA remodelling. 
Peritoneal and uterine horn tissue generation demonstrated peaks in total numbers of 
cells at 16 and 8 hours respectively. These were the primary result of the peaks in 
number density of inflammatory cells, with little to no influence from tissue generation 
volume. The second peak in number totals seen at 14 days for PTG was due to peak in 
PTG volume rather than an increase in number densities whereas the peak at 5 days for 
UTG was due to peaks in UTG volume and number densities. Thus the peak in 
inflammatory cells within tissue generation had no noticeable effect on the volume of 
fibrinous tissue generated, which is in contrast to the situation seen within PSAs. The 
peak in tissue repair cells demonstrated an effect of increasing tissue generated although 
this was a lesser extent in PTG compared to either PSA or UTG. Differences seen 
between PSA and tissue generation with regard to the response to inflammatory cell 
presence could be due to: (i) differences in number densities and totals within 
PSA/PTG/UTG, and/or (ii) PSA inflammatory cells being more "biochemically" active. 
Conclusions 
i. PSA, PTG and UTG demonstrated similar trends with regard to predominant cell 
types throughout their development: inflammatory cells (eosinophilic cells, basophilic 
cells and macrophages) predominant from I hour to I days, with tissue repair cells 
(fibroblasts and macrophages) predominant from 3 days onwards. 
I Peak in inflammatory cells were seen at 16 hours post injury, with the tissue repair cell 
peak at 5 days. 
iii. For PSAs, the inflammatory peak resulted in PSA modelling, however for PTG and 
UTG the inflammatory peak demonstrated no physiological effect. 
iv. The peak in tissue repair cells resulted in an increased volume of PSA and tissue 
generation, although this effect was reduced within peritoneal tissue. 
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Figure 3.14: Summary of cellular presence within tissue generated. 
3.7 Biochemical Analyses 
Formation of PSAs is a complex, dynamic process, involving cellular and biochemical 
systems. Although this activity occurs locally the possibility of systemic involvement has 
as yet remained uninvestigated. The aim of these experiments was to study any systemic 
changes in blood cell numbers and tumour necrosis factor alpha (TNF-(x) and 
transforming growth factor beta (TGF-0) (in both plasma and peritoneal fluid). 
Blood samples were taken at three points throughout the experimental procedure- 
i. blood sample I .- taken pre-operative, that 
is, following anaesthesia but before any 
surgical procedure. This sample acts as both an intra-case control and overall control 
for our animals in this study. 
ii. blood sample 2: taken immediately following initial laparotomy. This sample aims to 
identify any change in response to opening the peritoneal cavity, 
iii. blood sample I taken after the second (termination) laparotomy, with the aim of 
149 
Pathogenesis ofP&4s Chapter 3 
identifying systemic changes occurring with wound healing and/or PSA development. 
Peritoneal fluid samples were taken at two different points throughout the procedure: 
i. peritoneal fluid sample 1: taken immediately following the initial laparotomy to act as 
a (laparotomy) control sample. 
ii. peritoneal fluid sample 2: taken following the second (termination) laparotomy to 
identify any changes associated with wound healing and/or PSA development. 
3.7.1 Full and Differential Blood Counts 
All mammals have similar blood cell types: red blood cells (RBCs), platelets, and white 
blood cells (WBCs), with the latter further differentiated into neutrophils, eosinophils, 
basophils, monocytes and lymphocytes (refer to Appendix I Table 1.2 for cell functions). 
Morphological differences exist between human and several mammalian species, with the 
main difference between rabbit (Appendix III Table 3.16) and human blood cells is that 
rabbit neutrophils contain granules which stain pink, that is eosinophilic granules, which 
are absent in human neutrophils. This difference has lead to confusion with cell 
identification of rabbit blood cells over the years. For the purpose of this study, granular 
cells which contained eosinophil granuleswere termed eosinophilic cells and those with 
only basophil granules termed basophilic cells. In addition monocytes and lymphocytes 
were counted. 
Most routine human full blood counts are performed using automated technology due to 
the time consuming nature of manual counts and possible inaccuracies. For this study 
both automated and manual counts were carried out due to the automated analyser used 
being set up for human samples, hence will fail to identify differences between rabbit and 
human blood cells, producing incorrect differential counts. Results reported in this thesis 
for RBCs, platelets and total WBCs are taken from the auto-analyser with WBC 
differential counts results from manual counting methods. 
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Analysis of blood sample I (pre-operative) showed mean number of RBCs to be 5.31 
x1012/1, platelets 324 x109/1, and WBCs 6.62 x109/1. Differential counts showed 0.11 
x109/1 basophilic cells, 3.28 x109/1 lymphocytes, 0.42 x109/1 monocytes and 2.18 x109/1 
eosinophilic cells (Graph 3.22; Appendix III Table 3.17). 
Mean numbers of cells at blood sample 2 (post-laparotomy) were 5.27 x1012/1 RBCs, 
273 x109/1 platelets, 6.00 x109/1 WBCs, with 0.02 x109/1 basophilic cells, 3.13 x109/1 
lymphocytes, 0.51 x109/1 monocytes and 2.63 x109/1 eosinophilic cells (Graph 3.22; 
Appendix III Table 3.17). 
Overall mean numbers of cells at blood sample 3 (pre-termination) was 4.99 x1012/1 
RBCs. 311 x109/1 platelets, 5.96 x109/1 WBCs, with 0.08 x109/1 basophilic cells, 2.39 
x109/1 IYMphocytes, 0.30 x109/1 monocytes and 3.19 x109/1 eosinophilic cells (Graph 
3.22; Appendix III Table 3.17). 
Statistical analysis of mean numbers for each cell type between blood samples I and 2 
showed a significant difference in basophilic numbers only (P=0.0083). Analysis between 
blood samples I and 3 demonstrated significant differences for lymphocytes (P=0.0164), 
monocytes (P=0.0159), RBCs (P=0.0064) and platelets (P=0.0137). Whereas analysis of 
blood samples 2 and 3 showed significant differences for lymphocytes (P=0.0415), 
macrophages (0.0292) and RBCs (P=0.0051) (Graph 3.22; Appendix III Table 3.18). 
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Blood samples I and 2 were control samples, however sample 3 was an experimental 
sample taken at time points throughout wound healing or PSA development (Appendix 
III Table 3.19). Mean numbers of both RBCs and platelets for blood sample 3 at each 
time point showed very little variation compared to control samples (blood sample I and 
2) (Graph 3.23 and 3.24; Appendix III Table 3.19). However WBCs demonstrated 
differences in blood sample 3 compared to control samples (Graph 3.25; Appendix III 
Table 3.19). From 30 seconds to I hour mean numbers showed a trend to be lower in 
blood sample 3, with a rapid increase from I hour to a peak at 8 hours. Following this, 
mean numbers gradually decreased to control levels at 3 days post injury and WBC 
numbers remained consistent until the end of the study. 
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Basophilic cells demonstrated a trend to remain consistently low up to 3 days post injury, 
with levels similar to blood sample 2. After 3 days mean numbers increased and remained 
elevated between 5 and 14 days. Following this time point there was a trend for mean 
numbers to decrease (Graph 3.26; Appendix III Table 3.19). 
Mean numbers of lymphocytes showed a trend to decrease up to 30 minutes post injury 
with subsequent increases up to 3 days (Graph 3.27; Appendix III Table 3.19). From 
thereon mean numbers decreased to settle out at control levels from 5 days onwards. 
Mean numbers of monocytes for blood sample 3 demonstrated consistently reduced 
levels compared to controls up to 3 days following injury, after which numbers increased 
to control numbers (Graph 3.28; Appendix III Table 3.19). 
Eosinophilic cells demonstrated mean numbers similar to controls from 30 seconds to I 
hour (Graph 3.29; Appendix III Table 3.19). However, following this there was a rapid 
increase to a transient peak at 8 hours with numbers decreasing rapidly thereafter to 3 
days post injury. From 3 to 42 days levels remained akin to controls. 
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3.7.1.2 Discussion 
( 7itipler .ý 
Rabbits are frequently utilised in haernatological studies due to their inappreciable 
fluctuations and ease of bleeding. However previously published data by various authors 
demonstrate marked differences which can be attributed not only to technical skill 
differences but also the unreliability of these animals with regard to blood factors 
(Schermer, 1967). Venesection also exerts considerable effects on blood cell profiles, 
especially when volumes of 10 to 20ml are removed, which are shown on Figure 3.15. 
During this study a 5ml blood sample was taken pre-operatively, 5ml taken post- 
laparotomy, with a final 5ml sample taken prior to termination. For the post-laparotomy 
(sample 2) and pre-termination (sample 3) samples effects of venesection need to be 
taken into consideration. 
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Figure 3.15: Rabbits response to venesection (20ml) 
(Taken from Schermer, 1967). 
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Although several studies have investigated local cellular changes during adhesion-free 
healing and PSA development there is no published information on systemic cellular 
changes. Since marked local cellular and biochemical activity occurs throughout PSA 
formation it is feasible that cellular fluctuations are also demonstrated systemically. 
Since the invasive technique of laparotomy was utilised in the induction of PSAs, any 
potential cellular changes could be attributed to laparotomy rather than PSA 
development. To identify such changes and eliminate them from PSA development, a 
blood sample was taken following the initial laparotomy in addition to a pre-operative 
control sample and experimental, PSA development, sample. Statistical analysis 
demonstrated only a significant difference between the pre-operative control samples and 
post-laparotomy sample for basophilic cells. Since very few basophilic cells were present 
this difference is most probably due to biological variation rather than a physiological 
response. Hence in this study there was little systemic cellular response to laparotomy. 
Further support for this comes from statistical analysis of control samples (pre-operative 
and post-laparotomy) with experimental samples, with significant differences (P<0.05) 
seen with the same cell types (Appendix III Table 3.17). 
Total mean numbers of RBCs, platelets and WBCs for all blood samples taken fall within 
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normal ranges (refer to Appendix III Table 3.16). Since controversy exists with regard to 
rabbit WBC differentiation and identification it is only valid to compare lymphocyte and 
monocyte numbers, with results obtained in this study again failing with normal values. 
Overall it can be concluded that animals in this study provide a fair representation of 
normal haematology with regard to full and differential blood counts. 
Due to the limited number of cases (generally 4) it was not valid to perform statistical 
analyses between experimental blood sample 3 and control samples at time points 
following injury. However identification of trends could be carried out. 
There was little variation from control for both mean numbers of RM and platelets 
within experimental blood sample 3. Since RM are not involved in wound healing and 
platelets only involved in the formation of the platelet plug during haemostasis then their 
similarity to control blood counts was as expected. 
However predominant trends were present for both total and differential counts of 
WBCs throughout PSA development. Total mean numbers of WBCs showed a trend to 
be lower than normal during the first hour following injury, with a rapid increase in 
numbers thereafter. By 3 days systemic levels of WBCs could be seen to be similar to 
controls, with this pattern continued until the end of the study. The pattern seen mimics 
that seen with the effects of venesection, hence it is probable that these changes are due 
to blood collection rather than wound healing/PSA development. 
Mean numbers of basophilic cells demonstrated little variation during the first 3 days 
following injury, after which levels became elevated above normal values until 28 to 42 
days. Although the pattern up to 5 to 7 days appears to correspond to that seen with 
venesection, elevated levels seen after these time points appears to be due to other 
factors. Basophilic cells are primarily involved in the inflammatory stage of wound 
healing therefore increased systemic levels at the latter end and, completion of 
inflammation could be due to: (i) extended inflammatory period in this experimental 
model; (ii) basophilic cells involved in subsequent processes in this experimental model; 
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or (iii) over compensation in response to injury. 
Systemic numbers of lymphocytes demonstrated a trend to be lower than controls from 
30 seconds to 8 hours following injury. This depletion in systemic numbers was 
corrected by 16 hours, with slight peak in numbers at I and 3 days and levels normal 
thereafter. Although the time scale varies slightly ftom. that seen with venesection a 
similar pattern is observed and venesection is probably responsible for changes seen. 
Monocytes, highly phagocytic cells, also demonstrated consistently reduced levels from 
30 seconds until 3 days following injury, indicating monocytes leaving circulation and 
entering injured tissues during the process of inflammation. It is not until inflammation is 
near completion that systemic mean numbers of monocytes; return to control levels, 
highlighting their importance in wound healing. The effect of venesection was a mild 
increase in these cells after I day (Schermer, 1967) and hence does not appear to play an 
important role in the monocytic pattern seen during this study. 
Eosinophilic cells demonstrated control values throughout the whole of this study, 
except for the large transient peak at 8 hours post injury. Eosinophils have been 
implemented in PSA development (Milligan & Raftery, 1974), with their predominance 
in tissues seen at I and 3 days. Thus there appears to be a recruitment of eosinophilic 
cells into circulation prior to maximum local presence. As with monocytes, venesection 
had the effect of causing a mild increase in eosinophilic cells after I day (Schermer, 
1967) and again appears unimportant in this cell type. 
Conclusions 
L In this study there was little to no systemic cellular response to laparotomy. 
ii. Animals in this study provide a fair normal haematological representation with regard 
to full and differential blood counts. 
iii. There was little variation from controls for both mean numbers of RBCs and platelets 
for experimental samples taken throughout PSA development. 
iv. Predominant trends were present for both total and differential counts of WBCs 
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throughout PSA development, with some attributed to venesection and others PSA 
dependent. PSA associated changes were: 
o elevated basophilic cell numbers at 14 and 28 days 
* reduced numbers of monocytes from 30 seconds to 3 days 
e transient peak in eosinophilic cell numbers at 8 hours. 
v. Systen& cellular changes seen during this study should be interpreted cautiously due 
to the small numbers of samples at each time point, effects of venesection and the 
hypersensitivity and large variability of rabbit cell profiles. 
vi. PSA development demonstrated systemic changes with regard to WBCs, basophilic 
cells, monocytes and eosinophilic cells, primarily linked to the inflammatory stage of 
wound healing. 
3.7.2 TGF-p Concentrations 
The ELISA kits employed for detection of TNF-a (Genzyme) and TGF-P (Genzyme and 
R&D Systems) in plasma and peritoneal samples collected throughout this study were 
not specific for the detection of rabbit cytokines (refer to Chapter 2). After extensive 
experiments to detenrnine accurate and reproducible detection of rabbit cytokines, only 
the R&D Systems TGF-P ELISA kit was deemed to be acceptable. Due to time 
constraints only one plasma from time points I hour to 42 days and only one undiluted 
peritoneal fluid sample from 5 to 28 days were assayed, together with controls. 
3.7.2.1 Results 
Similar TGF-P concentrations were demonstrated in pre-operative control sample I and 
post-laparotomy sample 2, with 36% and 13% coefficient of variance within these 
samples respectively. With regard to experimental sample 3 fluctuations in TGF-P 
concentrations were seen throughout PSA development however these were all within 
control concentration except for a large peak at 3 days post injury (Graph 3.30; 
Appendix III Table 3.20) 
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TGF-P was detected in both post-laparotomy control peritoneal sample I and 
experimental peritoneal sample 2 (Graph 3.31; Appendix III Table 3.20). Control 
samples demonstrated small variability with 8% coefficient of variability whereas TGF-P 
concentrations in experimental samples showed a trend to peak at 7 days and 
subsequently decrease to control concentrations by 28 days post injury. 
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Graph 3.31: TGF-P concentration in peritoneal fluid samples. 
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3.7.2.2 Discussion 
Due to the very limited number of samples assayed definitive conclusions can not be 
made. However it is possible to propose emerging trends. 
All plasma and peritoneal fluid samples assayed demonstrated TGF-P present. Mean 
normal resting TGF-P concentrations in human serum and platelet poor plasma (EDTA) 
activated and assayed by R&D Systems were found to be 48.6nghnl and 2.26ng/ml 
respectively. Direct comparisons between human and rabbit resting levels of TGF-P can 
not be made but it is clearly evident that both species normally have TGF-P (active or 
inactive) within plasma. 
Both plasma and peritoneal fluid controls demonstrated an order of variation normally 
associated vAth biological variation. Hence this ELISA kit, although intended for 
detection of human TGF-P detects rabbit TGF-P, accurately and reproducibly (99% 
homology between species (Kondaiah et al., 1990; Massague, 1990)). 
Normal resting levels of TGF-P within plasma and peritoneal fluid appear to be relatively 
stable. With regard to experimental samples, the large peak in TGF-P at 3 days post 
injury detected in the plasma sample and elevated levels in peritoneal fluid samples from 
5 to 14 days can be seen to have possible biological significance. TGF-P is associated 
with wound healing and those cell involved in healing, including platelets, fibroblasts, 
myocytes, astrocytes and epithelial cells. TGF-P is released at wound sites by 
degranulating platelets and results in cellular chemotaxis, protein matrix synthesis and 
further secretion of factors which combine with TGF-P to mediate angiogenesis and 
fibrosis. The limited data obtained so far appears to indicate that TGF-P concentration 
are elevated during tissue remodelling, that is, collagen synthesis and angiogenesis. In 
addition, systemic levels of TGF-P are elevated prior to local levels and could be 
correlated with cellular presence. However the results interpretation is very preliminary 
and requires substantiating. 
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Support for elevation of cytokines within peritoneal and wound fluids comes from 
previous studies. Rong et al. (1997) demonstrated elevated levels of TNF-P, GM-CSF, 
TNF-(x and IFN-y for the first 5 to 7 days post injury and Ford et al. (1989) showed high 
levels of HA and 6., TNF and M-CSF in wound fluid with levels decreasing by the 
thirteen day. It is hypothesised that these cytokines are secreted at the injury site to 
promote tissue remodelling (Ford et al., 1989). 
Conclusions 
i. PSA development may exert an influence on TGF-P levels within plasma and 
peritoneal fluid sample. 
ii, Further experiments are required to authenticate or disprove this hypothesis. 
3.8 Discussion 
Scientific interest in PSAs has demonstrated specific trends: 
" very few studies investigating PSA formation and maturation 
" most studies concentrating on investigating potential PSA agents 
" use of a xvide variety of experimental models - with different species, different 
injury types and methods, different levels of severity 
" qualitative analysis (usually macroscopic) 
When considering these factors it is hardly surprising that to date there is no 
commercially available preventive agent. In order for PSAs to be prevented detailed 
knowledge on PSA development is required. 
This is the first study researching physiological, structural, cellular (local and systemic) 
and biochemical mechanisms occurring throughout PSA development, using a definitive 
experimental model and quantitative analytical procedures (Figure 3.16). 
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The reaction of peritoneal and uterine horn surfaces to injury was very rapid with fibrin 
strands seen connecting the two surfaces within 5 minutes and the surfaces adhered ill 
vivo within 30 minutes. However it was not until I hour that these fibrinous PSAs were 
tenacious enough to remain intact whilst undergoing tissue resection, slicing and 
processing. This tenacity was directly related to the structure of the PSA: from 30 
seconds to 30 minutes the exudate from and joining the injured surfaces was a blood cell 
clot primarily composed of exuded blood cells, however, at I hour the composition 
changed with fibrin strands easily visible between the two surfaces. Hence, as soon as 
fibrin strands were present to provide a framework for a link between surfaces, fibrinous 
PSAs were formed. By 8 hours following injury, fibrin strands had formed a meshwork 
and this increased structural strength of the fibrinous PSA had the effect of increasing the 
incidence of PSAs present, with all cases demonstrating PSAs. 
Further development of PSAs occurred during this early phase of formation, with 
maximum increase per unit time of PSA volume from 4 to 16 hours. This is primarily due 
to fibrin deposition and corresponds to increased/peak numbers of inflammatory cells, 
eosinoPhilic and basophilic cells within the PSA. Hence the infiltration and activity of 
inflammatory cells was a stimulator for the deposition of further fibrin, probably due to 
the release of chemical mediators. 
However this activity had no effect on the volume of tissue generation present on either 
the peritoneal wall or uterine horn. It has been generally considered that PSA and tissue 
generation have the same composition and dynamics, with the only difference being that 
PSA connects the two surfaces. This study has shown that overall structural and cellular 
presence throughout development are not significantly different, however it appears that 
their dynamics are divergent. This is probably a result of the connection of the two 
surfaces, hence PSAs have cellular and biochemical input from both the peritoneal wall 
and uterine horn. 
In addition to causing lay down of fibrin within PSAs, the infiltration of inflammatory 
cells seen up to 16 hours post injury also results in a significant increase in peritoneal 
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reaction and peritoneal cell concentration. Inflammatory cells present within PSAs and, 
to a lesser extent, tissue generation mount the inflammatory response to limit tissue 
injury and release chemical mediators which help co-ordinate the inflammatory response 
and recruit tissue repair cells (fibroblasts and macrophages) into peritoneal tissue to 
initiate the tissue repair. 
From I to 3 days following injury, there was a significant decrease in inflammatory cells 
and significant increase in tissue repair cells. Therefore there was rapid transition 
between the inflammatory response and tissue repair. This highlights the controlled 
regulation and co-ordination of PSA development and wound healing. 
Peak in the presence of tissue repair cells was seen at 5 days post injury and 
corresponded to peaks in PSA and tissue generation volumes. Once fibroblasts have 
entered the wound/PSA they proliferate and synthesise collagen and it was the deposition 
of collagen which was responsible for the peak in physiological volumes. Hence, by 5 
days, fibrinous PSAs have been replaced by established fibrous PSAs. 
By 7 to 14 days following injury PSA development was very near completion. Steady 
decreases in volume were observed due primarily to collagen contraction but also cellular 
evacuation. Within 2 weeks non adhered tissues were returning to normal. It therefore 
appears that the formation of PSAs and underlying tissue repair takes approximately the 
same time as adhesion free healing. 
The injury used in this experimental model was more than severe enough for all cases to 
develop PSAs as a result. However, the overall incidence was between 85-90%. Since all 
cases from 8 hours to I day had PSA present, it is highly probable that all cases did in 
fact develop fibrinous PSAs. However, some of these fibrinous PSAs were lysed before 
they formed fibrous ýSAs. Support for this hypothesis is found by adhered cases 
demonstrating greater percentages of fibrin at 5 and 7 days compared to non-adhered 
cases. 
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Although systemic cellular changes throughout PSA development were minimal, some 
effects were observed. Basophilic cell numbers were elevated from 7 to 14 days, 
monocyte numbers were reduced from 30 seconds to 3 days and a large transient peak In 
eosinophilic cell numbers was seen at 8 hours. Changes in circulating cells were primarily 
linked to the inflammatory stage of wound healing and PSA development. 
Conclusions 
The development of PSAs is a complex, multi-factorial processes, not so much the case 
of "wound healing gone wrong" but controlled interactions of physiological, structural, 
cellular and biochemical processes (Figure 3.17). This is the first study to define PSA 
development into two distinct phases: 
i. PSA modelling: up to/including 16 hours post injury 
Includes- inflammatory response 
fibrin deposition and maturation 
ii. PSA remodelling: from 16 hours onwards 
Includes: tissue repair 
collagen deposition and maturation 
chemical mediation by TGF-p 
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Figure 3.17: Conclusions. 
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4.0 Prevention of PSAs using VivostatTm System Human 
Derived Fibrin Sealant 
4.1 Introduction 
Problems associated writh the presence of PSAs have been recognised since the advent of 
surgical practices. During this century many potential preventative PSA agents have been 
tried, often with very little success, and to date no such agent is commercially available. 
Of all products investigated, physical barriers, especially fibrin sealants have been the 
most promising. 
Even though there are many pre-clinical studies which report a reduction in PSAs with 
the use of fibrin sealants (Lindenberg & Lauritsen, 1984; Larsson et al., 1986; de Virgilio 
et al., 1990; Koltai & Gerhard, 1990; Weiss-Fogh et al., 1990; Dulchavsky et al., 199 1; 
Bothin & Hallberg, 1992; Sheppard et al., 1993; De Laco et al., 1994) there are very 
few clinical studies published (Larsson et al., 1986; Brands et al., 1990; Alnot et al., 
1993; Izbicki et al., 1994). There are also studies which report that fibrin sealants do not 
reduce PSAs (Bilgin el al, 1995) and are associated with potential contamination and 
antigenicity problems. Currently available fibrin sealants utilise single donor or pooled 
human fibrinogen, together with exogenous thrombin and usually an anti-fibrinolytic 
agent such as aprotinin. Using such a system introduces potential risks with regard to 
viral contamination and the use of bovine products, such as bovine thrombin and 
aprotinin have risks of bovine spongiform encephalopathy (BSE) and antigenic reactivity 
(Hughes & Westwood, 1994). 
With a view to the above problems ConvaTecTM (BMS company) developed a novel, 
truly autologous fibrin sealant, derived from a single donor who is intended to be the 
recipient, with no need for exogenous proteins for fibrinogen cleavage (refer to Section 
1.3). Preliminary studies investigating the use of VivostatTm system human derived fibrin 
sealant (novel fibrin sealant) as a PSA preventative agent have demonstrated its ability to 
reduce the formation of PSAs in a rabbit uterine hom abrasion model. 
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However the mechanisms in which this is achieved are as yet undefined. It has been 
hypothesised that novel fibrin sealant is acting purely as a physical barrier separating 
injured surfaces, hence preventing fibrinous connections and, in turn, fibrous PSAs. 
However since novel fibrin sealant is derived from fresh whole blood it is possible that 
biochemical mediation of wound healing is also occurring. 
Aims of this study 
i. Further substantiate the ability of novel fibrin sealant to reduce both incidence and 
severity of PSAs in a definitive experimental model with quantitative analytical 
procedures. 
ii. Investigate physiological, structural, cellular and biochemical changes occurring 
during PSA prevention with novel fibrin sealant from I hour to 42 days following 
injury. 
iii. Identify possible modes of action for PSA prevention with novel fibrin sealant. 
4.2 Materials and Methods 
PSAs were induced in a rabbit uterine hom model (refer to Chapter 2). Analogous 
surgical, termination, sampling and analytical procedures were employed as in the 
Pathogenesis of PSA study (refer to Chapter 3) for fair and direct comparisons to be 
made between control and treated tissues. Following the creation of injury sites on the 
peritoneum and uterine hom positional sutures were tightened to bring the two abraded 
areas close together but not in contact and fibrin sealant was then applied. Volume of 
fibrin sealant applied to each experimental site was 0.7ml, applied using the VivostatTM 
applicator (15 0 micron diameter), mid-density spray (26glls) (refer to section 2.8.1.3). 
The PSA pathogenesis study was completed before this study was commenced and it 
was found from the former study that tenacious PSAs are first seen at I hour post injury. 
Sampling during this study started at this time point and at 4,8,16 hours, 1.3P 5,7,14, 
28 and 42 days following injury. 
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Resected tissues were fixed and transverse slices were cut in a uniform random manner 
(refer to Chapter 2). Odd numbered slices were processed to paraffin wax for volumetric 
analysis and even numbered slices were processed to resin for number density analysis 
(refer to Chapter 2). 
4.3 Macroscopical Analysis 
During the course of this study there were no mortalities and no animal demonstrated 
morbidity associated with the surgical procedure. 
All cases had mild to moderate PSAs associated with laparotomy, that is, PSAs involving 
the peritoneal suture line and underlying tissues, either the fat pad over the bladder 
and/or the bladder itself Several cases in addition had mild to moderate PSAs involving 
the distal suture(s) of experimental sites with the fat pad over the bladder and/or the 
bladder itself All of these PSAs were blunt dissected with relative ease and did not 
interfere with experimental sites. 
Macroscopically it was not possible to assess PSA presence at experimental sites in cases 
up to 3 days. In most of these cases the two abraded areas were joined together, but 
whether this was due to fibrin sealant or PSAs was undetermined at macroscopic level. 
All cases from 3 days onwards were easily identifiable as not adhered (Figures 4.1 and 
4.2) except for one 28 days case which was partially adhered at both left and right hand 
side experimental sites. Non-adhered injury areas were separate and clean, and appeared 
to be healing without problems. 
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Figure 4.2: Macroscopic appearance of novel fibrin sealant treated injury site at 14 days post 
injury. 
4.4 Volumetric Analysis of Tissue Zones 
In order to determine the mechanisms and timing of tissue repair with novel fibrin sealant 
physiological changes were quantified in an analogous method to PSA development. 
Volumes of PSA, tissue generated by and damage of the peritonea] wall and uterine 
horn, peritoneal reaction, peritoneal cell concentration, uterine horn haemorrhage, fibrin 
sealant remaining and fibrin sealant associated cell concentration were determined from I 
hour to 42 days. 
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Fixed resected tissues were uniform randomly sliced, with odd numbered slices were 
processed to paraffin wax. A 5ýLrn section was cut from each block and stained with 
haernatoxylin and eosin. Absolute volume of each tissue zone was then determined using 
the stereological technique of Cavalieri's principle (refer to Chapter 2). 
4.4.1 Results 
Microscopically PSAs were only evident in one animal, a 28 day case (Graph 4.1. - 
Appendix IV Table 4.1). Both experimental sites were partially adhered, with 33.80MM3 
of PSA present at the LHS expefimental site and 3 . 91MM3 present at the 
RHS site. 
However there was no statistically significant difference (P>0.05) between the 28 day 
group compared to other sample groups (Appendix IV Table 4.2). Overall the use of 
novel fibrin sealant produced a 98% reduction of PSAs in this study (Figure 4.3 and 4.4). 
10 
8 
0 - 
:3 :3 
00 
M T- Iq 
kv) tn rý IT co (0 IT 
Time Elapsed Following Injury 
Graph 4.1: Mean PSA volumes 
together with standard error of the mean (SEM). 
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Gr Peritoneal tissue generation (PTG) was present at all sample time points ( aph 4.21 
Appendix IV Table 4.1), with a trend for mean volume to increase up to 7 days, with 
significant increases at 4 hours (P<0.05), I day (P<0.001) and 5 days (P<0.05) 
(Appendix IV Table 4.2; Figure 4.5). From 7 days onwards a trend for mean volume to 
decrease was seen although there were no significant differences (P>0.05) from time 
point to time point. 
Uterine horn tissue generation (UTG) was evident at our first time point of I hour and all 
174 
Prevention of PSAs using Novel Rbfin Sealant Chapter 4 
subsequent time points (Graph 4.2; Appendix IV Table 4.1). Initially there was an 
increase in mean volume, peaking at I day, with significant increases (P<0.05) seen at 8 
and 16 hours and I day. At 3 days there was a significant decrease in volume (P<0.01), 
with another significant decrease (P<0.05) at 14 days (Appendix IV Table 4.2). Mean 
volume there after remained at a constant low level (Figure 4.6). 
Mean total tissue generation (TTG) showed an increase in volume up to 7 days post 
injury (Graph 4.3; Appendix IV Table 4.1), with significant increases seen at 4 hours 
(P<0.01), 8 hours (P<0.01), I day (P<0.001) and 5 days (P<0.01) (Appendix IV Table 
4.2). From 7 days onwards mean volume decreased with each time point although no 
significant differences were seen. 
Mean volume for peritoneal damage showed a trend to decrease from I to 16 hours 
although not significantly (P>0.05) (Graph 4.4; Appendix IV Tables 4.1 and 4.2). From 
16 hours to 5 days mean volume of peritoneal damage increased, peaking at 5 days, with 
significant increase (P<0.05) at I day. From 5 days onwards mean volume decreased 
steadily until the end of the study, a significant decrease (P<0.001) was seen at 14 days 
post injury (Figure 4.5). 
Uterine horn damage increased from I hour to I day, with a significant increase (P<0.05) 
at .1 day following injury (Graph 4.4; Appendix IV Tables 4.1 and 4.2). There was a 
significant decrease (P<0.001) in mean volume at 3 days and mean volumes for damage 
decreasing gradually there after (Figure 4.6). 
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Peritoneal reaction was present throughout the whole of our study (Graph 4.5; Appendix 
IV Table 4.1). Mean volume increased significantly at 4 hours (P<0.0001), 8 hours 
(P<0.01) and I day (P<0.01) (Appendix IV Table 4.2). A significant decrease was seen 
at 3 day post injury (P<0.01) followed by a significant increase at 5 days (P<0.01). From 
5 to 7 days there was little change in mean volume. However at 14 days following injury 
a significant decrease was seen (P<0.0001),, with volume remaining constant until the end 
of the study. 
Very little peritoneal cell concentration was evident throughout this study (Graph 4.6; 
Appendix IV Table 4.1). Up to 3 days post injury there were no detectable levels. At 5 
days there was a peak in mean volume although this was only transient as volume 
decreased after this, with a significant decrease (P<0.01) at 14 days (Appendix IV Table 
4.2). No peritoneal cell concentration was seen at either 28 or 42 days post injury. 
Uterine hom haemorrhage was present only up to I day following injury, with slight 
peaks in mean volume seen at I and 16 hours although not significantly (P>0.05) (Graph 
4.7; Appendix IV Tables 4.1 and 4.2). 
Human derived fibrin sealant was present at all injury time points except 42 days (Graph 
4.8; Appendix IV Table 4.1). There was a trend for mean volume to decrease between I 
and 16 hours, a significant decrease (P<0.001) at 4 hours. A relatively constant mean 
volume was evident between 16 hours and 5 days followed by a significant decrease was 
seen at 7 (P<0.01) and 14 days (P<0.001) post injury (Appendix IV Table 4.2). 
Fibrin sealant associated cell concentration was first present at 3 days following injury, 
increasing significantly (1.27 fold)(P<0.001) to peak at 5 days. At 7 days there was a 
trend for mean volume to decrease with a significant decrease (P<0.001) at 14 days. 
Mean volume remained low until 28 days and cell concentration absent at 42 days post 
injury (Graph 4.8). 
The coefficient of error for Cavalieri's analysis in this study was 9% 
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4.4.2 Discussion 
Novel fibrin sealant has the ability to significantly prevent PSAs in a definitive rabbit 
uterine hom abrasion model with 98% prevention in this study. Only one case out of 44 
showed PSA development. During surgery it was noted that this case received a severe 
injury to the LHS peritoneal wall and application of novel fibrin sealant was poor due to 
technical problems with the application system. These factors most probably contributed 
to PSA formation at the LHS experimental site in this animal. However the RHS 
experimental site also had a small PSA between the two abraded sites. Therefore it 
appears that this animal had increased fibrinogenic capacity or impaired fibrinolytic 
capacity, making it more susceptible to PSA development. Analysis of peritoneal fluid 
and plasma samples collected from this animal will hopefully substantiate this hypothesis. 
Tissue generated in response to abrasion injury demonstrated a similar pattern on both 
the peritoneum and uterine horn: constant/slowly increasing volumes during the first 16 
hours, followed by a'significant increase (P<0.05) to peak at 5 to 7 days for the 
peritoneal wall and I day for the uterine hom and then decreasing volumes thereafter. 
From previous studies (Johnson & Whitting, 1962; Eskeland, 1966.1; Eskeland, 1966.2; 
Raftery, 19731; Raftery, 1973. E; Ryan et al., 1973) (refer to section 1.1.6.3.2 of this 
thesis) we know that during adhesion-free healing, tissue generated in response to injury 
is composed of fibrin during the first 3 days, with fibrin lost thereafter and collagen 
taking its place. An analogous situation was found for PSA composition by Miligan & 
Raftery (1973) (refer to section 1.1.6.5.1 of this thesis). During the first 16 hours of 
healing with novel fibrin sealant there was a slow rate of tissue generation deposition on 
the injury surface. This is most probably due to the presence of the sealant. After this 
time fibrin is laid down at an increased rate with collagen deposition following thereafter. 
Volumes of total tissue generation showed two peaks, the first at I day corresponding to 
a peak in volume of fibrinous tissue generation (fibrin predominant) and a second peak at 
5 to 7 days, corresponding to a peak in fibrous tissue generation (collagen predominant). 
Interestingly although these two trends can be seen in both PTG and UTG, the peak in 
fibrinous tissue generation corresponds primarily to maximum UTG volume and the 
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fibrous peak to maximum PTG volume. It would appear that uterine hom generates its 
maximum repair tissue 4 to 6 days earlier than the peritoneum and undergoes noticeable 
fibrin loss, either by fibrinolysis and/or phagocytosis. Reasons for this could be: (i) the 
greater vasculature of the uterine horn; (ii) fibrin sealant remaining attached to the 
peritoneal wall in preference to the uterine hom leaving the uterine hom available for 
fibrinolysis at an earlier stage; or (iii) the uterine hom sustained a lower level of 
underlying tissue damage from the abrasion procedure. The latter hypothesis is the most 
probable and is explained below. 
Less repair tissue volume was generated by the uterine horn in response to injury 
compared to the peritoneal wall and this has been a common feature in all studies carried 
out in this Department. It is well recognised that there is a direct relationship between the 
amount of damage and tissue generated from that damage (Ellis, 1962; Belzer, 1967; 
Chapter 3 of this thesis). It is hypothesised that lower volumes of UTG compared to 
PTG are due to the fact that, although going through the same injury process, the uterine 
horn received a lower extent of underlying damage compared to the peritoneal wall. This 
is probably due to the differences in structure between these two organs, with the 
peritoneum "easier to injure". This highlights the importance of "non-visibk" damage of 
tissues during surgical procedures and the formation of fibrotic tissue and especially 
PSAs. 
Mean damage for uterine horn was significantly less (P<0.05) compared to the peritoneal 
wall for all sample time points. In previous studies in our Department we found that, 
initially, the level of damage for the two tissues was not statistically different, but after 3 
days there was a difference (refer to Chapter 3). This was due to both tissues receiving 
the same level of initial damage, with the peritoneal wall sustaining a greater level of 
underlying damage. Since the identical injury technique was used in this study it appears 
that novel fibrin sealant has some damage limitation effect on the uterine horn very 
quickly after injury- induction. This could be due to damaged tissue being enclosed by 
fibrin sealant and not in direct contact with the peritoneal environment. 
182 
Prevention of PSAs using Novel R bfin Sealant Chapter 4 
With regard to the pattern for peritoneal and uterine horn damage similar trends were 
evident: a constant volume of damage for the first 16 hours corresponding to the original 
volume of damage inflicted via the abrasion injury, followed by an increase due to tissue 
necrosis of damaged underlying and surrounding tissue with its subsequent removal by 
phagocytes following the normal procession of wound healing. Following the peak in 
damage, volumes decreased for the remainder of the study, with volumes lower by the 
end of the study then at I hour post injury. This indicates that wound healing has 
occurred successfully and damage tissue has been replaced with new repair tissue. In 
addition to actual damage seen within the uterine horn there were also small amounts of 
haemorrhage present from I hour to I day following injury. 
A reaction to injury was mounted very quickly within peritoneal tissue with detectable 
levels seen after I hour. Peritoneal reaction showed a multi-peak response pattern, 
peaking at 8 hours, 1 and 5 days. This follows a familiar pattern for cellular activity 
during wound healing. Following injury an inflammatory response is mounted. 
Neutrophils are recruited to the injury sites within several hours, being one of the 
predominant cell types between I and 3 days post injury (Johnson & Whitting, 1962; 
Hubbard et al., 1967; Ryan et al., 1973; Raftery, 1973 E). Neutrophils release 
chemotactic mediators., attracting other phagocytic cells, such as macrophages. When 
present at the injury site these phagocytic cells clear damaged/necrotic tissues in order 
for wound healing to process. Within the first 3 to 5 days much chemical and cellular 
activity is occurring within injured tissues and it is this activity which we are detecting as 
peritoneal reaction. Cellular concentrations within peritoneal tissue also correlate with 
that for reaction, with cellular activity being at its most intense at 5 days post injury. 
At our first sample time point of 1 hour, approximately I I% of the novel fibrin sealant 
sprayed was present at the injury site. This very large decrease in volume is due to: (i) 
loss of sealant through the aerosol process (approximately I SVo); (ii) sealant sprayed not 
reaching or adhering to the injury site (approximately 35%); (iii) loss of liquid from the 
sealant through compression and processing (approximately 40%). Thus the volume of 
sealant present at I hour is more representative of the actual volume of fibrin present 
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within the sealant at the site of injury. A further decrease was seen at 4 hours, however, 
even with this loss of volume, novel fibrin sealant was still in situP remaining between and 
joining the two injured surfaces. From 4 hours to 5 days post injury there were no 
significant Oferences (P>0.05) in mean volume, although subtle changes are occurring, 
with the sealant gradually not joining the two injuries surfaces. A rapid lysis of sealant 
occurred between 7 and 14 days, with minimal levels present at 14 and 28 days. All 
traces of fibrin sealant were absent at our final sample time point of 42 days. Therefore 
once in vivo novel fibrin sealant remains relatively unchanged during the first 5 days post 
injury/surgery, that is during PSA and tissue generation modelling and remodelling, with 
biodegradation thereafter. 
In associationwith novel fibrin sealant a reactive cell concentration was seen surrounding 
the sealant and in adjacent tissues from 3 days onwards, peaking at 5 days. This peak 
was only transient, with mean volume decreasing rapidly to 28 days, with no detectable 
levels at 42 days. As seen in previous studies, this is a cellular reaction mounted in 
response to the presence of foreign protein (human novel fibrin sealant) within a non- 
human experimental model. This reaction, however, appears to have little to no 
detrimental effects on the outcome of the wound healing of these animals or on PSA 
prevention. 
Conclusions 
i. Novel fibrin sealant totally prevented PSAs in 98% of cases in this experimental study. 
I The normal progression of wound healing was unaffected by the use of novel fibrin 
sealant. 
iii. Limitation of subsequent damage in underlying and surrounding tissues to the injury 
site was demonstrated by novel fibrin sealant. 
iv. Once in vivo novel fibrin sealant maintained at a relatively constant volume and 
position within the peritoneal cavity for 5 days post injury, with gradual lysis 
thereafter. 
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Figure 4.7: Summary of physiological changes during healing with novel fibrin sealant. 
4.5 Volumetric Analysis of Fibrin and Collagen 
in order to investigate mechanisms of action of PSA prevention by novel fibrin sealant, 
volumes of the main two structural proteins, fibrin and collagen, were studied. 5ýtm 
sections were cut from wax embedded blocks and stained with PTAH and/or Van Gieson 
for detection of fibrin and collagen respectively. Absolute volumes of fibrin and collagen 
in tissue generation and PSAs were determined using Cavalieri's Principle (refer to 
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Chapter 2). 
4.5.1 Results 
Fibrin was predonunantly present in tissue generation from I hour to 3 days post injury 
(Graph 4.9; Appendix IV Table 4.3; Figure 4.8). From 16 hours to 14 days mean 
percentage of fibrin decreased, gradually between 16 hours and 3 days then rapidly 
between 5 and 14 days. Significant decreases occurred between 16 hours and I day 
(P<0.01), 3 and 5 days (P<0.001), 5 and 7 days (P<0.05) and 7 to 14 days (P<0.001) 
(Appendix IV Table 4.4). The mirror image was seen for mean percentage of collagen 
present* first seen at I day post injury, with a rapid increase from 3 to 5 days, and then 
predominant at 5 days and for the remainder of the study (Graph 4.9; Appendix IV 
Tables 4.3 and 4.4; Figure 4.9). 
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Mean volume of fibrin increased from I hour post injury to peak at I day, with a 
significant increase (P<0.01) between 16 hours and I day. From I day onwards mean 
volume decreased significantly (P<0.05) to become absent by 14 days (Graph 4.10, 
Appendix IV Tables 4.3 and 4.4). 
Collagen mean volumes increased slightly from 16 hours to I day and then very rapidly 
to peak at 7 days (Graph 4.10; Appendix IV Table 4.3). Significant increases were seen 
at I (P<0.01) and 5 days (P<0.001) (Appendix IV Table 4.4). From 7 to 14 days 
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collagen volume decreased significantly (P<0.01) and then remained constant for the rest 
of the study. 
Comparison of mean percentage of fibrin present within peritoneal and uterine horn 
tissue generation revealed similar trends throughout this study. Significant differences 
(P<0.05) were seen at I and 7 days post injury, with PTG having significantly lower 
mean volume of fibrin compared to UTG (Graph 4.11; Appendix IV Tables 4.3 and 4-4). 
The reverse situation was seen with mean percentage of collagen present in tissue 
generation: significantly greater percentage of collagen present in PTG compared to 
UTG at I and 7 days post injury (Graph 4.12; Appendix IV Tables 4.3 and 4.4). 
The mean coefficient of error for this study was 6.2%. 
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Graph 4.10: Mean fibrin and collagen volumes 
together with SEMs and statistical differences. 
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together with SEMs and statistical differences. 
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4.5.2 Discussion 
For the first 16 hours of tissue repair using novel fibrin sealant, fibrin only was present in 
tissue generated in response to injury. Fibrin remained present up to 7 days and was the 
predominant structural protein present up to/including 3 days post injury. Whereas 
collagen was first detected at I day and was the predominant protein from 5 days 
onwards. Hence tissue generated in response to injury in the presence of novel fibrin 
sealant was fibrinous up to 3 days post injury and fibrous thereafter. 
This pattern and timing for the protein content of injury tissue corresponds with that seen 
with adhesion-free healing and PSA formation. In adhesion-free healing fibrin strands are 
seen rapidly at the site of injury, with complete coverage of the wound surface during the 
first 2 to 3 days, after which fibrin is eliminated from the wound site and collagen fibres 
are observed at 5 days onwards (Johnson & Whitting, 1962; Eskeland, 1966.1; Eskeland, 
1966.2; Raftery, 1973. L; Raftery, 1973. E; Ryan et al., 1973) (refer to section 1.1.6-3.2 
of this thesis). An analogous situation was found for PSA composition by Milligan & 
Raftery (1974) (refer to section 1.1.6.5.1 of this thesis). Treatment with novel fibrin 
sealant at injury sites to prevent PSAs had no effect on the timing of fibrin and collagen 
predominance. That is, the general pattern of wound healing was unaffected. 
The peak in volume of fibrinous tissue generation was seen at I day post injury, during 
the first day of wound healing with continuous fibrin deposition seen. There must 
therefore be a stimulatory effect from the site of injury for the further laying down of 
fibrin even when haemostasis has long been achieved. The origin of this stimulator is 
hypothesised to be cytokines and/or growth factors secreted from cells present at the site 
of injury. After I day there was a rapid and consistent decrease in the volume of fibrin 
present due to fibrinolysis and/or phagocytosis by inflammatory cells present at the 
wound site. 
From 3 to 7 days following injury there was a very rapid lay down of Collagen with peak 
volume of fibrous tissue generation at 7 days post injury. Deposition of Collagen from 
fibroblasts was very rapid causing the conversion from fibrinous to fibrous injury tissue 
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in only a couple of days. Volume of fibrous tissue generation decreased from 7 to 14 
days with little change thereafter. It is highly unlikely that collagen would have been lost 
from injury tissue and therefore the decrease in mean volume is due to contraction of 
collagen bundles within the tissue, which is a normal feature of wound healing (Ellis el 
at, 1965). By 14 days post injury structural development and maturation of tissue 
generated in response to injury was completed. 
Comparison of fibrin and collagen in PTG and UTG revealed significant differences at I 
and 7 days post injury, with PTG possessing lower percentages of fibrin and higher 
percentages of collagen compared to UTG at both time points. Although both types of 
tissue generation follow the same pattern as described above, collagen was seen in PTG 
at I day whereas it is not seen until 3 days within UTG. Since collagen is synthesised by 
fibroblasts it would appear that fibroblasts are present in peritoneal injury tissue before 
uterine horn injury tissue. The peritoneum has a connective tissue component within its 
structure which contains some fibroblasts which it appears are recruited to the injury 
tissue within the peritoneal wall. The uterine horn does not have this "connective tissue 
reservoie' and hence the arrival of fibroblasts through chemotaxis is later compared to 
the peritoneal wall. It is probably this "delay" in fibroblast presence and hence collagen 
synthesis which accounts for the greater presence of fibrin/reduced presence of collagen 
in UTG at 7 days post injury. By 14 days post injury both PTG and UTG tissues are 
composed completely of collagen and differences between them are eradicated by this 
time. 
There were no significant differences seen between PSA, PTG and UTG in this study. 
However since there was only one case which demonstrated PSAs it is dubious as to 
whether any difference could be detected. 
Conclusions 
i. Tissue generated in response to injury in the presence of novel fibrin sealant was 
fibrinous up to/including 3 days and fibrous thereafter. 
I Peak in fibrinous tissue generation was seen at I day and peak in fibrous tissue 
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generation at 7 days post injury. 
iii. Development and maturation of this tissue was complete by 14 days post injury and 
followed the pattern for adhesion-free healing and PSA development. 
iv. Decreased fibrin and increased collagen percentages in PTG compared to UTG at I 
and 7 days were due to fibroblast migration from the connective tissue in the 
peritoneal wall to the injury site. 
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Figure 4.10: Summary of structural changes in injury tissue with the use of novel fibrin 
sealant. 
4.6 Number Analysis of Cellular Components 
In order to gain an understanding of the mechanism(s) utilised by novel fibrin sealant to 
prevent PSAs, cellular presence and activity at the site of injury Is a necessIty. Number 
densities and totals of basophilic cells, eosinophilic cells, macrophages, fibroblasts and 
lymphocytes within PTG, UTG, PSA and fibrin sealant associated cell concentration 
were determined using a stereological technique, the optical brick. Even numbered slices 
of fixed resected tissues were processed to resin, with a 25pm section cut from each 
block and stained with a modified Giemsa stain (refer to Chapter 2). 
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4.6.1 Results 
4.6.1.1 Number Densities 
4.6.1.1.1 Cell Predominance 
Both PTG and UTG demonstrated a similar pattern with regard to cellular presence 
throughout this study. Up to and including I day post injury eosinophilic cells were 
predominant within injury tissue (Figure 4.11) and from 3 to 5 days onwards fibroblasts 
were the predominant cell type present (Graph 4.13; Appendix IV Table 4.7; Figure 
4.12). Whereas macrophages were predominant in fibrin sealant associated cell 
concentration at time points analysed (3 to 7 days), followed by either eosinophilic cells 
and fibroblasts (3 and 7 days) or fibroblasts and eosinophilic cells (5 days) (Graph 4.13, 
Appendix IV Table 4.7). 
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Of the two experimental sites which demonstrated PSAs only one site had PSA available 
for number density analysis following resin processing. This 28 day case had a total 
number density of 454 167 cells per cubic millimetre of PSA, with fibroblasts accounting 
for 68%, macrophages 29% and eosinophific cells 3%. No basophilic cells or 
lymphocytes were present within PSA of this case (Appendix IV Table 4.6). 
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(a = Mo x 10. b-- Mo x 100) 
Figure 4.12 : Tissue repair cell predominance at 5 day post injury 
(a = Mo x 10. b-- Mo x 100) 
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4.6.1.1.3 Peritoneal Tissue Generation 
Number density of total cells present within PTG increased significantly (P<0.05) and 
uniformly from I to 16 hours post injury (Graph 4.14; Appendix IV Tables 4.7 and 4.8). 
From 16 hours to 3 days little change was seen but subsequent peaks in number density 
were seen at 5 and 14 days. From 14 days until the completion of this study number 
density decreased with a significant decrease (P<0.05) between 28 and 42 days. 
Number density of basophilic cells demonstrated peaks at 4 hours and 14 days post injury 
(Graph 4.14; Appendix IV Tables 4.7 and 4.8). Little variation was seen at the 
intermediate time points, however, significant decreases (P<0.05) were present between 
8 and 16 hours and 28 and 42 days. Eosinophilic cells demonstrated a rapid increase in 
mean number density from I to 16 hours with significant increase between I and 4 hours 
(P<0.0001) and 4 and 8 hours (P<0.05) post injury (Graph 4.14; Appendix IV Tables 4.7 
and 4.8). Following the peak density at 16 hours, eosinophilic cell number density 
decreased steadily to 5 days and significant decreases between I and 3 days (P<0.0001) 
and 3 and 5 days (P<0.001). Number density then showed a trend to increase slightly 
from 5 to 28 days, with a significant increase (P<0.001) between 5 and 7 days and levels 
decreasing significantly (P<0.001) at the end of the study. 
Macrophage number density increased steadily from I hour to I day with a significant 
increase (P<0.05) between 8 and 16 hours (Graph 4.14; Appendix IV Tables 4.7 and 
4.8). This trend to increase was accelerated between I and 5 days with significant 
increases (P<0.05) throughout this time period. Following the number density peak at 5 
days a significant decrease (P<0.001) occurred between 5 and 7 days, with constant 
density between 7 and 28 days, and finally a significant decrease (P<0.001) from 28 to 
42 days. 
Fibroblasts were first evident within PTG at 16 hours post injury, writh a significant 
difference (P<0.001) between 8 and -16 hours (Graph 4.14; Appendix IV Tables 4.7 and 
4.8). A slight increase in fibroblast number density was seen from 16 hours to I day after 
which there was a rapid and significant increase (P<0.001) until 5 days. A transient drop 
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occurred at 7 days (P<0.001) with a second peak at 14 days (P<0.05). Fibroblast number 
density then decreased from 14 to 28 days, with constant levels seen until the end of this 
study. 
Very little variation was seen for lymphocyte number density within PTG throughout this 
study (Graph 4.14; Appendix IV Tables 4.7 and 4.8). Mean density demonstrated a trend 
to be greater during the first 16 hours and a significant decrease (P<0.05) was evident 
between 14 and 28 days post injury. 
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Graph 4.14: Mean cell densities throughout PTG development 
together with SEMs and statistical differences. 
4.6.1.1.4 Uterine Horn Tissue Generation 
Number density of total cells within UTG gradually increased from I hour to I day and 
then rapidly from I to 5 days (P<0.01) with density peaking at this time (Graph 4.15; 
Appendix IV Tables 4.7 and 4.8). A significant decrease (P<0.001) was seen between 5 
and 7 days and density remained unchanged from 7 days until the end of this study. 
Number density of basophilic cells within UTG remained relatively constant through the 
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whole of this study with no significant differences (P>0.05) (Graph 4.15; Appendix IV 
Tables 4.7 and 4.8). However transient peaks at 4 hours and 14 days were seen. In 
contrast eosinophilic cells demonstrated noticeable trends in number density throughout 
the course of this study. From I to 16 hours mean density increased, with elevated levels 
sustained until 3 days following injury, however, a significant decrease (P<0.05) was 
seen between 16 hours and I day (Graph 4.15; Appendix IV Tables 4.7 and 4.8). From 3 
to 5 days there was a rapid decrease with density remaining minimal for the remainder of 
the study and a significant decrease (P<0.01) between 7 and 14 days. 
There was little change in macrophage number density within UTG for the first 8 hours 
following injury, however from 8 hours to 3 days mean density increased si0ficantly 
(P<0.05) to a peak (Graph 4.15; Appendix IV Tables 4.7 and 4.8). From 3 until 42 days 
mean macrophage density gradually decreased, with a significant decrease (P<0.01) at 
the end of this study. 
16 hours post injury was the first time fibroblasts were detected within UTG with density 
significantly increasing (P<0.05) from this time until 5 days (Graph 4.15; Appendix IV 
Tables 4.7 and 4.8). Mean fibroblast density then significantly decreased (P<0.0001) 
from 5 to 7 days, with density slightly increasing from 7 to 14 days and remaining 
unchanged from thereon. 
Lymphocyte density within UTG were at their greatest at I hour following injury with 
density from I hour to I days demonstrating a trend to be greater compared to the rest 
of the study (Graph 4.15; Appendix IV Tables 4.7 and 4.8). Only one significant 
difference (P<0.05) was seen throughout the course of this study, a significant decrease 
(P<0.05) from I to 3 days. 
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Gra ph 4.15: Mean cell densities throughout UTG development 
together with SEMs and statistical differences. 
Fibrin Sealant Associated Cell Concentration 
Number density of total cells analysed within fibrin sealant associated cell concentration 
demonstrated similar values at 3 and 7 days post injury, with a significant trough at 5 
days (P<0.0001) (Graph 4.16; Appendix IV Tables 4.7 and 4.8). Number density of 
basophilic cells demonstrated a trend to decline from 3 to 7 days. Eosinophilic cells 
followed the pattern seen for total cells, alike values at 3 and 7 days with a significant 
decrease (P<0.001) at 5 days following injury. Mean macrophage density showed a 
significant decrease (P<0.001) from 3 to 5 days, with this level maintained at 7 days. 
Fibroblasts showed little variation throughout this time period, with a very slight trend to 
increase whereas lymphocytes were absent at 3 and 7 days but present in low densities at 
5 days following injury (Graph 4.16; Appendix IV Tables 4.7 and 4.8). 
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Graph 4.16: Mean cell densities within fibrin sealant associated cell concentration 
together with SEMs and statistical differences. 
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Comparison of number densities within PTG and UTG revealed differences for total 
cells, eosinophilic cells, macrophages and fibroblasts (Appendix IV Table 4.9). At the 
first sample time point of I hour PTG contained significantly greater (P<0.05) densities 
of cells (totals) compared to UTG. At 16 hours, 1,7,14 and 28 days post injury 
eosinophilic cell number densities were significantly greater (P<0.05) within PTG 
compared to UTG. Whereas at 42 days macrophage number densities were significantly 
greater (P<0.05) within UTG compared to PTG and 16 hours, I and 5 days UTG had 
significantly greater (PO. 05) densities of fibroblasts compared to PTG. 
4.6.1.2 Number Totals 
4.6.1.2.1 Cell Predominance 
The same pattern of cell predominance in tissue generation was seen with number totals 
as number densities. Eosinophilic cells were present in greatest number up to I day 
following injury after which fibroblasts were the predominant cell type (Graph 4.17; 
Appendix IV Table 4.10). 
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Within fibrin sealant associated cell concentration macrophages were the predominant 
cell type, followed by eosinophilic cells and then fibroblasts at 3 and 7 days and vice 
versa at 5 days post injury (Graph 4.17; Appendix IV Table 4.10). 
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Graph 4.17: Number density cell predominances in PTG, UTG and fibrin sealant associated 
cell concentration. 
4.6.1.2.2 Post Surgical Adhesion 
There were 15 350 745 total cells analysed within the PSA present in this study 
(Appendix IV Table 4.6). Percentage breakdown of each cell type is the same as that for 
number density: 68% fibroblasts, 29% macrophages and 3% eosinophilic cells. 
4.6.1.2.3 Peritoneal Tissue Generation 
Total cell numbers within PTG demonstrated a steady increase from I hour to 3 days, 
with significant increases between I and 4 hours (P<0.001), 4 and 8 hours (P<0.01), and 
16 hours and I day (P<0.01). From 3 to 5 days there was a massive significant increase 
(P<0.01) in total cells, peaking at this later time point and decreasing thereafter and a 
significant decrease (P<0.05) from 28 to 42 days post injury (Graph 4.18; Appendix IV 
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Tables 4.10 and 4.11). 
Numbers of basophilic cells within PTG were elevated at 4 and 8 hours and 14 days post 
injury (Graph 4.18; Appendix IV Tables 4.10 and 4.11). Significant increases (P<0.05) 
were present between 1 and 4 hours and 28 and 42 days and a si0ficant decrease 
(P<0.05) between 8 and 16 hours. Eosinophilic cell numbers increased constantly from I 
hour to I day, being significant between I and 4 hours (P<0.001), 4 and 8 hours 
(P<0.00 1) and 16 hours and I day (P<0.05) (Graph 4.18; Appendix IV Tables 4.10 and 
4.11). Following the peak at I day, mean numbers of eosinophilic cells decreased 
significantly (P<0.001) to 3 days, remained unchanged at 5 days and then demonstrated a 
significant increase (P<0.05) at 7 days. From 7 to 28 days there was little change in mean 
number, however, a significant decrease (P<0.001) was seen between 28 and 42 days 
post injury. 
Macrophage mean numbers within PTG increased from the first time point of I hour to 
peak at 5 days following injury, with this increase demonstrating an exponential nature 
and significant increases between 4 and 8 hours (P<0.05), 16 hours and I day (M-01), 
I and 3 days (P<0.001) and 3 and 5 days (P<0.001) (Graph 4.18; Appendix IV Tables 
4.10 and 4.11). From 5 days onwards mean numbers decreased, being significant 
(P<0.01) between 28 and 42 days. 
Mean numbers of fibroblasts present within PTG followed a similar pattern to 
macrophages. They were first present at 16 hours post injury and increased significantly 
(P<0.01) from this time to peak at 5 days (Graph 4.18; Appendix IV Tables 4.10 and 
4.11). From 5 to 42 days mean numbers decreased, with a slight increase at 7 days and a 
significant decrease (P<0.05) between 7 and 14 days. 
Lymphocytes were present throughout this study, with only minor fluctuations in mean 
number and no significant differences (P>0.05) (Graph 4.18; Appendix IV Tables 4.10 
and 4.11). 
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Graph 4.18: Mean cell numbers throughout PTG development 
together with SEMs and statistical differences. 
4.6.1.2.4 Uterine Horn Tissue Generation 
Chapler 4 
Total numbers of cells analysed with UTG remained unchanged from I to 4 hours 
following injury but increased rapidly and significantly (P<0.05) from 4 hours to I days 
(Graph 4.19; Appendix IV Tables 4.10 and 4.11). From I to 3 days there was a 
significant decrease (P<0.05) in mean total number immediately followed by a significant 
increase (P<0.05) to peak for a second time at 5 days. From 5 days to the end of this 
study mean numbers decreased steadily, with a significant decrease (P<0.05) between 7 
and 14 days and a slight peak at 28 days. 
There were no significant differences (P<0.05) between any concurrent time point for 
mean numbers of basophilic cells present in UTG (Graph 4.19; Appendix IV Tables 4.10 
and 4.11) although mean numbers demonstrated slight elevations at 8 hours and 42 days 
post injury. Little variation was seen for eosinophilic cell mean numbers between I and 4 
hours however, this was followed by a rapid and significant increase (P<0.05) to peak at 
I day post injury (Graph 4.19; Appendix IV Tables 4.10 and 4.11). An equally rapid 
decrease occurred from I to 5 days, with a significant decrease (P<0.01) between I and 
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3 days. From 5 to 42 days an overall decrease in mean numbers of eosinophilic cells 
within UTG was seen with a significant decrease (P<O. 0 1) between 7 and 14 days. 
Mean numbers of macrophages within UTG showed a significant increase (P<0.01) from 
8 hours to I day (Graph 4.19; Appendix IV Tables 4.10 and 4.11). Levels remained 
relatively constant between I and 7 days and then showed a trend to decrease until the 
end of this study. Significant decreases occurred between 7 and 14 days (P<0.01) and 28 
and 42 days (P<0.05) and a slight but not significant (P>0.05) increase was seen at 28 
days. 
Fibroblast mean numbers increased gradually from 16 hours to 3 days and then rapidly to 
peak at 5 days. Significant increases occurred between 8 and 16 hours (P<0.01) and 16 
hours and I day (P<0.05). From the peak at 5 days following injury mean numbers of 
fibroblasts decreased to 14 days, being significant (P<0.05) between 7 and 14 days and a 
slight increase at 28 days and then decrease to 42 days (Graph 4.19; Appendix IV Tables 
4.10 and 4.11). 
Mean numbers of lymphocytes were higher for the first day of this study compared with 
other time points, with a significant decrease (P<0.05) between I and 3 days post injury 
(Graph 4.19; Appendix IV Tables 4.10 and 4.11). Numbers remained similar for the rest 
of the study. 
203 
Prevention of PSAs using Novel Fibrin Sealant 
3.5e+6 
3.0e+6 
2.5e+6 
.s E 2. Oe+6 
:Z 
1.5e+6 
I. Oe+6 
5.0e+5 
O. oe+o 
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together with SEMs and statistical differences. 
4.6.1.2.5 Fibrin Sealant Associated Cell Concentration 
Clitipler 4 
Mean total numbers of cells within fibrin sealant associated cell concentration were not 
significantly different (P>0.05) from 3 to 7 days post injury (Graph 4.20; Appendix IV 
Tables 4.10 and 4.11). Basophilic cells demonstrated a reduction in mean numbers 
present between 3 to 7 days. Mean numbers of eosinophilic cells decreased significantly 
(P<0.001) from 3 to 5 days and then increased significantly (P<0.001) from 5 to 7 days. 
Macrophages demonstrated a trend to decrease in mean number from 3 to 7 days, 
whereas fibroblasts showed a trend to increase during the same time period. 
Lymphocytes were absent at 3 and 7 days post injury within fibrin sealant associated cell 
concentration but present at 5 days. 
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Graph 4.20: Mean cell numbers within fibrin sealant associated cell concentration 
together with SEMs and statistical differences. 
Comparison of mean numbers of cells within PTG and UTG revealed significant 
differences (P<0.05) for all cell types except lymphocytes (Appendix IV Table 4.12). 
PTG contained significantly greater (P<0.05) numbers of cells compared to UTG for: 
basophilic cells at 4 hours post injury, eosinophilic cells from 4 hours to 28 days, 
macrophages from 4 to 8 hours and I to 42 days, fibroblasts from 3 to 42 days and total 
cells from 4 hours to 42 days. 
The overall coefficient of error of this counting technique was 13.4%. 
4.6.2 Discussion 
The involvement of inflammatory cells in adhesion-free healing is well documented. They 
are present from I hour following injury, with macrophages being predominant together 
with some mast cells (Eskeland, 1966.1; Eskeland, 1966.2). By 12 hours, numbers of 
cells present have increased, with PMNLs predominant followed by macrophages, 
eosinophilic cells and mast cells respectively (Raftery, 1973, E). By I day a whole variety 
of inflammatory cells have been reported as present: neutrophils, eosinophils (Johnson & 
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Whitting, 1962; Hubbard et al., 1967; Ryan et al., 1973; Raftery, 1973 E), lymphocytes, 
histiocytes (Hubbard et al., 1967) and macrophages (Johnson & Whitting, 1962; 
Hubbard et al., 1967; Raftery, 1973 L; Raftery, 1973 E). At 3 days the general 
consensus is that macrophages are the only inflammatory cells present (Johnson & 
Whitting, 1962; Raftery, 1973 L; Raftery, 1973 E) with all inflammatory cells decreasing 
in number from 7 to 10 days (Raftery, 1973 E). With regard to fibroblasts, they have 
been reported at 2 days following injury (Ellis et al., 1965), with proliferation at 4 days 
(Johnson & Whitting, 1962; Raftery, 1973 L) and their presence still evident at 10 days 
(Raftery, 1973 E). 
The results of this study for adhesion-free healing with novel fibrin sealant are in 
agreement with these reported above. During the first day following injury inflammatory 
cells were the predominant cell types present in both peritoneal and uterine horn tissue 
generation. Eosinophilic cells were present in greatest percentages followed by basophilic 
cells and then macrophages. However between I and 3 days there was a change from 
inflammatory cell predominance to tissue repair cell predominance, with fibroblasts and 
then macrophages present in greatest percentages. 
With regard to number densities within PTG the peak in inflammatory cells, due 
primarily to a peak in eosinophilic, cells, was seen at 16 hours post injury and for tissue 
repair cells, due primarily to peak in fibroblasts, peaks were seen at 5 and 14 days post 
injury. Peaks in cells within PTG correlate with peaks in peritoneal reaction volumes seen 
at I day and 5 to 7 days and peak in peritoneal cell concentration at 5 days, 
demonstrating that cellular presence is distributed throughout injury and 
underlying/suffounding tissue. In addition peaks in inflammatory and subsequently repair 
tissue cells precede peaks in fibrinous and fibrous tissue generation volumes respectively. 
Hence maximum presence of inflammatory cells appears to stimulate fibrin deposition 
and maximum presence of tissue repair cells appears to lead to collagen deposition. 
However it was not until few inflammatory cells were present within PTG that maximum 
peritoneal damage was seen. 
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Maximum inflammatory cell densities within UTG occurred at 16 hours following injury 
and between 3 to 5 days for tissue repair cells. Peak in inflammatory cell densities again 
preceded the peak in fibrinous tissue generation and peak in uterine horn damage. Thus 
inflammatory cells are infiltrating into damaged tissues and removing such tissue by 
phagocytosis with tissue generated to replace removed tissue. Peaks in inflammatory 
cells also correspond to peaks in uterine horn haemorrhage. 
With regard to number totals within PTG and UTG, peaks in inflammatory cells occur at 
I days and 5 days for tissue repair cells. Hence tissue generated by either the peritoneum 
or uterine horn in response to abrasion injury and treated with novel fibrin sealant 
demonstrated the same cellular responses. The distinction between inflammatory and 
tissue repair ceUs also highlights the controlled nature of wound healing. 
Differences in number densities of total cells, eosinophilic cells, macrophages and 
fibroblasts were seen between PTG and UTG. It has been highlighted that although the 
peritoneum and uterine horn undergo the same injury process, the peritoneum sustains a 
greater extent of underlying and surrounding damage. This greater damage results in 
greater tissue ischaernia and necrosis requiring additional inflammatory cells to clear this 
damaged tissue, which is precisely the case with increased densities of inflammatory cells 
within PTG compared to UTG. Since the uterine horn has less damage to be cleared 
before tissue repair can be successfully initiated, tissue repair cells should be present in 
uterine horn tissue earlier than peritoneal tissue, which is again what was observed 
during this study. 
Macrophages were the predominant cell type within fibrin sealant associated cell 
concentration at all time points investigated (3 to 7 days). At 3 and 7 days, eosinophilic 
cells were the second most predominant followed by fibroblasts whereas, at 5 days, this 
order was reversed. This change was due to a drop in number density of eosinophilic 
cells compared to fibroblasts, with the reason for this being the reduction in inflammatory 
response. At 5 days post injury there was also a significant drop in total number density 
however little difference is seen for number totals. Therefore numbers of cells present 
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varied little from 3 to 7 days post injury, but an increase in volume of fibrin sealant 
associated cell concentration occurred at 5 days. This could be due to increased cell 
sizes., due to active phagocytosis and/or increased biochemical processes, with the 
outcome becoming decreased fibrin sealant volume. 
Conclusions 
L The normal cellular progression of adhesion-free healing was demonstrated with novel 
fibrin sealant. 
ii. Inflammatory cells (eosinophilic cells, basophilic cells, macrophages) were the 
predominant cell types present in tissue generated from injured peritoneum and 
uterine hom treated with novel fibrin sealant for the first day following injury. 
iii. Tissue repair cells (fibroblasts, macrophages) were the predominant cell types present 
in tissue generated from injured peritoneum and uterine horn treated with novel fibrin 
sealant from 3 days onwards following injury. 
iv. Inflammatory cells were associated with fibrinous tissue generation and tissue repair 
cells with fibrous tissue generation. 
v. Fibrin sealant associated cell concentration is an immune response to the presence of a 
foreign protein within the peritoneal cavity. Cells present were predominately 
macrophages, followed by eosinophilic cells and fibroblasts. 
vi. It is hypothesised that macrophages and eosinophilic cells attracted fibroblasts to the 
site of novel fibrin sealant, aiding wound healing. 
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Figure 4.13: Summary diagram of cellular presence in injury tissue. 
4.7 Biochemical analyses 
As for Pathogenesis of PSAs study, blood and peritoneal fluid samples were taken 
throughout the surgical and termination procedures to gain understanding of cellular and 
biochemical changes during PSA prevention with novel fibrin sealant. 
4.7.1 Full and Differential Blood Counts 
Three blood samples were taken during this study: blood sample I taken pre-operatively 
(control); blood sample 2 taken immediately following laparotomy (laparotomy control); 
and blood sample 3 taken prior to termination (experimental sample). Total numbers of 
RBCs, platelets and WBCs were determined using an auto-analyser whereas WBC 
differential counts were performed by manual methods (refer to Chapter 2). 
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4.7.1.1 Results 
Overall mean number of RBCs for control blood sample I was 5.60 x1012/1, with 253 
x109/1 platelets, 4.44 x109/1 WBCs, 0.15 x109/1 basophilic cells, 2.28 x109/1 lymphocytes, 
0.54 x109/1 monocytes and 1.68 x109/1 eosinophilic cells (Graph 4.21; Appendix IV Table 
4.13). 
Laparotomy control blood sample 2 demonstrated mean numbers of 5.16 x1012/1 RBCs, 
266 x10911 platelets, 4.06 x109/1 WBCs, with 0.10 x109/1 basophilic cells, 1.64 xlO 9A 
lymphocytes, 0.42 x109/1 monocytes and 1.91 x1ell eosinophilic cells (Graph 4.21; 
Appendix IV Table 4.13). 
Mean numbers of blood cells present in experimental blood sample 3 were 4.83 x1012/1 
RBCs,, 285 xlO 9A platelets, 4.26 x109/1 WBCs, with 0.12 xIO9/1 basophilic' cells, 1.39 
x109/1 lymphocytes, 0.28 x109/1 monocytes and 2.47 x109/1 eosinophilic cells (Graph 
4.21; Appendix IV Table 4.13). 
T test analysis demonstrated a significant difference (P=0.034) in mean numbers of RBCs 
between control and laparotomy control samples (blood samples I and 2). Comparison 
between control (blood sample 1) and experimental (blood sample 3) samples revealed 
significant differences in mean numbers of lymphocytes (P=0.0004), macrophages 
(0.0003) and RBCs (P<0.0001). A significant difference (P=0.037) was seen in mean 
monocyte number between laparotomy control (blood sample 2) and experimental 
sample (blood sample 3) (Graph 4.2 1; Appendix IV Table 4.14). 
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Mean numbers of both RBCs and platelets at time points following injury for 
experimental sample 3 demonstrated similar levels to controls and laparotomy control 
throughout this study, except for 14 day time point at which there was a decrease for 
both cell types (Graphs 4.22 and 4.23,, Appendix IV Table 4.15). 
Mean numbers of WBCs in experimental sample 3 fluctuated throughout the study 
(Graph 4.24; Appendix IV Table 4.15). An increase was seen between I and 8 hours 
after which numbers returned to control levels. A slight decrease occurred at 3 days, 
which was followed by an increase at 5 days and then subsequent decrease between 7 
and 14 days. By 28 and 42 days mean numbers were within normal control levels. 
Basophilic cells demonstrated a trend to increase in number from I hour to I day with a 
sharp decrease to 3 days (Graph 4.25; Appendix IV Table 4.15). Mean numbers 
remained below controls from 3 to 14 days, with an increase seen to 42 days post injury. 
)5 P PO( ý005 
PO, 
P-OC 
Pýo 0 ý 
Po 0, 
ý 
P-0 00 
= 
Pýo 
OO]C, ), r BlI samp: e I vs 2 -Bl( samp e1 vs 3 
-81( sample 2 vs 3 
211 
Blood Sample 3 Blood Sample 1 
Prevention of P&4s using Novel Fibrin Sealant 
o4 
.8 E3 
: 
X- 
E31 e2 
PI 1 
le 2 
bl ýSar7AeJ3 
NeEe >ý 0 9.0 0) 0 
00 (a m va ca m m IZ m000000 
'IT co (D 
M Lr) r- IT co C14 
C14 IT 
Time Elapsed FollovAng Injury 
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Mean numbers of lymphocytes in experimental sample 3 were generally slightly below 
control levels throughout most of this study, with only mild fluctuations demonstrated 
(Graph 4.26; Appendix IV Table 4.15). Little change was seen from I to 8 hours after 
which there was a trend to increase. Mean numbers showed a gradually decrease from I 
to 14 days with a subsequent increase to control levels by the completion of this study. In 
a similar manner monocytes were slightly below control levels throughout this study until 
42 days post injury (Graph 4.27; Appendix IV Table 4.15). There were no real trends in 
mean monocyte number. 
In experimental sample 3 eosinophilic cells demonstrated several trends in mean number 
from I hour to 42 days following injury (Graph 4.28; Appendix IV Table 4.15). From I 
hour eosinophilic cells rapidly increased to peak at 8 hours after which numbers steady 
decreased to control levels by 3 days. Another peak was seen at 5 days with a rapid 
decrease to 7 days with numbers returning to control values by 14 to 28 days post injury. 
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Graph 4.26: Mean numbers of lymphocytes for all blood samples 
together with SEMs. 
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4.7.1.2 Discussion 
Chapter 4 
As discussed in Section 3.7.1.2 systemic levels of rabbit cells show great variability and 
are effected by venesection of volumes of 10 to 20ml and above (Figure 4.14). Therefore 
these effects need to be considered when interpreting the results obtained in this study. 
I r_, l. I.. 
l. eukoc)les 
7 Days 
Figure 4.14: Rabbits response to vcnesection (20ml) 
(Taken from Schermer, 1967). 
All blood cell types demonstrated mean numbers within normal ranges for all blood 
samples. Mean numbers of WBCs and lymphocytes were at the very low end of the 
normal values reported by Sanderson & Phillips (1981) (Appendix III Table 3.16) 
however considerable variations in WBC count are well recognised (Schermer, 1967). 
Comparison of pre-operative control (sample 1) with laparotomy control (sample 2) 
demonstrated only one significant difference. The laparotomy control showed 
significantly lower mean number of RBCs compared to pre-operative controls. This is 
most probably due to plasma volume increasing in response to the removal of the first 
blood sample, diluting the blood cells. Support for this hypothesis is seen by lower, 
although not significantly (P>0.05) mean numbers of WBCs in the laparotomy control. 
This difference between RBCs and WBCs are attributed to the easier and quicker 
recruitment of WBCs into the circulatory system. 
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Mean numbers of both RBCs and platelets in experimental blood sample 3 showed little 
variation over the duration of this study. Hence neither venesection, prevention with 
novel fibrin sealant nor wound healing had any substantial effect on the cellular profiles 
of both these cell types. 
WBCs demonstrated an increase in mean number from I hour and levels remained 
slightly above normal until I day. This does not follow the pattern for venesection 
effected blood, indicating that either the introduction of novel fibrin sealant and/or 
wound healing had a rapid response on WBCs causing their increased circulation. The 
consequences of this appear to be extended throughout most of this study with the effect 
of blood collection undetermined. 
Mean numbers of basophilic cells at each time point demonstrated large variations 
probably due to their relatively low numbers. Changes in the number of these cells in 
circulation appears to be influenced by venesection rather than the presence of novel 
fibrin sealant and/or wound healing. 
Lymphocytes demonstrated lower levels at most time points compared to controls with 
few trends seen. Hence the expected effects of blood collection were absent, either due 
to no effects occurring or that these effects are masked by lymphocyte recruitment and 
migration out of circulation in response to novel fibrin sealant and/or wound healing. 
From the results in this study it appears that either in vivo application of novel fibrin 
sealant and/or wound healing lowered the mean number of systemic lymphocytes. 
Levels of systemic monocytes were similar to lymphocytes in that they were generally 
lower compared to controls and showed few fluctuations. Mild peaks in mean number 
were seen at 8 hours and I day, which could be attributed to blood collection, with a 
further peak at 42 days returning levels to normal values. Hence treatment with novel 
fibrin and/or wound healing had the general effect of lowering the level of circulating 
monocytes. 
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Novel fibrin sealant and/or wound healing had the greatest effect on circulating 
eosinophilic cells. During the course of this study two peaks were seen in mean number, 
at 8 hours and 5 days. From comparison with venesection results, these peaks are most 
likely to be due to the presence of novel fibrin sealant or wound healing. Eosinophils are 
been implemented in the early stages PSA development (Milligan & Raftery, 1974) with 
an anti-histan-ýine and therefore anti-inflammatory activity. It would appear that treatment 
with novel fibrin sealant and/or wound healing resulted in increased release of these cells 
into circulation, which may play some role in PSA prevention. 
Conclusions 
i. Care needs to be taken in interpreting full and differential counts obtained in this study 
due to the unreliability of rabbit blood factors, effects of venesection and small sample 
size for the differential counts. 
ii. Blood cell types demonstrated mean numbers within normal ranges for all blood 
samples. 
iii. LaparotoMY' control showed significantly lower mean number of RBCs compared to 
pre-operative controls due to plasma infiltration/dilution in response to the initial 
venesection. 
iv. Mean numbers of both RBCs and platelets showed little variation over the duration of 
this study. 
v. Introduction of novel fibrin sealant and/or wound healing had a rapid response on 
WBCs resulting in their increased circulation. The effect was extended throughout 
most of this study with the outcome of blood collection undetermined. 
vi. Mean numbers of basophilic cells at each time point demonstrated large variations 
probably due to their relatively low numbers with changes attributed to venesection. 
vii. Lymphocytes demonstrated lower levels at most time points compared to controls, 
with few trends seen, probably due to novel fibrin sealant treatment and/or wound 
healing. 
viii1evels of systemic monocytes were similar to lymphocytes in that they were generally 
lower compared to controls and showed few fluctuations. This is attributed to 
treatment with novel fibrin and/or wound healing. 
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ix. Two peaks were seen in eosinophilic cell mean number, at 8 hours and 5 days, most 
likely to be due to the presence of novel fibrin sealant and/or wound healing resulting 
in the increased release of these cells into circulation, which may play some role in 
PSA prevention. 
4.7.2 TGF-p Concentrations 
Only one of the ELISA kits investigated was found to detect rabbit cytokines accurately 
and reproducibly, the R&D Systems TGF-P ELISA. Due to time limitations only one 
plasma sample from each time point and one undiluted pen"toneal fluid sample from 3 to 
28 days, together with the peritoneal sample from the adhered case and controls were 
assayed (refer to Chapter 2 for methodology). 
4.7.2.1 Results 
TGF-P concentrations within pre-opera'tive control blood sample 1, post laparotomy 
sample 2 and experimental samples 3 -were all similar (Graph 4.29; Appendix IV Table 
4.16). Coefficient of variation was calculated to be 36% for control samples I and 13% 
for control samples 2. Overall experimental samples 3 demonstrated similar 
concentrations from I hour to 42 days however there was a peak at 7 days post injury. 
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Graph 4.29: TGF-P concentrations present in blood samples. 
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TGF-P concentrations were detected in all both control and experimental peritoneal fluid 
samples (Graph 4.30; Appendix IV Table 4.16). Control pentoneal fluid samples I 
demonstrated 8% variance . TGF-P 
levels in experimental samples 3 varied throughout 
wound healing with maximum concentration seen at 7 days and a decline thereafter to 
control values at 28 days. 
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Graph 4.30: TGF-P concentration present in peritoneal fluid samples. 
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4.7.2.2 Discussion 
Due to the very minimal numbers of samples assayed only preliminary results have been 
obtained and therefore should be cautiously interpreted. 
All plasma and peritoneal fluid samples demonstrated levels of TGF-P. Typically TGF-P 
is present in serum at low levels. Donor serum and plasma samples from apparently 
healthy individuals activated and assayed by R&D Systems demonstrated TGF-P 
concentration of 48.6ng/ml and 2.26ng/mI respectively. Since our study comprised of 
rabbit samples direct comparisons between resting levels of TGF-P can not be made. 
TGF-P is produced by many cell types including platelets, fibroblasts, myocytes, 
astrocytes and epithelial cells. This cytokine is associated with wound healing and is 
present at injury sites due to the presence of degranulating platelets. It causes cellular 
chemotaxis, protein matrix synthesis and further secretion of factors which combine with 
TGF-P to mediate angiogenesis and fibrosis. 
TGF-P concentrations within experimental samples were all within control levels and 
hence it appears that treatment of injury sites with novel fibrin sealant does not have any 
effect on systemic levels of TGF-P. However variations were seen with experimental 
peritoneal samples compared to controls with peak concentration at 7 days post injury, 
which follows the peak in fibroblast cell numbers. Hence it possible that fibroblasts 
present within injury tissue are secreting TGF-P which is in turn mediating angiogenesis 
and tissue fibrosis. 
Conclusions 
i. Biochemical control of wound healing by TGF-p may be occurring locally within 
peritoneal fluid. 
I Further work is required to substantiate or rebut this theory. 
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4.8 Conclusions 
Chapter 4 
Using a definitive, reproducible PSA inducing model, treatment with novel fibrin sealant 
prevented PSA formation in 98% of cases. This is by far the best reported PSA reduction 
with a fibrin sealant. The additional benefits of quick and easy preparation and 
application with minimal human input and elimination of potential viral and antigenicity 
problems, make novel fibrin sealant an excellent PSA preventative agent. 
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Treatment with novel fibrin sealant does not interfere with the normal progression of 
wound healing with regard to physiological, cellular and biochemical mechanisms (Figure 
4.15 and 4.16). Following injury fibrin exudate was released with the formation of repair 
tissue discretely located on each injury site but not joining the two. This repair tissue was 
fibrinous up to 3 days post injury, with maximum volume seen at I day, and fibrous from 
5 days onwards, with maximum fibrous volume at 7 days. 
Only damage from the original abrasion injury was present for the first 16 hours after 
which there was an increase corresponding to phagocytosis and clearance of damaged 
surrounding and underlying tissue by phagocytes. Following clearance damaged tissue 
was replaced with new repair tissue. 
During the first day following injury inflammatory cells (eosinophilic cells, basophilic 
cells, macrophages) were the predominant cell types present within injury tissue. 
Whereas tissue repair cells (fibroblasts, macrophages) were predominant from 3 days 
onwards. 
Local mediation of angiogenesis and fibrosis by TGF-P within peritoneal fluid may also 
be occurring. Further analyses are required to substantiate and expand on this hypothesis. 
Hence adhesion-free healing of mechanically injured tissues by novel fibrin sealant can be 
classified into two phases (Figure 4.16): 
i. Tissue modelling: up to/including I day post injury 
Includes: Inflammatory response 
Fibrin deposition 
ii. Tissue remodelling: from 3 days post injury and onwards 
Includes: Tissue repair 
Collagen deposition 
Biochemical modulation by TGF-P 
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In vivo volume of novel fibrin sealant remained relatively constant for the first 5 days 
following application, after which there was a rapid loss, due to either phagocytosis 
and/or fibrinolysis. Therefore novel fibrin sealant was present during tissue generation 
modelling, fibrin deposition, and during the initial stages of tissue generation 
remodelling, collagen deposition. Novel fibrin sealant presence at injury site(s) during 
these stages is highly important and probably the major reason behind its PSA prevention 
success. 
A cellular response to human novel fibrin sealant in this rabbit experimental model was 
evident from 3 to 7 days post injury, with maximum response seen at 5 days. This 
response primarily consisted of macrophages and eosinophilic cells. It is hypothesised 
that this is an immune mediated response to the presence of foreign protein within the 
peritoneum, with phagocytic cells attracted to phagocytose this foreign material. Such a 
response should be absent when novel fibrin sealant is used as intended, that is, as a truly 
autologous sealant. 
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5.0 Comparison of PSA Development and Prevention with 
VivostatTm System Human Derived Fibrin Sealant 
5.1 Introduction 
Chapter 3 of this thesis describes the first study in which physiological, structural, 
cellular (local and systemic) and biochemical mechanisms of PSA development have been 
simultaneously quantitatively analysed. In order to prevent PSAs such knowledge is 
essential not only in targeting of preventative agents but also to understand their 
mechanisms of action to potentially improve their efficiency. 
Many previous studies investigating (VivostatTm system human derived fibrin sealant) 
novel fibrin sealant have demonstrated its ability to prevent PSAs. In order to understand 
its mechanisms of action, analogous analyses were performed to those investigating PSA 
development: quantitative analysis of physiological, structural, cellular (local and 
systemic) and biochemical mechanisms (refer to Chapter 4), To Uly comprehend PSA 
prevention by novel fibrin sealant, direct comparisons need to be made between data 
from novel fibrin sealant PSA prevention and PSA development. 
A fault of previous studies has been the lack of fair comparisons which could be made 
between control and treated cases and between studies investigating different treatments. 
In this study these problems are overcome by: 
i. the use of an identical, definitive experimental model (standard and 
reproducible injury) 
H. identical sample time points 
iii. strict quantitative analysis which is unbiased and precise. 
During this chapter data obtained from the PSA development study will be refeffed to as 
control data/cases and from the PSA prevention with novel fibrin sealant as treated 
data/cases. 
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5.2 Volumetric Analysis of Tissue Zones 
5.2.1 Results 
Incidence of PSAs in the rabbit uterine horn abrasion model was 85% in the control 
group and 3% in the novel fibrin sealant group (fi-om 8 hours following injury and 
onwards). There was a 96% reduction in the incidence of PSAs with the use of novel 
fibrin sealant. Mean volume of PSAs for control cases was 339.62MM3 and 4.7 1 MM3 
novel fibrin sealant cases. If we assume control cases have a percentage mean volume of 
100% then novel fibrin sealant cases showed a percentage volume of 1.4% (Graph 5.1 ). 
Hence treatment with novel fibrin sealant produced a 98.6% decrease in volume of 
PSAs. 
With regard to mean volume of PSA at each time point, all control groups from I hour 
post injury and onwards demonstrated PSAs whereas only one human derived fibrin 
sealant novel fibrin sealant case (28 day) demonstrated PSAs (Graph 5.2). All controls 
groups from 8 hours onwards showed significantly greater (P<0.05) mean volumes of 
PSAs compared to novel fibrin sealant treated groups (Appendix V Table 5.1). 
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together with SEMs and statistical differences. 
Control and novel fibrin sealant groups demonstrated a similar trend for peritoneal tissue 
generation (PTG)-. (i) a constant level for the first I day; (11) an increase in mean volume 
from I day with control cases showing a rapid increase peaking at 14 days whereas novel 
fibrin sealant cases increased less severely, peaking to a plateau at 5 to 7 days; and (111) a 
decrease following the peak in mean PTG volume (Graph 5.3). Novel fibrin sealant cases 
showed lower mean volumes throughout this study, with significant differences at I 
(P<0.001), 4 (P<0.01) and 16 hours (P<0.001), 3 (P<0.001), 7 (P<0.05) and 14 days 
(P<O. 00 1) (Appendix V Table 5.1). 
Control cases showed an initial increase in uterine horn tissue generation (UTG) from I 
to 4 hours followed by constant levels from 4 hours to 3 days. This in turn was followed 
by a rapid increase, peaking at 5 days and decreasing rapidly to 14 days, after which an 
increase in mean volume was seen to 42 days (Graph 5.4). Novel fibrin sealant cases 
showed an increase in mean volume of UTG from I hour to I day, at which peak volume 
occurred, with a decrease from I to 3 days and levels remaining constant until the end of 
the study. Overall, novel fibrin sealant cases demonstrated lower mean volumes of UTG 
compared to controls, with significant differences at 4 (P<0.05) hours, I (P<0,05), 5 
(P<0.001), 7 (P<0.001), 14 (P<0.05) and 42 days (P<0.001) (Appendix V Table 5.1). 
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Both control and novel fibrin sealant groups showed similar trends for mean volume of 
total tissue generation (TTG): increasing mean volumes from I hour, peaking at 14 days 
and 5 day post injury respectively and subsequently decreasing for the remainder of the 
study (Graph 5.5). At all sample time points mean TTG volume in novel fibrin sealant 
cases was significantly less (P<0.05) compared to control cases (Appendix V Table 5.1). 
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Both peritoneal and uterine horn damage demonstrated a similar pattern for both control 
and treated cases: constant mean volumes followed by a significant increase to peak and 
then subsequently decreasing. Peritoneal damage was as follows: (i) constant mean 
volumes from I hour to 3 days post injury for control cases and 16 hours for treated 
cases; (ii) rapid increase to peak at 14 days for control cases and 5 days for treated cases; 
and (iii) decrease until the end of the study, with mean volumes similar to those at I hour 
post injury (Graph 5.6). Significantly greater mean volumes (P<0.05) were seen in the 
treated group at 4 hours and 3 days whereas significantly greater volumes were 
demonstrated in control cases at 14 (P<0.01) and 28 days (P<0.05) post injury 
(Appendix V Table 5.1). 
Uterine hom damage demonstrated a similar trend : (i) constant mean volumes from I 
hour to 3 days for control cases and 16 hours for treated cases; (ii) rapid increase to peak 
at 5 days for control cases and I day for treated cases; and (iii) a rapid decrease to 7 days 
and 3 days respectively, with a gradual decrease for the remainder of the study (Graph 
5.7). From 3 days onwards treated cases showed a trend to have lower mean volumes of 
uterine horn damage compared to controls, being significant (P<0.001) at 5 days 
following injury (Appendix V Table 5.1). 
A similar trend was seen for both control and novel fibrin sealant groups with regard to 
peritoneal reaction (Graph 5.8). Both groups demonstrated an increase in mean volume 
from the first sample time point of I hour, with peaks seen at 16 hours and 5 days post 
injury for controls and I and 5 to 7 days for novel fibrin sealant cases. Throughout the 
whole of this study, significantly lower (P<0.001) mean volumes of peritoneal reaction 
were seen for novel fibrin sealant cases compared to controls. 
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Peritopeal cell concentration also showed very similar patterns for control and novel 
fibrin sealant groups: initially constant/absent levels, followed by an increase to a peak 
and then decreasing until levels are again absent (Graph 5.9). Controls showed an 
increase between 16 hours and 3 days, with the peak at 3 days followed by a decrease 
and levels seen up to 14 days post injury. In contrast novel fibrin sealant cases showed an 
increase from 3 to 5 days where mean volume peaked, and a decrease up to 14 days, 
with levels absent thereafter. Mean volume of peritoneal. cell concentration for novel 
fibrin sealant cases were again less than control cases, with significant differences 
(P<0.0 1) at I and 3 days following injury (Appendix V Table 5.1). 
Overall novel fibrin sealant cases demonstrated a lower extent of uterine horn 
haemorrhage compared to controls, with significant differences (P<0.05) at 1,4,8 hours 
and I and 3 days (Graph 5.10; Appendix V Table 5.1). Control cases showed major 
peaks in mean volume at 8 hours and I day whereas novel fibrin sealant cases 
demonstrated minor peaks at I and 16 hours. 
Mean total cell concentrations, peritoneal cell concentration for control cases and 
peritoneal cell concentration and cell concentration associated with fibrin sealant for 
novel fibrin sealant cases, showed similar trends throughout this study (Graph 5.11). 
Controls showed minimal levels, increasing rapidly from I day to peak at 3 days 
following injury, with levels decreasing rapidly thereafter. Novel fibrin sealant cases also 
increased rapidly from I day but peaked at 5 days, with levels decreasing gradually to 7 
days and then rapidly thereafter. Significantly greater mean volume (P<0.01) for control 
cases compared to treated cases was seen at I day post injury, whereas significantly 
greater volumes were seen for treated cases at 5 (P<0.01), 7 (P<0.001) and 14 days 
(P<0.05) (Appendix V Table 5.1). 
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Prevention of PSAs using Novel Fibrin Sealant 
Figure 4.16: Overview of tissue repair with novel fibrin sealant treatment. 
Chapter 4 
In vivo volume of novel fibrin sealant remained relatively constant for the first 5 days 
following application, after which there was a rapid loss, due to either phagocytosis 
and/or fibrinolysis. Therefore novel fibrin sealant was present during tissue generation 
modelling, fibrin deposition, and during the initial stages of tissue generation 
remodelling, collagen deposition. Novel fibrin sealant presence at injury site(s) during 
these stages is highly important and probably the major reason behind its PSA prevention 
success, 
A cellular response to human novel fibrin sealant in this rabbit experimental model was 
evident from 3 to 7 days post injury, with maximum response seen at 5 days. This 
response primarily consisted of macrophages and eosinophilic cells. It is hypothesised 
that this is an immune mediated response to the presence of foreign protein within the 
peritoneum, with phagocytic cells attracted to phagocytose this foreign material. Such a 
response should be absent when novel fibrin sealant is used as intended, that is, as a truly 
autologous sealant. 
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pattern of wound healing. It does however exert the effect of decreasing the volume of 
physiological changes and the time taken for such changes to occur (Figure 5.1). 
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e 5.1: Summary of physiological changes. 
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We know that immediately following injury blood loss will be stopped by haemostasis, 
with a platelet plug and fibrin clot formed. Platelets present will secrete chemical 
mediators which attract cells and the inflammatory process is initiated. Tissue 
surrounding and underlying the abrasion injury will have sustained a level of damage and 
will subsequently undergo necrosis. In order for proper wound healing to occur this 
necrotic tissue is removed by phagocytes, with volume of damage increasing and 
increased volume of tissue generation to replace this removed tissue. Once completed, 
damage and tissue generation volumes decrease as injured tissue is repaired. 
From the data obtained during this study we know that the volume of damage sustained 
from the abrasion process was the same for control and treated cases. In treated cases 
subsequent decreases in volumes are due to alterations in the response to injury, that is, a 
decreased inflammatory reaction, decreased necrosis of surrounding and underlying 
tissue and in turn tissue generation. This decreased necessity for wound healing response 
after treatment with novel fibrin sealant in turn decreases the time required for tissue 
repair to occur. Reasons for limitation of wound healing time include: (i) novel fibrin 
sealant acting as a physical barrier preventing cellular and biochemical interactions 
between peritoneal and uterine hom and their interactions with the peritoneal cavity; 
and/or (ii) biochernical modulation of wound healing by novel fibrin sealant. 
Although significantly lower mean volumes of peritoneal reaction were seen in treated 
cases compared to control cases, a large cellular reaction to the presence of human blood 
derived novel fibrin sealant was seen. Although this does not impinge on the prevention 
of PSAs in this model, such concentrations of inflammatory and phagocytic cells may 
play additional roles which are not evident in this study. Biochemical investigations are 
recommended to clarify this further. 
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Conclusions 
L In this rabbit uterine horn abrasion model novel fibrin sealant: 
a. prevented PSAs formation in 96% of cases 
b. decreased the volume and severity of PSAs by 99% 
c. did not alter the pattern of wound healing 
d. decreased the extent of physiological changes and subsequently the time taken 
for those changes to occur 
ii. Mechanisms of action for PSA prevention and alterations of wound healing by novel 
fibrin sealant include: 
a. sealant acting as a physical barrier, preventing fibrin exudate from joining 
injured surfaces and, in turn, preventing interactions between surfaces and 
peritoneal contents 
b. biochemical modulations by the sealant. 
5.3 Volumetric Analysis of Fibrin and Collagen 
In order to further define the mechanisms in which novel fibrin sealant prevents the 
formation of PSAs, fibrin and collagen presence within injury tissue will be directly 
compared between control and novel fibrin sealant treated cases. 
5.3.1 Results 
Mean percentages of fibrin and collagen for control and novel fibrin sealant treated cases 
demonstrated very similar patterns, with fibrin predominant during the first 3 days and 
collagen predominant from 5 days onwards (Graphs 5.12 and 5.13). During the first 16 
hours post injury fibrin only was present in total injury tissue generated after which mean 
percentage decreased slightly to 3 days and then rapidly from 3 to 5 days, to be absent 
from 28 days onwards. In contrast collagen percentages were vice versa: first present in 
minimal percentages at I days, rapidly increased from 3 to 5 days, with collagen only 
present from 28 days and thereon. Significant differences between control and treated 
cases were seen at I and 14 days following injury with treated cases demonstrating 
significantly lower percentages (P<0.01 and P<0.05 respectively) of fibrin and therefore 
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significantly greater percentages of collagen compared to control cases (Appendix V 
Table 5.2). 
Mean volumes of fibrin for control and treated cases demonstrated similar trends 
throughout this study: (i) steadily increasing mean volumes from I hour to I day for 
control cases and 16 hours for treated cases; (ii) rapid increase to a peak in mean volume 
at 3 and I day respectively; (iii) rapid decrease to 5 days for both groups; and (iv) 
steadily decreasing mean volumes until absent at 28 days post injury (Graph 5.14). 
Overall, mean volume of fibrin was greater in the control group compared to treated 
group, with significantly greater volumes at 4 (P<0.05), 8 (P<0.01), 16 hours (P<0.01), 
3 (P<0.001) and 14 days (P<0.05) post injury (Appendix V Table 5.2). 
Control and treated groups also demonstrated a similar pattern for collagen mean 
volumes: (i) absent for the first 16 hours; (ii) minimal volumes at I and 3 days; (iii) rapid 
increase to peak at 14 days for control group and 7 days for treated group; (iv) decrease 
in mean volume to 42 days for control group and 14 days for treated group, with level 
remaining similar until 42 days for the later group (Graph 5.15). Throughout this study 
mean volume of collagen was greater in the control group compared to treated, with 
significantly greater mean volumes at I (P<0.01), 3 (P<0.05), 5 (P<0.05), 7 (P<0.01), 14 
(P<O. 00 1) and 42 days (P<O. 0 1) (Appendix V Table 5.2). 
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5.3.2 Discussion 
Both control and novel fibrin sealant treated cases demonstrated the same patterns for 
fibrin and collagen presence and predominances in total tissue generated in response to 
injury- fibrin predominant for the first 3 days with collagen predominant from 5 days 
onwards. Therefore tissue generated in response to injury was fibrinous for the first 3 
days and fibrous from 5 days onwards whether injury sites were left untreated or treated 
with novel fibrin sealant. 
Although novel fibrin sealant did not exert any major effect on the pattern of structural 
development of injury tissue, minor alterations were seen (Figure 5.2). From I to 14 days 
following injury greater mean percentages of collagen were seen in treated cases 
compared to controls, being significant (P<0.05) at I and 14 days. Thus treatment with 
novel fibrin sealant accelerated the presence of collagen in injury tissue due to increasing 
fibroblast migration and/or fibroblast synthesis of collagen and promoted an accelerated 
loss of fibrin. Hypotheses for this effect include: (1) novel fibrin sealant acting as a 
physical barrier preventing interactions between injured surfaces and between injured 
surfaces and peritoneal contents; and/or (ii) biochemical modulation of wound healing by 
the sealant. 
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Figure 5.2: Summary of structw-al changes. 
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The lower mean volumes of fibrin and collagen in treated cases compared to controls 
was due to the lower mean volume of tissue generated in resPonse to injury by treated 
cases (refer to Section 5-2). 
Patterns for fibrin mean volumes were similar for control and treated cases: fibrin laid 
down to prevent blood loss and protect tissues from the peritoneal environment 
occurring from injury to 3 days for controls and 1 day for treated cases, with decreasing 
volumes thereafter. Treatment with novel fibrin sealant decreased the time required for 
maximum fibrin presence and subsequent loss. Cellular and biochemical activity are the 
stimulators for fibrin deposition following haemostasis and it is likely that these were 
altered by the presence of novel fibrin sealant. Whether this alteration was due to direct 
biochemical modulation by novel fibrin sealant or due to isolation of injured tissues is as 
yet undetermined. 
Control and treated cases also demonstrated a similar pattern for collagen presence: 
absent during the first 16 hours, increasing mean volumes to peak at 14 days for controls 
and 7 day for treated cases, with subsequent decreasing volumes finally reaching a 
plateau in treated cases, only. Hence novel fibrin sealant accelerated both collagen 
synthesis and maturation. This increased rate of tissue repair is hypothesised to be due to 
novel fibrin sealant decreasing the inflammatory response and necrotic damage following 
injury, leading to tissues being available for repair at an earlier time. 
Conclusions 
i. Treatment with novel fibrin sealant: 
a. does not alter the pattern of structural protein presence and predoininance's 
within in ury tissues j 
b. accelerated maximum fibrin presence and fibrin loss 
c. accelerated collagen synthesis and maturation 
ii. Mechanisms of action of novel fibrin sealant responsible for these changes could be: 
a. the sealant acting as a physical barrier preventing interactions between injured 
surfaces and between injured surfaces and peritoneal contents; and/or 
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b. biochemical modulation of wound healing by the sealant. 
5.4 Number Analysis of Cellular Components 
Cellular involvement is essential for wound healing, PSA development or PSA 
prevention. In order to gain further understanding into the actions of novel fibrin sealant 
direct comparisons between control and treated cases is required with regard to cellular 
presence. 
5.4.1 Results 
Cell predominances for number densities followed similar trends for control and treated 
cases (Graph 5.16). For the first day following injury inflammatory cells (eosinophilic 
cells, basophilic cells and macrophages) were the predominant cell type, with tissue 
repair cells (fibroblasts and macrophages) being predominant from 3 day onwards. Minor 
differences between groups were present: control cases demonstrated greater 
percentages of basophilic cells throughout the study whereas treated cases demonstrated 
greater percentages of lymphocytes from I to 8 hours, fibroblasts at 16 hours and I day 
and macrophages throughout the study. 
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Graph 5.16: Cell predominances for number densities. 
Since similar trends for both number densities and total were demonstrated in PSAs, 
PTG and UTG for control and treated cases these injury tissue zones were grouped 
together as total tissue generation. In addition basophilic and eosinophilic cells were 
grouped together as granulocytes. 
5.4.1.1 Number Densities 
Both control and treated cases demonstrated similar trends with regard to total cell 
densities within TTG throughout this study (Graph 5.17). From I hours post injury mean 
densities increased to peak at 16 hours, with a decrease from I to 3 days for control 
cases whereas an increase was seen for treated cases. Both groups demonstrated 
increasing mean densities from 3 day, with a second peak at 5 days, with densities 
showing a trend to decrease until 42 days. Throughout the whole study control case 
mean densities were greater then treated cases, followed by significantly greater densities 
at I (P<0.0001), 4 (P<0.0001), and 16 hours (P<0.01) post injury (Appendix V Table 
5.3). 
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Mean densities of granulocytes (basophilic and eosinophilic cells) followed a similar 
trend to total cells. Densities increased from I hour to peak at 16 hours, with a sharp 
decline to 3 days and constant densities thereafter (Graph 5.18). From I to 5 days 
control densities were greater then treated, being significant at I (P<0.001), 4 
(P<0.0001) and 8 hours (P<0.05) and 5 days (P<0.05). Although both control and 
treated case densities were relatively constant from 5 days onwards, treated cases 
showed densities slightly above control cases with significantly greater values at 14 
(P<0.01) and 28 days (P<0.05) post injury (Appendix V Table 5.3). 
The overall pattern for macrophage densities was the same for control and treated cases. 
From I hour to I day for controls and to 8 hours for treated cases constant densities 
were seen, with a rapid increase thereafter to peak at 5 days with densities decreasing for 
the remainder of the study (Graph 5.19). From 16 hours onwards macrophage densities 
in treated cases were greater than those in control cases with this being significant at I 
(P<0.05), 14 (P<0.01) and 28 days (P<0.0001) (Appendix V Table 5.3). 
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together with SEMs and statistical differences. 
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Fibroblast densities were constantly low from I hour to I day for control and to 8 hours 
for treated cases (Graph 5.20). In treated cases density increased from 8 hours to I day 
with a rapid increase from I to 5 days in both groups. Following the peak at 5 days there 
was a decrease to 7 days with densities remaining stable thereafter. Significantly greater 
fibroblast densities were seen in treated cases at 16 hours (P<0.0001) and I day 
(P<0.001) whereas greater densities were seen in control cases at 4 hours (P<0.05) and 7 
and 14 days (P<0.01) (Appendix V Table 5.3). 
Lymphocyte density in control cases demonstrated little change throughout the course of 
this study, with only a n-tinor peak at 3 days post injury (Graph 5.21). However treated 
cases peaked at I hour with a decrease to 3 days and only mild fluctuations from then on. 
From I to 8 hours lymphocyte densities in treated cases exceeded those in control cases, 
with the situation reversed from I to 42 days. Significantly greater densities were seen 
with control cases at 3 (P<0.001), 7 (P<0.01) and 14 days (P<0.01) following injury 
(Appendix V Table 5.3). 
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Graph 5.19: Mean macrophage densities throughout TTG development 
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Graph 5.20: Mean fibroblast densities throughout TTG development 
together with SEMs and statistical differences. 
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together with SEMs and statistical differences. 
Chapter 5 
5.4.1.2 Number Totals 
Cell predominances for number totals followed a similar trend to those seen for number 
densities. Inflammatory cells (eosinophilic cells, basophilic cells and macrophages) were 
predominant for the first day whereas tissue repair cells (fibroblasts and macrophages) 
were predominant from 3 days onwards for both control and treated groups (Graph 
5.22). Differences between groups included: greater percentages of basophilic cells for 
controls throughout this study; greater percentages of lymphocytes from I to 8 hours, 
fibroblasts at 16 hours and I day and macrophages throughout the study in the treated 
group. 
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Graph 5.22: CcIl predominances for number totals. 
Chapter 5 
Control and treated cases both demonstrated a similar pattern for total cell numbers 
(cells analysed) throughout this study (Graph 5.23). From I hour to 3 days there was a 
steady increase in mean numbers, with control cases only showing a minor peak at 16 
hours. A rapid increase was seen from 3 days with numbers peaking at 5 day post injury. 
Following this peak numbers decreased but with a minor peak at 14 days in both groups. 
At all time points investigated control cases demonstrated significantly greater (P<0.05) 
total cell numbers compared to novel fibrin sealant treated cases (Appendix V Table 5.4). 
Control cases showed an increase in granulocyte mean numbers from I hour to peak at 
16 hours with a rapid decrease to 3 days and a steady decline thereafter (Graph 5.24). 
Whereas treated cases showed an increase from I hour to I day, a rapid decrease from I 
to 3 days, a second increase from 3 to 14 days and decreasing numbers until the end of 
the study (Graph 5.24). At all time points, except 7,28 and 42 days, mean numbers of 
granulocytes were significantly greater (P<0.05) in the control group compared to 
treated. Whereas at 28 days post injury significantly greater (P<0.05) mean numbers 
were present in treated cases compared to controls (Appendix V Table 5.4). 
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Similar trends were seen in both control and treated cases with regard to mean 
macrophage numbers (Graph 5.25). Minimal numbers were present from I hour to I day 
for control cases and 16 hours for treated cases. A rapid increase was seen from I to 5 
days in control cases whereas a steady increase from 16 hours to 3 days followed by a 
rapid increase to 5 days was demonstrated by treated cases. Both groups peaked at 5 
days and then decreased to 42 days. Significantly greater numbers (P<0.05) were present 
in control cases compared to treated at I hour and 3 days whereas at I and 28 days 
significantly greater numbers (P<0.05) were seen in treated compared to control cases 
(Appendix V Table 5.4). 
Control and treated cases showed the exact same trend for fibroblast mean numbers 
throughout the first 42 days of healing (Graph 5.26). Fibroblasts were first evident at I 
day and a slight increase was seen from this time point to 3 days. Mean numbers rapidly 
increased to peak at 5 days and a second peak at 14 days, with declining numbers for the 
remainder of the study. Control cases demonstrated significantly greater numbers 
(P<0.05) compared to treated cases at 4 hours and from 3 days onwards (Appendix V 
Table 5.4). Significantly higher numbers (P<0.001) were seen with treated cases at I day 
compared to controls. 
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Mean numbers of lymphocytes in control cases showed minimal numbers with little 
variation from I hour to I day post injury. From I to 3 days there was a sharp increase 
to peak with numbers decreasing thereafter (Graph 5.27). Treated cases were the same 
as control during the first day however from 3 to 28 days numbers fluctuated frequently. 
At all time points control cases demonstrated greater mean numbers of lymphocytes with 
this being significant (P<0.01) at 3,7 and 28 days (Appendix V Table 5.4). 
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5.4.2 Discussion 
Control and novel fibrin sealant treated cases demonstrated the same trend for cell 
predominances within injury tissue. For the first day following injury, inflammatory cells 
(eosinophilic cells, basophilic cells, macrophages) were the predominant cell types and 
from 3 days onwards tissue repair cells were predominant (fibroblasts, macrophages). 
Hence treatment with novel fibrin sealant does not effect the overall cellular pattern of 
wound healing but it did exert subtle changes with the main modifications being the 
greater percentages of fibroblasts at 16 hours and I day and greater percentages of 
macrophages from 5 days onwards in treated cases compared to control cases. These will 
be discussed shortly. 
Similar trends in cell densities and totals further substantiates that novel fibrin sealant 
does not alter the course of wound healing (Figure 5.3). Volumetric analysis of control 
and treated cases with regard to tissue zones found that total tissue generation was 
significantly greater in controls consequently it follows that all number totals were 
greater in control cases. This pattern was also found in all cellular densities except 
macrophages where cell densities were greater in treated cases. Therefore PSA 
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development attracts a greater cell presence compared to PSA prevention by novel fibrin 
sealant. Since cells present release cytokines and growth factors which, in turn, induce 
further cell recruitment and so forth, this reciprocal spirals and probably exacerbates 
wound healing and PSA development. Reduced cellular presence in novel fibrin sealant 
cases is indicative of chemical modulation or limitation due to either tissue isolation or 
via direct chemical activity by novel fibrin sealant. 
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Figure 5.3: Sununary of cellular changes. 
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At I hour post injury, greater total cell densities were demonstrated in controls 
compared to treated cases. We know that novel fibrin sealant is an effective haemostatic 
agent reducing the necessity for natural haemostatic mechanisms. Therefore treated cases 
will have reduced natural fibrin and platelet plug which in turn means less factors 
secreted by platelets present and, as a net result, reduced cellular recruitment to the site 
of injury. Even at I hour following injury the effects and benefits of novel fibrin sealant 
are clearly evident. 
Peaks in total cell densities were seen at 16 hours for controls and I day for treated and 
5 days for both groups. We know that from I to 16 hours PSA modelling is actively 
occurring with fibrin lay down in both control and treated cases. During this time 
inflammatory cells are predominant and these appear to play a major role in continual 
fibrin deposition. In contrast from 16 hours to I day onwards, PSA and tissue generation 
remodelling is occurring. The second peak in /cell densities at 5 days is directly related to 
the presence of tissue repair cells, especially fibroblasts synthesising collagen, within 
injury tissue. 
The peak in granulocyte densities at 16 hours for control cases was much greater 
compared to the peak at I day for treated cases. Control cases experience a much greater 
inflammatory reaction to injury compared to treated cases. This is due to biolimitation by 
novel fibrin sealant with reduced inflammatory response having the knock on effects of 
reducing tissue necrosis and therefore reduced repair tissue required. 
Macrophage densities were greater in treated compared to control cases, 'With increased 
phagocytic activity within treated cases. This is most probably due to the non-autologous 
nature of the fibrin sealant utilised in this experimental model since macrophages were 
the primary cell type seen in fibrin sealant associated cell concentration. Increased 
macrophages mean increased phagocytosis which has the effect of rapid necrotic tissue 
clearance and reduced time required for wound healing. 
Significantly greater fibroblast densities were seen at 16 hours and I day post injury in 
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treated compared to control cases. This shows that the second stage of wound healing, 
tissue repair/remodelling is initiated earlier with novel fibrin sealant treatment. This is 
possibly due to reduced amount and time taken for the inflammatory reaction following 
injury, allowing tissue repair to be initiated earlier. 
Lymphocytes were present in greater densities in treated cases compared to controls 
from I to 8 hours however this relationship was reversed at 3,7 and 28 days post injury. 
It may be that the introduction of a foreign protein leads to a rapid lymphocyte mounted 
immune response. It is also possible that novel fibrin sealant has anti-bacterial properties 
or that with limited inflammation and consequent necrosis there is a reduced lymphocyte 
response. 
Conclusions 
L Treatment with novel fibrin sealant does not alter the pattern of cellular involvement 
in wound healing. 
ii. Treatment with novel fibrin sealant does reduce both densities and numbers of 
eosinophilic cells, basophilic cells, fibroblasts, lymphocytes and macrophages (number 
totals only) present in injury tissue from a very early stage of wound healing (I hour 
or maybe earlier post injury). 
iii. Greater macrophage densities with novel fibrin sealant in this study could be due to: 
* introduction of a foreign protein 
9 actual effect of treatment with novel fibrin sealant 
iv. Treatment with novel fibrin sealant does exert alteration on wound healing as follows: 
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INJURY 
Treatment with novel fibrin sealant 
Sealant initiated hacmostasis 
Reduced natural hacmostasis 
Reduced platelet presence 
Reduced amount of chemical mediators 
released 
Reduced inflammatory presence 
Reduced tissue necrosis 
? Increased phagocytic cell presence 
Earlier presence of tissue repair cells 
Reduced tissue repair 
cell presence 
ACCELERATED PSA-FREE WOUND 
5.5 Biochemical Analyses 
5.5.1 Full and Differential Blood Counts 
In an attempt to identify systemic changes occurring with the use of novel fibrin sealant, 
full and differential blood counts from animals within control and treated groups will be 
compared. 
5.5.1.1 Results 
Full and differential blood counts for control and treated cases at blood sample I 
demonstrated significant differences for between the two groups (Graph 5.28; Appendix 
V Table 5.5). The control group had significantly greater mean numbers of WBCs 
(P<0.001), lymphocytes (P<0.05) and platelets (P<0.01) compared to the treated group. 
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Similar differences were present between control and treated samples at blood sample 2, 
with the control group having significantly greater mean numbers of WBCs (P<0.001), 
lymphocytes (P<0.01) and RBCs (P<0.05) (Graph 5.29; Appendix V Table 5.5). 
At blood sample 3 significant differences between control and treated cases were also 
present, with the control group demonstrated significantly greater mean numbers of 
WBCs (P<0.001), lymphocytes (P<0.001) and eosinophilic cells (P<0.05) (Graph 5.30-, 
Appendix V Table 5.5). 
Since blood samples I and 2 are resting controls and post-laparotomy controls 
respectively, significant differences between control and treated groups mean direct 
comparison between experimental blood sample 3 for the groups is invalid. To determine 
whether novel fibrin sealant is exerting any systernic effects which are unique to itself and 
not attributed to PSA development, differences between experimental sample 3 and its 
own intra-case controls need to be examined. 
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Graph 5.28: Full and differential blood counts at blood sample I 
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RBCs and platelet mean numbers at experimental blood sample 3 demonstrated no 
significant differences from blood samples I or 2 in either control or treated group. 
Mean numbers of WBCs in blood sample 3 did demonstrated differing trends for control 
and treated cases (Graph 5.3 1). In control cases mean numbers increased from I hour to 
peak at 8 hours and then decreased to intra-case control values by 3 days, with a minor 
second peak at 5 to 7 d4ys. Whereas treated cases also increased from I hour to peak at 
8 hours and then decreased to 3 days to drop below intra-case control levels. A second 
peak was seen at 5 days with a rapid decrease to 14 days, with levels returning to intra- 
case control values by the end of the study. 
Basophilic cell mean numbers showed different trends for control and treated groups 
(Graph 5.32). In control cases mean numbers remained low for the first day afler which 
they increased to peak at 5 and then 7 days, with values returning to intra-case controls 
by 42 days. Treated cases demonstrated mean numbers increasing from I hour to peak at 
I day, with a rapid decrease from 3 to 14 days and values rising to 42 days post injury. 
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Graph 5.31: Mean numbers of WBCs for all blood samples 
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Control and treated groups demonstrated different trends in cell numbers with regard to 
lymphocytes (Graph 5.33). Mean numbers increased from I hour to peak at I to 3 days 
in control cases, with values decreasing to just below intra-case controls for the 
remainder of the study. However treated cases showed little change in lymphocyte mean 
numbers from I to 8 hours., after which there was a peak at 16 hours and I day, with 
levels decreasing slightly to 14 days and then returning to intra-case control mean 
numbers. 
Control and treated groups also demonstrated different patterns for mean monocyte 
numbers throughout this study (Graph 5.34). From I hour to 3 days mean numbers for 
control cases remained below intra-case controls, however they increased rapidly in 
intra-case controls at 5 days with values remaining similar to 42 days. Treated cases on 
the other hand showed little variation from I hour to 42 days, with mean numbers below 
intra-case controls. 
Both control and treated cases demonstrated a similar trend for mean numbers of 
eosinophilic cells (Graph 5.35). Both showed increases in mean numbers of eosinophilic 
cells from I hour to peak at 8 hours. This was followed by a rapid decrease to 3 days 
after which mean numbers increased to peak for a second time at 5 days post injury. 
Mean eosinophilic cell numbers then decreased steadily in control cases and rapidly for 
treated cases with levels settling out by the end of the study. 
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Graph 5.34: Mean numbers of monocytes for all blood samples 
together with SEMs. 
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Blood samples I and 2 were taken to act as intra-case controls at resting and post- 
laparotomy respectively. Although full and differential blood counts at blood samples I 
and 2 for control and treated groups fell within normal values for New Zealand White 
rabbits they were significantly different between groups. This made direct comparisons 
between control and treated groups, that is, PSA development and prevention with novel 
fibrin sealant respectively, of blood counts at blood sample 3 invalid. Hence the only way 
to identify changes associated with either PSA development or prevention was to 
compare differences with intra-case controls. Since PSA development and PSA 
prevention with novel fibrin sealant were different studies, they were performed at 
different times, with animals admitted to the department at different times. It is most 
probable that animals obtained were from different breeding lines, which would account 
for slightly different haernatological base levels. 
Neither PSA development or PSA prevention with novel fibrin sealant had any notable 
effect on mean numbers of RBCs or platelets during the course of this study. Since these 
cells do not play major roles in wound healing following haemostasis these results are as 
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expected. 
WBCs on the other hand are heavily involved in both PSA development and PSA 
prevention with novel fibrin sealant and the data obtained during this study demonstrates 
that these two processes do produce differing effects on systemic cell numbers. However 
care needs to be taken when interpreting this data due to the effects of venesection on 
cell numbers. Chapters 3 and 4 both detail whether changes in cell numbers at blood 
sample 3 are due to venesection or PSA development/prevention vAth novel fibrin sealant 
respectively. Table 5.4 summaries cell number changes and identifies their probable 
cauw. 
Group Cell Type Changes Associated with: 
Venesection PSA Development or Prevention 
Control WBCs Changes from 16 Increased numbers from 1 to 8 hours 
hours onwards 
Basophilic Cells Changes up to 7 days Elevated levels at 14 and 28 days 
Lymphocytes Allchanges - 
Monocytes Reduced numbers from I hour to 3 
Jays 
Eosinophilic Peak at 8 hours 
Cells I 
Novel Fibrin WBCs Undetermined cffcct Increased numbers from I hour to I 
Sealant Treated day 
? peak at 5 days 
Basophilic Cells Allchanges 
4yrnphocytcs Allchangcs 
Monocytcs Lower mean numbers throughout the 
study 
Eosinophilic Peaks at 8 hours and 5 days 
Cells 
Tabic 5A Changes in WBC numbers associated with vcncscction and PSA development or 
prevention with novel fibrin sealant. 
Both PSA development and treatment with novel fibrin sealant increased mean numbers 
of WBCs from I hour to 8 hours and I day respectively. Following injury there is a 
transient elevation in mean numbers of circulating WBCs whether injury sites are treated 
or not due to mobilisation of extra WBCs from storage tissues. In addition a peak in 
WBC numbers was seen at 5 days post injury for the novel fibrin sealant treated cases. It 
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is hypothesised that this is due to the immune reaction initiated by the presence of human 
fibrin in the rabbit peritoneum and in the proposed system for novel fibrin sealant 
(human: human) this systemic reaction would not be present. 
PSA development did exert an effect on basophilic cells, with elevated numbers 
circulating at 14 and to a lesser extent 28 days following injury. No effect was seen in the 
novel fibrin sealant treated group. It is probable that these elevated numbers at the later 
stages of PSA development are due the sustained reaction induced by PSA formation. In 
treated cases wound healing is completed at an accelerated rate with reduced reaction 
and necrotic damage, therefore these later systemic effects are absent in the treated 
group. 
Neither PSA development nor prevention with novel fibrin sealant demonstrated 
noticeable effects on systemic lymphocyte numbers. Initially lower levels in both groups 
can be directly attributed to venesection and lower circulating levels from 3 days 
onwards in the treated group is probably due to biological variation, No infection was 
seen in any of the animals in this study and although fibrin sealant induced an immune 
response it did not attract great quantities of lymphocytes. 
PSA development produced reduced numbers of monocytes from I hour to 3 days post 
injury. It is hypothesised that this is due to the large role played by these phagocytic cells 
during inflammation and tissue repair, with monocytes leaving the circulatory system and 
entering tissues. A similar effect is also seen in the treated group although to a lesser 
degree. This corresponds with the reduced inflammatory reaction seen with novel fibrin 
sealant treatment. 
Both PSA development and treatment with novel fibrin sealant resulted in a peak in 
circulating eosinophilic cells at 8 hours post injury. The involvement of eosinophilic cells 
in PSA development is well documented, with these inflammatory cells attracted to the 
site of injury to be predominant at 16 hours post injury (Chapters 3,4 and 5 of this 
thesis). It appears that additional eosinophilic cells are recruited into the circulatory 
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system to meet the high tissue demand. An additional peak in numbers was seen at 5 
days for the treated group which is due to the immune mediated reaction to the presence 
of human blood derived novel fibrin sealant in this rabbit model. 
Throughout this study cell numbers for PSA development demonstrated a greater range 
of variation compared to prevention with novel fibrin sealant. It is well established by the 
studies contained in this thesis that treatment with novel fibrin sealant limits the reaction 
mounted to injury and it appears that this local limitation has the effect of reducing 
systemic changes. 
Conclusions 
i. PSA development or PSA prevention with novel fibrin sealant: 
a. Had no notable effect on mean numbers of: 
9 RBCs 
9 Platelets 
9 Lymphocytes 
b. Increased mean numbers of WBCs from I hour to 8 hours and I day 
respectively. 
c. Reduced mean numbers of monocytes from I hour to 3 days post injurY 
(to a lesser degree in the treated group) 
d. Resulted in a peak in circulating eosinophilic cells at 8 hours post injury 
ii. PSA development did exert an effect on basophilic cells, with elevated numbers 
circulating at 14 and to a lesser extant 28 days following injury. No effect was seen in 
the novel fibrin sealant treated group. 
iii. Treatment with novel fibrin sealant caused an additional peak in eosinophilic cell and 
WBC mean numbers at 5 days due to the immune mediated reaction to the presence 
of human novel fibrin sealant in this rabbit model. 
iv. PSA development demonstrated a greater range of variation of cell numbers 
compared to prevention with novel fibrin sealant. 
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5.5.2 TGF-O Concentrations 
TGF-O concentration in plasma and peritoneal fluid samples collected throughout these 
studies were determined via an ELISA kit from R&D Systems. Due to time limitation 
only one plasma sample from I hour to 42 days was assayed for each group and one 
undiluted peritoneal fluid sample from 3 to 28 days together with controls. 
5.5.2.1 Results 
Comparison of blood samples 3 from control and treated cases showed that control cases 
demonstrated greater fluctuations with regard to TGF-P concentrations (Graph 5.36). 
All treated samples were similar to normal levels but, although most control samples 
were within these limits, a large peak in TGF-P was seen at 3 days post injury. 
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Graph 5.36: Comparison of TGF-P concentrations present in blood samples. 
With regard to TGF-P concentrations within peritoneal fluid samples, control and treated 
cases demonstrated a similar trend (Graph 5.37). Maximum concentration was seen at 7 
days with levels decreasing to normal values by 28 days. 
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Graph 5.37: Comparison of TGF-P concentrations present in peritoncal fluid samples. 
5.5.2.2 Discussion 
Chapler 5 
Since only one sample from each time point was assayed for each group it is invalid to 
draw real conclusions from this study. Further analyses are required. 
it does appear from the results obtained so far that PSA development exerts an effect on 
systemic levels of TGF-O whereas treatment with novel fibrin sealant does not. 
Throughout this study it has been demonstrated that treatment with novel fibrin sealant 
reduces the level of inflammation associated with injury, with decreased tissue necrosis 
and repair tissue generated. Hence the lack of systemic elevation of TGF-O in treated 
samples correlates with reduced tissue response to injury. 
TGF-O concentration within peritoneal fluid were elevated to similar levels and at the 
same time points in both control and treated samples and suggests that the limitation 
effect by novel fibrin sealant treatment is less pronounced locally. Since treated sites are 
covered with the protective layer of fibrin sealant, exposure to peritoneal fluid and 
contents will be reduced compared to uncovered controls. Hence even if similar 
concentrations TGF-O are present within peritoneal fluid of treated cases, the actions of 
these chemical factors on cells present within tissue generation may be curbed. 
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Conclusions 
Insufficient data is available at present to make definitive conclusions concerning the 
effects of PSA development and prevention with novel fibrin sealant on TGF-P 
concentration within plasma and peritoneal fluid. 
ii. Prelinýnary data suggests: 
PSA development elevated systemic TGF-P concentration in blood at 3 days 
and in peritoneal fluid at 7 days post injury. 
9 Treatment with novel fibrin sealant has no effect on blood TGF-p 
concentration but elevates peritoneal fluid concentrations at 7 days post injury. 
5.6 Conclusions 
Volumetric Conclusions 
i. In this rabbit uterine horn abrasion model, treatment with novel fibrin sealant 
prevented PSAs formation in 96% of cases and decreased the volume and hence 
severity of PSAs by 99%. 
I PSA development and prevention with novel fibrin sealant demonstrated the same 
pattern with regard to physiological, structural, cellular (local and systetnic) and 
probably biochemical mechanisms. 
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INJURY 
HAEMOSTASIS 
Fibrin clot and platclet plug 
Rcleasc of chcmical mcdiators (chcmotactic) 
FIBRIN DEPOSITION AND INFLAMMATION 
0 to at least I day 
Formation of fibrinous PSAs and tissue generation 
Predominant cells present: eosinophilic cells, 
basophilic cells, macrophages 
1. Infection prevention 
2. Phagocytosis of damages and necrotic tissue 
3. Attraction of ftirther inflammatory cells and tissue 
repair cells 
TISSUE REPAIR 
3 to 5 days onwards 
Formation of Fibrous PSAs and tissuc generation 
Predominant cells present: fibroblasts, macrophages 
1. Fibrin Loss 
2. Collagen deposition 
? Angiogenesis 
iii. Novel fibrin sealant decreased the extent of changes and subsequently the time taken 
for those changes to occur: 
" decreased volume of ischaernic and necrotic damage 
" decreased volume of repair tissue generated 
" decreased volume of pentoneal reaction 
" accelerated maximum fibrin presence and fibrin loss 
" accelerated collagen synthesis and maturation 
" reduced densities and numbers of eosinophilic cells, basophilic cells, 
fibroblasts, lymphocytes and macrophages (number totals only) present in 
injury tissue from a very early stage of wound healing (I hour or may earlier 
post injury). 
" eliminated elevated numbers of circulating basophilic cells at 14 and 28 days 
following injury seen with PSA development. 
" decreased magnitude of systemic cellular number changes compared to PSA 
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development 
iv. Greater macrophages densities with novel fibrin sealant in this study could be due to- 
9 introduction of a foreign protein 
9 actual effect of treatment with novel fibrin sealant 
v. Caused an additional peak in systemic numbers of eosinophilic cell and WBC mean 
numbers at 5 days due to the immune mediated reaction to the presence of human 
novel fibrin sealant in this rabbit model. 
vi. Mechanisms of action for PSA prevention and alterations of wound healing by novel 
fibrin sealant include: 
a. sealant acting as a haemostat and physical barrier, preventing fibrin exudate 
from joining injured surfaces and in turn preventing interactions between 
surfaces and peritoneal contents 
b. biochemical modulations by the sealant. 
INJURY 
Treatment with novel fibrin sealant 
Sealant induced HAEMOSTASIS 
Reduced natural haemostasis 
Reduced Platelet presence 
Reduced amount of chemical mediators released 
Reduced INFLAMMATION and FIBRIN DEPOSITION 
inflammatory cell presence 
? increased phagocytic cell presence 
TISSUE REPAIR 
Earlier tissue repair cell presence 
Reduced tissue repair cell presence 
ACCELERATED PSA-FREE WOUND HEALING 
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6.0 Comparison of Preparation and Application Methods of 
VivostatTm System Human Derived Fibrin Sealant for 
The Prevention of PSAs 
6.1 Introduction 
Previous studies, some of which are reported in this thesis (refer to Chapter 4), have 
shown that VivostatTm system human derived fibrin sealant (novel fibrin sealant) 
significantly reduces and nearly completely prevents the incidence of PSAs in a definitive 
rabbit uterine horn abrasion model. All of these studies used automated preparation and 
application techniques (VivostatTm processor and spray applicator) (refer to Section 
2.8.1). 
During early product development stages of novel fibrin sealant, preparation of the 
sealant was performed manually. Although this preparation technique was relatively easy 
and quick for scientists, it was non-viable for a commercial surgical product. Hence the 
fully automated VivostatTm processor (Section 2.8.1) was introduced, using the same 
biochemical processes but with minimal human input and decreased preparation time. 
Since these two preparation methods utilise the same chemical processes the resulting 
fibrin sealant should be analogous, however fibrin sealant produced via manual and 
automated techniques has not been compared for PSA prevention to date. 
Technical developments have also occurred with regard to application systems for novel 
fibrin sealant. Although the VivostatTm automated spray applicator (Section 2.8.1) is the 
system of choice, several different systems have been investigated for sealant application, 
the main alternatives being: 
i. UNES gun -a manual alternative to the device applicator comprising of a dual 
synnge system, based on the Duploject system (Figure 1.12). As with the device 
applicator, one syringe contains fibrin I solution and the other carbonatelbicarbonate 
buffer (pH 10.0). Syringes are mounted into a casing where depression of the trigger 
releases the contents of the two syringes in appropriate ratios, mixing taking place in 
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the Y-Piece where repolymensation of fibrin I is initiated, with the resultant fibr'n 11 
sealant ejected from the attached needle (Figure 6.1), 
Carbonatc/ 
Bicarbonate Bufl 
(pH 10. Ca") 
Fibrin I 
go 
Fibrin II Sealant 
Figure 6.1: UNES gun VivostatT? A system human derived fibrin sealant applicator system. 
ii. Needle applicator -a modification of the VivostatTM spray applicator (automated 
applicator unit and spray applicator) (refer to Section 2.8.1). Unlike the spray 
applicator, no air is used to drive the application process and hence a slower delivery 
rate is achieved, with the intention of greater control and precision during the 
application process. 
Aims of this study 
To compare: 
i. manually (bench) and automated processor (device) prepared novel fibrin sealant with 
regard to PSA prevention, 
ii. the efficiencies of spray, needle and UNES gun application systems for prevention of 
PSAs. 
6.2 Materials and Methods 
This study utilised a rabbit uterine horn abrasion model (refer to Chapter 2), with animals 
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randomised to one of five experimental groups (Table 6.1). Volume of novel fibrin 
sealant applied to each experimental site was not dictated by the study protocol and was 
left to the discretion of the surgeon (Table 6.1). Spray and needle applications used the 
VivostatTm 300gl applicator. 
Treatment Application Mean Volume of Mean Number Number of 
Method Sealant Applied Fibrin I of Experimental 
(VivostatTm) (m]) Concn (mg/ml) Animals Sites 
Control N/A N/A N/A 7 13 
Novel Fibrin Sealant Spray 0.64±0.05 14.81±0.50 6 12 
- Device Prepared 
Novel Fibrin Sealant LINES Gun 1.05±0.09 15.66±1.30 6 12 
- Device Prepared 
Novel Fibrin Sealant Needle 0.88±0.05 16.87±0.79 6 12 
- Device Prepared I I 
Novel Fibrin Sealant UNES Gun 
II 
0.80±0.09 - F20.10±2.81 6 12 
- Bench Prepared 
Table 6.1: Summary of experimental group details. 
Mean volumes and concentrations of fibrin sealant applied together with SEMS. 
Surgical, ternination (14 days post surgery) and histological procedures were as 
previously described (Chapter 2). Tissues were all processed to paraffin wax, sections 
cut at 5gm and stained with haematoxylin and eosin, with analysis provided by Cavalieri's 
Principal for determining absolute volumes (refer to Chapter 2). 
6.3 Results 
During this study there were no mortalities and no animal demonstrated morbidity 
associated with the experimental procedure. 
6.3.1 Macroscopic Results 
All experimental animals demonstrated the formation of general PSAs associated with a 
laparotomy procedure, that is, PSAs between the peritoneal suture line and underlying 
tissues, for example, the fat pad over the bladder or the bladder itself (Appendix VI 
Table 6.1). 
All control cases had PSAs present at all experimental sites, with all treatment groups 
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showing a reduction in experimentally-induced PSAs. Bench prepared (BP) UNES gun 
demonstrated a complete reduction of PSAs with an incidence of 0% PSA, device 
prepared (DP) needle 8.3%, DP spray 16.7% and DP UNES gun 58.3% incidence of 
PSAs at experimental sites (Graph 6.1, Appendix VI Table 6.1 and 6.2). 
All treated groups demonstrated novel fibrin sealant remaining at experimental sites at 14 
days post surgery, with incidence varying with the application method employed. DP 
needle showed the lowest incidence of 33.3%, followed by DP UNES gun with 41.7%, 
DP spray with 75% and finally the BP UNES gun with 100% incidence (Graph 6.2, 
Appendix VI Table 6.1 and 6.2). 
Graph 6.1: Mean macroscopic PSA incidence. 
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Graph 6.2: Mean macroscopic novel fibrin sealant remaining incidence. 
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6.3.2 Microscopical Quantitative Results 
Mean volume of PSAs for the control group was 73.93mmý, DP spray application 
17.32mmý, DP UNES gun 39.37mn? and DP needle 24.66mmý, with BP UNES gun 
5.40rnff? (Graph 6.3, Appendix VI Table 6.3). All treatment groups demonstrated 
significantly lower (P<0.05) mean volumes compared to controls, with no significant 
difference (P>0.05) between treatment groups (Appendix VI Table 6.4). 
Assuming that controls have 100% volume of PSAs, BP UNES gun showed the greatest 
reduction with 7.3 1% volume, followed by DP spray with 23.43%, DP needle with 
33.36% and finally DP UNES gun with 53.25% (Graph 6.4, Appendix VI Table 6.3). 
Peritoneal tissue generation (PTG) mean volume for controls was 48.71mrr?, with DP 
spray 101.93mmý, DP UNES gun 101.27mm3, DP needle 96.31mmý and BP UNES gun 
80.46nirný (Graph 6.5, Appendix VI Table 6.3). DP treatment groups all had significantly 
greater mean volumes (P<0.01) compared to controls whereas BP UNES gun showed a 
trend to have greater mean volume but not significantly (P>0.05) (Appendix VI Table 
6.4). However there was no significant difference (P>0.05) between treatment groups 
(Appendix VI Table 6.5). 
Mean volume of uterine hom tissue generation (UTG) showed a trend to be greater in 
treated groups, with controls having 12.42mm% DP spray 22.38mm% DP UNES gun 
22.12mm% DP needle 17.17nurO and BP UNES gun 24.84nuT? (Graph 6.6, Appendix VI 
Table 6.3). Only DP UNES gun showed a significant increase (P>0.05) compared to 
controls (Appendix VI Table 6.4), however there was no significant difference (P>0.05) 
between treated groups (Appendix VI Table 6.5). 
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Graph 6.3: Mean PSA volumes 
together with SEMs and statistical differences. 
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Graph 6.4: Mean PSA percentage volumes. 
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Graph 6.5: Mean PTG volumes 
together with SEMs and statistical differences. 
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Graph 6.6: Mean UTG volumes 
together with SEMs and statistical differences. 
No significant differences (P<0.05) were seen between control and treated groups or 
within the treated groups with regard to mean volume of total tissue generated (TTG) 
(Graph 6.7, Appendix VI Tables 6.3,6.4 and 6.5). The control group showed a mean 
volume of 136.07mm3, DP spray 144.86MM3 , 
DP UNES gun 164.3 1 MM3 , 
DP needle 
141 . 
99MM3 and BP UNES gun 115.88mm'. 
The control group demonstrated a mean volume of peritoneal damage of 44-29mm', with 
DP spray 31.32MM3 , DP UNES gun 33.73 MM3 , 
DP needle 35.46MM3 and BP UNES gun 
25.32mm 3 (Graph 6.8, Appendix VI Table 6.3). Only the BP UNES gun group 
demonstrated a significantly lower (P=0.024) mean volume compared to controls 
(Appendix VI Table 6.4) with no significant differences (P>0.05) between treated groups 
(Appendix VI Table 6.5). 
Mean volume of uterine horn damage was 20.26MM3 for controls, 
7.49MM3 for DP 
spray, 12.87MM3 for DP UNES gun, 11.93 MM3 for DP needle and 11.72mm' for BP 
UNES gun (Graph 6.9, Appendix VI Table 6.3). Only the DP spray group had a mean 
volume significantly lower (P=0.0208) than the control group (Appendix VI Table 6.4) 
and again, there was no significant difference (P>0.05) between the treatment groups 
(Appendix VI Table 6.5). 
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No significant differences (P>0.05) were seen for mean volume of peritoneal reaction, 
either comparing control and treated groups or between treatment groups (Appendix VI 
Tables 6.4 and 6.5). Mean values were 108.62MM3 for controls, 109.62MM3 for DP 
spray, 118.49MM3 for DP UNES gun, 91.78mm3 for DP needle and 88.64MM3 for BP 
UNES gun (Graph 6.10, Appendix VI Table 6.3). 
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Graph 6.7: Mean TTG volumes 
together with the SEMs and statistical differences. 
50 
40 
E 30 
10 
10 
0 
Graph 6.8: Mean peritoncal damage volumes 
together with the SEMs and statistical differences. 
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Graph 6.9: Mean uterine horn damage volumes 
together with SEMs and statistical differences. 
Graph 6.10: Mean peritoneal reaction volumes 
together with the SEMs and statistical differences. 
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Mean volumes of cell concentration were significantly greater (P<0.01) for treated 
compared to control groups (Graph 6.11, Appendix VI Table 6.4). Controls showed a 
mean volume of 1.6 IMM3, with DP spray 26.87MM3 , 
DP UNES gun 23.80mm', DP 
needle 19.63MM3 , and 
BP UNES gun 51.67mm3 (Appendix VI Table 6.3). There was 
also a significant difference (P=0.0028) between device and bench prepared fibrin sealant 
groups (Appendix VI Table 6.5). 
Novel fibrin sealant remaining at the completion of this 14 day study varied between 
device and bench prepared treatment groups, with bench prepared having significantly 
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greater (P=0.0014) volumes compared to device prepared (Graph 6.12, Appendix VI 
Table 6.5). Volume of sealant remaining was 10.43 MM3 for DP spray, 6.87 mm 
3 for DP 
3 UNES gun, 9.40mm' for DP needle and 56.93 mm for BP UNES gun. 
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Graph 6.11: Mean cell concentration volumes 
together with SEMs and statistical differences. 
Graph 6.12: Mean novel fibrin sealant remaining volumes 
together with SEMs and statistical differences. 
6.4 Discussion 
Novel fibrin sealant, either device or bench prepared, applied using spray, needle or 
UNES gun systems significantly (P<0.05) reduced PSA formation, both incidence and 
volume, in the rabbit uterine horn abrasion model. This supports data from all previous 
studies investigating PSAs prevention with novel fibrin sealant. 
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This study demonstrated variation in incidence and mean volume of PSAs, although not 
statistically significant (P>0.05), between bench and device prepared novel fibrin sealant. 
Bench prepared sealant showed greater effectiveness in reducing both incidence and 
volume of PSAs compared to device prepared sealant. There were also differences, again 
not significant (P>0.05), between the device prepared fibrin sealant with regard to 
application methods employed, with spray producing the greater PSA reduction, 
followed by needle and then UNES gun. 
There are several factors which could be responsible for these variations: (i) volume of 
fibrin sealant applied; (ii) concentration of fibrin I in the fibrin sealant; (iii) cross-linking 
of the fibrin sealant; (iv) content of the fibrin sealant; and (y) coverage with the fibrin 
sealant. These will be discussed in turn. 
i. Volume of fibrin sealant applied to experimental sites was determined by the surgeon 
during this study and hence varied between application methods. There were 
significant differences between the volume of sealant applied for several application 
methods (Appendix VI Table 6.6): mean volumes of DP spray were significantly 
lower (P<0.01) than DP UNES gun and DP needle; mean volumes of DP UNES gun 
were significantly greater (P<0.05) than DP needle. These variations appear to exert 
some effect on PSA prevention (Graph 6.13) with a trend for lower volumes of fibrin 
sealant applied resulting in lower PSA volumes. However no significant differences 
(P>0.05) were seen between treatment groups with regard to PSA volume. Hence 
volumes of fibrin sealant applied in this study appear to have little influence on PSA 
volume. 
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Graph 6.13: Mean PSA volume against mean volume of novel fibrin sealant applied 
together with SEMs. 
ii. The concentration of fibrin I present prior to polymerisation to fibrin (11) sealant could 
also potentially affect PSA prevention ability. Previous studies have demonstrated that 
the minimum effective concentration of fibnn I in novel fibnn sealant for effective 
haemostasis is between 5 and 10mg/ml. All experimental groups used fibrin sealants 
which were well above this minimum value, with no significant differences (P>0.05) 
demonstrated between treatment groups (Appendix VI Table 6.6). In addition there 
was no correlation between concentration of fibrin I and PSA volume (Graph 6.14). 
Hence concentrations of fibrin I in this study do not appear to be responsible for the 
differences seen in PSA reduction ability. 
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Graph 6.14-. Mean PSA volume against fibrin I concentration 
together with SEMs. 
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iii. Variation in the degree and effectiveness of cross-linking and polymerisation of fibrin 
I to fibrin 11 in the fibrin sealant is another potentially variable factor when using 
automated and non-automated systems, with automated techniques designed to 
optimise mixing and hence polymerisation. Although the non-automated UNES gun 
was the least effective of the DP methods, BP UNES gun was the most effective 
technique of the study as a whole. This, in addition to no si0ficant differences 
between automated and non-automated application methods, appears to eliminate this 
as a cause of the different efficacies seen. 
iv. Analysis of bench and device prepared human derived fibrin sealants revealed no 
differences in protein content with regard to fibrin I, biotin-batroxobin and avidin- 
agarose. However significantly (P<0.01) greater volumes were present at 14 days for 
BP sealant compared to DP sealant. No further investigations into differences 
between BP and DP sealants were carried out due to no significant difference 
(P<0.05) in PSA reduction. 
v. Variations in intervention of PSAs seen in this study are most probably attributed to 
the way in which the sealant was applied to injured surfaces. In order to achieve 
complete PSA prevention, it is assumed that a continuous layer of fibrin sealant is 
needed to separate the surfaces. In these conditions fibrous exudate produced on each 
injured surface can not reach the apposed injury or other tissue sites, hence fibrinous 
adhesions are prevented. From this study, is appears that this is attained most 
regularly by UNES gun for bench prepared novel sealant, followed by, in order of 
effectiveness, spray, needle and then UNES gun for device prepared novel fibrin 
sealant. 
This study indicates that control and treated cases generated similar volumes of tissue in 
response to abrasion injury but the location/type of tissue generated varied. Control cases 
demonstrated greatest volumes of PSA, followed by PTG, UTG and then free floating 
tissue generation (FFTG) (tissue generation which, in transverse section, does not appear 
to be attached to either the uterine horn or peritoneal wall), whereas treated cases 
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showed largest mean volumes of PTG, PSA or UTG and least in FFTG. Hence treatment 
with novel fibrin sealant prevents tissue generated from injury sites from forming PSAs 
but does not prevent tissue being generated in response in injury. 
Treatment with novel fibrin sealant has a slight protective effect with regard to tissue 
damage seen at 14 days, with treated groups demonstrating a trend for lower mean 
damage volumes. However significant differences (P<0.05) were only seen for BP UNES 
gun for peritoneal damage and DP spray for uterine horn damage. From previous studies 
(refer to Chapter 3) it has been demonstrated that damage associated with the abrasion 
injury in the rabbit uterine horn abrasion model follows the normal progression for 
wound healing: damage from the initial scraping injury only is seen for the first few days, 
followed by an increase in mean volume associated with clearing of necrotic underlying 
and surrounding tissues, which in turn is followed by a decrease in damage volume as 
new wound replacement tissue is laid down. By 14 days the final replacement process is 
occurring with the difference seen between control and treated cases in this study most 
probably due to novel fibrin sealant having a protective effect on injured and surrounding 
tissues, limiting the volume of underlying and surrounding tissue necrosis and hence 
damage. The mechanisms involved in this tissue protection could either be due to the 
sealant providing a barrier between the injury site and peritoneal cavity and its contents, 
or the sealant having biochemical effects on tissue. Further analysis will hopefully clarify 
these mechanisms further. 
Treatment with novel fibrin sealant had little to no effect on the volume of reaction seen 
in the peritoneum at 14 days post injury. This appears to support the above hypothesis 
that fibrin sealant protects injured tissue from damage due to a barrier effect as opposed 
to exerting a biochemical influence. 
As observed in all previous novel fibrin sealant studies, treatment with novel fibrin 
sealant using this rabbit uterine horn abrasion model induced a local cell reaction, seen as 
areas of cell concentrations. This is most probably an immune response mounted to the 
introduction of a foreign protein (human blood derived fibrin). However even with this 
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cellular response, novel fibrin sealant significantly reduced the formation of PSAs. The 
significant difference (P<0.01) seen between device and bench prepared fibrin sealant 
with regard to cell concentration is most probably due to bench prepared sealant 
remaining in vivo longer than device prepared, with longer residency time leading to a 
more sustained reaction. 
6.5 Conclusions 
Novel fibrin sealant, either device or bench prepared, applied using spray, UNES gun 
or needle systems, significantly (P<0.05) reduced PSA formation in the rabbit uterine 
horn abrasion model. 
I There were no significant differences (P>0.05) between mean volume of PSAs for 
device and bench prepared fibrin sealant or application techniques used, however the 
trend for PSA reduction was BP UNES gun (93%), DP spray (77%), DP needle 
(67%) and DP UNES gun (56%). 
iii. Differences in reduction of PSAs seen with dilfferent preparation and application 
methods are most probably due to the coverage of sealant over injured surfaces. 
iv. Prevention of PSAs by novel fibrin sealant appeared to be due to its acting primarily 
as a physical barrier. 
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7.0 Comparison of Vivostatm System Human Derived 
Fibrin Sealant, Tissucol@ and CRYO for the Prevention of 
PSAs in the Rabbit Uterine Horn Abrasion Model 
7.1 Introduction 
Much interest has been shown in the use of fibrin sealants as surgical tools for 
haemostasis, tissue sealing and reduction of PSAs (refer to Chapter 1). With regard to 
PSA reduction, the absolute value of the different fibrin sealants investigated and their 
benefits over others is difficult to assess since previous studies have used a variety of 
experimental models and qualitative analytical procedures. Studies investigating 
VivostatTm system human derived fibrin sealant (novel fibrin sealant) (refer to Chapters 4 
and 6) have demonstrated the significant reduction and near complete prevention of 
PSAs using a definitive experimental model together with strict quantitative analyses. No 
such comprehensive information is accessible on commercially available fibrin sealants. 
TissucolO (Immuno AG, Vienna, Austria) was the first commercially available fibrin 
sealant utilising pooled human fibrinogen concentrate. Like many subsequent sealants, 
TissucolO uses a two component system: 
i. pooled human fibrinogen (in an aprotinin solution); and 
I bovine thrombin (in a calcium chloride solution), 
with the mixing of these leading to the formation of fibrin II polymerised sealant. Many 
studies have investigated the efficiency of Tissucol@ to reduce PSAs with most being 
supportive of its use (Lindenberg & Lauritsen, 1984; Lindenburg et al, 1985; Larsson et 
al., 1986; De Laco et al., 1994). 
Legislation against the use of pooled fibrinogen products introduced in the United States 
in 1978 prompted the search for preparation systems using autologous fibrinogen 
resulting in autologous fibrin sealants. The method of CRYO precipitation was 
established to obtain autologous fibrinogen from blood over coming the problems of 
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pooled blood products. "CRYO" fibrin sealants, like TissucolID still require the addition 
of exogenous thrombin in order for the autologous fibrinogen to form fibrin 1. Generally, 
studies detailing the use of CRYO fibrin sealants for prevention against PSA formation 
are supportive (CRYO: Sheppard el al., 1993; Ethanol precipitate: Weiss-Fogh el al., 
1990), however the clinical use of CRYO sealants has been limited by its time consuming 
production. 
Aims of this study 
i. Assess the ability of 
a. VivostatTm system human derived fibrin sealant (novel fibrin sealant) 
b. CRYO at two different bovine thrombin concentrations (4 and 500 units) 
c. Tissucolg at two different bovine thrombin concentrations (4 and 500 units) 
to reduce/prevent PSAs compared to controls in a definitive rabbit uterine horn 
abrasion model using quantitative analysis 
ii. Identify possible mechanisms in which these potential PSA preventative agents are 
working 
7.2 Materials and Methods 
A summary of experimental groups together with volumes of fibrin sealant applied are 
shown in Table 7.1. 
Treatment Group Number of Mean Volume of Mean Fibrin I 
Animals Experimental Sealant Conc" 
Sites Applied (ml) (MR/ml) 
Control 7 13 N/A N/A 
Novel Fibrin Sealant 6 12 0.93±0.06 14.90±2.41 
(Needle Application) 
Tissucol@ 6 Total: 11 17.50-28.75 
-4 Units Bovine Thrombin 5 0.50±0.03 
500 Units Bovine Thrombin 6 1.12±0.11 
CRYO 6 Total: 12 10.64± 
-4 Units Bovine Thrombin 6 0.47±0.02 0.84 
500 Units Bovine Thrombin 6 0.33±0.03 
Table 7.1: Experimental group details. 
Number of animals and experimental sites and mean volume and concentration of fibrin 
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swlant applicd togcthcr with SEMs. 
A rabbit uterine hom abrasion model was utilised in this study with standard surgical, 
termination (14 days post surgery) and histological procedures carried out (refer to 
Chapter 2). TissucolID and CRYO were prepared as the manufacturer's instructions 
(refer to Chapter I and Appendix MI). 
For the application of novel fibrin sealant a 300[d VivostatTm applicator was used, with 
Duploject systems (refer to Chapter 2) used for Tissucol@ and CRYO (as recommended 
by suppliers). 
Resected tissues were processed'to paraffin wax, 5gm sections cut and stained with 
haernatoxylin and eosin and Cavalieri's analysis was carried out for determination of 
absolute volumes (refer to Chapter 2). 
7.3 Results 
There were no mortalities in this study and no animal demonstrated morbidity from the 
experimental procedure. 
All animals demonstrated the formation of PSAs associated with laparotomy, that is, 
PSAs involving the peritoneal suture line and one or more of the following: omentum, fat 
pad over the bladder, or the bladder (Appendix VII Table 7.1). 
7.3.1 Macroscopic Results 
All of the control groups (13/13) showed PSAs joining the abraded areas of the 
peritoneal wall and uterine horn. The macroscopic incidence of experimentally induced 
PSAs for treatment groups was 8.3% for novel fibrin sealant, 16.7% CRYO 4 units 
thrombin, 66.7% CRYO 500 units thrombin, 100% TissucolO 4 units thrombin and 50% 
TissucolO 500 units thrombin (Graph 7.1; Appendix VII Table 7.1). 
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7.3.2 Microscopic Quantitative Results 
Chapler 7 
Mean volumes of PSAs were 73.93MM3 for the control group (Figure 7.1), 11.3 OMM3 fo r 
the novel fibrin sealant treated group (Figure 7.2), 21.06 and 179.98mm 3 for the CRYO 
treated groups with 4 and 500 units thrombin respectively (Figures 7.3 and 7.4) and 
106.12 and 69.42MM3 for the TissucolS treated groups with 4 and 500 units thrombin 
respectively (Figures 7.5 and 7.6) (Graph 7.2; Appendix VII Table 7.2). Significant 3. 
reduction in mean PSA volume compared to controls was seen with novel fibrin sealant 
(P<0.001) and CRYO (P=0.0152) 4 units thrombin treated groups only (Appendix VII 
Table 7.3). 
Assuming that the control group demonstrated 100% PSA formation, the percentage 
volume of PSAs for each treatment was 15.28% novel fibrin sealant, 28.49% CRYO (4 
units thrombin), 243.46% CRYO (500 units thrombin), 143.55% Tissucole (4 units 
thrombin) and 93.90% Tissucol@ (500 units thrombin) (Graph 7.3; Appendix VII Table 
7.2). 
291 
Comparison ofFibrin Sealants. for PS4 Prevention 
250 
PP. 
- 
200 
E 150 
E 
100 
50 
0 
Control Novel CRYO CRYO Tissucol Tissucol 
Fibrin 4 Units 500 Units 4 Units 500 Units 
Sealant Thrombin Thrombin Thrombin Thrombin 
Graph 7.2: Mean PSA volumes 
together with SEMs and statistical differences. 
250 
200 
E 150 
U 
CL 
100 
50 
0 
Controls 
Graph 7.3: Mean PSA percentage volume. 
Figure 7.1: Control Case 
(NL x2) 
PSA 
Chapter 7 
292 
Novel CRYO CRyO Tissucol Tissucol 
Fibrin 4 Units 500 Units 4 Units 500 Units 
Sealant Thrombin Thrombin Thrombin Thrombin 
Comparison qf Fibrin Sealants. for PSA Prevention 
Figure 7.2: Novel fibrin sealant treated case. 
(K. x2) 
Non- 
adhered 
tissue 
generation 
VIF7 
L N't V, 
Figure 7.3: CRYO (4 units thrombin) treated case 
(K x2) 
Chapter 7 
Non-adhcrcd 
tissuc 
gcncration 
PSA 
ir 
4 
171 PSA 
'A' 
71 
Figure 7.4: CRYO (500 units thrombin) treated case. 
(K, x2) 
293 
Comparison (? f Fibrin Sealants. for PSA Prevention 
Figure 7.5: Tissucol (4 units thrombin) treated case. 
(K, x2) 
PSA 
A& 
IMP Ron 
Figure 7.6: Tissucol (500 units thrombin) treated case. 
(Mo x2) 
PSA 
Chapter 7 
Treatment groups all demonstrated greater mean volumes of peritoneal tissue generated 
(PTG) compared to controls. Mean PTG for the control group was 48.71 mm 1 compared 
to 68.75 MM3 for novel fibrin sealant treated, 111.20 and 136.24MM3 for CRYO treated 
(4 and 500 units thrombin respectively) and 82.34 and 137.09MM3 for TissucolO with 4 
and 500 units thrombin respectively (Graph 7.4, Appendix VII Table 7.2). Both CRYO 
groups and TissucolO 500 units thrombin demonstrated volumes that were significantly 
greater than controls (P<O. 00 1) (Appendix VI I Table 7.3). 
3 Mean volumes of uterine horn tissue generation (UTG) were 12.42mm -1 for the control 
group, 6.69mm'for novel fibrin sealant, 13.95 and 33.95mm-3 for 4 and 500 unit thrombin 
CRYO and 14.45 and 28.26mm 3 for TissucolO 4 and 500 units thrombin groups 
respectively (Graph 7.5; Appendix VII Table 7.2). Mean volumes were significantly 
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greater (P<0.05) than controls in the 500 unit thrombin groups (CRYO and Tissuco1g) 
(Appendix VII Table 7.3). 
All treatment groups, except novel fibrin sealant, demonstrated greater mean volumes of 
total tissue generated (TTG) compared to controls in response to the abrasion injury 
(Graph 7.6; Appendix VII Table 7.2). The control group showed a mean volume of 
136.07MM3 compared to 89.1 1 MIn3 for novel fibrm sealant, 147.70 and 350.94mm' for 
CRYO (4 and 500 units thrombin respectively) and 204.23 and 238.04mm' for 
TissucolO (4 and 500 units thrombin respectively). Both 500 unit thrombin groups 
(CRYO and Tissucolg) possessed significantly greater (P<0.05) volumes of TTG 
compared to controls, whereas significantly lower (P<0.05) volumes were seen with 
novel fibrin sealant (Appendix VII Table 7.3). 
Mean volumes of peritoneal damage were 44.29MM3 for controls, 18.02MM3 for novel 
fibrin sealant, 48.78 and 46.13MM3 for 4 and 500 units thrombin CRYO and 50.62 and 
35.20n, M3 for Tissucolg treated groups (4 and 500 units thrombin respectively) (Graph 
7.7; Appendix VII Table 7.2). Only novel fibrin sealant showed any significant difference 
from the control group with volumes being significantly lower in the treated group 
(P<0.01) (Appendix VII Table 7.3). 
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M3 Uterine horn damage mean volumes were 20.26m for controls, 2.50mm' for novel 
fibrin sealant, 8.89 and 37.38MM3 for CRYO (4 and 500 units thrombin respectively) and 
18.08 and 2.7 1 MM3 for 4 and 500 units thrombin with Tissucol@ (Graph 7.8). Both 
novel fibrin sealant and Tissucol 500 units thrombin groups had significantly lower mean 
volumes compared to the control group (P<0.0001 and P<0.05 respectively). There was 
also a significant difference (P<0.01) between TissucolO treatments with 4 and 500 units 
thrombin (Appendix VII Table 7.3). 
Mean volume of peritoneal reaction of the control group was 108.62mm3, compared to 
79.58MM3 for novel fibrin sealant, 88.18 and 174.90MM3 for CRYO (4 and 500 units 
thrombin respectively) and 122.09 and 137.72MM3 for TissucolO (4 and 500 units 
thrombin) (Graph 7.9; Appendix VII Table 7.2). The novel fibrin sealant group 
demonstrated significantly lower (P<0.01) volumes of pentoneal reaction compared to 
controls whereas the CRYO 500 units thrombin group showed significantly greater 
volumes (P<0.01) compared to controls. A significant difference was also observed 
between CRYO groups (P<0.0001), with 500 units demonstrating greater volumes 
(Appendix VII Table 7.3). 
All treatment groups had fibrin sealant remaining at the completion of this 14 day study. 
Mean volume of novel fibrin sealant was 21.20MM3, compared to 13.64 and 97.07mm-1 
for 4 and 500 units thrombin with CRYO and 42.47 and 110.70mm3 for 4 and 500 units 
thrombin with TissucolS (Graph 7.10; Appendix VII Table 7.2). Significant differences 
(P<0.05) were seen between the novel fibrin sealant groups and the 500 units thrombin 
groups (CRYO and Tissuco, 16) and between 4 and 500 units CRYO groups (P<0.01) 
(Appendix VII Table 7.3). 
Cell concentration volumes were all significantly greater (P<0.01) for all treated groups 
compared to the control group. Controls demonstrated 1.61mm 3, compared to novel 
fibrin sealant with 29.62MM3, CRYO 22.87 and 79.16mm3 (4 and 500 units thrombin 
respectively) and TissucolO 35.33 and 72.48MM3 (4 and 500 units thrombin respectively) 
(Graph 7.11; Appendix VII Table 7.2). A significant difference (P<0.01) was seen 
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between 4 and 500 units thrombin with CRYO (Appendix VII Table 7.3). 
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7.4 Discussion 
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This study utilised a definitive rabbit uterine horn abrasion model together with 
quantitative analysis to assess PSA reduction and/or prevention using novel fibrin 
sealant, TissucolO and CRYO. Since the same PSA induction procedure and unbiased 
and precise quantitative analytical procedures were used for all groups, fair and valid 
comparisons can be made. 
Only two of the treatments investigated, novel fibrin sealant (P<0.001) and CRYO with 
4 units thrombin (P<0.05), significantly reduced the formation of PSAs. Tissucole with 
500 units thrombin showed only a 6% reduction in PSAs however Tissucole 4 units 
thrombin and CRYO 500 units thrombin groups demonstrated an increase in the volume 
of PSAs present, with an additional 44 and 144% respectively. Hence Tissucolg 4 and 
500 units thrombin and CRYO 500 units thrombin did not significantly reduce either the 
incidence or volume of PSAs compared to controls. These results are in contradiction to 
previously published papers supporting the use of Tissucol@ (Lindenberg & Lauritsen, 
1984; Lindenburg el al., 1985; Larsson el al., 1986; De Laco el al., 1994) and CRYO 
(CRYO: Sheppard el al., 1993; Ethanol precipitate: Weiss-Fogh el aL, 1990) as PSA 
preventative agents. As with all potential PSA preventative agents, previous studies 
investigating Tissucol@ have used a wide variety of experimental models coupled with 
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subjective qualitative analytical techniques. Since this study eliminated the problems 
associated with these investigation methods, it is conclusive that Tissucols (4 and 500 
units thrombin) and CRYO (500 units thrombin) do not significantly reduce/prevent 
PSAs in this rabbit uterine horn abrasion model. This gives support to studies which also 
do not support the use of TissucolO as an anti-PSA agent (Bilgin el al., 1995). 
Effectiveness of PSA prevention by fibrin sealants appears to be independent of the 
volume applied (Graph 7.12) and fibrin I concentration (Graph 7.13) within the limits 
used in this study. Of the fibrin sealants investigated, novel fibrin sealant demonstrated 
little variation in PSA volume even with larger variations in volume applied and fibrin I 
concentration. 
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With the exception of UTG present in the novel fibrin sealant group, all treatment groups 
demonstrated greater volumes of PTG and UTG compared to controls. In both 500 units 
thrombin groups (CRYO and Tissucolg) this increase in mean volumes of PTG and 
UTG was significant (P<0.05) compared to controls. It is generally assumed that one of 
the mechanisms in which fibrin sealants prevent PSAs is by acting as a physical barrier, 
preventing fibrin exuded from damaged tissues from adhering to other surfaces, thus 
preventing the formation of fibrinous and subsequently fibrous adhesions. If fibrin 
sealants are acting solely as a physical barrier, with no biochemical actions, then injured 
surfaces should produce the same volume of fibrin in response to injury but this will be 
discretely located on injured surfaces rather than joining them together. The increase in 
PTG and UTG in treatment groups compared to controls supports this hypothesis. 
To substantiate this theory the mean total tissue generated from treated and control 
groups should be similar. However this is only true for 4 units thrombin groups (CRYO 
and Tissucol@). The novel fibrin sealant group demonstrated a significantly lower 
(P<0.05) mean volume of TTG compared to controls, indicating physiological 
modulation occurring to reduce the amount of tissue generated in response to injury. 
Results from 500 unit thrombin groups (CRYO and Tissucolg) also indicate some type 
of modulation., however in these groups there is significant (P<0.05) stimulation of tissue 
generated. This phenomena of tissue fibrosis by thrombin dependent fibrin sealants has 
been highlighted by other authors, especially with nerve fibrosis (Fairbrother, 1997). 
Increased stimulation of fibrotic tissue in response to damage is not a desirable effect of a 
fibrin sealant, since the greater volume of tissue generated the greater risk of problems 
associated with that tissue. 
None of the treatments except novel fibrin sealant had any effect on the mean volume of 
both peritoneal and uterine horn damage, which demonstrated a significant decrease 
compared to controls (P<0.01 and P<0-0001 respectively). Since all experimental 
animals underwent the same injury process, that is, a similar volume of initial injury 
within biological limits, then this significant decrease seen in mean damage volumes with 
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novel fibrin sealant indicates a limitation in subsequent tissue damage, that is, necrosis of 
underlying and adjacent tissues. This is further evidence that novel fibrin sealant exerts 
physiological regulation of tissue repair, with further support from the significant 
decrease (P<0.01) in mean volume of peritoneal reaction compared to controls. It is 
hypothesised that novel fibrin sealant limits the inflammatory response mounted in 
response to tissue damage, either due to tissue isolation from external factors or by 
biochemical modulation, which in turn reduces the amount of damage induced by the 
inflammatory response, and therefore the amount of tissue generated in response to 
damage. Many studies have demonstrated that there is a direct relationship between PSA 
formation and the extent of tissue damage (Ellis, 1962; Belzer, 1967) and hence the 
reduction in damage volume with novel fibrin sealant is most probably associated with 
the reduction seen in PSAs and TG. 
Mean peritoneal reaction volumes of all of the other treatments (except CRYO 500 units 
thrombin) showed no change from controls, indicating that they do not influence the 
tissue reaction mounted in response to injury. The, significant increase (P<0.01) in 
peritoneal reaction seen with CRYO 500 units thrombin is due to the increased thrombin 
concentration used, since 4 units thrombin showed no such difference and there was a 
significant increase (P<0.0001) between 4 and 500 units thrombin. 
High concentrations of thrombin per se ý have several effects including macrophage 
migration into the fibrin clot, reduction or inhibition of fibroblast migration into the clot, 
reduction or inhibition of fibroblast attachment and mitogenesis, induction of lung injury, 
brain oedema and cerebral vasospasm, vascular thrombogencity and fibrosis in nerve 
repair (Fairbrother, 1997). Although thrombin is not added directly into areas treated 
with thrombin dependent fibrin sealants, it can enter the body via inadequate mixing of 
the sealant and release from the sealant matrix. The above adverse effects are potentially 
possible with the use of these fibrin sealants. From this study it is clear that some of these 
effects can be seen, specifically increased cellular migration,, into injured tissue and 
excessive tissue fibrosis. 
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TissucolO has been designed to use one of two thrombin concentrations, 4 and 500 
units. The use of 4 units thrombin has been recommended for all tissue adaptation 
applications, for example, skin grafting and microsurgical operations, with the high 
thrombin concentration suggested for haemostasis to ensure instantaneous clotting 
(Fairbrother, 1997). However due to the slower clotting time of the lower thrombin 
concentration many surgeons have tended to use the high concentration thrombin and 
ignore potential problems associated with the higher concentration. 
The concentration of thrombin utilised in fibrin sealants has generally focused on the 
optimal concentration required for rapid cleavage of fibrinogen to fibrin and subsequent 
cross-linking of the fibrin II rather than on safety. However the disadvantages of using 
high thrombin concentration are beginning to be noticed and the trend for the use of 
lower thrombin concentrations in fibrin sealants has begun to emerge. Unlike other fibrin 
sealants, no exogenous thrombin is required for novel fibrin sealant polymerisation, with 
the sealant containing less than I unit of endogenous thrombin. The results from this 
study highlight the advantages of such a system over traditional fibrin sealants. 
All treatment groups demonstrated fibrin sealant still remaining at the completion of this 
14 day study. There were significant differences (P<0.05) seen between 500 units 
thrombin for both CRYO and TissucolID compared to novel fibrin sealant, and between 4 
and 500 units thrombin with CRYO. It appears that the addition of 500 units thrombin 
for fibrinogen cleavage significantly increases the residency time of the resulting fibrin 
sealant in vivo. This does not appear to be directly related to the volume of fibrin sealant 
added., but could be due to increased fibrinolytic resistance of the sealant or increased 
amount of fibrinogen polymerised by the faster acting 500 units of thrombin. 
The addition of exogenous proteins to the peritoneal cavity is highly probable to induce a 
foreign body reaction. This was indeed the case with all fibrin sealant treatment groups 
demonstrating significantly greater (P<0.001) volumes of cell concentration compared to 
controls. Although novel fibrin sealant is intended as an autologous fibrin sealant, this is 
naturally not the case in this study since human derived novel fibrin sealant was used to 
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treat injuries in the rabbit peritoneum. 
7.5 Conclusions 
i. PSAs were significantly reduced by: 
a. Novel fibrin sealant - 85% reduction 
It is hypothesised that this is due to: 
Chapter 7 
* it acting as a physical barrier, separating and protecting injured 
surfaces from external influences, and/or 
* biochemical modulation (limiting the inflammatory response to injury, 
decreasing damage volume and volume of tissue generated). 
b. CRYO 4 units thrombin - 72% reduction 
It is hypothesised that this due to: 
* it acting as a physical barrier, separating and protecting injured 
surfaces from external influences 
ii. No significant effect on PSAs was seen with: 
a. CRYO 500 units thrombin - 144% increase 
b. TissucolO 4 units thrombin - 44 % increase 
c. TissucolO 500 units thrombin - 6% reduction 
iii. f1igh exogenous thrombin concentrations (500 units) exerted several physiological 
effects: 
significantly increased volumes of total tissue generated 
increased volumes of peritoneal reaction 
significantly increased cell concentration volumes 
increased the residence time of fibrin sealants in vivo 
iv. All non-autologous fibrin sealants induce a cell mediated foreign body reaction in 
vivo. The magnitude of this reaction was increased with exogenous thrombin 
conce r ion. 
v. Novel fibrin sealant demonstrated unique actions compared to the other fibrin 
sealants investigated - significant reduction (P<0.05) in volumes of PSAs, TTG, 
damage and peritoneal reaction. Hence novel fibrin sealant reduces and prevents PSA 
formation and modulates tissue repair. 
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vi. In this direct comparison study, novel fibrin sealant was more effective and safe than 
Tissucolg or CRYO (4 and 500 units thrombin) for the prevention of PSAs in this 
rabbit uterine abrasion model. 
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8.0 Pathogenesis of PSAs and Prevention with VivostatTm 
System Human and Porcine Derived Fibrin Sealant in 
the Pig Abrasion Model - Pilot Study 
8.1 Introduction 
All studies investigating the effect of VivostatTm system derived human fibrin sealant 
(novel fibrin sealant) on PSA development using the rabbit uterine horn model have 
demonstrated significant reduction to near complete prevention of PSAs (refer to 
Chapters 4,6 and 7). To date the rabbit is the only species utilised for prevention of 
PSAs with novel fibrin sealant. For regulatory approval of a product for clinical trials 
effectiveness and safety needs to be demonstrated in two distinct animal species. Thus a 
second species, pig, was selected for investigation due to its physiological similarities to 
man and also its large size. Although previous rabbit experimental studies have good 
clinical representation they do not utilise novel fibrin sealant as intended, that is, as a 
truly autologous fibrin sealant. In order for this to occur blood needs to be taken from a 
subject (animal or human), novel fibrin sealant prepared and then used to treat that 
subject. This is unattainable using small experimental models, such as the rabbit, but 
attainable with a larger porcine experimental model. 
The aims of this study were to: 
i. assess the ability of human and porcine derived novel fibrin sealant to reduce PSAs in 
a porcine abrasion model using quantitative analysis. 
ii. identify possible mechanisms of PSA prevention. 
iii. compare human and porcine derived novel fibrin sealant for PSA prevention in a 
porcine model. 
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8.2 Materials and Methods 
Chapter 8 
This pilot study comprised of 3 experimental groups (Table 8.1) all recovered 7 days 
post operative. Surgical and ternýnation procedures were as described in Chapter 2. 
Volume of novel fibrin sealant applied to each experimental site was left to the discretion 
of the surgeon and ranged between 1.2 and 2. Oml per site (Table 8.1). 
Treatment Number Injury Number of Volume of fibrin Fibrin I Cone 
Group of Site Experimental sealant Applied (mg/ml) 
Animals Sites (ml) 
Control 3 Stomach 3 N/A N/A 
Colon 4 
Caecum. 2 
Total: 9 
Human 3 Stomach 2 1.56 ± 0.06 18.01 ±2.29 
novel Colon 4 
fibrin Caecum. 2 
sealant Total: 8 
Porcine 2 Stomach 1 1.25 ± 0.05 19.45 ± 2.93 
novel Colon 2 
fibrin Caecum 2 
sealant Total: 5 
Table 8.1: Study summary. 
Formalin fixed resected tissues were uniform randomly sliced transversely, with all slices 
processed to paraffin wax. 51im sections were cut from each block, stained with 
haernatoxylin and eosin and analysed using Cavalieri's principal for determining absolute 
volumes. 
Due to small sample size for each injury site statistical analysis was not performed. 
8.3 Results 
There was one mortality during this study, a porcine novel fibrin sealant treated animal. 
Post mortem revealed the cause of death to be strangulated hernia due to suture 
breakdown. There was no other morbidity or mortality during the course of this study. 
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8.3.1 MacroscoPic Results 
All animals demonstrated general PSAs between the peritoneal suture line and underlying 
tissues: most frequently the omenturn, ileum, caecurn, spleen and liver respectively. All 
these PSAs were separated by blunt dissection and did not interfere with experimental 
sites. 
All control experimental sites were adhered, many being quite severe. 5 out of the 8 sites 
treated with human novel fibrin sealant were clear of adhesions, with the remaining sites 
joined by either PSAs or fibrin sealant. 2 out of the 4 porcine novel fibrin sealant treated 
sites were identified as non-adhered with the other sites joined by either PSAs or fibrin 
sealant. 
8.3.2 Microscopic Quantitative Analysis 
Mean volume of PSAs for the control group was 207.25mmý for the colon, 31.33mmý 
for the caecum (Figure 8.1) and 248.11 mm3for the stomach (Figure 8.2), with an overall 
mean of 181.78mm3. Human novel fibrin sealant treated group demonstrated mean 
volumes of 42.83mmý,. 8.96mrný and 204.47mn? for the colon, caecum (Figure 8.3) and 
stomach (Figure 8.4) respectively, with an overall volume of 74.77mn?. Whereas no 
PSAs were present in colon and caecum (Figure 8.5) experimental sites treated with 
porcine novel fibrin sealant, with 6.25mrný for the stomach (Figure 8-6) and a group 
mean of 1.27mmý (Graph 8.1; Appendix VIII Table 8.1). 
Assuming that the control group demonstrated 100% volume of PSAs, reduction with 
human novel fibrin sealant was 79,71 and 18% for the colon, caecum and stomach 
respectively, with an overall reduction of 59%. Porcine novel fibrin sealant demonstrated 
100% reduction for both colon and caecum, 97% for the stomach and overall 99% 
reduction of PSAs compared to controls (Graph 8.2; Appendix VIII Table 8.1). 
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All experimental sites treated with human novel fibrin sealant demonstrated much greater 
mean volumes of inflammation compared to control or porcine novel fibrin sealant 
groups (Graph 8.3; Appendix VIII Table 8.1). Mean volumes of inflammation for control 
sites were 45.54,0.00,9.01 and 23.24mm' for the colon, caecum, stomach and overall 
mean and for porcine derived novel fibrin sealant they were 9.17,16.28,55.24 and 
21.23mm' for colon, caecum, stomach and overall mean. However, for human derived 
novel fibrin sealant mean inflammation volumes were 280.20,375.02,429.27 and 
341.17MM3 for colon, caecum, stomach and overall mean. 
AJI experimental sites treated with either human or porcine fibrin sealant demonstrated 
fibrin sealant remaining at the end of this 7 day study (Graph 8.4; Appendix VIII Table 
8.1). Human novel fibrin sealant sites had mean volumes of 128.87,162.82,174.12 and 
311 
'AL 
Porcine PSA Pilol.. 'Ytu4v Chapter 8 
148.67MM3 at the colon, caecum, stomach and overall mean respectively. Sites treated 
with porcine novel fibrin sealant demonstrated mean volumes of 100.45,132.38, 
139.23 MM3 for colon, caecum and stomach sites respectively with an overall mean for 
the group of 120.98n=3. 
The coefficient of error for this study was calculated to be 12%. 
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8.4 Discussion 
Treatment of abraded colon, caecum or stomach apposed with abraded peritoneum, with 
human or porcine novel fibrin sealant reduced both the incidence and severity of PSAs. 
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Overall reduction of PSAs with human novel fibrin sealant was 59% and with porcine 
novel fibrin sealant 99%. There are several possible reasons for the differences seen 
between PSA reduction using human and porcine novel fibrin sealant in this experimental 
model: 
i. It is well recognised that there is a relationship between volume of damage and extent 
of - PSAs formed (Ellis, 1962; Belzer, 1967; Chapter 3). Hence differing PSA 
reductions could be due to differences between the extent of initial and subsequent 
damage sustained by treated sites, with greater volumes in those treated with human 
compared to porcine fibrin sealant. However the probability of such differences is low 
since all animals underwent the same standardised injury process to induce PSAs and 
therefore sustained the same extent and volume of original damage within biological 
variation. 
I More effective application of porcine novel fibrin sealant compared to human derived 
fibrin sealant. Again this is unlikely since application of both fibrin sealants was 
carried out using the VivostatTm spray applicator and, although variations do occur 
with regard to application quality, these were not marked during this study. 
iii. Differing fibrin I concentrations for porcine and human preparations. The VivostatTm 
processor is designed to produce final fibrin I concentrations of approximately 
20mg/H, altering the final volume of fibrin I in order to achieve this objective. Hence 
any variations in fibrin I concentration are minimal which was the case in this study, 
with mean concentrations of 18.01±2.29mg/mi for human fibrin I and 
19.45±2.93mg/ml for porcine fibrin 1. 
iv. TrulY autologous, fibrin sealants possess greater PSA reduction properties compared 
to non autologous fibrin sealants. This is the most probable explanation for the 
differences observed and is highlighted by volumes of inflammation present with the 
human novel sealant group being 15 fold greater than controls whereas pig novel 
fibrin sealant groups demonstrated no difference. The inflammatory response is 
hypothesised to be an immune mounted response due to the introduction of human 
protein into the pig peritoneum. Although both incidence and severity of PSAs were 
reduced, this increased inflammatory response will exacerbate the inflammatory 
response which naturally occurs in response to injury, thus delaying and potentially 
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hampering the progression of wound healing. Hence PSAs are probably not maximally 
prevented with non-autologous fibrin sealant. 
The site of PSA induction demonstrated an effect on the volume of PSA generated, with 
the stomach having the highest mean volume, followed by the colon and finally the 
caecum. With such a small number of experimental sites it is not possible to say whether 
these are significantly different, however the lower mean volumes seen in the colon and 
caecurn could be due to: 
i. motility of the bowel leading to some fibrinous PSAs being disrupted, and hence a 
smaller volume of fibrous adhesions 
ii. difference in fibrinolytic capacity between the bowel and stomach (Marshall, 1985). 
stomach sustaining a greater volume of underlying and adjacent damage during the 
injury process, with the well recognised relationship between PSAs and damage (Ellis, 
1962; Belzer, 1967; Chapter 3 of this thesis) resulting in a greater volume of PSAs. 
With regard to novel fibrin sealant stability in vivo, both human and porcine derived 
sealant was present at the conclusion of this 7 day study. Similar volumes were present in 
the two groups with a trend for lower volumes with porcine fibrin sealant. Hence the 
autologous nature of the fibrin sealant appears to play only a minor role in its clearance, 
at least at 7 days post injury. 
Conclusions 
1. Treatment with human or porcine fibrin sealant reduced both the incidence and 
severity of PSAs in this definitive porcine abrasion model. 
2. In this porcine model the overall reduction of PSAs with human novel fibrin sealant 
was 59% and with porcine novel fibrin sealant 99% with the difference in efficiency 
due to the autologous nature. 
3. Experimental sites investigated demonstrated differing PSA induction capacities using 
the same PSA induction technique, with stomach having greatest PSA volumes, 
followed by colon and finally caecum. 
4. Both human and porcine derived fibrin sealant was present at 7 days post injury with 
314 
Porcine P&I Pilot Study Chapter 8 
clearance in vivo only n-fildly affected by the autologous nature of the fibrin sealant at 
this time. 
5. Truly autologous fibrin sealant has greater PSA prevention potential compared to 
non-autologous fibrin sealant. 
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9.0 Pathogenesis of PSAs and Prevention with VivostatTm 
System Human Derived Fibrin Sealant in the Pig 
Abrasion Model - Main Study 
9.1 Introduction 
Previous studies have demonstrated that VivostatTm system human derived fibrin sealant 
(novel fibrin sealant) significantly reduces both the incidence and severity of PSAs in 
rabbit (refer to Chapters 4,6 and 7) and porcine (refer to Chapter 8) experimental 
abrasion models. Although many studies, some within this thesis, have utilised the rabbit 
abrasion model only one pilot study has utilised the porcine abrasion model, therefore 
further data is required on this second model. 
The aims of this study were to: 
i. further substantiate PSA prevention with novel fibrin sealant in a definitive porcine 
abrasion model using quantitative and statistical analyses. 
ii. define PSA pathogenesis in a porcine model. 
iii. identify possible mechanisms used by novel fibrin sealant to prevent PSA development 
in a porcine model. 
9.2 Materials and Methods 
This study consisted of two experimental groups: (i) Controls, and (ii) Human derived 
novel fibrin sealant treated. Each animal in this study was injured at two sites, stomach 
and colon (together with apposed peritoneum) with each experimental site randomised to 
either the control or treated group (Table 9.1). Surgical procedures were as described in 
Chapter 2, with novel fibrin sealant derived from human whole blood via the VivostatTm 
processor. The 100pl VivostatTm applicator was used to apply the sealant to injury sites, 
with volumes ranging between 1.2 - 2. Oml with a mean of 1.34±0.07ml. Mean fibrin I 
concentration was 17.84±0.59mg/iW. 
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Treatment Group Number of 
Animals 
Injury Site Number of 
Experimental Sites 
Control 5 Stomach 5 
Colon 5 
Total: 10 
VivostatTm system human 6 Stomach 6 
derived fibrin sealant. Colon 6 
Total: 12 
Table 9.1: Study group details. 
All animals were recovered for 14 days, with termination and histological procedures as 
described in Chapter 2. Fixed tissues were uniformly randonily sliced and processed to 
paraffin wax. A 5pm section was cut from each block and stained with H&E for 
volumetric analysis using Cavalieri's principal. 
9.3 Results 
During the course of this study one animal died (allocated to the control group). Cause 
of death was a strangulated hernia due to suture breakdown. There were no other 
morbidity or mortalities with any other animal in this study. 
9.3.1 Macroscopic Results 
All animals demonstrated PSAs associated with laparotomy, that is, PSAs between the 
peritoneal suture line and underlying tissues (omentum, colon, liver and spleen). None of 
these PSAs interfered with any experimental site. 
10/10 control sites were fully adhered along their length whereas only 2/12 novel fibrin 
sealant treated sites were adhered. However 7/12 novel fibrin sealant treated sites, 
although clear in the centre of the experimental site, showed PSAs on the outside 
edge(s). 
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9.3.2 Microscopic Quantitative Analysis 
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Mean volumes of PSAs at both colon and stomach expenmental sites were significantly 
less (P>0.01 and P>0.05 respectively) in the novel fibrin sealant group compared to 
controls (Graph 9.1; Appendix IX Tables 9.1 and 9.2). If it is assumed that the control 
group represents 100% PSA volume, the incidence of PSAs in the novel fibrin sealant 
group was 1.92% at colon sites and 37.83% at stomach sites, with an overall incidence 
of 23.57% (Graph 9.2; Appendix IX Table 9.1). 
Peritoneal and colon or stomach tissue generation mean volumes were greater in the 
novel fibrin sealant group compared to controls (Graphs 9.3 and 9.4ý- Appendix IX Table 
9.1). Significantly greater (P<0.05) mean volumes were seen at treated colon sites, with 
regard to both colon and peritoneal tissue generation (Appendix IX Table 9.2) and 
overall mean peritoneal and colon or stomach tissue generation volumes. 
Graph 9.1: Mean PSA volumes 
together with SEMs and statistical differences. 
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However mean volumes of total tissue generation (PSA and tissuc generation volume%) 
were lower in the novel fibrin sealant group compared to controls (Graph () S. Appendix 
IX Table 9 1) Significantly lower (1) -0 05) volumes of total tissue gcnelation were 
found at colon sites and overall means ot'novel fibnn sealant treated cases compared to 
controls (Appendix IX Table 9 2) 
Experimental sites treated with novel fibrin sealant demonstratcd lower mcan volunics ()I' 
peritonea] and colon or stomach damage compared to controls (Graphs () (I and 1) 7, 
Appendix IX Table 9 1) SignificantIv lower mean volumes werc prc. scnt in the 
peritoneum of colon treated sites (1) -0 05) and overall peritonea] damage 0' -0 01) of' 
novel fibrin sealant group compared to controls (Appendix IX Tablc 1) 2) 
Significantly greatcr (P -0 01) mean volumcs of inflammation wcrc prc. scrit in novd fibrin 
sealant sites compared to controls at all experimental sites (Graph 1) 9. Appendix IX 
Tables 91 and 9.2) 
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33.3% of colon treated sites and 100% of stomach treated sites demonstrated novel 
fibrin sealant present (Graph 9.9. - Appendix IX Table 9.1). Stomach experimental sites 
demonstrated greater mean volumes of sealant present compared to colon although not 
significantly (P>0.05) (Appendix IX Table 9.3). 
There were no significant differences (P>0.05) between colon and stomach sites in the 
control group for tissue zones analysed (Appendix IX Table 9.3). However significant 
differences were present in the novel fibrin sealant group: significantly greater mean 
volumes of PSA (P<0.01), total tissue generation (P<0.05) and inflammation (P<0.05) 
were present at the stomach compared to colon site. 
The overall coefficient of error for this study was 13%. 
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Graph 9.9: Mean novel fibrin sealant remaining volumes 
together with SEMs. 
9.4 Discussion 
There have been very few studies investigating PSAs which have utilised large 
experimental models such as the pig, due primarily to their increased cost and with 
smaller models being acceptable for most PSA work. Those studies which have used 
porcine models have found that pigs generated PSAs in response to injury or trauma 
(Fowler et aL, 1994; Christoforoni el aL, 1996; Reissman et aL, 1996) and have shown 
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some success using potential PSA preventative agents. 
The porcine model used in this study produced 100% PSA incidence in response to the 
PSA inducing abrasion process with no clinical morbidity. Hence this porcine peritoneal 
to colon or stomach abrasion model is a valid and definitive PSA experimental model. 
When used in conjunction with quantitative analysis it is an ideal large experimental 
model for investigating both PSA development and prevention with PSA preventative 
agents. 
Treatment with novel fibrin sealant significantly reduced PSA volume with a 98% 
reduction at colon sites and 62% at stomach sites and an overall reduction of 76%. With 
regard to incidence of PSAs, there was a 83% reduction at colon sites, no reduction at 
stomach sites but a 42% reduction overall. The reason that incidence reduction of PSAs 
does not follow the same pattern as volume reduction is that at many treated stomach 
sites the central area was completely clear of PSAs however PSAs were present on 
outside edges of the experimental sites. Hence in areas were novel fibrin sealant was 
present there were no PSAs but in areas which were not fully covered or were bordering 
non-covered areas PSAs developed. Reasons for incomplete coverage could be due to 
poor sealant application or more probably the elasticity of the stomach. However it is 
clearly evident that novel fibrin sealant reduced both incidence and severity of IPSAs in 
this porcine model. 
The response to abrasion injury at both peritoneal and colon or stomach treated 
experimental sites was injury tissue which was generally discretely located on either 
surface, rather than joining the two. Peritoneal and colon or -stomach tissue generation 
volumes were greater in treated cases compared to controls. However, when comparing 
total tissue generated, controls showed greater mean volumes compared to treated cases. 
Thus,, in addition to affecting the location of injury tissue, treatment with novel fibrin 
sealant decreased the volume of injury tissue generated. This is most probably due to the 
lower damage volumes seen at 14 days in the novel fibrin sealant group. 
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Since all animals underwent the same injury process, volumes of the original abrasion 
injury will have been similar for control and treated groups. However, by 14 days, lower 
damage volumes were seen in the treated group indicating that they either had decreased 
subsequent damage (due to necrosis of surrounding and underlying tissue) or that 
damage was repaired at a faster rate compared to controls. Since there is a direct 
relationship between volume of damage and tissue generated in response to that damage 
(Ellis, 1962; Belzer, 1967; Chapter 3) the first of these hypotheses is the most probable. 
Treatment with novel fibrin sealant limits surrounding and underlying tissue damage and 
subsequently tissue generated in response to damage. 
Si0ficantly greater volumes of inflammation were seen in novel fibrin sealant treated 
cases compared to controls. For this study peritoneal reaction mounted in response to 
injury and cell mediated response to novel fibrin sealant was termed inflammation. 
Increased inflammation seen with treated cases was primarily due to the immune 
response mounted to the presence of human protein within the pig peritoneum. This is 
highlighted by greater volumes of inflammation at stomach experimental site at which 
there are greater volumes of fibrin sealant remaining. Reasons for the greater residency 
of novel fibrin sealant at stomach compared to colon experimental sites included 
potential differences in fibrinolytic capacities (Marshall, 1985) and motility of these 
tissues. 
Conclusions 
i. This porcine peritoneum to colon or stomach abrasion model is a valid definitive 
model for investigating PSA development and prevention. , 
ii. Novel fibrin sealant significantly reduced both incidence and severity of PSAs. 
iii. Novel fibrin sealant demonstrated a protective effect against necrosis of surrounding 
and underlying tissues with reduced injury tissue the final outcome. 
iv. Human novel fibrin sealant produced an inflammatory response in the pig peritoneum. 
v. The residency time of novel fibrin sealant was influenced by its location within the 
peritoneal cavity. 
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10.0 Discussion 
The formation of adhesions following surgical therapy is almost inevitable. PSA 
presence is directly related to number of operations (Weibel & Majno, 1973; Luijendijk 
et al., 1996) and there is a 93% incidence following major abdominal surgery (Menzies 
and Ellis, 1990; Duron et aL, 1993). In today's medical climate, with many patients 
undergoing multiple surgery therapies, PSAs are more pertinent than ever. Not only can 
PSAs result in the need for re-operation due to associated pathogenesis or failed surgical 
therapy but they also make re-operation difficult. This is especially problematic in 
cardiac surgery where the fon-nation of PSAs ultimately limits the number of operations 
which can be attempted. 
The actual mechanics of surgery present ideal situations for PSA development: tissue 
injury and/or ischaemia, bleeding, introduction of foreign materials, potential 
presentation of infectious agents and reduced fibrinolytic capacity. All of these factors 
have been identified as causes of PSAs with authors choosing their preferences (refer to 
Chapter 1). It is most probably a combination of these factors which promote PSA 
formation in all types of surgical procedures. 
In order to gain a comprehensive clinical understanding of PSA formation, maturation 
and finally prevention, valid experimental models are required. An ideal PSA 
experimental model is one in which PSAs are induced in 100% of cases via standardised 
and reproducible techniques which have good clinical representation. Unfortunately this 
has not been the trend with regard to most PSA models. Previous experimental models 
have shown variations in animal species (rat, rabbit, pig, dog, monkey, calf, chicken and 
human), induction methods (rubbing of caecal surface, chemical trauma, crushing caecal 
wall, mesentric division, polythene/ omental wrap around devascularised intestine and 
liver lobe scraping with scapula blade), severity of techniques (rubbing, crushing, and 
scalpel scraping), site of PSA induction (caecum, intestine, liver and uterine hom) and 
end point (incidence, length of adhesion attachment and type of adhesion) (Appendix X 
Table 10.1). With such divergent models, collation of published data, which may be 
morphological, cellular or biochemical, is very difficult. Abrasion models, rabbit and 
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porcine, utilised in the studies contained within this thesis eliminate problems 
encountered previously. The PSA induction technique was standardised with regard to 
the area of tissue injured and the amount of abrasion procured and was designed to be a 
severe PSA inducer. Although for the purpose of investigating PSA formation through 
normal surgical trauma these models may be extreme, they were also designed with a 
view to test potential PSA preventative agents where a potent PSA inciter is a necessity. 
Another major benefit of the data contained within this thesis compared to most 
previously published PSA data is that it was quantitatively microscopically analysed 
using strict unbiased techniques. Qualitative analyses have been predominant in this 
field of science and have the innate problems of inaccuracy, imprecision and potential 
for bias. These are eliminated with stereological techniques as long as basic principles 
are observed (refer to Chapter 2). Differences between qualitative macroscopical data 
and quantitative microscopical data are highlighted in the results contained within this 
thesis (Table 10.1) 
Study Chapter Percentage Incidence of PSAs % PSA Volume 
Number 
Macroscopic Microscopic 
Analysis Analysis 
Pathogenesis of PSAs 3 90 85 100 
Prevention of PSAs 4 2 2 
Application Comparison 6 Controls: 100 Controls: 100 Controls: 100 
Treated: 21 Treated: 63 Treated: 29 
Fibrin Sealant 7 Controls: 100 Controls: 100 Controls: 100 
Comparison Treated: 71 Treated: 80 Treated: 105 
Pig PSA Pilot Study 8 Controls: 100 Controls: 100 Controls: 100 
Treated: 0- 42 Treated: 62 Treated: 22 
Pig PSA Main Study 9 Controls: 100 Controls: 100 Controls: 100 
Treated: ? 58 Treated: 58 Treated: 24 
Table 10.1: Percentage incidence of PSAs. 
Although both incidence and volume of PSAs for controls groups do not vary this is 
certainly not the case for treated groups. In general, macroscopic incidence of PSAs is 
less than microscopic due to the more strict and precise detection by microscopical 
methods. Thus PSA reduction has a trend to be overestimated by macroscopical 
observations which is highly significant for detennining the efficacy of potentia PSA 
preventative agents. In order to gain a comprehensive idea of PSA presence and 
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reduction, the severity of PSA, determined by accurate microscopically analyses, is 
actually a more precise and valid method of evaluating potential anti-PSA agents. There 
is a potential for PSAs to be disturbed during processing to microscopical Material, 
however, the results of these studies demonstrate that, with normal careful tissue 
handling, this should not occur after 8 hours post injury. Of course such microscopical 
analyses are only normally possible for pre-clinical studies but if such strict assessments 
can be made at this stage good clinical results should be the reward. 
Accurate knowledge concerning the formation and maturation of PSAs is essential for 
limitation of PSAs through surgical practices, development of effective preventative 
agents and also for a degree of acceptance by surgeons. Limitation of PSA formation 
through meticulous surgical techniques is well accepted, with methods such as strict 
asepsis, minimal gentle handling of tissues, avoidance of foreign material 
contamination, to name just a few (refer to Chapter 1). However studies by Scott- 
Coombs et al (1993) and Holmdahl & Risberg (1997) highlight that maximum surgical 
care is not routinely practised by surgeons, leading to the formation of avoidable PSAs 
with the main culprits being the use of starch gloves and suturing the peritoneum. The 
studies contained within this thesis also demonstrated the importance of damage, 
especially underlying and non-visible, on the formation of PSAs. Therefore all 
limitation techniques need to be fully implemented to help combat PSAs. 
Although significant effort and resources have been directed against finding potential 
PSA preventative agents there is to date no such product available. There has been a 
typical trend seen with these agents: initial enthusiasm followed by more comprehensive 
experiments which result in less encouraging data and ultimately abandonment, with 
very few agents ever reaching clinical trials (Ellis, 1982). The main reason for the high 
failure rate amongst these products is due to lack of knowledge concerning mechanisms 
governing PSA development. Potential preventative agents have been mainly targeted 
towards preventing PSAs primarily by separating surfaces but also by lysis of formed 
PSAs by chemical or mechanical means, with little consideration of subsequent 
repercussions. With information on the dynamics of PSA development, areas suitable 
for targeting agents can be deduced together with the optimal timing for prevention and 
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the physiological effects of such prevention at that stage of PSA development. 
Due to the pathogenesis and problems associated with PSAs they are generally seen as 
sinister, a result of wound healing "gone wrong'7excessive wound healing. The results 
of this study demonstrate the formation and maturation of PSAs to be a highly regulated 
complex process which is the bodies natural defence to injury and inflammation. There 
are other authors who have expressed positive views on PSAs: Ellis (1962) described 
adhesions as "vascular grafts" preventing necrosis, gangrene or perforation; 
Myllarniemi & Karpinen (1968) stated that preventing adhesions may hamper recovery, 
promoting infection leading to gangrene and necrosis; Deaver (1923) described 
adhesions as ladders for phagocytic cells to reach injured tissues to limit infection. 
Hence the formation of PSAs following surgical therapy, inflammation and/or infection 
has the benefit of acting as a pathway for cells, nutrients and chemical mediators to 
reach damaged tissues quickly. Therefore PSAs should gain a greater respect within the 
surgical community. 
Since PSAs only lead to pathogeneses in a minority of cases, some authors (for 
example: Ellis) feel that PSAs should not been seen as sinister and that they should 
received less attention. However in an era where many patients undergo multiple 
surgical therapies and economic awareness is at its greatest the problems associated with 
PSA formation overshadow any advantages of their presence. 
This is the first study to simultaneously analyse PSA development with regard to 
physiological, structural, cellular (local and systemic) and biochemical mechanisms. 
The dynamics of PSA development are shown in Figure 10.1 demonstrating the 
formation and maturation of PSAs to be a complex, multi-system and controlled 
process. Comparison with adhesion-free healing (Section 1.1.6.3) and PSA development 
(Section 1.1.6.5) show compatible results with regard to mechanisms involved. 
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Figure 10.1: PSA dcvelopment. 
It would appear that the only reason that PSA development occurs as an alternative to 
adhesion-free healing is due to fibrin exudated from damaged surfaces coming in 
contact with another surface, which has some degree of damage, visible at the 
macroscopic level or not, which provides an adherent interface. It is once PSAs have 
formed that their presence propagates their existence, deviating slightly from adhesion- 
free healing. If we assume that tissue generated from the peritoneum and uterine horn 
which does not form PSAs is typical of adhesion-free healing then the dynamics of their 
formation are dependent upon volume of damage and regeneration of repair tissue to 
replace removed necrotic and non-viable tissue. The effects of the inflammatory 
response are not noted on tissue generation but have the indirect effect on their volume 
by involvement in the clearing of damaged tissue and therefore the resulting tissue 
generation. However this is not the case with PSA development. The inflammatory 
response demonstrated a direct effect on the volume of fibrinous PSAs and, of course, 
tissue repair showed a similar effect on fibrous PSA volume. Hence adhesion-free tissue 
generation is solely concerned with replacement of damaged tissue, that is, wound 
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healing, whereas PSA development is associated with the inflammatory response and to 
a degree wound healing. Thus the inflammatory response is very important for PSA 
formation and as such is a potential target for PSA prevention. 
The overall incidence of PSAs during the PSA development study was 85%. The injury 
used in these studies was a severe PSA inducer and hence all cases probably developed 
primary fibrinous PSAs. The actual incidence for fibrinous PSAs (8 hours to 3 days) 
was 97%, with only one 3 day experimental site lacking PSAs. Whereas the incidence 
for fibrous PSAs (5 to 42 days) was 75%. Hence some animals which, in all probability, 
would have developed fibrinous PSAs, lysed this primary PSA evading the formation of 
established fibrous PSAs. From the data obtained during these studies we know that 
from 3 days onwards there is a rapid decrease in fibrin volume, that is, loss of fibrinous 
PSA volume and at the same time collagen synthesis is just beginning in earnest. Hence 
there is a transition period in which fibrinous PSAs are being broken down and fibrous 
PSA being established and it was at this time that the first drop in PSA incidence was 
seen. This is another potential target for PSA prevention. 
Previous studies have demonstrated a significant drop to complete removal of 
fibrinolytic activity following trauma for at least the first 24 hours following trauma 
(Ryan et aL, 1973; Raftery, 1981; Scott-Coombs et d, 1995). This will naturally 
promote the formation of fibrinous PSAs. However once this activity returns and, in 
animals which either have greater fibrinolytic capacities or have a more rapid return of 
fibrinolytic activity, lysis of fibrinous PSA occurs at this stage. In animals in which this 
does not happen, fibrin lysis occurs from 3 days onwards however the linkage already 
contains collagen and thus an established PSA develops. 
Within 14 days post injury, PSA development and maturation was near completion. The 
physiological parameters were characteristic of an established PSA, with cellular 
content limited primarily to fibroblasts trapped within the contracting collagen matrix. 
With regard to PSA prevention the ideal solution is to prevent fibrinous linkages from 
forming, which is probably achieved most easily by a physical barrier placed at the time 
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of surgery. Increased fibrinolytic activity could be promoted, although this may carry of 
risk of interfering with haemostasis. An alternative would be to break the fibrinous PSA 
that is fori-ned during the first I to 3 days following injury. This could be achieved via 
fibrinolytic agents although care would need to be taken to not disrupt wound healing, 
or via mechanical methods although this would carry the risk of inducing further PSA 
development. What ever agent is chosen it should not induce an inflammatory response, 
which is directly associated with PSA formation and promotion. With regard to the 
residency time of a potential PSA agent it should prevent fibrinous PSAs and in turn 
fibrous PSAs. We know from these studies that fibrin deposition during PSA 
development occurs for at least the first 3 days post injury, so this is the minimal 
residency time for PSA prevention agents. 
Comparison of data obtained from PSA prevention with novel fibrin sealant and 
previous studies investigating adhesion-free healing (Section 1.1.6.3) and PSA 
development (Section 1.1.6.5) showed similar dynamics with regard to structural, 
cellular and biochemical processes (Figure 10.2). Hence treatment with novel fibrin 
sealant does not change or interfere with normal wound healing mechanisms. Since the 
only other study to quantitatively analyses these dynamics was the PSA development 
study then only direct comparisons with this study can be made. 
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Figure 10.2: PSA prevention with novel fibrin sealant. 
Although the same pattern was seen for PSA development, treatment with novel fibrin 
sealant had the effects of (i) decreasing volume of necrosis and underlying tissue 
damage; (ii) decreasing the volume of tissue generated in response to that injury; (iii) 
decreasing the volume of reaction within peritoneal tissue; (iv) increasing the rate of 
structural changes; (v) decreasing the magnitude of inflammatory and tissue repair cell 
presence, (vi) decreasing systemic cellular number changes; and (vii) decreasing 
biochemical mediators (TGF-0). Although all aspects of wound healing have been 
altered, these alterations probably result from changes at the first stage of wound healing, 
haemostasis. Fibrin sealants have been developed primarily as haemostatic agents, with 
their potential to reduced PSA formation discovered by accident during second-look 
procedures. Since fibrin sealants modulate haemostasis, the bodies natural haemostatic 
practices will be reduced. This will in turn result in a lesser presence of platelets and 
natural fibrin at the in . ury site. Platelets are very important in the initial stages of wound 
healing, with their degranulation leading to vasoconstriction, the formation of a platelet 
plug, fibrin deposition and chemotaxis of inflammatory cells. 
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With reduced platelet number the amount of chemical mediators released will also be 
reduced, resulting in lower numbers of inflammatory cells, fibrin lay down and in turn 
lower numbers of tissue repair -cells and fibrotic tissue. The net result of this is 
accelerated, PSA-free wound healing. 
It could however be argued that novel fibrin sealant is bio-active, that is, healing 
processes are affected by chemical mediators released from the sealant when in vivo. 
Further biochemical analyses are required to clarify this situation. 
The importance of the peritoneal environment should not be overlooked. Previous 
studies have demonstrated that peritoneal fluid is a medium for cellular (Eskeland, 
1966.1; Eskeland, 1966.2; Raftery, 1973. L; Shimanuki et aL, 1986) and biochemical 
interactions (Rong et aL, 1990; Ford et aL, 1990) which may modulate tissue 
remodelling (Ford et aL, 1990). The preliminary results of TGF-P concentrations within 
peritoneal fluid of control and novel fibrin sealant treated cases lends support for this 
hypothesis. Hence isolation of injured tissue from peritoneal fluid may be sufficient to 
cause the changes seen. Support for this comes from the similar dynamics of PSA 
formation and tissue generation from treated cases both of which are isolated from the 
immediate peritoneal environment. Inflammatory cells were associated with fibrinous 
tissue deposition and tissue repair cells with fibrous tissue. Whereas in tissue generation 
of control cases, which had direct contact with the peritoneal environment, fibrinous 
tissue formation appeared to be independent of inflammatory cell interactions. This 
isolation theory has also been identified by Sheppard et aL (1993) who stated that fibrin 
sealant acts as a physical barrier as well by isolating the healing wound and its 
inflammatory mediating factors from the rest of the site. 
Although biochemical modulation of wound healing by novel fibrin sealant can not be 
ruled out at the present time, it is most probable that PSA prevention is primarily due to 
the sealant inducing artificial haemostasis and acting as a physical barrier, separating 
injured surfaces from themselves and other surfaces and the peritoneal environment. 
These studies have shown that PSA development has a close relationship with the 
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inflammatory response, therefore, ideally, an anti-PSA agent should not induce any 
additional inflammatory reaction. However, in these studies investigating human 
derived novel fibrin sealant in a rabbit experimental model, an inflammatory response 
was mounted against the sealant. This in theory should have reduced PSA prevention in 
these cases however this does not appear to be the case. The reaction to the sealant 
present was highly concentrated around the sealant and did not really impinge on the 
tissues themselves and this the reason why this local immune mediated foreign body 
reaction was not overly detrimental. 
From spraying of the sealant to I hour in vivo there was a 89% decrease in volume of 
novel fibrin sealant. Since fibrinolytic activity is almost totally eradicated for at least the 
first 24 hours following surgery (Ryan et aL, 1973; Raftery, 1981; Scott-Coombs et aL, 
1995), lysis of the fibrin sealant is highly improbable. Therefore reasons for this 
dramatic decrease are due to loss by aerosol during the spraying process, over spraying 
of tissues due to spray pressure and fluid loss from the sealant. This dehydration was 
continued until 4 hours post application. Hence the volume of sealant at I to 4 hours 
post application was the volume of fibrin present in vivo available to prevent PSAs. 
From 4 hours to 5 days the volume of fibrin present remained relatively constant, with 
sealant joining surfaces for up to 3 days post injury and covering at least one site up to 5 
days in all cases. Sealant was present at all experimental sites at 7 days, 63% of cases at 
14 days, 50% of cases at 28 days and absent in all cases at 42 days. Therefore once in 
vivo novel fibrin sealant is very stable during the first 5 days following application, that 
is, during the generation of fibrinous tissue generation and PSAs and conversion to 
fibrous tissues. This is a critical time period for PSA development and the stability of 
preventative agents during these times is very important. Biodegradation of the product 
is also important and novel fibrin sealant can be seen to gradually decrease from 14 to 
28 days and be completely absent by 42 days. 
Comparison of PSA reduction with novel fibrin sealant in the studies utilising the rabbit 
uterine horn abrasion model included in this thesis demonstrated a mean reduction in 
PSA volume of 79.5% (Table 10.2). Whether novel fibrin sealant was bench or device 
prepared, applied using the VivostatTm applicator spray (100PI or 300pl), needle or 
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UNES gun, significant reduction of PSAs was seen compared to controls (Table 10.3). 
Differences in PSA reduction efficiency are due primarily, to application methods used. 
The VivostatTu spray applicator is the method of choice for novel fibrin sealant and this 
delivery system has demonstrated a mean PSA reduction of 87%. During the 
development of VivostatTm novel fibrin sealant technology two spray systems have been 
used in recent years, the 300gl spray which was then replaced by the 100gl spray. The 
300[d spray (titilised in Application Comparison (Chapter 6) and Fibrin Sealant 
Comparison (Chapter 7) studies) demonstrated a mean PSA reduction of 81% compared 
to 99% for the I 00pl spray (PSA Prevention Study). Hence this second generation I 00pl 
spray is more effective for the application of novel fibrin sealant for PSA prevention. 
This highlights the importance of the method of sealant application for prevention of 
PSAs. In order to achieve complete PSA prevention complete coverage of damaged 
tissue is essential and this is only achieved via precise application of fibrin sealant by an 
appropriate application system. 
Study Chapter 
Number 
Preparation 
Method 
Application 
Method 
Percentage 
Reduction 
in PSAs 
Application Comparison 6 Device Spray (300ýd) 77 
Device Needle 67 
Device UNES Gun 56 
UNES Gun 93 
Fibrin Sealant Comparison 7 Device Spray (300ýtl) 85 
PSA Prevention 1 4 1 Device I Spray (100gl) 1 99 
Table 10.2: Percentage reduction in PSA volume by novel fibrin sealant in rabbit uterine norn 
abrasion model studies. 
In three different studies, treatment with novel fibrin sealant in an experimental rabbit 
uterine hom abrasion model consistently significantly reduced volume of PSAs, total 
tissue generation (TTG), damage and peritoneal reaction and significantly increased 
volume of cell concentration (Table 10.3). Considering differences in VivostatTm spray 
applicators (300gl or 100pl) these studies have yielded similar results. Hence treatment 
with novel fibrin sealant produces consistent and reproducible effects on wound healing 
in a definitive rabbit uterine horn model. 
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Study 
Tissue Zone Application Fibrin Sealant PSA Prevention Overall 
Comparison Comparison (Chapter 4) 
(Chapter 6) (Chapter 7) 
PSA 
PTG 
UTG 
TTG 
Peritoneal damage -4, */** (5 Days 0 
Uterine hom damage (3/5 Days I-) 
Peritoneal reaction 
Peritoneal cell concentration T*/*** (5 Days 4) 
Table 10.3: Tissue zone volumes from novel fibrin sealant rabbit uterine horn abrasion 
studies (VivostatTM spray only) compared to controls. 
Note: decreasing volume. T= increasing volume. 
P<0.05,1 ** = P<0.01; *** = P<0.001-, **** = P<0.0001. 
M significant difference/expected significant difference. 
*/** = minimum significant diffcrence/maximum significant difference. 
In the second animal species investigated, porcine abrasion model, reduction of PSAs 
with human blood derived novel fibrin sealant ranged from 59 to 76% with a mean of 
67.5% whereas with porcine blood derived novel fibrin sealant PSA reduction was 99%. 
Similar results with regard to tissue zone volumes of treated compared to control cases 
were found (Table 10.4). Treatment with novel fibrin sealant significantly reduced 
volumes of PSAs, TTG and damage and significantly increased volume of inflammation. 
Differences between efficacy of PSA prevention between these two experimental models 
could be due to species differences however is more likely to be due to the different 
experimental sites investigated. This will be discussed shortly. 
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Study 
Tissue Zone Pilot Main Overall 
(Chap er 8) (Chapter 9) 
Porcine Human Human 
Sealant Sealant Sealant 
PSA 
PTG 
Colon or stomach TG 
TTG 
Peritoneal damage 
Colon or stomach damage 
Inflammation 
Table 10.4: Tissue zone volumes from novel fibrin sealant porcine abrasion studies 
(VivostatTMspray only) compared to controls. 
Note: decreasing volume. T= increasing volume. 
P<0.05-. ** = P<0.01; *** = P<0.001. 
significant difference/expectcd significant difference. 
In addition to rabbit and porcine models a recent study has been conducted investigating 
PSA development and prevention with novel fibrin sealant in a rat caecum to peritoneum 
abrasion model. Treatment with novel fibrin sealant significantly reduced the formation 
of PSAs by 80.2% (Graph 10.1; Appendix X Table 10.2). 
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Graph 10.1: Mean volumes of PSAs, fibrin sealant remaining and fibrin sealant associated 
reaction 
together with SEMs and statistical differences. 
It has been shown that VivostatTMsystem novel fibrin sealant significantly reduces PSA 
development in 3 different animal species - rabbit, pig and rat. In addition novel fibrin 
sealant significantly reduces PSA development at uterine horn, stomach, colon and 
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caecal abraded sites to abraded peritoneum in a severe PSA testing model. The clinical 
implications of PSA prevention at these sites within the peritoneum is great. The main 
pathogeneses associated with PSAs are intestinal obstruction, infertility and abdominal 
pain. Approximately 0.69% (Stewart et aL, 1987) to 1% (Menzies & Ellis, 1990) of all 
laparotomies result in intestinal obstruction, with adhesions being the primary cause of 
intestinal obstruction in the western world (Nemir et aL, 1952; Perry et aL, 1955; 
Playforth et al., 1970; Stewardson et aL, 1978; Bizer et aL, 1981; Menzies & Ellis, 
1990; Stricker et al., 1994). This condition is associated with mortality ranging from 0 
to 37% depending upon adhesion type, patient age, surgical complications, duration 
before treatment and types of treatment received (refer to Section 1.1.3.7 ). Whereas 
15-20% of female infertility is attributed to adhesions (Soules et aL, 1982; Hull et aL, 
1985) and their presence is also thought to be responsible for some cases of chronic 
pelvic pain (Kersch et aL, 1984). The prevention of PSAs at these sites within the 
peritoneum would lend to reduced patient mortality and morbidity. 
PSA prevention would have great economic and workload benefits. In 1994 $1.3 billion 
was spent on adhesiolysis in the Unites States (Ray et aL, 1998). A previous study by 
Ray et al. (1993) demonstrated that the rate of adhesiolysis, approximately 1% of 
admissions, had remained stable in the US between 1988 and 1994 even with the 
increased use of laparoscopic techniques. In the UK there are 8400-9600 admissions 
each year for adhesional intestinal obstruction with half of these actually undergoing 
surgery (Scott-Coombes et aL, 1993). With an average length of hospitalisation being 
15 days (McEntree et aL, 1987) this is a large drain on the National Health Service. Any 
agent which could prove consistent PSA prevention would, within limits, be 
economically viable. 
With regard to PSA prevention in the past, many different PSA prevention agents have 
been tried ranging from separation of surfaces by foils of metal (Boys, 1942; Ellis, 
1982), hydroflotation by hypertonic solutions (Pijlman et aL, 1994; Risberg, 1997) to 
inhibition of fibroblast proliferation via cytotoxic drugs (Ellis, 1971; Ellis, 1982). Most 
of these agents tried have induced PSA development rather than reduced incidence, due 
to inflammatory response induction. In addition many of the chemical agents have 
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associated non acceptable side effects (Examples: dextran (Holtz, 1984; DiZerega, 
1994; Pijlman et aL, 1994; Risberg, 1997), corticosteroids (DiZerega, 1994; Pjjlman et 
aL, 1994; Risberg, 1997) and heparin (Connolly & Smith, 1960; Ellis, 1971; Pijlman el 
aL, 1994)). 
Much greater success has been achieved with the less drastic methods of PSA 
prevention, that is the use of physical barriers to isolate damaged surfaces. The most 
successful artificial non-absorbable barrier to date is Gore-Tex surgical membrane 
(W. L. Gore & Associates, Flagstaff, AZ, USA) however, the main limitation with this 
product is the need for it to be held in place via sutures as a perinanent foreign material 
(DiZerega, 1994; Risberg, 1997). This is probably responsible for the conflicting reports 
for PSA prevention although most clinical studies have yielded positive results 
(DiZerega, 1994; Pijlman et aL, 1994). 
Of the artificial absorbable barriers InterceedS (Johnson & Johnson Medical Inc., 
Arlington, TX, USA) and SeprafilMTM(Genzyme Corporation, Cambridge, MA, USA) 
have demonstrated the greatest PSA reduction potential. SeprafilMTm has regulatory 
approval for prevention of PSA formation in many European countries and North 
America and received a lot of attention when it was first available. However both of 
these products have technical limitations: InterceedID requires removal of intraperitoneal 
irrigants, excess peritoneal fluid and blood and SeprafilmTm needs to be kept completely 
dry, handled gently with dry hands and tissue contact avoided until correct application 
site reached. These problems have lead to limited success of these products in the 
clinical surgical field. 
Fibrin sealants provide an alternative, natural, absorbable barrier system. There are 
currently five fibrin sealants commercially available - Tisselo, BeriplastO, BiocolO, 
Bolheal and Quixil, with several others in the clinical pipeline (Table 10.5). These 
products have been developed primarily as haemostats with studies and regulatory 
approval concentrating on this aspect and, to a lesser extent on tissue sealing. However 
these may not be the most appropriate applications for fibrin sealant, with further 
applications in wound healing and being a carrier medium for cells, antibiotics and 
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chemical mediators presenting potential applications. 
Fibrin Sealant Company I Regulatory 
Approval 
Products on the mar ket 
TisseelO Immuno 1978 (Gertnany) 
1998 (US) 
BeriplastO Centeon 1983 (Gen-nany) 
Biocolg LFB - Lille 1984 (France) 
Bolheal Cherno-Sero Inst. (Japan) 
Ouixil Omrix 1997 (Israel) 
Products in clinical ipelin 
Fibriseal/Sealgen American Red Cross/Baxter Expected 
Haemaseel _ Haemacure Clinical trials 
SNTB Fibrin 
Sealant 
SNTB Pcnding 
ViGuard Vitex Clinical trials 
Table 10.5: Fibrin sealants 
(Taken from Brodniewicz, 1998). 
Chapter 10 
There are very few clinical studies which have investigated the potential of fibrin 
sealants to prevent PSAs (Larsson et al., 1986; Brands et al., 1990; Alnot et al., 1993; 
Izbicki et al., 1994). Overall, pre-clinical data supports the use of fibrin sealants for PSA 
reduction (Lindenberg & Lauritsen, 1984; Larsson et al., 1986; Koltai & Gerhard, 1990; 
Dulchavsky et al., 1991; Sheppard et al., 1993; De Laco et al., 1994) although 
conflicting reports do exist (Bilgin et al., 1995). The study investigating Tissucol 
(Tisseelg) prevention of PSAs contained in this thesis demonstrated that it did not 
significantly reduced PSA formation and that, with 4 units of thrombin, actually 
increased PSA volume compared to controls. This has previously been seen with prior 
in house studies. This study did, however, use bovine thrombin which was associated 
with a reactive response and change to the use of pooled human blood derived thrombin 
with Tissucolg, although not ideal, will probably be associated with reaction with a 
reduced reaction magnitude, and potentially, increased PSA reduction properties. The 
exclusion of animal proteins and anti-fibrinolytics currently used in fibrin sealants is an 
emerging issue. During the studies of this thesis it has been highlighted numerous times 
that inflammation has the effect of inducing PSA formation and any agent which causes 
an additional inflammatory response will hinder PSA prevention. In fact the use of non- 
340 
Discussion Chapter 10 
autologous, thrombin fibrin sealants is associated with tissue fibrosis (Fairbrother, 1997) 
which is antagonistic to PSA prevention. 
The overall reduction of PSAs using novel fibrin sealant (automated preparation and 
application) for studies (rabbit, pig and rat) reported in this thesis ranged from 59-99%, 
with an overall mean of 79%. These results have been determined using very strict and 
unbiased quantitative analyses and no other study available for our reference has used 
such a strict system to assay potential PSA preventative agents. Previous studies have 
lent support for many potential PSA preventive agents, especially fibrin sealants 
(Tisseelg, cryoprecipitate), SeprafilmTm, InterceedS (TC7), and tissue plasminogen 
activators (refer to Appendix I Table 1.3). Although many of these studies report a 
significant reduction in PSA formation their qualitative or semi-quantitative 
methodology prevents direct comparisons with studies investigating novel fibrin sealant. 
The consistent reduction to near complete prevention of PSAs using novel fibrin sealant 
appears to highlight that it is the best PSA preventative agent developed at present. 
It is a perverse concept that fibrin, which is responsible for the formation of fibrinous 
and ultimately fibrous PSAs, is also the substance which has demonstrated the most 
promise for preventing them. In fact it was initially thought that fibrin sealants would 
form a fibrin matrix which would allow fibroblast migration, increasing the potential for 
PSA formation (Sheppard et aL, 1993). This is not the case, as fibrin sealants form a 
barrier which is generally inaccessible to host cells. Since fibrin is naturally present in 
these situations and artificial fibrin possesses very similar properties to natural fibrin, 
resulting in haemostasis and forming a temporary protective covering over damaged 
surfaces, application of fibrin sealant mimics the first stages of wound healing without 
the meshwork for fibrous PSA formation being established. This supports Lindenberg & 
Lauritsen (1984) who postulated that fibrin sealant may seal lymph and blood vessels 
and thus prevent fibrin exudate from injured surfaces. 
During the course of these studies, both rabbit and porcine abrasion models have been 
utilised. The development and prevention of PSAs in the rabbit model have been 
extensively studied from 1 hour to 42 days post injury. Less analyses have been 
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conducted in the porcine model however the two studies performed sampled tissue at 7 
days (pilot study) and 14 days (main study) following injury. Although the porcine data 
at 7 days is limited by small sample numbers it does give us some insight into the 
dynamics occurring throughout this time window. For control cases, PSA volume 
increased by 3.72 fold from 7 to 14 days whereas inflammation volume decreased by 
6.24 fold. Treated cases demonstrated a similar pattern with PSA volume increasing by 
1.62 fold and inflammation volume decreasing by 1.48 fold from 7 to 14 days. In 
addition, volume of fibrin sealant remaining decreased by 6.98 fold. This suggests that 
PSA maturation is still ongoing from 7 to 14 days with the volume increase most 
probably due to collagen deposition by fibroblasts. However, the inflammatory response 
to injury is decreasing throughout this time, with tissue repair predominant. 
This follows the overall trend seen in the rabbit model but there is a difference with 
regard to PSA volume dynamics. In the rabbit model from 7 to 14 days in both control 
and treated cases mean volume of PSA decreased by 1.17 fold and 1.39 fold (total tissue 
generation) respectively. Although this could be due to species differences it is more 
likely due to differences in PSA induction sites. Previous studies have demonstrated that 
fibrinolytic capacities of different organs vary significantly in humans (Albrechtsen, 
1957; Sandberg et aL, 1963) with large amount of plasminogen activator present in 
uterine tissue (Albrechtsen, 1957). Marshall (1985) compared the levels of extractable 
fibrinolYtic activity within human tissues (Appendix X Table 10.3) and demonstrated 
that tissue intrinsic fibrinolytic abilities differ, with uterus having the greatest capacity, 
followed by colon and finally stomach. This demonstrates an inverse relationship with 
the results obtained by the studies within this thesis, with PSAs greatest at stomach, 
colon, and uterine horn experimental sites respectively. Hence the tissues own 
fibrinolYtic capacity influences the degree of PSA formation. With regard to PSA 
prevention with novel fibrin sealant, PSA presence was significantly reduced at all sites 
but followed the same pattern as control sites (stomach, colon and uterus respectively). 
This could be due to tissue fibrinolysis and/or due to fibrin sealant coverage, either 
during application or subsequently influenced by organ expansion and motility. This 
increased fibrinolytic ability could decrease the time required for tissue modelling and 
hence promote earlier tissue remodelling, producing the results demonstrated in our 
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Chapter 10 
All fibrin sealants currently commercially available are non-autologous with the use of 
pooled human fibrinogen and exogenous proteins such as thrombin, calcium ions and 
aprotinin. The use of such agents leads to potential viral contamination and antigenicity 
problems. In the studies in this thesis the use of non-autologous novel fibrin sealant was 
associated with an acute inflammatory response even though no exogenous proteins 
were present. However this inflammatory response was absent in autologous novel 
fibrin sealant with only local trauma tissue reaction present. Although data for 
autologous and non-autologous novel fibrin sealant is limited to the results of one pilot 
study, PSA prevention varied greatly between them with reductions of 99% and 59% 
respectively. Although differences in efficacy can be attributed to experimental 
differences such as sealant application, the reduced volume of inflammation in the 
autologous group (16 fold less) lend support for this being a true difference in PSA 
prevention potential. We know from this data and others that PSA severity is associated 
with damage severity (Ellis, 1962; Belzer, 1967). Inflammation will induce damage and 
is therefore associated with severity of PSA formed. Increased inflammation, whether 
trauma induced or foreign material induced will lead to a greater severity of PSAs, that 
is, greater incidence and greater volume. Autologous fibrin sealants which do not induce 
an inflammatory response are a much more desirable PSA preventive agent. 
Angiogenesis plays a pivotal role in wound healing accounting for up to 60% of repair 
tissue (Dyson et aL, 1991). Since all tissues require a circulatory system for the delivery 
of nutrients, cells and chemical mediators, rapid formation of blood vessels at injury 
sites occurs both with adhesion-free healing and PSA development. Preliminary data 
concerning length density and total length of blood vessels within PSAs and tissue 
generation in both control and novel fibrin sealant treated cases was obtained via 
stereological analyses (Appendix X Table 10.4). 
The first new blood vessels were seen at I day post injury in both control and novel 
fibrin sealant treated cases using a rabbit uterine horn abrasion model. This is very rapid 
generation of vascular tissue, which has previously been associated with PSA 
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development (in-house observation). Since these results are very preliminary 
interpretation is cautious, however it does appear that cases treated with novel fibrin 
sealant have reduced vessel length density and total length compared to control cases. 
This is probably related to reduced inflammation and injury tissue generated in novel 
fibrin sealant treated cases. 
The studies within this thesis have been concerned with abdominal adhesions and 
therefore the discussion has concentrated on this PSA type. However, adhesion 
formation causes problems with many surgical therapies, especially tendon, pleural and 
cardiac. Successful repair of divided digital tendon continues to remain a surgical 
challenge primarily due to adhesion development. Poor surgical technique may actually 
accentuate previous tendon damage with additional adhesion induction. Adhesion 
presence prevents the tendon from sliding freely within its sheath and finger function is 
severely impaired with associated weakness and stiffness (Bucknall & Ellis, 1984). 
Prevention of this type of adhesion would have great patient benefits and in turn 
economic relief from re-operations and physiotherapy. 
The formation of pleural and cardiac adhesions also have serious consequences. Pleural 
adhesions can potentially lead to restrictive disturbances of ventilation and partial 
respiratory insufficiency (Kaiser et aL, 1979) whereas the main problem with cardiac 
adhesions is with reoperation where there is an increased risk of damage to the heart 
during resternotomy (Milgalter et aL, 1985). This ultimately limits the number of 
operations which can be safely attempted. Since peritoneal, pleural and cardiac cavities 
have several physiological similarities: delicate surface covered with a single layer of 
loosely connected mesothelial cells bathed in an extracellular fluid, it is highly probable 
that these membranes undergo matching processes during PSA development. Therefore 
PSA prevention should be able to be tackled in a like manner. 
Although extensive assays were performed using TNF-cc and TGF-P ELISA kits 
purchased from Genzyme Diagnostics inaccurate and non-reproducible results were 
obtained using control samples. Since specific anti-rabbit commercial kits are not 
available, alternatives were used: an anti-mouse TNF-a ELISA kit and anti-human 
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TGF-P ELISA kit. Since no cross reactivity data comparing these kits with rabbit 
samples was available, amino acid homologies were compared. The amino acid 
homology of mouse and rabbit TNF-cc is 77.87% (data obtained from Genzyme 
Diagnostics) and 98% for species homology of TGF-P species (Massague, 1990; 
Kondaiah et A, 1990). Despite the high amino acid sequence homologies these kits 
failed to detect rabbit TNF-(x and TGF-P. Thus the antigen used for the detection of 
these cytokines was either absent or altered making it unavailable for the antibody 
coated on the base of the ELISA kit. This non-detection of rabbit cytokines by these kits 
was not totally unexpected as these kits are designed to be highly specific for their 
antigen of choice, with cross-reactivity actively avoided in their design. 
For the detection of fibrin in formalin fixed, paraffin wax embedded rabbit tissues an 
anti-human fibrin IgG1 (American Diagnostica Inc, Greenwich, USA. Supplied by 
Alpha Laboratories Ltd, Eastleigh, Hampshire, England) was assessed and human 
(Interstitial) collagen I, II, III clone MCI-HA monoclonal antibody (Monosan, 
Netherlands, supplied by: Bradshaw Biologicals Ltd, Loughborough, England) was 
assessed for collagen detection. Although these anti-human antibodies were the most 
promising at the time of these experiments, both failed to detect rabbit proteins even 
with protocol modifications in primary antibody incubation time and temperature and 
alteration of proteinase incubation for fibrin detection. As with the ELISA failures this 
was due to the antibody directed against an epitope which is either not present on the 
rabbit proteins or not available. 
Analyses of the collagen antibody to detect rat tail collagen (performed by Dr J 
Featherstone, Oxford BioResearch) found that at a dilution of 1: 10 collagen was 
detected, however negative results were found at a dilution of 1: 30. The usual 
concentration of this antibody used in immunohistochemistry in this study was 1: 20. 
This dilution may have been too weak. However the concentrated nature required for 
detection brings the quality of this antibody into question. 
345 
Discussion Chapter 10 
10.1 Study Limitations 
During the course of the work for this thesis several limitations were evident: 
i. The use of static time points to interpret a dynamic process. 
Although the rabbit PSA development and prevention studies sampled PSAs 
and surrounding tissues extensively throughout their formation and 
maturation, a certain amount of data extrapolation is required. Although I feel 
that these studies provide a precise and unbiased account of the mechanisms 
occurring changes at time points not sampled must be acknowledged. The 
presence of these intermediate changes would not change the pattern of PSA 
development and prevention but may slightly alter the time scale in which 
these processes are thought to occur. 
ii. The use of a rabbit model. This small experimental model has the benefits of being 
accepted as a model for PSA investigations with utilisation by many studies. 
However, 
a. it prevents the use of novel fibrin sealant as truly intended, a totally 
autologous fibrin sealant and therefore does not actually use this agent as it 
will be used clinically. 
b. the resultant inflammatory response mediated due to the presence of foreign 
protein and the undetermined effect of this reaction on PSA development 
needs to be taken into consideration when analysing prevention of PSAs by 
novel fibrin sealant and the effect on overall wound healing. 
c. the small circulating blood volume in the rabbit complicates the taking of 
blood for biochemical analyses with marked effects of venesection of blood 
cell profiles. 
d. the inconsistency of rabbits with regard to blood factors (Schenner, 1967) is 
also a fact to be aware of in analysis of these studies. 
e. the lack of uniform blood cell nomenclature requires specific study 
definitions. 
f the lack of commercially available antibodies directed against rabbit antigens 
makes very precise biochemical and immunohistochernical analyses very 
difficult. 
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iii. The sampling technique for tissues taken to resin made assumptions concerning 
cellular distribution throughout PSAs and tissue generation with the middle portion 
sampled only. Although practical reasons governed this procedure this should be 
avoided in subsequent studies. I do not feel that this invalidates the results obtained 
since all tissue will treated equally and the conclusions drawn, that is, cellular 
presence throughout PSA development, PSA prevention with novel fibrin sealant and 
comparison between the two, are unaffected. However if this work was to be directly 
compared to other work of this kind (of which there is currently none) then this 
sampling regime would have be acknowledged. 
iv. Since tissue zone volumes were calculated from wax sections and cell number 
counting was performed using resin sections processing differences may exert an 
affect on number densities. Comparison of wax and resin sections as concurrent 
sections for estimation of volumes of uterine hom width and height, peritoneum 
height, PSA, PTG and UTG, showed a mean percentage difference between wax and 
resin of 14% for all parameters and 27% for tissue generation only (PSA, PTG and 
UTG) (Appendix X Table 10.5). Since these volume comparisons were taken from 
concurrent sections (for example, L3 (wax), L4 (resin) and L5 (wax)) and not the 
same sections, these percentage differences are within the limits of biological 
variation. Although a difference may exist in shrinkage between resin and wax 
processing it only exerts a minor effect on cell number densities for these studies. 
v. 25[im resin sections were used for cell number analyses and consistent staining 
throughout the whole section thickness proved difficult. The main problem was the 
inadequate staining of eosinophilic granules with some staining very pale pink. This 
may have potentially lead to incorrect differential classification of eosinophilic and 
basophilic cells. For this reason eosinophilic and basophilic cells were grouped 
together as granulocytes for comparisons between PSA, development and prevention 
with novel fibrin sealant. 
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Chapter 10 
i. Studies contained within this thesis have demonstrated that PSA development is a 
complex, multi-factorial highly regulated process. This is the first study to identify 
that PSA development has two distinct stages: 
a. PSA modelling: Fibrinous PSA formation and maturation (1 to 16 hours) 
Including - fibrin deposition and maturation 
- inflammatory response 
- initiation of clearance of necrotic tissue I 
b. PSA remodelling: Fibrous PSA formation and maturation (1 to 14 days) 
Including - collagen deposition and maturation 
- completion of necrotic tissue clearance 
- tissue repair. 
ii. Prevention of PSA development by fibrin sealants is now a reality with VivostatTM 
system human derived (novel) fibrin sealant. Treatment of surgical injuries with this 
sealant resulted-in repair tissue generation discretely located on injured surfaces, not 
adhering to other surfaces. Tissue generation development proceeded in a similar 
manner to PSA development with two stages seen: 
a. Tissue generation modelling: Fibrinous tissue generation formation and 
maturation (1 hour to 1 day) 
Including - fibrin deposition and maturation 
- inflammatory response 
- initiation of clearance of necrotic tissue 
b. Tissue generation remodelling: Fibrous tissue generation formation and 
maturation (1 to 7 days) 
Including - collagen deposition and maturation 
- completion of necrotic tissue clearance 
- tissue repair. 
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iii. Treatment with novel fibrin sealant reduced the amount of injury-associated 
inflammation, necrotic tissue damage and repair tissue generated. The net result was 
improved, more rapid tissue repair. 
iv. PSA prevention and acceleration of wound healing by novel fibrin sealant appears to 
occur as a result the sealant acting as a haemostat and as a physical barrier. Thus 
reducing the body's response to injury and preventing the exudation of fibrin and 
other tissue/serous fluids from abridging injured surfaces and interacting with 
surfaces and peritoneal contents. 
10.3 Future Research Options 
Due to the physical limitations placed upon this thesis with respect to time, a number of 
research options have not been included which may present avenues along which future , 
studies may be explored. 
i. Further understanding of biochemical mechanisms in PSA development and 
prevention with novel fibrin sealant. 
ii. Further work on autologous novel fibrin sealant (porcine novel fibrin sealant). 
iii. Prevention of secondary PSAs by novel fibrin sealant. 
iv. Prevention of cardiac PSAs by novel fibrin sealant. 
v. Prevention of tendon PSAs by novel fibrin sealant. 
vi. Prevention of PSAs by novel fibrin sealant via laparoscopy. 
vii. Further development of VivostatTm applicator for precise delivery of novel fibrin 
sealant to small areas. 
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APPENDIX I 
Factor Stimulating 
migration of 
endothelial 
cells 
Stimulating 
mitosis of 
endothelial 
cells 
Inhibiting 
migration or 
proliferation of 
endothelial cells 
Basic fibroblast growth factor + + 
Granulocyte-macrophage + + 
colony stimulating factor 
Vascular endothelial growth factor + + 
/vascular permeability factor 
Interleukin 8 + + 
Substance P + + 
Angiotropin + 
Human angiogenic factor + 
Platelet derived growth factor ?+ ?+ 
Interleukin 6 ?+ ?+ 
Interleukin I ?+ ?+ + 
Transforrning growth factor-beta low + low + high + 
Tumour necrosis factor-alpha low + high + 
Transforming growth factor-alpha + 
Insulin-like growth factor + 
Interferon-alpha - + 
Interferon-gamma - + 
Thrombospondin 1 - + 
Monocyte-derived endothelial cell - + 
inhibitor 
Macrophage-derived endothelial - + 
cell inhibitor 
Table 1.1: Macrophage Derived Mediators of Angiogenesis 
(taken from Sunderkotten et aL, 1994) 
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Proteolytic Enzymes 
Papain SD rats + dogs Stevens, 1968 110 1111111)itol" CH"A-1 [)poil f0linatioll OfPcIltolical III týýO ý; pccjcý' Could he 
I 
deinoiist rated 
Papase (anti -inflammatory) Monkeys Kapur el al.. 1960 oral administration was found to be very effective in preventing peritoneal adhesions 
Papase (anti-Mflammatory) Male Albino rats Nair el al.. 1974 oral administration immediately post operative was found to reduce markedly the 
incidence and extent of adhesions. Equally effective in reducing the incidence and 
extent of reformation of adhesion after their lysis 
Hylauromdase Wistar rats Chandy & Rhoads, 1946 60% adhesion prevention 
Separation of Surfaces 
32% Dextran 70 Human (women) Rein & Hill, 1989 
Human (women) Adhesion Study Group, 
1983 
Female NZW rabbits Soules ef al., 1982 
Male Patient Krinsky et al., 1984 
Human (women) Jansen, 1985 
Gore-Tex Surgical Female NZW rabbits Boyers & Jansen, 1990 
Membrane 
Female Mongrel dogs McCabe Fowler et al.. 
1991 
511astic (silicone rubber) Monizrel doizs Youmons et al., 1968 
[7arboxymethylcellulose Female NZW rabbits Heidrick et al., 1994 
CMQ 
Male SD rats Ryan & Sax, 1995 
, odium CMC + Vitainin E SD rats Hemadeh et al.. 1993 
)xidised Regenerated 
. ellulose (ORC) 
, esoluble 
hydrogel barrier Female NZW rabbits Hill-West et al., 1994 
Ixycel Male SD rats McGaw et al., 1988 
IRC Female NZW rabbits Shimanuki et al., 1987 
Male Mongrel dogs 
iterceedg (TC7) Female rabbits Diamond et al., 1990 
iterceedO (TC7) Human (Female) Malinak, 1990 
larrier methods with/without Female NZW rabbits Soules et al.. 1982 
)extran 70 
, ydrophilic polymer Mongrel dogs Duncan ef al., 1988 
olutions 
polyvinylpyrroliodme &a 
nethylcellulose derivative) 
3encardial meshing 
----------------- 
Mongrel dogs 
-------------- 
Milgafter et al., 1985 
L 
-------------- 
( 
( 
C 
C 
significantly inhibited lymphocyte proliferation and macrophage phagocytosIs (but not 
cell viability). This immunosuppressive effect In vitro suggesting a new mechanism by 
which 32% dextran 70 may reduce PSA formation 
IP high molecular weight dextran was found to reduce PSA formation effectively 
degree of adliesion formation did not differ to controls (inconclusive results) 
50ml of Hyskon instilled at time of laparoscopy. 26 hours later at subsequent 
laparotomy, 255ml of peritoneal fluid was presented, demonstrating that Hyskon was 
able to promote transfer of a large volume of fluid into the peritoneal cavity. By 
separating fibrm-coated surfaces, this hydroflotation effect inhibits adhesion formation 
no enipiric basis to support the use to prevent peritoneal adhesions 
mean scores for extent, type and tenacity of adhesions were significantly lower for 
Gore-Tex covered lesions. Gore-Tex covered defects also reformed adhesions at a 
significantly lower rate than controls. 
appears to increase post-radical adh, -sions 
silastic prevented adhesions, both pleural and pencardial, and was not implicated in a 
single case of infection 
SCMC if effective in preventing PSAs formation in NZW rabbits 
more effective than InterceedO in preventing PSAs. Action not due to inhibition of 
TGF-P expression or macrophage derived fibrinogenic factors. Highlights the 
importance of local barrier effect In adhesion prevention. 
synergistic beneficial effect of oral supplements of Vitamin E and IP administration of 
SCMC solution in reducing the incidence and degree of IP adhesions 
highly effective for reduction of periovarian adhesions In this model 
some benefits in decreasing PSA formation in the rat 
graded reduction in adhesion formation and significantly prevented adhesion 
reformation 
InterceedO (M) significantly reduces postoperative adhesion formation. The 
material is resorbed by the body, presumably by intraperitoneal processes over a very 
short time, and without evidence of typical foreign body reaction 
Interceed(g) adhesion barrier effectively reduced the incidence, extent and severity of 
postoperative adhesion. 
bamers used: Gelfilm, Surgicel, Silastic, Gelfbam paste, amnion, peritoneum and 
omentum. Generally increased formation of adhesion was seen with these barrier 
methods compared to control or dextran treated animals 
polyvMylpyrroliodme &a methylcellulose derivative as intraoperative irngating 
solutions significantly reduce pericardial adhesion formation compared to Ringer's 
Lactate 
pericardial meshing is superior to the pericardial substitutes examined (Silicone; 
Bovine) as adhesions and epicardial reactions are significantly reduced and the 
coronary anatomy is readily identifiable -------------------------- 
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APPENDIX 11 
2.10 Histology - Paraffin Wax 
2.10.1 Processing 
Tissue-Tek@ VIP 2000 Tissue Processor (Bayer Diagnostic, Basingstoke, UK) 
Routine Schedule 
Reagent Incubation Time 
10% formal saline 2 Hours 
70% alcohol I flour 
Absolute alcohol I Hour 
Absolute alcohol I Hour 
Absolute alcohol 1 Hour 
Absolute alcohol I Hour 
Absolute alcohol 1 Hour 
Xylene 30 Minutes 
Xylene 1 Hour 
Xylene 30 Minutes 
Wax 1 30 Minutes 
Wax 2 1 Hour 
Wax 3 1 Hour 
Wax 4 1 Hour 
2.10.4 Haernatoxylin and Eosin Staining 
Shandon Varistain 24-4 (Shandon, Southem Products Ltd, Astmoor, Runcom, 
Cheshire, England) 
Reagents 
e Cole's Haematoxylin 
Haematoxylin 0.6g 
Saturated aqueous potassium alum 280ml 
1% iodine in 95% alcohol 20ml 
Distilled water looml 
Haematoxylin was dissolved in warmed distilled water and then mixed with the 
iodine solution. Alum solution was added and the mixture was brought to the 
boil and then quickly cooled and filtered. The solution was immediately ready 
for use but required occasional filtering after storage. 
Eosin Stock Solution 
Eosin 
Tap Water 
Working Solution 
Dilute stock solution 1: 10 with tap water 
e acid alcohol 
I% hydrochloric acid in 70% alcohol 
Procedure 
5mg 
looml 
Reagent Time 
Xylene 5 minutes 
Xylene 2 minutes 
Absolute alcohol 2 minutes 
Absolute alcohol 2 minutes 
70% alcohol I minute 
50% alcohol I minute 
Distilled water 2 minutes 
Cole's Haernatoxylin 10 minutes 
Running tap water 2 minutes 
1% acid alcohol 3 seconds 
Running tap water 4 minutes 
0.5% eosin 5 minutes 
Running tap water 20 seconds 
Absolute alcohol I minute 
Absolute alcohol 3 minutes 
Xylene 2 minutes 
Xylene I minute 
lene I minute 
Results 
Nuclei 
Cytoplasm 
Muscle fibres 
Red blood cells 
Collagen 
Fibrin 
Blue-black 
Varying shades of pink 
Deep pink-red 
Orange/red 
Pale pink-red 
Deep pink 
2.15.1 Hema-Tek 200 using modified Wright's Stain for Blood Films 
Herna-Tek 200 uses a Hema-Tek Stain Pak, which consists of three reagents: Stain 
solution (methanol dissolved stain), buffer solution and rinse solution. Slides are placed 
into the staining machine and pass on a conveyer system, with reagents delivered on the 
conveyer belt. 
Procedure 
1. Slides were first immersed in staining solution for approximately 2 minutes for 
fixation. 
2. Buffer solution was then mixed with the stain solution and slides were stained in the 
resulting solution for approximately 7 minutes. 
3. Slides were then rinsed with rinse agent for approximately 1 minute. 
4. Slides were then air dried. 
2.16.1.1 Validation 
TNF-cc release from Activated Blood Monocytes 
(References consulted: Boyum, 1983; Boyurn, 1984; Mattsson et al, 1994) 
Materials 
9 Nycodenz-NaCI Separation Solutions 
Animal Conc. Volume Volume of Density Osmolarity 
NaCl of NaCl 27.6% (g/mI) (mosmol/1) 
Solution (MI) Nycodenz 
(%) 
- 
Solution (ml) 
Rabbit 1.02 3 T5 2 1.068 330 
Rat 1.08 2.55 2 1.068 340 
* Medium 199, enriched with Earle's salt solution (Sigma-Aldrich, Dorset, England) 
9 Lipopolysaccharide (LPS) solution (250ng/ml) 
LPS Stock Solution (1.25mg/ml) diluted 1: 5000 with phosphate buffered saline 
(pH 7.3). 
Isolation of Monocytes from Whole Blood 
1.4-5ml of rat (terminal bleed) and rabbit (non-terminal bleed) blood was collected into 
EDTA. Home office guidelines dictate that 6% of the animals total blood volume 
(50-60ml of blood/Kg) can be collected from a non-terminal bleed. On the 
conservative side this is approximately 3ml blood/Kg body weight. 
2. Monocyte count was checked using Coulter counter. 
3. Nycodenz-NaCI separation solution was prepared. 
4.3ml EDTA blood was layered over 3ml Nycodenz-NaCI solution. 
5. The separation mixture was centrifuged at 600xg for 15 minutes 
6. Plasma was cleared down to 3-4mm above the interface between plasma and 
separation solution. 
7. The remaining plasma was collected together with slightly more than half the volume 
of separation solution. 
8. Monocyte count was again checked using Coulter counter. 
9. The sample was centrifuged at 800xg for 15 minutes and remove -1.5ml of 
supernatant to reduce volume of separation solution and plasma. 
10.1.5ml of pre-warmed (370C ) medium 199, enriched with Earle's salt solution, was 
added to the monocyte concentrate, and mixed for 10 minutes to distribute cells 
through the media. 
Activation of Monocyte to Release TNF-a 
1. Cells (150ýtl cell media) were transferred to 96-well flat-bottomed tissue culture plate 
and incubated in 5% C02 for 1 hour to allow adherence. 
2. LPS solution was prepared. 
3. Non-adhered cells were carefully removed by aspiration (to leave monocyte 
monolayer). 
4. Monocytes were incubated with 100ul of LPS solution in 5% C02 at 370C for 18 
hours. 
5. Supernatant was collected and centrifuge at 3000xg for 30 minutes to remove cells. 
6. Excess supernatant was subsequently stored ("TNF high control) at -700C. 
2.16.1.1 Production of Tumour Necrosis Factor Alpha from Whole Blood 
(Reference consulted: Desch et al, 1989) 
Materials 
o Whole blood (collected into Heparin IOU/nil final) 
Conforming to Home Office guidelines described in 2.16.1.1 
o Lipopolysaccharide [Escherichia Coli serotype 055: B5] 1 Ong/ml 
LPS solution diluted in RPMI-1640 cell culture media (Sigma-Aldrich, Dorset, 
England) 
Method 
For each blood sample multiple tubes/plate wells were run 
1. Rat (terminal bleed) and rabbit (non-terminal bleed) blood samples were collected 
into heparin. 
2.225ýd of heparinised blood was pipetted into sterile eppendorf tube/cell culture plate 
well. 
3. LPS (10ng/ml) was subsequently added to the blood sample and mildly stirred. 
4. The sample was then incubate at 37C for 4-6 hours. 
5, The contents were then collected and centrifuge at 500xg for 6 minutes. 
6. The supernatant was then collected and stored at either 40C for same day analysis or - 
800C for future analysis. 
2.16.2.1 Validation 
TGF-P Extraction from Whole Blood 
Preparation of Platelet Concentrate 
1. Fresh human and rabbit peripheral whole blood were collected into EDTA (9ml 
sample). Conforming to Home Office guidelines described in 2.16.1.1. 
2. A sample of whole blood was taken for platelet count using Coulter Counter. 
3. Whole blood was centrifuged at 220xg for 10 minutes. 
4. Platelet rich plasma was then collected and a sample for platelet count using Coulter 
Counter. 
5. Platelet rich plasma was then centrifuged at 1000xg x 15 minutes. 
6. Platelet poor plasma was removed, with approximately 0,5ml volume remaining and 
platelet plug. 
7. Platelet concentrate was then placed on agitator and left for at least I hour 
8. A sample of platelet concentrate was taken for platelet count using Coulter Counter. 
Platelet Lysis via Freeze/Thaw Cycle 
1. Platelet concentrate was placed into -80"C freezer until thoroughly frozen 
(approximately 30 minutes). 
2. The sample was then thawed at room temperature and TGF-P concentrate collected. 
APPENDIX III 
Injury Time Percentage Incidence of PSAs 
10 Minutes 87.5 
30 Minutes 100.0 
I Hour 75.0 
4 Hours 75.0 
8 Hours 100.0 
16 Hours 100.0 
I Day 100.0 
3 Days 87.5 
5 Days 100.0 
7 Days 75.0 
14 Days 87.5 
28 Days 100.0 
42 Days 87.5 
Table 3.1: Macroscopic incidence of PSAs at each time point following injury. 
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Table 3.3: T test analysis of volumetric results between concurrent time points. 
Normality Test Failed; Mann-Whitney Rank Sum Test ran. 
= Equal Variance Test Failed; Mann-Whitney Rank Sum Test ran. 
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P VALUE 
Injury Total Tissue Generation 
Time Volurne Percentage 
Fibrin Collagen Fibrin Collagen 
30 Seconds -I Minute 0.7980 1.0000 1.0000 1.0000 
I Minute -3 Minutes 0.0 104* 1 1.0000 1.0000 1.0000 
3 Minutes -5 Minutes 0.3816* 1.0000 1.0000 1.0000 
5 Minutes - 10 Minutes 0.7210* 1.0000 1.0000 1.0000 
10 Minutes - 30 Minutes 0.4193 1.0000 1.0000 1.0000 
30 Minutes -I Hour 0.7841 1.0000 1.0000 1.0000 
I Hour -4 Hours 0.00Y)* 1.0000 1.0000 1.0000 
4 Hours -8 Hours 0.1104* 1.0000 1.0000 1.0000 
8 Hours - 16 Hours 0.9450 1.0000 1.0000 1.0000 
16 Hours - 24 Hours 0.4679 0.4420* 0.4420* 0.4420* 
24 Hours -3 Days () 0019* 0. () 0 1) () "ý (00295* 002W, 
3 Days -5 Days 000 11* 0.00021* . (). 0001 0.0001 
5 Days -7 Days 0.5740* 0.0506 0.1300* 0.1300* 
7 Days - 14 Days 0.1067 0.0644 0.5050* 0.5050* 
14 Days - 28 Days 0,0 104 * 0.0207' (1 () 104* () () 104 * 
28 Days - 42 Days 1.0000 0.4420* 1.0000 1.0000 
Table 3.5: T test analysis of fibrin and collagen mean volumes and percentages between control and 
treated cases. 
Normality Test Failed; Mann-Whitney Rank Sum Test ran. 
= Equal Variance Test Failed; Mann-Whitney Rank Sum Test ran. 
Injury P VALUE 
Time PSA against PTG PSA against UTG PTG against UTG 
I Hour - - - 
4 Hours - - - 
8 Hours - - - 
16 Hours - - - 
24 Hours 0.959* 0.721 0.721 
3 Days 0.959* (), ()OlM* 000 "II 
5 Days 0.222* 0.0653 0.382* 
7 Days 0.045 1 (), () 1(), )* 0.798* 
14 Days 0.142 0.0593* 0.328* 
28 Days - - - 
42 Days I - -I - 
Table 3.6: T test analysis comparing fibrin and collagen mean percentages within tissue zones. 
*= Normality Test Failed; Mann-Whitney Rank Sum Test ran. 
II 11 VALUE 
Injury Total Tissue Generation 
Time Vol ume Percentag 
Fibrin Collagen Fibrin Collageii 
I Hour 0.3622 1.0000 1.0000 1.0000 
4 Hours - - - - 
8 Hours - 
16 Hours - 
24 Hours - 
3 Days - - - 
5 Days 0.3797 0.9340 0.9340 
7 Days 0.0531 0.0635 0.0771 0.0771 
14 Days 0.7983 0.3599 0.7927 0.7927 
28 Days 1.0000 0.0714** 1.0000 1.0000 
42 Days 1.0000 ww)o 1.0000 1.0000 
Table 3.7: T test analysis of fibrin and collagen composition within adhered and non adhered control 
cases. 
Normality Test Failed; Mann-Whitney Rank Sum Test ran. 
= Equal Variance Test Failed; Mann-Whitney Rank Sum Test ran. 
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P VALUE 
Injury Tissue Generation Damag e Zone Peritoncal Peritoncal Utcrine 
Time 
I 
PSA Peritoneal Uterine 
HOM 
Total Peritoncal Uterine 
Ilorn 
Reaction 
Zone 
Cell 
Concentration 
I lom 
flacmorrhage 
I Hour 0.0952* 0.0952** 0.3810* 0.0004 0.8570* 0.1900* 0.2036 N/A 0.9774 
4 Hours 0.1070 0.1956 0.4860** 0.2609 0.4860** 0.6860** 0.6102 0.3567 0.9501 
8 Hours N/A (all cases Adhered) 
16 Hours N/A (all cases Adhered) 
I Day N/A (al I cases Adhered) 
3 Days N/A N/A N/A N/A N/A N/A N/A N/A N/A 
5 Days 0.0246 0.4087 0.7860** 0.0605 0.2895 0.5597 0.1087 0.2826 0.5710* 
7 Days 0.0001 0.7828 0.9495 0.2066 0.2581 0.1146 0.8490 1.0000* NIA 
14 Days 0.1114 0.3473 0.0714* 0.1676 0.2689 0.4055 0.0050 N/A N/A 
28 Days N/A N/A N/A N/A N/A N/A N/A N/A N/A 
42 Days N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Table 3.9: T test analysis of volumetric results of tissue zones for adhered and non-adhered cases. 
Injury POSTSURGICAL ADHESION PERITONEAL TISSUE GENERATION UTERINE I IORN TISSUE GFN1,1RATION 
Th 
Basophilic Eosinophilic Basophilic Eosinophilic Basophilic Eosinophilic ne Cells Cells Macrophages Fibroblasts Lymphocytes Total No. Cells Cells Macrophages Fibroblasts Lymphocýtes Total No. Cells Cells Macrophages Fibroblasts Lymphocytes Total No. 
1 
Hour 
Mean 
% 
N/A N/A N/A N/A N/A N/A 79474.20 36144.70 37286.36 0.00 6967.31 159772.56 179351.81 24086.30 32639.26 395.62 9828.81 246301.80 0.00 0.00 0.00 0.00 NIA 0.00 49.43 22.77 23.48 0.00 4.33 100.00 72.82 9.78 13.25 0.16 3.99 100.00 STI) N/A N/A N/A N/A NIA N/A 59056.66 32631.19 61644.53 0.00 12619.33 49436.51 123403.39 22010 13 30487.15 734.54 16446.63 98164.11 SEM 0.00 0.00 0.00 0.00 NIA 0.00 20879.68 11536.87 21794.63 0.00 4461.25 17478.45 43629.69 
. 
7781 76 10778 83 259.70 5814.76 31170.72 CVO/O NIA N/A N/A N/A NIA NIA 26.61 31.92 58.45 NIA 64.96 11.01 24.33 
. 
32.31 
. 
33.02 65.64 59.16 12.66 
4 
Hours 
Mean 
% 
58724.28 191069.96 47695.47 238'6.83 5473.25 305349.79 60890.66 175498.16 12054.77 798.06 'i293.43 251535.07 97359.42 219774.73 27453.57 0.00 4338.04 348925.76 19.23 62.57 15.62 0.78 1.79 100.00 24.21 69.77 4.79 0.32 0.91 100.00 27.90 62 99 7 87 0.00 1 24 100.00 STI) 29584.93 88046.10 38964.33 3315.76 4179.94 97806.56 32533.81 72163.41 21 11651 854 84 2216.81 89041.91 57760.69 
. 
69533 45 
. 
43748.47 0.00 
. 
5114.94 78710.34 SEM 17080.87 50833.44 22496.06 1914.35 2413.29 56468.64 11502.44 25513.62 
. 
4119 33 
. 
302 23 783.76 31481.07 21931.49 
. 
26281 17 16535 37 0.00 1933.27 29749.71 CVO/O 29.09 26.60 47.17 80.20 44.09 18.49 18.89 14.54 
. 
34.17 
. 
37.87 34.17 12.52 22.42 
. 
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. 
60.23 #DIV/01 44.57 8.53 
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Mean 
% 
62440.69 264448.99 11737.60 320.83 2980.44 341928.55 59682.38 224140.95 16341.45 0.00 2552.13 302716.91 96729.48 296246.48 9075.16 1258.93 2926.51 396136.56 
STI) 
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SEM 
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CVO/ 
13699.27 27937.60 2923.53 244.86 1080.05 28128.36 16633.03 72654.62 2655.46 0.00 2051.32 73047.16 34463.48 79858.02 4556.72 718.25 1667.78 108036.77 
O 21.94 10.56 24.91 76.32 36.24 8.23 27.87 32.41 16.25 NIA 80.38 24.13 35.63 27.90 50.21 57.05 59.00 27.27 
16 
Hours 
Mean 
% 
106844.62 366206.34 25679.63 5254.49 4578.61 508563.70 191559.11 520639.79 30524-84 0.00 0.00 732722.74 139525.77 361160.10 49186.75 16264.94 5486.97 571624.53 21.01 72.01 5.05 1.03 0.90 100.00 24.78 71.06 4 17 0 00 0.00 100.00 24.41 63.18 8.60 2.85 0.96 100.00 STI) 37991.69 82242.07 15749.49 5904.01 4306.06 96224.16 103684.17 260135 07 
. 
15 10263 
. 
0 00 0 00 338849.75 42124.33 16905 16 54595.35 8036.88 7759 75 45172 80 SEM 
CVIY 
13432.09 29076.96 5568.28 2087.38 1522.42 34020.38 59862.09 . 150189.05 
. 
5925.43 
. 
0.00 
. 
0.00 195634.99 29786.40 
. 
11953.75 39604.74 5682.93 
. 
5486.97 
. 
31941.99 
O 12.57 7.94 21.68 39.73 33.25 6.69 32.97 28.85 19.41 NIA N/A 26.70 21.35 3.31 78.49 34.94 100.00 5.59 
1 
Day 
Mean 
% 
85890.32 300495.90 17686.15 2205.25 3190.53 ' 409468.15 65791.71 260303.54 9751.16 1322.14 974.83 338143.38 93971.13 163610.19 19086.52 2777.78 462.96 279808.59 
STI) 
20.98 73.39 4.32 0.54 0.78 100.00 19.46 76.98 2.88 0.39 0.29 100.00 33.55 58.47 6.82 0.99 0.17 100.00 
SEM 
15732.22 124564.93 19496.79 3146.53 2735.50 148663.49 38288.76 147655.41 8085.76 1832.19 1541.47 170659.62 63714.57 104233.70 38564.06 6211.30 1035.22 93145.80 5562.18 44040.36 6893.16 1112.47 967.15 52560.48 17123.25 66033 51 3616 06 819 38 689 37 76321.30 28494.02 46614 73 17246.37 2777.79 462 96 41656 07 CVO/O 6.48 14.66 38.97 50.45 30.31 12.84 26.03 . 25.37 
. 
37.08 
. 
61.97 
. 
70.72 22.57 30.35 
. 
28.49 90.36 100.00 
. 
100.00 
. 
14.89 
3 
Days 
Mean 
% 
52636.00 25201.19 115539.96 1.07856.64 7065.35 308299.14 47646.60 22182.57 108520.72 137440.23 4549.55 320339.69 13127.26 31049.95 76040.94 169189.46 2134.03 291541.54 17.07 8.17 37.48 34.98 2.29 100.00 14.87 6 92 88 33 42 90 1.42 100.00 4.50 10.65 26.08 58.03 0.73 100.00 STI) 53383.31 20593.67 77194.83 88611.11 5418.02 153752.50 61822.09 
. 
25101 11 
. 
89 71797 
. 
71046 05 6082.97 130203.80 9644.79 57020.11 91060.33 116480.26 2781.39 191476.29 SEM 23873.74 9209.77 34522.58 39628.10 2423.01 68760.21 25238.76 
. 
10247 48 
. 
36 29311 
. 
29004 43 2483.36 53155.48 4822.40 28510 05 40530.16 59240.13 1390.70 95739.15 CVO/O 45.36 36.54 29.88 36.74 34.29 22.30 52.97 
. 
46.20 
. 
27.01 
. 
21.10 54.60 16.59 36.74 
. 
91.82 53.30 34.42 65.17 32.84 
5 
Days 
Mean 
% 
42689.59 23550.28 156747.67 425713.16 1394.56 650094.25 22295.76 5451.42 80232.94 270746.18 939.34 379565.53 25575.51 2984.62 99617.00 393476.87 1744.63 513298.63 6.57 3.62 24.11 65.49 0.21 100.00 5.87 1 44 21 14 71 33 0.22 100.00 4.98 0 56 19.41 74.71 0.34 100.00 STI) 38891.30 27883.62 105068.49 173573.36 162105.25 332798.08 28300.81 
. 
3593.58 
. 
24028 85 
. 
123055 76 1314.70 140287.69 40847.32 
. 
76 4310 56936 80 213458.41 1956.75 286616.28 SEM 15877.31 11383.44 42894.03 70861.03 66179.19 135864.25 11553 76 1467 07 
. 
9809 74 
. 
50237 30 536.72 57272.21 16675.85 
. 
86 1759 
. 
23244 35 87144.03 798.94 117010.61 CVO/O 37.19 48.34 27.37 16.65 4779.79 20.90 
. 
51.82 
. 
26.91 
. 
12.23 
. 
18.56 63.95 15.09 65.20 
. 
61.01 
. 
23.33 22.72 45.79 22.80 
7 
Days 
Mean 
% 
12834.71 4187.38 57339.77 225933.41 489.03 300784.30 8026.69 6607.44 76943.46 241357.90 1198.76 334134.15 21557.57 4598.36 52379.59 273338.09 3149.54 355013.14 4.27 1.39 19.06 75.11 0.16 100.00 2.40 1.98 23 03 72.23 0.36 100.00 6.07 1.29 14.75 76.99 0.89 100.00 SID 30009.80 2991.57 59556.36 94871.06 763.60 177815.65 18900 87 7933 92 
. 
00 82100 74 84291 1495-08 100074.89 53515.11 4779.87 54117.12 90677.53 5266.26 77734.96 SEM 12251.45 1221.30 24313.78 38730.95 311.74 72592.94 
. 
7143.86 
. 
2998.74 
. 
88 31030 
. 
31859.28 565,09 37824.75 20226.81 1806.62 20454.35 34272.88 1990.46 29381.05 CVO/O 95.46 29.17 42.40 17.14 63.75 24.13 89.00 45.38 
. 
40.33 13.20 47.14 11.32 93.83 39.37 39.05 12.54 63.20 8.28 
14 
Days 
Mean 
% 
14354.00 1250.14 28592.79 222256.36 1233.15 267686.43 9158.45 1386.43 16875.42 280601.32 797.03 309919.65 9947.15 1006.20 24936.27 313608.17 3363.41 352422.44 
STI) 
5.36 0.47 10.68 83.03 0.46 100.00 2.97 0.45 5.46 90.86 0.26 100.00 2.79 0.29 7.08 88.99 0.95 100.10 
SEM 
34036.55 1654.49 26767.91 94766.06 1248.93 114490.71 22354.85 1486.19 14360.16 84198.16 1168.46 90345.80 22436.86 1749.22 19660.91 84540.32 6838.95 108230.73 
CV0/ 
13895.36 675.44 10927.95 38688.08 509.87 46740.64 8449.34 561.73 5427.63 31823.91 441.64 34147.50 9159.81 714.11 8026.53 34513.44 2791.99 44185.01 
0 96.80 54.03 38.22 17.41 41.35 17.46 92.26 40.52 32.16 11.34 55.41 11.06 93.02 70,97 32.19 11.01 83.01 12.54 
28 
Days 
Mean 
% 
10447.14 1416.12 24006.75 313167.74 1264.56 350302.31 142.45 877.93 13449-23 193832.96 2502.07 210804.64 0.00 131.45 10272.67 291785.52 1287.33 303476.99 
STI) 
2.98 0.40 6.85 89.40 0.36 100.00 0.07 0.42 6.38 91.95 1.19 100.00 0.00 0.04 3.38 96.15 0.42 100.00 
SEM 
26785.88 2103.84 30055.90 76567.48 1656.20 89196.96 402.91 1511.32 9088.63 48134.72 4498,52 48543.89 0.00 347.79 8208.02 96059.23 2013.44 95267.67 
CVO/ 
10124.11 795.17 11360.06 28939.79 625.98 33713.28 142.45 534.33 3213.32 17019.19 1590.47 17162.86 0.00 131.45 3102.34 36306.60 761.01 36007.79 O 
, 
96.91 56.15 47.32 9.24 49.50 9.62 100.00 60.86 23.89 8.78 63.57 8.14 #DIV/01 100.00 30.20 12.44 59.12 11.87 42 
Days 
Mean 
% 
7"3.72 
3 33 
536.77 10655.80 219552.50 967.76 239706.55 31498.67 2416.98 24389-97 226737.24 2155-59 297197.25 19504.61 6464.95 
v 
22258.23 284724.39 1667.99 333620.15 
. 0.22 4.45 91.59 0.40 100.00 10.97 0.84 849 * 78.95 
0.75 100.00 5.55 i. 94 6.67 85.34 0.50 100.00 
S 
STI) 
EM 
14344.32 1314.81 16055.47 179726.62 1550.33 198170.35 34011.42 3702.61 13723 04 133048.61 4180.04 155283.25 20749.61 7872.12 15912.57 109435.15 2711.72 135245.17 
CVO/O 
5856.04 
73 26 
536.77 6554.62 73373.08 632.921 80902.71 12855.11 1399.46 5186-82 50287.65 1579.91 58691.55 8470.99 3213.78 6496.28 44676.71 1107.05 55213.61 1 . 100.001 61.51 33.421 65.40 33.75 40.81 57.901 21.27 22.18 1 73.291 20.44, 45.78 49.71 29.19 15.69 66.37 , 
16.55 
Table 3.10: Mean number densities of cell types within PSAs, PTG and UTG from Ihour to 42 days, together with mean percentages, SDs, SEMs and CV/o. 
P Value P Value P Value 
injury Post Surgical Adhesion Peritoneal Tissue Generation Uterine Horn Tissue Genera tion Time Basophilic Eosinophilic Macrophages FibToblasts LyniphocYl(n- Total No. Basophilic E, Osinopbilic MuTophaps Fibroblasts I. Yniphoc. NILý Tolal No, INSophilk F, (Ki? I0J)hIIIL Mactophages Fihfoblxýts I N1141114"me, Iola] No. 
Cells Cells Cells Cells CeI Is Cells 
1-4 Hours - - - - - 0.2611 0 6940* 0.12 10* 0 7790* .II. 0 5350* 3930* 0 0 9693 0 0644 4-8 Hours 0.8850 0.2143 (). ()249 0.0899* 0.2986 0.5359 0.9518 0.4685 
. 
0.1270* 0.0647 
. 
0.6220* 0.4752 0.9868 0.2452 
. 
0.7880* 
. 
0.2300* 
. 
0.6480* 
. 
0.4896 
8-16 Hours 0.0-163 0.0243) 0.0437 0028 1* 0.4063 0.0020 0.0714** 0.1430* 0ý0443, 1.0000 0.3930* 00-4 71 0.4396 0.8000** 0.2670** 0.1330** 0.5691 0.1330** 
16 Hours-I Day 0.3820** 0.2335 0.1950* 0.3820* 0.4543 0.1358 0.1430** 0.1136 (), ()184 0.2717 0.3297 0.0655 0.4050 0.0529 0.3810* 19()()* 0.57 10* () 00, 
1-3 Days 0.1410 0,0005 0.0062*" 0 003) 1* 0.2840** 0.2633 0.5834 (). OOIS 7* (). ()()4. )** o()()4, )* 0.2361 0.8485 0.1110** 0.0578 (). I 110* 0141 0.2491 0.9066 3-5 Days 0.7312 0.5370* 0.3911 0.0007 0.0 17)* (). () II1; 0.3826 0.0649* 0.9370** (). 0444 0.1750 0.4660 0.9140* 0.7620* 0.6006 0.1076 0.2150 
5-7 Days (). 0411 * 0.1320* 0.0260* 0.0095 0.8180* 0,0089 0.10 10* 0.9450* 0.2950* 0.6206 0.73 10* 0.5104 0.2340* 0.5168 0.1537 0.2382 0.8360* 0.1858 
7-14 Days 0.9370* 0.0616 0.5890* 0.9478 0.3940* 0.7095 0.9020* 0.0973* () ()'02* 0.4560* 0.5857 0.6283 0.6280* 0.1116 0.2662 0.4279 0.73 10* 0.9609 
14-28 Days 0.6280* 0.9450* 0.73 10* 0.0818 0.9450* 0.1714 0.2810* 0.5360* 0.5849 () 0. '(0) 0.9550* () () 1 1) " 0.3660* 0.5340* 0.0980 0.6748 0.4040 
28-42 Days 0.5340* 
- 
0.4450* 
. 
0,5340* 
, 
0.4544 
, 
0.8360* 
J 
0.4412 
1 
0.0939* 0.6940* 0.0881 0.7790** 1 0.7790* 1 
0.7790** 
1 
0.1380* 
1 
0.2340* 
1 
0.1082 
1 
0.9036 0.6472_1 
Table 3.11: T test analysis comparing number densities of cell types with PSAs.. PTG and UTG between concurrent time points. 
Injury 
P Value 
PSA vs PIU 
P Value 
PSA vs UIU 
P Value 
PI Uvs UIU 
Time Basophilic Eosinophilic Macrophages Fibroblasts Lýmrhocýles Total No, Basophilic 1-10sinophilic 'Macrophages Fibroblasts Lymphmýlcs Total No Basophilic N)sinopbilic MaLm1phages Fibroblasts Lmphocýqcs '1()181 'ýo. 
Cells Cells Cells Cells Cells Cells 
I Hour 
0.1967 0.3202 0.3830* 0.3830* 1 
4 Hours 0.9223 0.7690 0.0848* 0.7760** 0.1249 0.4054 0.3144 0.5923 0.2670* 0,1170* 0.7456 0.4732 0.1890** 0.2495 0.8670* 0.1210* 0.3220 o ()441 
8 Hours 0.9015 0.5562 0.3050 0.5240* 0.8422 0.5690 0.2604 0.5562 0.6254 0.3680* 0.9392 0.4610** 0.3001 0.5365 0.1986 0.2860* 0.9050* 0.3985 
16 Hours 0.3760** 0.7760** 0.6382 0.0848* 0.1086 0.1004 0.3146 0.9361 0.7110** 0.0552 0.8195 0.4083 0.8000** 0.4715 0.5753 () () "I'1 0.2722 o. 5705 
I Day 0.2840** 0.6077 0.4350* 0.6220* 0.1296 0.4424 0.7240** 0.0659 0.1270* 0.2840* 0.0588 0.17 10* 0.4228 0.2658 0.3 100* 0.8410* 0.6900* o. 5212 
3 Days 0.6620* 0.6620* 0.8697 0.5501 0.4825 0.8911 0.1110* 0.4130* 0.4411 0.3948 0.1293 0.8879 0.2570* 0.7411 0.5234 0.6027 0.7620* 0.7822 
5 Days 0.2948 0.3 100* 0.0559 0.0486 0.8180* 0.0204 0.1800* 0,1075 0.1955 0.6792 0.4850* 0.3571 0.8180* 0.1800* 0.5890** 0.3940* 0.3940* 0.3288 
7 Days 0.8360* 0.4973 0.5340* 0.7619 0.3175 0.6786 0.6280* 0.8360** 0.5340* 0.3773 0.3660* 0.4787 0.9020* 0.5748 0.4560* 0.3830* 0.7100* 0.6706 
14 Days 1.0000* 0.8360* 0.3360 0.2643 0.5289 0.4838 0.8180* 0.8180* 0.4850* 0,1086 0.8180* 0.2171 0.9450* 0.6280* 0.4116 0.4965 0.9450* 0.4447 
28 Days 0.5360* 0.8670* 0.7790* 0,0028 1.0000* 0,0021 0.3830* 0.3180* 0.2590* 0.6534 1.0000* 0.3612 0.6940* 0.3970* 0.4926 (1 W4 0.9550* n'(i 42 Davs 0.3660** 1 0.4450* 1 0.3738 1 0.6311 0.9450* 0.9394 0.5117 0.0989 0.5553 0.7917 0.8180* 0.6537 0.4338 0.2485 0.8001 0.4144 1.0000 0.5805 
Table 3.12: T test analysis of comparing number densities of cell types present within tissue zones from I hour to 42 days post injury. 
Time I I Basophilic Calls FAminophilic Calls maorophages Fibroblasts I Lynipbocytes Total No. Basophilic calls Eosinaphilic Calls Mer. ph. g. Fibroblasts 1, ý7mhocvtm Total Wo. 
I 
Beflophillo Collis Celli mactophalt" 
I 
Fil"blasto 
: 
I Mean 
Ho 
N/A NIA NIA NIA NIA NIA 1693287.71 627356.58 35OS70.14 0.00 97030.74 296944S. 16 167S90.62 47392.62 68113 72 39 
L Total No. 
ur % 0.00 0.00 0.00 0.00 WA 0.00 57.04 21.14 11.55 0.00 3.27 100.00 52.88 14 95 , UZ 
33458.25 316932.94 6932,94 
9 
316932-84 
SID WA MA NIA VA N/A MA 2760941.51 804457.22 1003822.39 0.00 205190.19 3387014.31 117932.56 . 80293.60 120694 39 
0.12 
734 54 
10.56 100.00 100-00 1 00,00 SEM 0.00 0.00 0.00 0.00 NIA 0.00 976104.89 284418.58 354904.81 0.00 72545.69 1197490.39 41695.46 28381.07 . 42671 91 . 259 70 
13534.26 8 227 372.48 Cvv* WA MA VA NA NIA N/A 57.65 45.32, 64.46 NA 74,77 40.34 24.83 59. " . 62.0 . 65 64 
29533.82 80459.02 80459.02 
4 Mean 
H 
700239.03 2234500.31 274248.54 29372.71 43793.87 3282154.49 1104027.30 30180,15.15 2OS674.49 16271.84 35972.93 4379891.71 353850.41 IOSS128.94 305744 94 
. 
0 00 
88.27 25.39 
ours % 21-33 69.08 8.36 0 . 89 1.33 100.00 25.21 68.91 4.70 0.37 0.82 IDO. Oc 20.29 60.51 
. 
17.53 . 0 00 
29108.16 1743829.44 
SID 792376.86 2478295.46 142370.14 37246.48 54845.18 3396981.43 732801.76 1322155.21 245915.82 20020.13 34230.57 1764466.64 324057.49 1041321.01 708192 79 . 0 00 
1.67 100.00 
SEM 457478.99 1430844.55 12197.44 21504.26 31664.88 1955416.90 259084.55 467452.46 86944.37 7079.18 12102.34 623833.16 122492.21 393592.37 . 267671.71 . 0 00 
47810.55 2009 1 og. ii 
CV6/6 65.33 64.03 29.97 73.21 72.30 59.59 23.47 15.49 42.27 43.50 33.74 14.24 34.61 37.30 17.55 . #DIV/01 
11070.69 759371.99 
8 Mean 69509711 2900985.07 130031.21 264S. 09 36729.07 37SS493.66 933690.96 2407225.59 280537.69 0.00 51207.33 3672661.87 761389.24 3316596.541 149913.22 13279 02 
62.09, 43.35 
Hours % 11.24 7725 3.46 0.07 0.98 100.00 25.42 65.54 7.64 0.00 1.39 100.0c 17.75 77.34 3.47 . 0 31 
48344.10 4288421.12 
STD 49957L52 1236486.42 96070.34 4937.97 46410.29 1582495.03 987924.85 1260333.85 197595.56 0.00 113289.11 2227320.69 106976.49 2964756.92 262865 791 . 21650 39 
1.13 100.00 
SEM 176627.33 437163.97 33966.00 5 1745 . 84 16408.51 559496.49 397092.06 563638.43 88362.95 
0.00 50664.43 996088.09 403498.24 1482378.46 32 0 
: 1314 9 . 10825 20 
16553.71 365731 6.3c 
CVI/O 25.79 15.07 26.12 66.00 44.69 14.90 42.53 23.41 31.50 NIA 98.94 21.12 52.99 44.70 88.32 2 . 81 52 
43276. s5 112865 1 81 
16 mean 3063127.98 10519691. " 924925.63 164797.76 118299.60 14690732.95 $647994.94 IS182536.11 839487.18 0.00 0.00 21670008.13 667722.69 1694683.95 216806 02 
- 
74373 46 
19-52 42 
Hours % 20.85 71.61 561 1.12 0.81 100.00 26.06 70.06 3.97 0.00 0.00 100.0c 24.94 63.30 . 1.10 . 2 73 
23738.76 2677324 so 
STD 1094924.49 2924408. 9 0 699249.22 212893.19 107975.97 3825285.40 3658003.95 8653529.11 53923.34 0.00 0.00 11783564.34 272868.98 113771. io 230536.20 . 29106.74 
0.89 
61 33571 
100.00 
SEM 387114.27 ý 0 1033934 247221.93 75265.57 38175.27 1352442.64 2111949.57 4996117.36 31132.65 0.00 0.00 6803244.04 192947.50 10443.32 163014.13 20581.5g . 23738 76 
93424.1, 
CV% 12.64 9.83 29.97 
1 
45.67 32.27 
1 
9.21 37.39 32.91 3.71 NIA NDIV/01 31.39 28.90 4.75 75.19 27.67 . 00 100 
66061.3c 
I Mean 2499721.45 9439377.03 
1 
600711.49 90670.38 99473.21 12707953. $6 
1 
1673319.95 7136917.04 293312.93 52607.02 ISS63.04 9161719.79 3480SI. 29 792141.64 172718.17 26398.153 
. 
4399 74 
2.47 
Day % 19.66 74.28 4.73 0.63 0.70 100.00 18.26 77.90 3.09 0.57 0.17 100.00 25.90 51.93 12 15 12.15 1 15 1.96 . 0 33 
1343709.39 
STD 1269200.39 7359024.94 898214.64 140422.45 70507.62 9419937.21 945236.56 5072335.61 289605.93 76315.70 25081.66 5866211.61 407431.75 59171383 * 
: 0 370130.12 59028,92 . 15 9839 
100.00 
SEM 448730.10 2601808.13 317566.93 49646.83 24929.21 3330097.19 422722.64 2268417.41 129515.71 34129.42 11216.86 2623449.61 182209.02 47 264622. 0. 16594059 26393-53 . 4399 76 
1026658-97 
CW4 17.96 27.56 52.97 61.54 28.18 26-20 25.26 31.79 45.71 64.99 72.07 28.63 52.35 33.41 96.02 100.00 . 00 100 
459135. U 
3 Mean 2784981.99 1949364.23 6495647.27 6MS41.37 419692.76 17681197.62 2997763.60 1522400.01 713492437 * 89330S7.60 313169.36 20791311.14 
63176.36 186581.91 440662.93 1001007.93 
. 
76 4432 
34.17 
Days % 15.75 11.02 36.68 34.18 2.37 100.00 13.89 7.32 34 32 42.97 1.51 100.00 3.73 11.00 25.98 59.03 . 0 7A 
1695861.93 
SID 3835444.94 3095995.24 9664338.58 9903252.99 462146.33 23340435.41 4073160.89 1656747.33 5300516.87 5362673.69 403421.42 10029492.61 59127.20 364712.16 661427.69 1029420.33 . 5150.11 
100.00 
1722217 24 SEM 1715263 , 12 1394571.16 4322023.61 4428869.39 206678.12 10439160.04 166296097 676364.27 2163926.95 2189302.31 
164696.10 4094523.21 29563.6o 182356.08 334213.84 314710.17 2575. Os . 861108 6 CW4 61 59 71 06 66 64 73 28 OX 59 D4 57.58 44 43 30.33 24.51 52.59 19.69 46.8C 97.74 75.14 51.42 09 59 . . , . . . . . 50.7 
5 Mean 2809130.22 2722696.63 111519196.155 31399180.23 214414.83 49664626.46 3500094.43 914381.92 1291589S. 50 42585121.72 79450.16 59894943.73 1674062.08 199986.50 64S4443.91 24380197.30 103297.96 32811977 7s Days % 3.77 5.59 23.67 64.52 0.44 100.00 5.84 1.36 21.56 71.10 0.13 100.00 5.10 0.61 19.67 74.30 0.31 . 100.00 
SID 2738949.45 4433663.37 10135849.80 26508737.17 517821.25 42067573.90 4022830.31 730951.32 9576164.46 30897601.07 130775.65 39416209.86 2607257.09 278505.14 4848272.84 17849487.53 111210.84 24342945 43 
SEM 1119130.60 1810035.49 4137943.35 10922146.63 211399.64 17174015.13 1642313.60 298409.63 3909452.77 12613992.82 53388.93 16091600.29 1064401.24 113699.25 1979299.10 728702177 45401.64 . 9937965.86 
CV9/4 39.80 66.49' 35.92 34.47 
1 
98.59 35.291 46.92 36.64 30.27 29.62 67.2C 26.81 63.59 56.83 30.67 29. tq 43.96 30.2 
7 Mean 1280034.85 375756.88 5243468.78 17315439.79 42894.941 2445759S. 2S 2333113 2 1 1167869.85 14003229.91 35923816.48 232645.53 53560670.79 1277550.56 171638.70 239096%20 10463677.17 120992.63 14424826.2 
Days % 5.23 1.54, 21.44 71.62 0.1 1 100.00 6 4. 3 lit 26.14 66.88 0.43 100.00 1.86 1.19 16.58 72-54 0.14 100. 
SID 3010014.61 267494.19 6354399.50 12730216.57 66767.2A 21606162.63 5772936.49 1693684.35 16246549.54 19079497.10 282025.97 34471147.71 3275764.57 211529.3S 3409435.11 4173878.73 110897.84 6262467.05 
SEM 1229833.32 109204.05 2594168.65 519709915 27257.62 $920678.96 2181964.90 636372.87 6140618.53 7211368.29 106595.90 13028969.18 1238122.63 79950.38 1218267.38 1577577.1& 68372.96 2366990.06 
0 Cvv 96.00 29.06 49.47 29.67 63.55 36.07 93.52 54.49 43.85 20.13 45.82 24.33 
96.91 46.58 53.89 15.09 56.51 16.41 
14 Mean 359612 . 23 95574.92 1983071.39 14146004.12 104667.03 16578929. 
S9 5243388.35 343990.51 4373616.30 77546268.06 231047.87 87738211.09 102061.09 9556.78 23740532 258"89 71 422". 52 2974390.6 
Days % 2 2.17 0.52 11.36 85.33 0.63 100.00 5.98 0.39 4.98 88.33 0.26 100.00 3.43 0.32 7.99 86.19 1.42 100. 
STD F550183 3.07 4 100520.16 1676734.35 10606665.18 126475.38 11601712.98 13645999.81 449391.45 5857377.55 79718999.16 
458712.60 91979728.11 247698.75 22271.28 255398,64 1707790.10 88061.93 2124145.35 
SEM 306260.96 41037.18 684523.93 4330152.93 51633.36 4736379.49 515770313 , 169854.00 2213980.62 29752985.03 
173377.07 34765069.46 101118.51 9092.21 104266.06 697202.68 35951.13 167178.71 
Cvvf 85.16 47.95 36.35 30.61 49.33 29.57 7 9837 49.39 50.62 38.37 75.04 39.62 99.09 
95.14 43.92 26.98 85.04 29.15 
28 Mean 05 3916S3 46528 35 8OS942.74 10039512.65 29302,18 11312938.97 4580.66 40263.08 23SO059.71 24380540.38 147274.85 26922718.69 
0.00 6244.04 213699.37 88$1639.03 63138.63 6134721.09 
Days % . 346 
. 
0 41 7121 89.74 0.26 100.00 0.02 0.15 1.73 90.56 0.55 100.0c 
0.00 0.10 3.48 95.39 1.03 100. 
STD 10 642 44 0 
. 
74405 59 2 1180157: 1 7203316.94 39135.18 3 7822459.0 12956.07 1 1511.32 9098.63 49134.72 4499.52 49543.89 
0.00 347.79 1208.02 96051: 2 3 2013.44 95267.6 
SEM 8 
. 
3' 585 6 7 26 
. 
67 22122 50 446057 5 2722597.85 14413.741 2956611.61 4590.66 534.33 3213.32 17018.19 1590.47 17162.86 
0.00 131.45 3102.34 0 36306 6 761.01 36007. 
CvY* 96.66 . 60.44 
. 
5.35 5 27.12 49. 9 1 26.13 100.00 1.33 0.14 0.07 1.08 0.06 #DIV/01 
2.11 1.45 0 0.62 1.21 0.5 
42 Mean 695077.99 10 49406 43 646729 13215070.46 43529.62 14639912.59 1454686.84 1 136416.21 1094686.46 11493278.48 142628.52 14321696. S2 $69464.95 151430.89 
574958.14 7898778.19 46234.98 9239867.16 
Days % 69 4 
. 
33 0 
. 
42 4 
1 
90.27 0.30 100.0 0 10,16 0.95 7.64 80.25 1.00 100.00 6.15 1.64 6.22 15.49 0.50 100.00 
STD . 06 1292904 . 231 119570 . 81 1199%9 17139539.86 71154.69 19913763.65 1536070.48 225496.00 487632.24 5733094-53 31457002 6544820.75 631220.44 19694931 367112.79 46201 
7.4 84922.23 5542614.02 
SEM . 39 523743 . 10 48406 
. 62 499985 85 6997187 29049.78 7721511.69 
1 
590590,07 15229.48 184307.66 2166906.05 
1 
119996: 29 
1 
2473709.73 
1 , 
257694.66 76321: 33 
1 149873.17 1886151.13 34669.35 2262762.70 
CVV/s . 76.45 . 
1 
100. 
. 
75.75 
. 
52.95 66.73 52.75 39.91 6148 16.84 18.85 93.36 17.27 45.33 50 
26.07 23.88 74.99 24.49 
Table 3.13: Men uunjW total, oirgen ý? cs within pSAs. pM and jrG front 1 hon, to 42 days, togthm with nmn pmentages, Srt, SENfi and CV! /*. 
kjury 
-jur. Time 
In I ur 
. 
TIn 
77 
r 
Basophilic 
Cells 
I Eosinophilic 
Cells 
P Value 
Post Surgical Adhesion 
Nfacrophages Fibtoblasts L. %7Mhocyles I otal No. "t, Basophilic 
cells 
ýý)6nophiljc 
cells 
P Value 
Peritonea] Tissue Generation 
kinrophage., ý Fibroblaos I mq)hm % k, Ila-phill, 
Celk 
P Value 
I JIM ne I forn Tiss, 77G-encral ion 
urr 1-4 1-4 Hours 0.8670* 0.7790* 0.12 10 0.5397 0.5 350 7 100 0 0 3830 )()20* mmmý 
4-8 Hours 0.9700 0.5531 0.0802 0.1940* 0.8340 0.92 10** 0.8694 0.4350* 0.0653* 0.1710* 0.7240* 0.6220* 0.2137 0.1640 
: 
300 0: 2 1 
8-16 Hours <() 000 1 -0.0()()] 
1 
(). () 104 * 
1 
0.0207* 
1 
0.1610* 
1 
() ()()()2 ý, () 0316 0.1430* 
1 
()1 1.0000 0.3930* 0 () '11) 1 0.8713 0.8()()()** 0.5330* 
. 
0041 1 0 7302 
0.1221 
. 1.0000** 16 Hours-I Day 0.3571 0.7054 0.3280* 0.5050* 0.5237 0.5899 0.0518 0 1405 ý7 0.2916 0.3382 0.0852 0.38 10* 0.0982 0.38 10* 0 3810* 57 10* 0 . . . 0.1434 1-3 Days 0.5749 0.0295* 0.0062* 0.00" 1* 0.0932** 0.8330* 0.93 10* 0.0519** 0.0043* ()()4 0.1770* 0.0635* 1110* 110* 0.0685 0.7300* 0.7127 
3-5 Days 0.7999 1.0000* 0.5941 0.0876 0.0823* 0.2294 0.8180* 0.3608 0.2248 0, ()26()** 0.3940* 0.2400** 0.0667* 0.9140* ()1, )()* i () fj()oS** 0.6 lo()** 00 1,; 5-7 Days 0.1320* 0.3940* 0.2270 0.2734 0.8180* 0.2374 0.2950* 0.6441 0.8885 0.6384 0.2489 0.7628 0.18 10* 0.8490 0.0916 0.0734** 0.8360* (). I () I ()* * 
7-14 Days 0.9370* 0.0 3) 21 0,2400* 0.6292 0.3940* 0.4496 0.7100* 0.2348 0.0728* 0.1280* 0.7100* 0.5350* 0.4450* 0.0904 ()()()471 () ()() 1. ) ý* 0.3660* () (M ýI 14-28 Days 0.5340* 0.6280* 0.4450* 0.4252 0.1596 0.3513 0.2810* 0.1890* 0.0939* o () 14W 0.8670* (ý( 
)( 1ý ? ', 4 0.3660* 0.6280* 0.73 10* 0.3900 0.8360* 0.4311 
1 28-42 Days 0.4450* 0.6280* 1.0000* 0.3704 1 0.9450* 1 0.3616 0.0939* 0.6130* 
. 
0.2320* 0.5360* 0.8670* 1 0.2810* 1 0.1380* 1 0.2340* (). 0888 
ý 
0.1380* 0.9450* 0.1380* 
Table 3.14: T test analysis comparing number totals of cell types with PSAs. PTG and UTG between concurrent time points 
P Value P Value P Value 
Injury lnjurý PSA VS PIU PSA VS UIU (3 vs 
Time Time Basophilic Eosinophilic 'Macrophages Fibroblasts Lv"bocvtes Total No. Basophilic lophilic Eosit Nvlacrophages Fibroblasts LNuphocyles lotal No flam)phili, Vo, mophili, 
I Ma, ropfmg- Fibrohla, t, 1,. %wph., ) lotal \o, 
Cell's Cells 
I 
Cells c Cells IN 
Hour 0 830* 3 0.5350* 
4 Hours 0.4448 0.5009 0.4970* 0.4570 
1 
0.7752 
1 1 
0.4855 0.3314 0.2972 0.1830* 0,1170* 
1 
0.5170* 
1 
0.3854 
1 
ý) o2w) () ()() 0.12 10* 0: 1 210: 0.5360* (). () 1-4 (ý 
8 Hours 0.1786 0.6220* 
1 
o. 0074 
1 
0.5240* 0.8330* 0.1555 0.8312 0.9330** 0.2830* 0.5700* 0.6830* 0.8080** 0.4235 0.7300* 0.1970 0.2860 1.0()()()* 
1 
0.4479 
1 
16 Hours 0,4970** 0.3760** 0.9728 0.0848* 0.0848* 0.4970** 00 0.2769 0.5820 0.2734 0,00 
0.1656 0.1276 0.2000* 0.0167 
I 
0.2722 0.1193 
I Day 0.2386 0.5542 0.4350* 0.6220* 0.0505 0.4696 1) ou4o 000 16* 0.0653* 0.2220* (), ()-)44 (Qwý ()15()* 0.1510* 0,6900* 0.6900* 
3 Days 0.7920* 0.7920* 0.8207 0.4290* 0.4290* 0.9545 (), M io* 0.0635* 0.0 1 ý9* 0.0635* 0.1037 
() () ', 17 0.0667* 0.1580 () ()()') ý; I () (1, W) 0.2570* 0 001) 
5 Days 0.7369 0.8180* 0.8109 0.5157 0.8180* 0.6430 0.5092 0-0931* 0.2888 0.5925 0.4850* 
0.4336 0.3940* 0.0874 0.1658 0.2310 0.8180* 0.1746 
7 Days 0.5340* 0.3660* 0.2423 0.0715 0.1378 () 03 5 () * 0.9450* 0.1524 0.2950* 0.1920 0.5340* 
0.2629 0.5350* 0.0728* () () 175* () 00) "* 0.3953 () 00 12* 
14 Days 0.9450* 0,1978 0.4450* (). 0047* 0.7310* (), ()02.1* 0.5890* 0.1006 0.1320* 0.0931** 
0.3448 0.0649** 0.73 10* 0.2340* 0022 14 f) 0.6280* 
28 Days 0 5360* 0.9550* 0,7790* 1.0000* 0.9550* 1.0000* 0.3830* 0.3830* 0.1650* 0.3475 
0,9020* 0.2790 0.6940* 0,4630* () ()4(11 ý 0.0939* 0.8670* 0.072 1 
42 Days . 0.5111 0.4450* 0.9072 0.4731 1 1.0000* 1 0.5879 1 0.5560 1 0.3 100* 1 0.4322 1 0.2445 
1.0000* 1 0.6990** 1 0.4450** 1 0.9450* 1 0.0558 1 0.2447 1 1.0000* 1 (). 1()3() 
Table 3.15: T test analvSis of comparing number totals of cell tvpes present within tissue zones 
from I hour to 42 days post in . un'. 
Cell Type Morphology Diameter Mean 95% 95% % of 
(AM) Number Lower Upper WBC 
(1 109/1) 
_(X 
10, A) (I 10, A) Total 
Erythrocytes Anuclear, stained pink. 6.7-6.9 ' 5.35 x 4.23 6.47 
101/1 x 101/1 x 10111 
Platelets A group of reddish-violet granules 1-3 342 151 533 
surrounded by pale blue cytoplasm. 
White Blood 7.7* 4.4 13.4 100 
Cells 
Neutrophils Nucleus is segmented stains a deep 10-15 1.9* 0.6 5.8 25 
purple-blue colour; segments are 
connected by fine strands of 
chromatin. 
Cytoplasm is almost colourless and 
contains two types of granules: the 
smallest granules stain a pink colour, 
giving the cytoplasm an overall 
pinkish colour, the second types stain 
a deep pinkish-red colour and are 
quite large. 
Eosinophils Nucleus stains a deep-purple colour 12-16 0 0 0.2 0 
and maybe bilobed or horseshoe 
shaped. 
Cytoplasm is completely filled with 
large granules which have a foamy 
appear and stain a dull pinky-orange 
colour 
Lymphocytes Nucleus is round or oval which may Small: 4.9* 2.6 9.2 64 
have a slight indention on one side 7-10 
and stains a deep purple-blue colour. Large: 
Cytoplasm, stains medium to deep 10-15 
blue, of the small lymphocyte forms 
only a narrow rim around the nucleus 
and may appear to be almost non- 
existent, whereas large lymphocytes 
have more abundant cytoplasm. 
Monocytes Nucleus may be lobulatcd, horseshoe- 15-18 0.4 0 0.9 5 
shaped or bean-shaped and stains a 
purpic-blue colour with a lace-like or 
stringy appearance. 
Cytoplasm is plentiful and stains a 
grey-blue colour with a mottled 
appearance. 
Basophils Nucleus is usually obscured by the 10-15 0.3 0.0 0.7 4 
granules in the cytoplasm but when 
visible stains a purple-blue colour and 
may be a band form or segmented 
structure. 
Cytoplasm stains a pale grey-blue 
colour and is filled with large purple- 
black granules which overlay the 
nucleus. 
Table 3.16: Rabbit blood cell cletails 
I (Adapted from Sanderson & Phillips, 198 1). log transform 
I 10,1/1 i 
Cell Type Mean SID SEM CV% 
Blood Sample I 
R BCs (x I 0'/1) 5.31 0.65 0.08 1.51 
Platelets 323.92 144.82 18.39 5.68 
WBCs 6.62 2.59 0.33 4.98 
Basophilic Cells 0.11 0.11 0.03 23.62 
Lymphocytes 3.28 1.40 0.34 10.34 
Monocytes 0.42 0.21 0.05 11.82 
Eosinophilic Cells 2.18 0.75 0.18 8.37 
Blood Sample 2 
RBC s (x I 0'/1) 5.27 0.78 0.10 1.90 
Platelets 272.52 143.73 18.56 6.81 
WBCs 6.00 2.30 0.30 5.00 
Basophilic Cells 0.02 0.03 0.01 40.57 
Lymphocytes 3.13 1.45 0.35 11.24 
Monocytes 0.51 0.46 0.11 21.82 
Eosinophilic Cells 2.63 1.56 0.38 14.44 
Blood Sample 3 
RBCs (X 103/1) 4.99 0.61 0.08 1.60 
Platelets 311.31 158.53 20.64 6.63 
WBCs 5.96 3.23 0.42 7.06 
Basophilic Cells 0.08 0.15 0.02 24.22 
Lymphocytes 2.39 1.35 1.18 7.35 
Monocytes 0.30 0.28 0.04 11.86 
JEosinophilic Cells 3.19 2.52 0.33 10.31 
Table 3.17: Mean numbers for full and differential blood cell counts for 
blood samples 1,2 and 3 together with STD, SEM and CV%. 
Basophilic Lymphocytes Macrophages Eosinophilic WBCs RBCs Platelets 
Cells Cells 
Blood sample I vs 2 0,0083, 0.7652 0.7570* 0.2901 0.2689 0.6630* 0.13 10* 
Blood sample I vs 3 0.1010* 0.0 164* 0.0 159* 0.3470* 0.0975* (), 0064 * ()o I ', 7* 
Blood sample 2 vs 31 0.0658* 1 00415* 0.0292* 1 0.7743* 1 0.4360* 1 o. ()()31* 1 0.1683 
Table 3.18: T test analysis of full and differential blood cell counts for blood samples 1,2 and 3. 
*= normality test failed; Mann Whitney rank sum test ran. 
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Sample 
Time 
Blood 
Sample I 
Blood 
Sample 2 
Control 
Blood 
Sample 3 
Peritoneal 
Sample I 
Control 
Peritoncal 
Sample 2 
1 Hour 3617.14 
4 Hours 2845.71 
8 Hours 6411.43 
16 Hours 2794.29 
I Day 4191.43 
3 Days 12257.14 
5 Days 2211.43 3171.43 
7 Days 6265.71 6565.71 
14 Days 2400.00 3171.43 
28 Days 4834.29 1705.71 
42 Days 3522.86 
Mean 4568.57 2997.14 - 1740.00 
STD 2877.51 696.05 193.95 
SEM , 1661.33 401.86 137.14 
%1 
E 
C 36.36 13.41 7.88 
Table 3.20: TGF-P concentrations within plasma and peritoneal fluid samples. 
APPENDIX IV 
Injury 
Tifirne 
ý Mm 
Adhesion Tissue Generation 
Peritoneal Uterine Free Total 
Hom Floating 
DaMR20 Zone 
Peritoneal Uterine 
Hom 
Peritoneal 
Reaction 
Zone 
Peritoneal 
Coll Cono 
Uterine 
Hom 
Hemorrhage 
Fibrin 
Sealant 
Remaining 
F/Sealant 
Associated 
Coll Cone. 
I IIOU R ;= 0. (w 4.50 0.37 0.00 4.88-aaa am ý1726 4.14 9.15 0.00 2.27 
mma`779ý. 04 0.00 
STD 0.00 1.99 0.38 0.00 1.92 2.52 0.99 1.98 0.00 1.80 12.97 0.00 
SEM 0.00 0.67 0.13 0.00 0.68 0.89 0.35 0.70 0.00 0.64 4.55 0.00 
O/OCV N/A 14.87 35.69 N/A 13.93 5.17 8.45 7.67 N/A 29.04 5.76 N/A 
4 HOURS MEAN 0.00 7.98 1.20 0.00 9.09 17.11 6.23 19.96 0.10 0. " 50.66 0.00 
STD 0.00 2.70 1.46 0.00 2.90 7.90 3.99 5.28 0.28 0.84 11.37 0.00 
SEM 0.00 0.96- 0.51 0.00 1.02 2.79 1.41 1.87 0.10 0.30 4.02 0.00 
O/QCV N/A 12.14 42.86 N/A 11.29 16.32 22.63 9.35 100.00 29.98 7.93 N/A 
8HOURS MEAN 0.00 15.29 3.30 0.00 19.59 14.31 7.95 32.77 0.00 0.65 41.64 0.10 
STD 0.00 8.91 2.15 0.00 8.26 3.75 2.99 7.54 0.00 0.49 14.62 0.28 
SEM 0.00 3.15 0.76 0.00 2.92 1.33 1.06 2.67 0.00 0.17 5.17 0.10 
*/OCV N/A 20.59 23.04 N/A 15.72 9.28 13.47 8.14 N/A 26.61 12.41 100.00 
16 HOURS MEAN 0.00 12.14 5.99 0. (W 19.13 11.29 7.63 29.82 0.24 1.64 32.20 0.21 
STD 0.00 4.83 1.95 0.00 6.17 3.91 2.86 9.06 0.69 2.90 9.23 0.55 
SEM 0.00 1.71 0.65 0.00 2.18 1.39 1.01 3.20 0.24 1.02 2.91 0.19 
O/OCV N/A 14.08 10.89 N/A 12.03 12.25 13.26 11.12 100.00 62.51 9.03 93.16 
1 DAY MEAN 0.00 29.55 13.00 0.00 42.55 21.16 14.56 58.41 0.00 0.36 45.73 0.29 
STD 0.00 9.24 6.31 0.00 12.40 10.63 7.73 23.97 0.00 0.49 16.23 0.58 
SEM 0.00 3.27 2.23 0.00 4.39 3.76 2.73 8.48 0.00 0.17 5.74 0.21 
O/QCV N/A 11.06 17.16 N/A 10.31 17.76 18.76 14.51 N/A 46.44 12.54 70.15 
3 DAYS MEAN 0.00 29.67 3.13 0.00 31.80 34.74 2.14 23.11 0.09 0.00 43.44 37.12 
STD 0.00 6.77 1.26 0.00 7.67 15.82 1.23 7.30 0.27 0.00 9.99 17.06 
SEM 0.00 2.39 0.44 0.00 2.71 5.59 0.44 2.59 0.09 0.00 3.53 6.03 
O/OCV N/A 8.35 14.20 N/A 8.53 16.11 20.36 11.17 100.00 N/A 9.13 16.25 
5 DAYS MEAN 0.00 71.32 5.52 0.14 76.99 44.03 1.21 46.59 3.71 0.07 42.35 47.20 
STD 0.00 30.41 2.65 0.39 30.32 19.33 1.06 19.06 5.09 0.12 16.34 34.91 
SEM 0.00 10.75 0.94 0.14 10.72 6.93 0.38 6.74 1.80 0.04 5.78 12.34 
O/QCV N/A 15.08 16.97 100.00 13.93 15.52 31.10 14.47 48.40 65.47 13.64 26.16 
7 DAYS MEAN 0.00 76.08 7.12 1.30 84.50 32.33 , 0.81 45.59 1.70 0.00 19.77 34.89 
STD 0.00 30.17 3.23 1.92 32.54 6.64 0.88 9.34 1.40 0.00 9.96 8.28 
SEM 0.00 10.67 1.14 0.69 11.50 2.35 0.31 3.30 0.49 0.00 3.49 2.93 
O/QCV N/A 14.02 16.02 52.16 13.61 7.26 38.65 7.24 29.09 N/A 19.59 9.40 
14 DAYS MEAN 0.00 57.63 3.14 0.55 602 14.79 0.57 18.24 0.02 0. (W 0.92 3.73 
SID 0.00 17.37 3.91 0.77 19.55 6.48 0.99 6.59 0.07 0.00 0.91 2.99 
SEM 0.00 6.14 1.38 0.27 6.91 2.29 0.35 2.33 0.02 0.00 0.32 1.05 
0/0CV N/A 10.65 44.03 49.22 11.27 15.51 60.86 12.77 100.00 N/A 35.03 28.27 
29 DAYS MEAN 4.71 43.65 5.24 0.00 53.61 10.19 0.45 20.56 0.00 0.00 2.97 5.44 
STD 11.83 16.64 3.65 0.00 11.01 2.91 0.93 9.14 0.00 0.00 5.46 8.02 
SEM 4.18 5.89 1.29 0.00 3.89 1.03 0.33 3.23 0.00 0.00 1.93 2.94 
0/0CV 88.75 13.47 24.65 N/A 7.26 10.11 72.32 15.72 N/A N/A 64.96 52.15 
42 DAYS MEAN 0.00 37.45 4.16 0.71 42.32 6.46 0.42 15.05 0.00 0.00 0.00 0.00 
STD 0.00 16.56 3.52 1.75 17.93 4.56 0.78 7.78 0.00 0.00 0.00 0.00 
SEM 0.00 5.86 1.24 0.62 6.30 1.61 0.27 2.75 0.00 0.00 0.00 0100 
O/OCV N/A 1 15.64 1 29.92 1 86.91 14.90 24.98 65.53 1 19.29 N/A N/A N/A N/A 
Table 4.1: Volumes of tissue zones, together with standard derivation, standard error of the mean and percentage cocfficient of variation. 
I'VAUJI, 
Injur)l I issue Generaficin Damage Zone Pentoneal Periloncal I JtCline I- ibrin I /Scalant 
Time PSA Pentoneal Ulenne Total PeriloneA Uterine Reaclion Cell Coot: lion) Scalmil As%ocialcd 
I lom I lom Anic I laemortimpt: RcillaIIIIII). Cell Conc 
I fir-4 [Irs 1.0000 0.1418 0.8780** 0.5050** 0.7210* 0.0913 1.0000 
4 Hrs -8 IIrs 1.0000 0-0650* 00 1"N ; 0.5740** 0.3730 0.7210* 0.3311 0,1997 0.7210* 
8 Hrs - 16 [Irs 1.0000 0.3946 (H) I -- 0.9024 0.1377 0.8818 0.3594 0.7210* 0.7980* 0.1339 0.72 10* 
16 Hrs -I Day 1.0000 0.0003 001-1)" 00002 0028.1" 0012l 000'o 0.7210* 0.8780* 0.0540 0.9590* 
I Day -3 Days 1.0000 0.8310 0 00 19, 0.0560 0.0636 0,0006" 0001 1 0.7210* 0.1050* 0.7385 mmw- 
3 Days -5 Days 1.0000 Oý0104** OM3W) 00011 0.2340* 0.1288 oo()70** 0.0650* 0.4420* 0.8745 0.4754 
5 Days -7 Days 1.0000 0.7581 0.16 10* 0.6400 0.1050** 0.4243 0.8968 0.2981 0.4420* 0 00 1(, 0.72 10* 
7 Days - 14 Days 1.0000 0.1560 0.0 104* 0.1060 0 00M 0.1300* 0,000 1 0 00 19, 1.0000 0,0002 " 0.00(i ,,, 
14 Days - 28 Days 0.4420* 0.1225 0.1950* 0.3476 0.0891 0.2340* 0.5696 0.72 10* 1.0000 0.8780* 0.5802 
28 Days - 42 Days 1 0.4420* 1 0.4668 1 0.5563 1 0.1498 1 0.0718 1 11.0000* 1 0.2152 1 1.0000 1 1.0000 1 0.1050* 1 0.1050* 
Table 4.2: T test analysis between concurrent time points. *= Normality Test Failed; Mann-Whitney 
Rank Sum Test Ran; ** = Equal Variance Test Failed; Mann-Whitney Rank Sum Test Ran. 
,a 
Injury 
Time 
PSA Peritoneal 
Tissue 
Generation 
Uterine Hom 
Tissue Generation 
Free Floating 
Tissue Generation 
Total 
Tissue Generation 
Percentage 
Fibrin Collagen Fibrin Collage Fibrin Collagen Fibrin Collagen Fibrin Collagen Fibrin Collagen 
n 
I Hour MEAN 0.00 0.00 1.32 0.00 0.59 0.00 0.00 0.00 1.91 0.00 100.00 0.00 
STI) 0.00 0.00 1.27 0.00 0.49 0.00 0.00 0.00 1.37 0.00 0.00 0.00 
SEM 0.00 0.00 0.45 0.00 0.17 0.00 0.00 0.00 0.48 0.00 0.00 0.00 
%CV N/A N/A 33-89 N/A 29.35 N/A N/A N/A 25.39 N/A 0.00 N/A 
41fours MEAN 0.00 0.00 1.39 0.00 0.73 0.00 0.00 0.00 2.12 0.00 100.00 0.00 
STD 0.00 0.00 0.65 0.00 0.73 0.00 0.00 0.00 0.89 0.00 0.00 0.00 
SEM 0.00 0.00 0.23 0.00 0.26 0.00 0.00 0.00 0.31 0.00 0.00 0.00 
%CV N/A N/A 16.60 N/A 35.38 N/A N/A N/A 14.83 N/A 0.00 N/A 
811ours MEAN 0.00 0.00 2.06 0.00 0.95 0.00 0.00 0.00 3.01 0.00 100.00 0.00 
STD 0.00 0.00 0.72 0.00 1.03 0.00 0.00 0.00 1.50 0.00 0.00 0.00 
SEM 0.00 0.00 0.25 0.00 0.36 0.00 0.00 0.00 0.53 0.00 0.00 0.00 
%CV N/A N/A 12.28 N/A 38.30 N/A N/A N/A 17.70 N/A 0.00 N/A 
161fours MEAN 0.00 0.00 3.02 0.00 1.41 0.00 0.00 0.00 4.43 0.00 100.00 0.00 
STD 0.00 0.00 4.11 0.00 0.96 0.00 0.00 0.00 4.99 0.00 0.00 0.00 
SEM 0.00 0.00 1.45 0.00 0.34 0.00 0.00 0.00 1.76 0.00 0.00 0.00 
%CV N/A N/A 48.11 N/A 24.10 N/A N/A N/A 39.76 N/A 0.00 N/A 
I Day MEAN 0.00 0.00 9.59 0.25 4.78 0.00 0.00 0.00 14.37 0.25 98.54 1.46 
STD 0.00 0.00 7.47 0.28 2.60 0.00 0.00 0.00 5.89 0.28 1.15 1.15 
SEM 0.00 0.00 2.64 0.10 0.92 0.00 0.00 0.00 2.08 0.10 0.41 0.41 
%CV N/A N/A 27.56 40.09 19.21 N/A N/A N/A 14.48 40.09 0.41 27.89 
3 Days MEAN 0.00 0.00 5.95 0.23 1.16 0.03 0.00 0.00 7.11 0.26 96.64 3.36 
STD 0.00 0.00 2.38 0.18 0.23 0.05 0.00 0.00 2.34 0.19 1.97 1.97 
SEM 0.00 0.00 0.84 0.06 0.08 0.02 0.00 0.00 0.83 0.07 0.70 0.70 
%CV N/A N/A 14.11 28.18 7.08 55.01 N/A N/A 11.63 25.20 0.72 20.70 
5Days MEAN 0.00 0.00 1.96 28.95 0.37 3.13 0.04 0.05 2.36 32.13 8.81 91.19 
STI) 0.00 0.00 2.07 16.77 0.29 1.24 0.10 0.14 2.17 16.91 7.69 7.69 
SEM 0.00 0.00 0.73 5.93 0.10 0.44 0.04 0.05 0.77 5.98 2.72 2.72 
%CV N/A N/A 37.41 20.48 27.64 14.05 100.00 100.00 32.51 18.61 30.83 2.98 
7Days MEAN 0.00 0.00 0.50 43.88 0.24 5.31 0.00 0.50 0.74 49.69 1.42 98.58 
STD 0.00 0.00 0.46 18.66 0.16 2.07 0.00 0.40 0.44 18.94 0.60 0.60 
SEM 0.00 0.00 0.16 6.60 0.06 0.73 0.00 0.14 0.16 6.70 0.21 0.21 
%CV N/A N/A 32.50 15.04 23.89 13.80 N/A 28.05 20.90 13.48 14.86 0.21 
14Days MEAN 0.00 0.00 0.00 27.15 0.00 2.42 0.00 0.17 0.00 29.74 0.00 100.00 
STD 0.00 0.00 0.00 7.89 0.00 3.01 0.00 0.31 0.00 9.79 0.00 0.00 
SEM 0.00' 0.00 0.00 2.79 0.00 1.06 0.00 0.11 0.00 3.46 0.00 0.00 
%CV N/A N/A N/A 10.28 N/A 44.03 N/A 63.51 N/A 11.64 N/A 0.00 
28Days MEAN 0.00 4.08 0.14 30.65 0.03 3.73 0.00 0.00 0.17 38.47 0.46 99.54 
STD 0.00 10.01 0.18 11.34 0.07 2.37 0.00 0.00 0.23 10.11 0.66 0.66 
SEM 0.00 3.54 0.06 4.01 0.03 0.84 0,00 0.00 0.08 3.57 0.23 0.23 
%CV N/A 86.61 46.36 13.08 100.00 22.48 N/A N/A 48.25 9.29 51.17 0.24 
42Days MEAN 0.00 0.00 0.00 32.03 0.00 3.58 0.00 0.12 0.00 35.73 0.00 100-00 
STD 0.00 0.00 0.00 19.41 0.00 2.13 0.00 0.17 0.00 19.41 0.00 0.00 
SEM 0.00 0.00 0.00 6.86 0.00 0.75 0.00 0.06 0.00 6.86 0.00 0.00 
%CV I N/A I N/A I N/A 1 21.42 1 N/A 1 21.05 1 N/A 52.67 1 N/A 1 19.21 1 N/A f 0.00 
Table 4.3: Mean volumes and percentages of fibrin and collagcn, together with SD, SEM and %CV. 
k 
P VALUE 
Injury Total Percentage 
Time Tissue Generation 
Fibrin Collagen Fibrin Collagen 
I Hour -4 Hours 0.7188 1.0000 1.0000 1.0000 
4 Hours -8 Hours 0.1744 1.0000 1.0000 1.0000 
8 Hours - 16 Hours 0.72 10* 1.0000 1.0000 1.0000 
16 Hours - 24 Hours 0.00-30* (). 0 () I () * 0 ()()1()* () 00 1 1) 
24 Hours -3 Days 0.070** 0.9093 0.0830* 0.0830* 
3 Days -5 Days 0.0009 (YO00-11 () ()002** () 000ý1 
5 Days -7 Days 0.0207* 0.0707 0.0148* (A 148 
7 Days - 14 Days 0.0002* (). () I C) -1 (YO002* 0000 - 
"I 
14 Days - 28 Days 0.1050* 0.1011 0.1050* 0.1050* 
28 Days - 42 Days 0.1050* 0.7283 0.1050* 0.1050* 
Table 4A T Test analysis of fibrin and collagen volumes and percentages. 
Normality Test Failed; Mann-Whitney Rank Sum Test Ran. 
= Equal Variance Test Failed; Mann-Whitney Rank Sum Test Ran. 
Injury P VALUE 
Time PSA vs PTG PSA vs UTG PTG vs UTG 
I Hour - - - 
4 Hours - - - 
8 Hours - - - 
16 Hours - - - 
24 Hours - - 0.00 18()* 
3 Days - - 0.234** 
5 Days - - 0.5945 
7 Days - - Oý0104*1 
14 Days - - - 
28 Days 0.400* 0.889* 0.328* 
42 Days - - 
Table 4.5: T Test analysis comparing percentages of fibrin and collagen between tissue zones. 
Normality Test Failed; Mann-Whitney Rank Sum Test Ran. 
= Equal Variance Test Failed; Mann-Whitney Rank Sum Test Ran. 
Injury Post Surgical Adhesion 
Time Basophilic Eosinophilic Macrophages Fibroblasts Lymphocytes Total 
Cells Cells Number 
Number 28 Days Mean 0.00 12500.00 133333.33 308333.33 0.00 454166.67 
Density STI) N/A N/A N/A N/A N/A NIA 
SEM N/A N/A N/A N/A N/A N/A 
CV% N/A N/A N/A N/A N/A N/A 
% 0.00 2.75 29.36 67.89 0.00 100.00 
Number of Mean 0.00 422497.56 4506640.63 10421606.45 0.00 15350744.63 
Total STI) N/A N/A N/A N/A N/A N/A 
SEM N/A N/A N/A N/A N/A N/A 
CV% N/A I N/A N/ A N/A N/A N/A 
% 0.00 2.75 29.36 
J 
67.89 0.00 100.00 
Table 4.6: Mean number density and total for cell types within PSAs. 
Injury Peritoneal Tissue Generation Uterine Horn Tissue Gen ion Fibrin Sealant Associated Cell Concentratio Time Basophillo Eosinophilic Macrophages Fibroblasts Lymphoc Basophillo I! oslnophlllo Macrophages Flbroblasts Lymphocytes Total No. Basophillo Eoslnophlllc Macrophages FIbroblests Lymphocyte Total No. Cells 
"Neeleael7a 
Cells 
I Cells Cells Cells 
Cells 
I 
Hour 
Mean 
STD 
4924.91 
5710 34 
6142J3 8709.11 roo 3403.08 23179.43 0.00 2=319.62 17832.65 0.00 49382.72 90534-98 
SEM . 
10295.82 7919.41 0.00 3741.55 18157.79 0.00 20299.93 18556.58 0.00 85533.37 51399.16 
CVO/ 
2018.91 3640.12 2799.59 0.00 1322.84 6419.75 0.00 11720.17 10713.65 0.00 49382.72 29675.32 9 
% 
40.99 59.26 32.15 NIA 38.87 27.70 N/A 50.26 60.08 NIA 100.00 32.78 21.25 26.50 37.57 0.00 14.68 100.00 0.00 25 76 19 70 0.00 54.55 100.00 4 
Hours 
Mean 
STD, 
14534.09 81086.75 11524.15 0.00 4060.81 111205.79 10934.74 
. 
103556.73 
. 
21575.54 0.00 16813.64 152880.66 
SEM 
11431.33 35050.37 9056-56 0.00 3878.39 47054.75 19106.44 100436.31 16260.54 0.00 27560.17 112375.38 
CVO/ 
4041.59 12392.18 3201.98 0.00 1371-22 16636.37 7221.55 37961.36 6145.91 0.00 10416.76 42473.90 
O 
% 
27.91 15.28 27.78 N/A 33.77 14.96 66.04 36.66 28.49 NIA 61.95 27.78 13.07 72.92 10.36 0.00 3.65 100.00 7.15 67.74 11 14 0.00 11.00 100.00 9 
Hours 
Mean 
STD 
7308.92 
10211 oi 
160574.75 17540-94 0.00 3956.91 199391.42 7485.60 150107.95 
. 
9617.53 0.00 10035.95 177247.03 
SEM . 3610 14 
86453.93 11199.36 0.00 3863.77 84553.60 9351.80 70668.60 8273.05 0.00 9952.05 75975.27 
CV% . 
30566.08 395957 ' 0.00 1366.05 29894.21 3534.65 26710.22 3126.92 0.00 3761.52 28715.95 49.39 19.04 22 57 N/A A 34.52 15.79 47.22 17.79 32.51 N/A /A 3748 43 16.20 3.86 84.79 9.26 26 0.00 ýO 2.09 100.00 4.22 84.69 5.43 0.00 00 . 66 
66 5 100.00 
16 
H 
Mean 0-00ý 241"2.61 37320-32 2 15344.66 56 219941 * 
1 296517.01 0001 ' 164427.99 35099.561 29656.96 86 Is 333119 232519.60 ours STD 0.00 64758.06 8 21341.58 5433.65 ,5 3243 57 ' 73946.58 
ýO 
0. 48 3 8920 03 21612 08 U 13102 93 19 3291.19 43474.59 SEM 0.00 22895.433 7545.39 9 9 1921.09 1146. 78 8 26144.061 0.00 0 . 17295 84 4 
. 
7641.02 
. 4632.58 8 1160.08 3 15370-59 9 CVO/Q N/A 7 9,47 2022 2 12*52 2 52.38 8 8.82 2 '2 NIA . 10.52 2 21.77 7 15.62 2 FS 34.78 6.61 61 % 0.00 50 810 1 12 9 59 7 5,17 4 0.74 0 100.0 0 0.00 70.72 2 0 15.10 5 12.75 ý3 1.43 100.00 00 
Mean 231.48 196782 . 82 49715.12 16033.14 991.56 263644.13 3 440.92 127503.40 65311.01 39089. (W 2087.05 234431.37 7 3 Day STD 654.73 S 61059.76 23912.69 I 8780.23 1307.21 79422.34 4 1247.10 11961.63 25838.97 7 5130.22 2 1776.06 6 35658.40 40 
SEM 231.48 21587.88 8454.41 3104.28 462.17 28080.04 440,92 4229108 9135.45 1813.81 627.933 12607.15 
CVO/O 100.00 10.97 17.01 1936 52.43 
J 
10.65 100.00 3.32 13 * 
99 0 4.64 30.09 g 5.39 
% 0.09 I 74.64 18.86 6.08 0.33 100.00 0.19 54.39 27.86 F 16.67 0 0.89 )0 100.00 
3 Mean 
1 
803.76 36393.68 137353.04 115470.90 0.00 290021.28, 0.00 135931.86 164442.48 1 160155.79 1 0.00 4 460430.1 1736.11 329890.09 656092.69 216360.55 0-00 1204079.43 
1 
Days STD 1564.12 29265.83 51413.55 42364.77 0.00 93146.79 0.00 228419-95 84456.92 85409.74 0.00 241039.46 4910.46 195095.66 113461.61 51473.86 0.00 143210.69 
1 1 
SEM 553.00 10347.03 18177.44 14978.21 0.00 32932.36 0.00 93252.06' 34479.35 34867.97 0.00 99403.95 40114.74 18198.76 65441.20 1736.11 0.00 50632.62 
CVO/O 68.90 28.43 13.23 12.97 N/A 11.36 N/A 68-65 20.97 21.77 NIA 21.37 100.00 19.84 6.11 9.41 NIA 4.21 
% 0.28 12.55 47.36 39.91 0.00 100.00 0.00 29-50 35.71 34.78 0.00 100.00 0.14 27.40 54.49 
17.97 0.00 100.00 
5 Mean 429.55 9169.92 201419.67 246999.51 1499.10 459505.75 1302.08 9242.24 161930.24 343100.65 744.05 516319.26 1135.54 11974.43 406045.04 261694.42 4659.43 685498.96 
Days STD 1214.96 5469.34 46531.43 39493.31 4208.97 85144.86 3682.85 14076.15 41833.89 66729.39 2104.48 95148.86 2132.55 12014.02 92763.89 83377.38 5305.39 145070.32 
SEM 429.55 1933.70 16451.35 13962.99 1488.10 30103.26 1302.08 4976.67 14790.51 23592.40 744.05 33640.20 753.97 4247.60 29261.45 29479.36 1975.74 51290.10 
CVO/O 100.00 21.09 8.17 5.65 100.00 6.55 100.00 53.85 9.13 6.88 100.00 6.52 66.40 35.47 7.21 11.26 40.26 7.48 
% 0.09 2.00 43.83 53.75 0.32 100.00 0.25 1.79 31.36 66.45 0.14 100.00 0.17 1.75 59.23 38.17 0.68 100.00 
7 Mean 165.34 32064.47 109124.48 152644.39 330.69 294329.37 - 0.00 7559.09 135138.14 169309-62 0.00 312006.85 0.00 483655.75 479985.12 
307093.25 0.00 1270734.13 
Days STD 467.66 23118.36 28522.99 39052.20 935.33 56814.55 0.00 4467.31 42231.90 36878.24 0.00 71654.71 0.00 155263-95 123414.13 37746.68 0.00 102189.02 
SEM 165.34 8173.58 10084.40 13807.04 330.69 20086.98 0.00 1689.49 15962.16 13939.66 0.00 27082.94 0,00 54894.10 43633.48 13345.47 0.00 36128.92 
CVO/O 100.00 25.49 9.24 9.05 100.00 6.82 N/A 22.34 11.81 9.23 NIA 8.68 NIA 11.35 9.09 
4.35 NIA 2.84 
% 0.06 10.89 37.08 51.86 0.11 100.00 0.00 2.42 43.31 54.26 0.00 100.00 0.00 38.06 37.77 24.17 0.00 100.00 
14 Mean 14661.42 42565.59 102746.12 251149.57 3559.48 414691.19 1 7390.15 0.00 94315.50 249464.24 2351.56 352521.45 
Days STD 37063.03 19605.07 68950.25 96524.60 4823.27 197316.49 41437.12 0.00 56846.91 94460.14 6221.64 173602.81 
SEM 13103.76 6931.44 24377.59 34126.60 1705.28 66226.38 1 5661.76 0.00 21486.07 35702.58 2351.56 65615.69 
CVO/O 89.38 16.28 23.73 13.59 47.91 15.97 90.06 N/A 25.48 14.37 100.00 19.61 
% 3.54 10.26 24.78 60.56 0.86 100.00 4.93 0.00 23.92 70.48 0.67 100.00 
29 Mean 0.00 49170.91 108376.09 167361.33 0.00 324909.23 0.00 4900.34 103599.41 2 03691.23 OJW 312199.98 
Days STD 0.00 47264.40 40079.48 54840.20 0.00 124065.94 0.00 9348.55 31478.46 73419.30 0.00 73570.70 
SEM 0.00 16710.49 14170.24 19388.94 0.00 43863.93 0.00 2951.66 11129.32 25957.64 0.00 26011.17 
CV% N/A 33-98 13.08 11.59 N/A 13.50 N/A 60.23 10.74 
1 
12.74 N/A 8.33 
% 0.00 15.13 33.36 51.51 0.00 100.00 0.00 1.57 33 , Is 65.25 0.00 
100.00 
42 Mean 6153.53 2916.47 31076.70 1 69578.55 1496.76 210122.01 9950-62 641.24 226704.97 44446.84 253.69 280997.35 
Days STD 9435.29 3370.62 10792.91 67824.20 1866.47 76726.36 20791.75 1447.91 11797.40 107621.81 717.51 1 18142.24 
SEM 3335.88 1191.69 3815.87 23979.48 659.90 27126.86 7347.46 511.921 4171.01 38050.06 253.68 41769.59 
CVO/O 54.21 42.31 12.28 14.22 44.09 12.91 82.091 79.83 9.38 16.781 100-00 14.86 
% 2.93 1.34 14.79 80.23 0.71 100.001 3.19 
1 
0.23 15.92 so 0.09 100.00 
Table 4.7: Numbcr densities for basophilic cclIs, cosinophilic cclls, macrophages, fibroblasts, lymphocytes and totals within PTG, UTG and fibrin sealant associatcd cell concentration. 
P Value P Value P Value 
- injury Peritoneal Tissue Generat ion ---Ut-eri ne Horn Tissue Generation Fibrin Sealant Associa ted Cell Concentrat ion 
Time Basophilic Eosinophilic Macrophages Fibroblasts Lymphocytes Total No. Basophilic Eosinophilic Macrophages Fibroblasts Lymphocytes Total No. Basophilic Eosinophilic Macrophages 
To I No Fibroblasts Lymphocytes 
Cells Cells Cells Cells 
MMMMMý 
Cells Cells 
1-4 Hours 0.0650** f 0.5188 1.0000 0.7351 0.0621 0.2209 0.7560 1.0000 0.3634 0.3956 - - 
4-8 Hours 0.1950* 0.03 0.2571 1.0000 0.9579 (). 03X-4 0.9020* 0.3357 0.1085 1.0000 0.4560** 0.6431 - - 
8-16 Hours () ý () 104 * 0.0520 0,0, ), ý') fý 1)(M 2* 0.3820* () () 17 ý, 0.0721* 0.6940** (), ()1 Is (), (W., 
0.0944 0.2320** - - 
16 Hours-I Day 0.7210* 0.1757 0.2925 0.7980* 0.7210* 0.4060 0.72 10* 0.1950** (). 0237 O. "N' 0.3601 0.9247 - - 
1-3 Days 0.6450* --0.0001 0,0000 ()()()2* 0.2340* 0.5520 0.7550* (1.0426* imo 7 (1 ()2()()* ow - - 
3-5 Days 0.7210* () 0006* 0.0204 (). 000 1 0.7210* 000 1 (1 0.7550* 0.0593* 0.9425 o 11) 7 0.7550* O(if 0.7980* (, ()ý II1 0.2118 
5-7 Days 0.9590* 0 000., * 0.0001) 0.0003 0.9590* 0.0004 0.6940* 0.6130* 0.2398 0 OW 1 0.6940* noow; 0.4420* O(H) 0.1811 0.1923 
7-14 Days 0.16 10* 0.3438 0.3820* 0.01,81 0.0650* 0. ()49()* 0.2090* (1,004 1* 0.0819 0.0612 0.7100* 0.5787 - - - 
14-28 Days 0.1050* 0.7205 0.5050* 0.0509 0 W179* 0.2774 0.1890* 01320* 0.4226 0.3207 0.6940* 0.8670* 
28-42 Days () II', 71) - f! I 10 1 0.9691 1 0.1050* 1 1 0.4420* 1 0.5740* 
- 
1ý If -ýI" 1 0.6251 1 0.72 10* 1 0.5364 
Table 4.8: T Test analysis of number density for each cell types between concurrent time points. 
Injury P Value 
Time 132SOphilic Eosinophilic Macrophages Fibroblasts Lymphocytes Total No. 
Cells Cells 
I Hour 0.1825 0.0866 0.4970** 1.0000 0.92 10* 
4 Hours 0.6601 0.9550** 0.1559 1.0000 1.0000 0.7790** 
8 Hours 0.9550* 0.8033 0.1481 1.0000 0.1331 0.7760 
16 Hours 1.0000 00 175 0.8391 1 l)4* 0.3820* 0.0533 
1 Day 0.9590* 0.0 1()4** 0.2307 ()()() -) * 
0.16 10* 0.3587 
3 Days 0.4910* 0.7550* 0.4697 0.4910* 1.0000 0.0899 
5 Days 0.9590* 0.9894 0.0959 0001ý 0.9590* 0.2288 
7 Days 0.6940* 000 1) * 0.1805 0.4129 0.6940* 0.6031 
14 Days 1.0000 0003* 0.4630* 0.9575 0.2320* 0.2810* 
28 Days 1.0000 0.7948 0.2810 1.0000 0.8067 
42 Days 0.3820* 0.16 10* () () I" () 0.2171 
. 
0.1950* 0.1766 1 
Table 4.9: T Test analysis comparing PTG and UTG with regard to number density for each cell type. 
Injury 
Time 
Peritoneal Tissue Generation Uterine Horn Tissue Generation FiMn Sealant Associated Coll Concen tration 
Basophilic Eosinophilic Macrophaps Fibroblasts Lymphocytes Total NO. Ba7sophilic i" E08inophilic Macrophages Fibroblasts Lymphocytes Total No, Basophilic Eosinophilic Macrophages Fibroblasts Lymphocytes Total No Cells Cells 
M I Calls - 
Cells Cells Cells 
I 
. 
I 
Hou 
Mean 
r Sm 
24350.64 26109.13 34171.62 ý0.00 ý10127.41 94759.80 I 0.00 16246.91 13996.39 0.00 41558.16 71801.46 
SEM 
32902.62 40994.49 31295.63 0.00 10076.29 83961.03 0.00 17778.33 18702.63 0.00 71980.84 52222.56 
CVO/ 
11597.49 14493.74 11064.68 0.00 3562.50 29684.71 'I 0.00 10264.32 10797.97 0.00 41559.16 30150.71 O 
% 
47.63 55.51 32.38 NIA 35.18 31.33 NIA 63.19 77.15 NIA 100.00 41.99 25.70 27.55 36.06 0.00 10.69 100.00 0.00 22.63 19.49 0.00 57.88 100.00 4 
H 
Mean 123686.69 642413.04 83261.21 0.00 27281.57 876642.50 1702-81 54036.32 25429.95 0.00 19122.20 100291.28 ours SM 114325.87 350144.87 74420.73 0.00 26669.91 467957.27 2933.91 53939.66 47943 35 0 00 45680 77 56979 35 SEM 40420.30 123794.91 26311.70 0.00 9429.20 165447.88 1108.87 20387.27 . 19120 89 . 0 00 . 17265 71 . 21536.17 CV% 32.69 19.27 31.60 NIA 34.56 19.97 65.12 37.73 . 71 26 . NIA . 90.29 21.47 % 14.11 73.28 9.50 0.00 3.11 100.00 1.70 53.98 . 25.36 0.00 19.07 100.00 
Ho 
Mean 112433.32 2054102.63 246674.35 0.00 66411.06 2479621.36 25426-61 331017.49 32019.39 0.00 25033.33 613496.83 urs SM 135491.59 874125.95 151101.22 0.00 79943.94 973074.38 26908.03 362394.15 30333 53 0 00 26693 93 392911.52 SEM 47903.51 309050.16 53422.35 0.00 29264.42 344033.75 10170.29 136972.11 . 11465 00 . 0 00 . 10089 32 148506 60 CV% 
% 
42.61 15.05 21.66 NIA 42.56 13.97 40.00 25.79 . 35.81 . N/A . 40.30 . 24.21 4.53 92.94 9.95 0.00 2.68 100.00 4.14 86.56 5 22 0 00 4.09 100.00 16 
Hours 
Mean 
STD 
0.00 3022093.14 444111.83 177949.76 25751.54 3669906.26 0.00 964591.18 
. 
223355.31 
. 
182604.09 20443.33 1390993-91 0.00 1716980.27 286366.03 69509.19 39149.86 1972474.47 0.00 348499.95 170712 17 111617 14 18265.59 478745.35 SEM 0.00 607044.20 101245.68 24574.95 13489.01 697375.04 0.00 123213.34 . 60355 97 . 39462 62 6457.96 169262.04 CV% N/A 20.09 22.80 13.91 52.38 19.0c NIA 12.77 . 27 02 . 21.61 31.59 12.17 % 0.00 92.35 12.10 4.85 0.70 100.00 0.00 69.35 . 16.06 13.13 1.47 100.00 
Da 
Mean 
SM 
6239.15 5993510.72 1471043.46 468545.03 34121.71 7973460.08 1416.62 1620792.89 778814.59 522457.14 25097.24 2948579.47 y 17646.98 2752498.76 778339.74 260943.42 54494.34 3572879.20 4006.80 724839.34 426933 11 26 281718 30922.92 1323864.62 SEM 6239.15 973153.27 275194.65 92222.09 19266.66 1263203.20 1416.62 256269.05 . 150908 29 . 99602.45 10932.90 468056.83 CV% 100.00 16.24 19.71 19.68 56.46 15.94 100.00 15.81 . 19 39 19.06 43.56 IS. V % 0.08 75.17 19.45 5.98 0.43 100.00 0.05 54.97 . 26.41 17.72 0.95 100.00 
3 Mean 27324.16 1025740.55 3815827.08 3192380.91 0.00 8061272.70 0.00 332456.65 76 529924 485021.56 0.00 1347402.97 111490.99 12712063.44 23954541.08 7962306.63 0.00 44740402 04 Days SM 54896.04 884237.65 1347464.67 1026665.01 0.00 2357301.47 0.00 435195.67 . 388604.34 320996.36 0.00 766005.99 315343.94 9667610.98 10979633.43 3921104.20 . 0.00 21636224.7( SEM 19409.68 312625.22 476400.70 362980.99 0.00 833431.93 0.00 177663.90 158647.06 131046.21 0.00 312720.64 111490.99 3419016.64 3881886.63 1350964.34 0.00 7649560.6( CV% 71.03 30.48 12.48 11.37 NIA 10.34 NIA 53.44 29.94 27.02 NIA 23.21 100.00 26.99 16.21 16.97 N/A 171C % 0.34 12.72 47.34 39.60 0.00 100.00 0.00 24.67 39.33 36.00 0.00 100.00 0.25 29.41 53.54 17.80 0.00 100.0c 
Mean 7382.95 667856.08 14641750.66 17584521.11 170026.51 33071537.31 7692.97 42051.71 892246 32 1868441.69 1442.14 2811874.83 49178.91 744295.01 21378869.96 12946905.11 145246.13 35264495.1! Days SM 20892.13 481569.95 7719135.26 8226335.71 480907.59 16451935.33 21759-01 63589.35 . 436196.74 973626.98 4079.98 1279756.15 105643.36 850106.67 20271447.52 11464340.63 161710.09 32171466.98 SEM 7392.95 170260.69 2728772.99 2908449.98 170026.51 5816637.52 7692.97 22482.23 154219.84 308873.75 1442.14 452462.13 37350.57 300559.10 7167039.00 4053256.50 57173.15 11374331.23 CV% 100.00 25.49 19.64 16.54 100.00 17.59 100.00 53.46 17.28 16.53 100.00 16.09 75.95 40.38 33.52 31.31 39.36 32.25 
% 0.02 2.02 44.27 53.17 0.51 100.00 0.27 1.50 31.73 66.45 0.05 100.00 0.14 2.11 60.62 36.71 0.41 100.00 
7 Mean 10602.68 2339293.59 8584626.80 11692974.95 21205.36 22648703.38 0.00 52089.47 959986.77 1195508.44 0.00 2207583.68 0.00 17601996.72 16266550.02 10637236.00 0.00 44505782.75 Days STI) 29998.90 1656223.14 4785010.86 5515928.28 59977.91 11207973.74 0.00 32789.67 579659.95 559065.28 0.00 1126570.23 0.00 9059432.59 4472530.02 2541372.27 0.00 11576993.17 
SFM 10602.68 585563.31 1691756.81 1950175.15 21205.36 3962617.12 0.00 12393.33 219090.49 211306.91 0.00 425903.52 0.00 2849096.17 1591279.15 898581.49 0.00 4093049.83 
CV% 100.00 25.03 19.71 16.68 100.00 17.5C NIA 23.79 22.82 17.68 NIA 19.29 N/A 16.19 9.72 8.45 VA 9.2C 
% 0.05 10.33 37.90 51.63 0.09 100.00 0.00 2.36 43.49 54.15 0.00 100.00 0.00 39.55 36.55 23.90 0.00 100.00 
14 Mean 1022463.51 2465000.31 6380251.03 15194050.28 212972.20 25274737.33 8436-84 0.00 213681.13 700467.40 198&72 924574.09 Days SM 2677450.08 1644270.97 5554967.29 9285521.36 301774.63 16968467.30 15861.92 0.00 193356.23 739609.68 5261.66 912973.74 
SEM 946621.55 591337.59 1963977.52 3282927.56 106693.45 5999259.15 5995.20 0.00 73091.79 279546.19 1989.72 345071.64 
CV% 92.58 23.59 30.78 21.61 50.10 23.74 71.06 N/A 34.20 39.91 100.00 37.32 
% 4.05 9.75 25.24 60.12 0.94 100.00 0' 91 0.00 23.11 75.76 0.22 100.0c 
28 Mean 0.00 2210137.10 4739159.49 6890300.64 0.00 13839597.23 0.00 23375.30 545968.81 1195057.34 0.00 1764401.45 Days SM 0.00 2313039.77 2179045.99 2520040.69 0.00 6508867.86 0.00 34183.50 405709.53 109767151 0.00 1448295.31 
SEM 0.00 917782.70 770409.10 990969.93 0.00 2301232.3 0 0,00 12085.69 143439.98 398085.84 0.00 512046.18 
CV% NIA 37.00 16.26 12.93 N/A 16.63 NIA 51.70 26.27 32.47 N/A 29.02 
% 0.00 15.97 34.24 49.79 0.00 100.00 0.00 1.32 30.94 67.73 0.00 100.00 
42 Mean 140028.68 122421.36 1186493.62 6197540.24 1 52200.41 769868431 ' 2274177 1"1"' 3224.19 164800.48 717392.40 2771.20 910930.04 Days STI) 196694.69 195930.09 646253.57 3660985.03 67584.95 4179487 82 59737.94 6049.09 110217.23 352477.77 7839.14 449897.43 
SEM 69542.07 69271.751 228495.14 1294353.67 23994.95 1477672.09 
1 
0 20767-00 2139.32 38967.68 124619.71 2771.20 
1 
159059.23 
CV% 49.66 
1 
56.58 19.26 20.98 I 45.78 19.19 2 91.32 66.32 23.65 17.37 100.00 17.46 
% 1.82 
1 
1.59 15.41 80.50 0.68 100.00 D 2.50 0.35 19.09 79.75 0.30 100.00 
Table 4.10: Number totals for basophilic cells, cosinophilic cells, Mac-Phages, fib-blast4 lymphocytes and totals %ithin PTG, UTG and fib6n "Allant associated cell concentration 
P Value P Value P Value 
Injury Peritoneal Tissue Generation Uterine Horn Tissue Generation Fibrin Sealant Associa ted Cell Concentration 
T M, ime Basophilic Eosinophilic Macrophages Fibroblasts Lvinphomes Total No. Basophilic l'o%inophific Mmophages, Fibroblasts 1, NmiphocNIe% -1 otal No. Basophilic Fminophific Murophages I %inph, nNte, I I)IRI \o 
Cells Cells Cells Cells Cells Cells 
1-47ours ()4()()** Oý . 1075 
ýj 
. 0000 (). 1109 ()()(J2 0.5170* 0.2827 1.0000* 1.0000 0.8330* 0.4907 4-8 Hours 0.7980** 0.0003** 0.0 1 1.0000 0.7210** 0.00()6** 0.1650* 1 0.3830* 1.0000 0.1650* 001 
8-16 Hours 0.0 104 * 0.1772 0.1066 0.0002* 0.2790* 0.1481 0.072 1* 0346 0. ()()()6** (). oo22* 0.7005 
16 Hours-I Day 0.7210* 0.0214 0.0087 0.9590* 0.0099 0.7210* () 169 0.00ý"()** 0.02()7**, 0.7195 k 
1-3 Days 0.6450* 0.0003** 0.0008 0.0002** 0.2340* 0.9545 0.7550* N)25 0.2741 0.8117 0.0200 1 0 (''1. 
3-5 Days 0.6450* 0.3318 0.00()7* 0.0007* 0.7210* 0. ()03()** 0.7550* 0.1080* 0.1260 0.0030 0.7550* o ()248 0.7980* 0.7567 0.2790* 0.5007 
5-7 Days 0.9590* 0.0159 0.0801 0.1146 0.9590* 0.1608 0.6940* 0.7137 0.8005 0.1046 0.6940* 0.3527 0.4420* 0.9590* 0.8780* 1 
71) 0.1050* 
7-14 Days 0.16 10* 0.8811 0.1950* 0.3747 0.0830* 0.8780* 0.2090* () 004 1* 0.00 12 * (). 0379* 0.7100* (1 () 175 1 - - - - - - 
14-28 Days 0.105* 0.2790* 0.4496 0.0207* (). ())79* 0.9680 0.1890* 0-2320* 0.0701 0.3325 0.6940* 0.2100 
1 28-42 Days () 
- 
0.6660 
- 
0.1050* 
. 
0.04 14 
. 
0.4420* 
, 
0.5050* 
.ý': ), 
(, -, ý, 
1 
0.2608 
. 
0.7210* 
. 
0.2340** 
Table 4.11: T Test analysis of number totals for each cell types between concurrent time points. 
Inj ury P Value 
Time Basophilic Eosinophilic Macrophages Fibroblasts Lymphocýles Total No. 
Cells 
mmýý 
Cells 
777 I Hour 0.. 2452 0.7038 
ý 
0.3305 1.0000 0.2183 0.6741 
4 Hours 0.0040* 0,0004** 0.0205* 1.0000 0.1520* 0. ()004** 
8 Hours 0.1202 0.0004** 0.0022** 1.0000 0.2155 0.000 3 *- * 
16 Hours 1.0000 0.0002** 0.0821 0.9217 0.9590* 0,0000** 
I Day 0.9590* 0.0030** 00446 0.6972 0.6450* 0.000.1 ** 
3 Days 0.4910* 0.04260 0.0007* 0.0007* 1.0000 0.0007** 
5 Days 0.9590* 0.0070* (). 0002* 0.0002 * 0.9590* 
7 Days 0.6940* 0.0003* 0.0003* 0.000 * 0.6940* 0.000 
14 Days 0.3970* 0.0003* (). 0003* 0.000 * 0.0721* 
28 Days 1.0000 0.0002* 0.0003** <0.00() 1 1.0000 0.000 1 42 Days 0.1610* 
. 
0.0830* 
, 1 (). 
()0()2** 
1 
0.1610* 
11 
Table 4.12: T Test analysis comparing PTG and UTG with regard to number totals for each cell type. 
I 109/1 
Cell Type Mean SD SEM CV% 
Blood Sample 1 
RBCs (X 103/1) 5.60 0.50 0.08 1.49 
Platelets 252.50 123.09 19.00 7.52 
WBCs 4.44 1.08 0.17 3.83 
Basophilic Cells 0.15 0.11 0.03 22.63 
Lymphocytes 2.28 0.80 0.24 10.61 
Monocytes 0.54 0.25 0.08 13.96 
Eosinophilic Cells 1.68 0.80 0.24 14.33 
Blood Sample 2 
RBCs (X 103/1) 5.16 0.53 0.09 1.74 
Platelets 266.00 105.36 17.32 6.51 
WBCs 4.06 1.32 0.22 5.42 
Basophilic Cells 0.10 1.13 0.04 39.27 
Lymphocytes 1.64 0.83 0.25 15.15 
Monocytes 0.42 0.21 0.06 14.91 
Eosinophilic Cells 1.91 0.88 0.26 13.81 
Blood Sample 3 
RBCs (x 103/1) 4.83 0.93 0.15 3.18 
Platelets 284.97 153.70 25.27 8.87 
WBCs 4.26 1.65 0.27 6.37 
Basophilic Cells 0.12 0.11 0.02 14.22 
Lymphocytes 1.39 0.65 0.11 7.64 
Monocytes 0.28 0.17 0.03 9.70 
jEosinophilic Cells 1 2.47 1 1.39 1 0.23 1 9.26 
Table 4.13: Mean numbers of cell types for all blood samples, together 
with the SEM, SD, SEM and CV%. 
Basophilic Lymphocytes Macrophages Eosinophilic WBCs RBCs Platelets 
Cells Cc] 
I 
Blood sample I vs 2 0.3278 0.0809 0.2158 0.5141 0.1453 0ý00314 0.6192 
Blood sample I vs 3 0.5000* 0.0004 o ()()() " 0.0781 0.3070** 0.1471 
Blood sample 2 vs 3 0.2590* 0.2867 (). 03 )7 0.2164 0.5334 0.7410* 0.2902 
Table 4.14: T test analysis of cell types for blood samples. 
normality test failed; Mann Whitney rank sum test ran. 
= equal variance failed; Mann Whitney rank sum test ran. 
Injury Number of White Blood Cell (xIO"A) RBCs Platelets 
Time Basophilic Cells Lymphocytes Monocytes Eosinophilic Cells Total (x I 0'2A) (x I O'A) 
I flour MEAN 0.06 1.22 0.22 1.94 3.45 5.42 316.00 
STD 0.05 0.31 0.14 1.10 0.83 0.41 64.92 
SEM 0.02 0.15 0.07 0.55 0.42 0.21 32.46 
CV% 39.90 12.60 31.59 28.43 12.10 3.80 10.27 
4 Hours MEAN 0.11 1.34 0.16 3.26 4.87 5.62 438.50 
STI) 0.10 0.37 0.02 0.69 0.50 0.90 422.14 
SEM 0.06 0.21 0.01 0.40 0.29 0.52 298.50 
CV% 50.13 15.94 5.76 12.28 5.97 9.27 68.07 
8 Hours MEAN 0.15 0.90 0.33 4.66 6.05 4.97 180.00 
STD 0.20 0.77 0.21 1.39 2.10 0.54 128.01 
SEM 0.10 0.39 0.11 0.70 1.05 0.27 73.91 
CV% 66.32 42.85 32.00 14.94 17.32 5.39 41.06 
16 Hours MEAN 0.16 1.80 0.16 2.75 4.87 4.61 391.67 
STD 0.15 0.45 0.04 0.20 0.78 1.00 156.11 
SEM 0.09 0.26 0.02 0.12 0.45 0.58 90.13 
CV% 56.32 14.36 14.89 4.29 9.21 12.53 23.01 
1 Day MEAN 0.23 1.89 0.37 2.34 4.80 4.82 187.00 
STD 0.09 0.81 0.20 0.80 0.77 0.33 59.16 
SEM 0.04 0.40 0.10 0.40 0.39 0.16 29.58 
CV% 18.33 21.37 27.09 17.07 8.07 3.40 15.82 
3 Days MEAN 0.05 1.38 0.18 1.46 3.08 4.71 359.75 
STD 0.01 0.73 0.09 0.29 0.78 0.30 68.66 
SEM 0.01 0.37 0.04 0.14 0.39 0.15 34.33 
CV% 10.06 26.65 23.40 9.85 12.76 3.16 9.54 
5 Days MEAN 0.08 1.56 0.29 4.36 6.30 4.57 326.67 
STD 0.03 0.40 0.25 0.80 0.87 0.30 54.93 
SEM 0.02 0.23 0.15 0.46 0.50 0.18 31.71 
CV% 22.09 14.63 50.52 10.60 7.99 3.84 9.71 
7 Days MEAN 0.12 1.28 0.31 1.19 2.90 5.07 270.67 
STD 0.13 0.22 0.06 0,62 0.87 0.13 228.95 
SEM 0.08 0.13 0.03 0.36 0.50 0.08 132.19 
CV% 62.01 9.82 11.25 30.19 17.24 1.49 48.84 
14 Days MEAN 0.04 0.80 0.35 0.94 2.13 2.81 56.00 
STD 0.04 0.55 0.18 0.73 1.10 2.05 4.24 
SEM 0.02 0.32 0.10 0.42 0.63 1.18 2.45 
CV% 59.92 39.25 29.31 44.65 29.69 42.18 4.37 
28 Days MEAN 0.15 1.32 0.30 1.64 3.40 5.25 223.50 
STI) 0.08 0.48 0.10 0.40 0.56 0.12 89.01 
SEM 0.04 0.24 0.05 0.20 0.28 0.06 44,51 
CV% 27.65 18.15 16.72 12.33 8.23 1.13 19.91 
42 Days MEAN 0.21 2.10 0.53 2.86 5.70 5.03 424.00 
STD 0.03 1.50 0.34 0.96 2.83 0.46 66.47 
SEM 0.02 1.06 0.24 0.68 2.00 0.32 47.00 
CV% 11.06 50.58 44.47 23.74 35.09 6.47 11-08 
Table 4.15: Mean numbers of cell types for blood sample 3 at time points following injury, together with 
SD, SEM and CV%. 
Sample 
Time 
Blood 
Sample I 
Blood 
Sample 2 
Treated Blood 
Sample 3 
Pcritoneal 
Sample I 
Treated 
Peritoneal 
Sampl 3 
1 Hour - 3128.57 
4 Hours - - 2931.43 
8 Hours - - 3222.86 
16 Hours - - 3205.71 
I Day - - 2151.43 
_ _ 2 2ays - 2854.29 3480.00 
_ _ LDa jyý - 3831.43 4371.43 
_ _ 7 Days . - 4637.14 4885.71 
14 Days 2974.29 2674.29 
ZLDays 2237.14 1860.00 
_ jZpays 2965.71 - 
_ 
Mean 4568.57 2997.14 - 1740.00 
STD 2877.51 696.05 .- 193.95 
401.86 137.14 
cv% 36.36 13.41 7.88 
1 
Table 4.16: TGF-P concentrations in plasma and peritoneal fluid samples. 
APPENDIX V 
P VAH T 
Injury PSA Fissue Generation Damage Zone Peritoneal Peritoneal t Iterine Total 
Time Peritoneal Uterine I o1al Peritoncal Uterine Reaction Cell I lorn Cell 
I lorn Horn Zone Concentration Ilaernorrhage Concentration 
II four 0.4420* 0.3820* 0.3832 0.4656 (1 (1, ii ýI1 1.0000 OM', 1.0000 
4 flours 0.1050* OM070* 0 0499* 0.0002" 0017(, 0.4939 0.0002** 0.4420* 0.4420* 
81 fours 0.0002* 0.0513 0.1478 () 000 1 0.5050** 0.2398 0,000 1 0.4420* 001 1) 0.4420* 
16 flours 0.0002* Oý0002 0.6114* 00(101 0.2559 0.1173 OA)002 - 0.7980* 0.16 10* 0.6450* 
I Day 0 0002* 0.8690 (), () IS I'll 001(,; 0.2672 0.0801 ()MO I (), 00 1 1) * () 0002* () 00h ý 
3 Days ()()()19* (). ()()()0** 0.5050* 000 02, * 0,0310 0.2340* 0.0002* O. OW2, 00 179' 0.9590* 
5 Days 0.0379* 0.2790** 0.0002* O. Om)(ý 0.6661 0.0002* 0.0002** 0.72 10* 0.7980* 000', 
7 Days 0.0379* 0.0379** 0.0006* 0.0001. 0.1300* 0.1950* 0.0002* 0.1050* 1.0000 0.0002 
14 Days 0.0104* 0.0003* 0.0281 * 0.0002* 0.00 19* 0.9590 0.0002* 0.72 10* 1.0000 ()0101, 
28 Days 0.0 148* 0.9590* 0.5740* 0.0070* 0.0499* 0.1300* 0.0002** 0.72 10* 1.0000 0.1950 
42 Days ...... 1 0.0955 1 () I () ()(), ý(, ý1 0.2340* 1 0.1050* () 0001. *I1 1.0000 1.0000 1.0000 
Table 5.1: T Test analysis between control and treated cases with regard to physiological volumes. 
Normality Test Failed-, Mann-Whitney Rank Sum Test Ran; 
= Equal Variance Test Failed; Mann-Whitney Rank Sum Test Ran. 
Note: Total Cell Concentration : Control Peritonea] Cell Conc. vs Treated 
[Peritoneal Cell Conc. + Fibrin Sealant Assoc. Cell Conc. ] 
P Value 
Injury Total Percentage 
Time Tissue Generation 
Fibrin Collagen Fibrin Collagen 
I Hour 0.1976 1.0000 1.0000 1.0000 
4 Hours 0.0207* 1.0000 1.0000 1.0000 
8 Hours 0.0084 1.0000 1.0000 1.0000 
16 Hours 0.0030* 1.000() 1.0000 1.0000 
I Day 0.6147 0.0047, () ()030* () 00,10, 
3 Days 0.0002* 0,0281 0.4420* 0.7210* 
5 Days 0.1050* 0.0104 1.0000* 1.0000* 
7 Days 0.4420* 0.0030 0.9590* 0.9590* 
14 Days 0.0 104* 0,000.1 i () () 104* 0.0 104 
28 Days 0.1050* 0.2340* 0.1050* 0.1050* 
42 Days 1.0000 1.0000 1.0000 
Table 5.2: T Test analysis comparing fibrin and collagen in 
control and treated cases. 
I Hour 
4 Hours 
8 Hours 
16 Hours 
I Day 
3 Days 
5 Days 
7 Days 
14 Days 
28 Days 
42 Davs 
P Value 11 Value 11 Value 
Peritoneal Tissue Gericration Uterine I lom Tissue (Temeration Total Tissue (kne-ration 
' Basophilic ' 'op" I Eosinophilic Inflammatory I Macrophages I I Fibroblasts 1,. Vmphocylcs 1,0181 No, ' Basophilic: ý, osinophilic Macrophages Fibroblasts L. NTriphoc. Nics I offil \o. 11m, ophilic '. OSIHOP It IL 11 R11MIR 0I'% utop age, ýi iroblasts I NIIIP m \o Cells Cells 'CIIS 
I I 
CCIIS 
I 
Cells (, c IN 
I I I I 
"CIIIS '01IN '011, 
I 
III 
ý' (o, j 0.0 1(ý" 0.5998 0.3422 0.8531 0.6206 0.5 170* 0.8330* 1 f 0.4560** 018.30 1 0.38JO* 
0 00ý1ý 0.8780* 0.1050* 0.2820 0.7100* 0.8050* 0.9780* 0.2993 
() ()() iI* 0.3720 0.1211 0.8310 0.5639 0.1240 0.0411.1, (I () 12 4 () ol-12" 0.9227 0.2300* 0.2032 1, '")X I () ý I(, Ii ý' (). I Xi ,ý (I 21S, I, o. 9249 0.2340* 0.1300* () (1ý .ý, 
(i u 121 * 0.0242** 0,003.1 0.6179 () () 121 * 0.2875 00047 () ()-111.1 1 () 0007 () 000 1 0.5416 0.2151 0.7110** (ý ()()( II i, 111)1)21 0.959()** (). 105()** (). 1950* () ()()() 1 0.8646 0.6450* 
() ()()1(, * 0.2957 0.0787 0.004" 0,0010' 0.9430 0.3027 0,00 1 (" 0.6220* 0.0932 0.0451 * 0001o, 0,0929 0.2323 1, () () 1. (1 NI 0.0650** ,ýI lý I' I H002 * 0.4182 0.3290** 
H f, 127* 0.1810* 0.5730* 0.3967 0.4825 0'0426* 0,6194 0.0667 0.3520* 0.4760* 0.1384 0.8902 0.2570* 0.2759 o(); W 0.1050* 1.0000* 0.2785 1.0000* () 0002 0.7436 
() 0.1752 0.5730* 0,000 1 0.6142 0.6620* 0.2090 1 ()21) 1' 0.6620* 0.4910* ') 031,1 0.6201 0.3450* 0.6620** 0.9590* 1 0499* 0.0920 0.9780** 0,4420* (). 959()** 
0.1210* () 00ý9* 0.0721 * 0.0721 * (), 019o 0.1890* 0.3525 0.0728* 0.2528 0.8050* 0,007X (H) I S-I 0.0728* 0.3030 11 )(111). 0 () 11ý 0.1050* 0.2200 ,I( 1()()ý 1 000" 0.0589 
0.7790* (1 1)()()1** 0.0200* 0,000 1 0.5427 0.1649 0.2320* 0.8360* 0.3660* 0.9450* 03 1 0.2203 0.6280* 0.8360* 0.6450* ýý ()()I) ýý - ) 0070* 001 P 0.3820** 0.9590* 0.9471 
0.7210* 000021 () OM Q4 0 ()(10.1 * 0.3222 0.2340* ýI - 0.3970* 0.3970* ('im I; 0.0655 0.1890* 0.8448 0.4420* () 01 ýI)* I ,I;., I () (" )(' I I, I ýý ,, ( f)(11 ) 
0.1045 
. 
0.3360** 
, 
0.6130* 
, 0.4630** 1 0.4630* 1 0.2959 1 0.7790* 1 0.3360** 1 0.4910* 1 0.2820* 1 0.1420* 1 () M Wý 1 0.3411 1 0.4910* 1 0,4527 a 0.3920* 1 0.1791 1 0.2340* 1 0.0524 1 0.1197 . 0.1869 , 
0.1583 
Table 5.3: T test analysis of number densities with PTG, UTG and TTG for control and treated cases. 
P Value P Value P Value 
Peritoneal Tissue Generation Uerine Hom Tissue Generation Total Tissue (nmeration 
Injury Basophilic Eosinophilic Inflammatory Macrophages, Fibroblasts Lymphocytes Total No. Basophilic Eosinophilic Inflammatory Macrophages Fibroblasts Lymphocytes Total No. Basophilic Eosinophilic Inflammatory Macrophages Fibroblasts Lymphocytes Total No. 
Time 
` ý 
Cells Calls Cells Cells Calls Cells Cells Cells Calls 
IH 
7u 
r 1 0.0614 - 0.3926 00 121 011, 0.7990 
77" IMM= 
0 
ý4990 
0.5170" 
70.83 ý30 
-1ý 0.3830* 0.3830* 
4 Hours 0,00021, 0.0650* 0.1050* 0.5843 0.00021 0,00 1 1.1 0.004' ,7 W) I '. 1 0.4450* 0.5340* (002, Oo- 
woo., 0.0650* ,ý ,I"; 0,4420* 
8 Hours f, 1ýi)3 I* 0.0932* 0,02951 0.3038 0.6220* 0.0451 0.001)", 0.0667** () 0095** 0 9140* 0 2570* 0.6172 () (), , 1, 10006 0. ()11,, ) 0047' 0.2576 0.2340* 0.8455 fl 011 
16 Hours fIýýI"Iý (H) 121 ** 0.0 121 * o, O 1w) 0.0 121 * 0.2875 0.0 121 * 0,04-441 0 022X, () ()()11 
. 
0.9643 
. 
0.2282 0.8462 1ý 00h, i1 o002* 0.00() ;, o. 0002" 0.0875 0.0773 0.1950** 
I Day o, 0 () I (" 0.6048 0.2840** (H)OX0 00057 0.8330* 0.6553 00 16* 0.0557 0.3175 0.0241 0.1710* 00 12 1 0002* 0.0 31 1 0.0051 ()1 ýJx, 1ý 0.2773 
3 Days ()1,74 0.8520* 0.3450* 0,011" 0.042w ()(Q7' 0.0667* 0.3520* 0.4760* 0.2570* 1.0000** 0.2570* 1.0000** o030* 0.2790* 0.020- 1991 (1 ooo2* 
5 Days 0 ()()X()* 0.6583 0.1420* 0.7148 0.1810** 0.6620* 0.2820** 0.5730* OM27* 0 (Wi 0.18 10* 0 000- floO2* 0.0830* ()(), 17, ), 0.2208 0.2340* 7 Days 0.0939* 0.0541 * 0.1520* 0.3825 0 0022** 0.0939* 00 140' 0.0728* 0.5350** 0.1650* 0.3830* 0.0006, 0.0728* 0, ()( 0.1050* 0.3820* 0.9590* 0.0001, (ý (w 11 14 Days 1.0000* (). (Y) 1; X () 0205* 0.0721 * 0.0012, 0.7790* 0,009 11 0.8360* 0.3660* 0.6280* 0.8523 0.0223 0.5340* 0 04M, 0.8780* () 003X ý ,I IN' 0.3280* 0 ()()1 11 0.6450 
28 Days 0.7210* 0.0003- 0,00o II () o2-071 0.8780* 0.2340* 0.5050* 0.4630* 0.4630* () I, 0.3360* 0.1890* 0.2062 0.4420* 0 OW)(11 ', I H-I, ''. ý 1-,;, 1 42Days 
. 
0.3360** 
1 0.7790* J 04630** 0.7640 0.049N 0.7790* (W11(1 0.2820* 0.2820* 0, ý 0.4910* () 0"ý- 0.1950* 0.2426 0.16 
10* 0.1164 . 0.3920* , 
Table 5.4: T test analysis of number totals with PTG,, UTG and TTG for control and treated cases. 
P Value 
Platelets RBC WBC Basophilic Lymphocytes Monocytcs Eosinophilic 
Cells Cells 
BloodSamplel 0.8190* -(). 0001** 0.3504 0(41, 0.1964 0.1053 
Blood Sample 2 0.8016 (), ()2', 0* (). 0001** 0.0986* 0,0050 0.85 10* 0.1804 
Blood Sample 31 0.7140 1 0.3920* (ý (), )ý ý! -ýI iloww I (ý i li, ()! ,1 0.4860* 1 0.3350* 
Table 5.5: T test analysis comparing full and differential blood counts for control and treated cases 
at blood samples 1,2 and 3. 
Normality test failed. Mann-Whitney Rank Sum test ran: 
= Equal variance test failed; Mann-Whitney Rank Sum test ran. 
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Treatment Percentage 
Incidence of PSAs 
Percentage Incidence of 
Sealant Remaining 
Controls 100.0% N/A 
Device Prepared Spray 16.7% 75% 
Device Prepared UNES Gun 58.3% 41.7% 
Device Prepared Needle 8.3% 33.3% 
Bench Prepared UNES Gun 0% 100% 
Table 6.2: Macroscopic results. 
Treatment Post Percentage Fibrolic Tissue Generation Damage Zone Perdoneal Fibrm Call 
Surgical at Periloneal utenn Free Total Peritonead Uterine Read= Seadent concentration 
Adhesion PSA Horn Floating Horn Zone Rerriaming 
control Mean 73.93 100.00 48.71 12.42 1.01 136.07 44.29 20.26 108.62 0.00 1.61 
STD 45.18 13ý 13 1817 1,80 64.61 2099 1869 28.42 000 254 
SEM 1253 364 504 050 1792 582 518 788 000 070 
CV% 16,95 7.48 40.59 49.45 13,17 1314 25.58 7,26 #DIV/01 4373 
Device Mean 17.32 23.43 101.93 22.38 3.23 144.86 31.32 7.49 109.62 10.43 26.87 
Prepared STD 2418 40.03 16,44 4.50 52.27 2311 9ý51 44 64 11 71 2050 
Spray SEM 698 11ý56 4ý 75 1.30 15.09 6.67 2.75 IZ89 3.38 592 
CV% 40.30 11.34 21ý211 40.31 10.42 21.30 3668 11 76 32,40 2203 
Device Mean 39.37 53.25 101.27 22.12 1.54 164.31 33.73 12.87 118.49 6.87 23.80 
Prepared STD 65ý 13 47.34 11.85 1.94 93.27 2278 13.69 45A3 11 77 1993 
Unes Gun SEM 1&80 13.67 3.42 0.56 26,93 6,58 395 1311 340 575 
CV% 47.76 13.50 15.46 36.27 16.39 19.49 30.70 11 07 49A6 2417 
Device Mean 24.66 33.36 96.31 17.17 3.65 141.99 35.46 11.93 91.78 9.40 19.63 
Prepared STD 27,49 40.60 1471 3,75 7125 21ý82 13.81 2134 1120 1914 
Needle SEM 7.94 11.72 4.25 1.08 20.57 630 3.99 6.27 323 553 
CV% 32.17 12.17 24.73 28.12 14.48 17.76 33.42 6.84 34.37 2815 
Bench Mean 5.40 7.31 80.46 24.84 5.18 115.88 25.32 11.72 88.64 56.93 51.67 
Prepared STD 8.26 4128 22.35 5.15 60.57 2024 1329 1680 4616 25.42 
Unes Gun SEM 238 12.49 645 149 1749 5,84 3.84 4,85 13.32 734 
CVO/O 44.12 15,53 25 98 28.68 15.09 2308 32 71 5.47 23,40 1420 
Table 6.3: Tissue zone volumes (mm-) for each treatment group. 
P VALUES 
Post Fibrotic Tissue Generation Dama e one Peritoneal Cell 
Treatment Surgical Peritoneal Uterine Free Tota I 
I 
Peritoneal Uterine Reaction Concentration 
Adhesion Horn Floating Horn Zone 
Device Prepared 
Spray 00008 0.0001 0.0535 0.209 0.7133 0.121 ') j20, -, 0.9465 11 000 1 
Unes Gun 0018 0.00146 0024 0.495 0.479 0.121 0.221 0.5174 <0 0001 
Needle 00035 000146 0.0727 00165 0.8295 0.3135 0.341 0.112 00019. " 
Bench Prepared 
Unes Gun <0 0001 0.0606 0.149 0 0153 0.4296 0 0"! 0.121 0.109 001, i 
Table 6.4: T Test Analysis of Treatment Groups Compared to Control. 
P VALUES 
Post Fibrotic Tissue Generation Damaq e Zone Peritoneal Fibrin Cell 
Surgical 
Adhesion 
Peritoneal Uterine 
Horn 
Free 
Floatin 
Total Peritoneal Uterine 
Horn 
Reaction 
Zone 
Sealant 
Remaia Un 
Concentration 
0.0737 
I 
0.585 
I 
0.726 
I 
0.206 0.429 
I 
0.47 0.51 0-122 00 1 . 1, 
I -. j 
ý*: I' I., ý, t ý fl. '' "., . ý., t 1.1, ýý: ý. -"ý"i;! -,,, I, ý:, ic ýý'. i, .1 Applhcotiomý 
Table 6.5: One way ANOVA analysis of treatment groups. 
P VALUES 
Device Prepare Bench Prepared 
Spray UNES Gun Needle UNES Gun 
Device Prepared Spray - 0.0023 0.1750** 
tr UNES Gun - 0,0406 0.5160 
it Needle - - 0.5440** 
Bench Prepared UNES Gun - 
Table 6.6: T test Analysis comparing volume of fibrin sealant applied for each treatment group. 
** = Equal Variance Test Failed-, Mann-Whitney Rank Sum Test Ran. 
P VALUES 
Device Prepared Bench Prepared 
Spray UNES Gun Needle UNES Gun 
Device Prepared Spray - 0.6185 0.1000* 0.1373 
It UNES Gun - - 0.4798 0.1749 
it Needle - - 0.3213 
Bench Prepared 
. 
UNES Gun - - 
Table 6.7: T test analysis comparing fibrin I concentration (mg/ml) for each treatment group. 
*= Normality Test Failed-. Mann-Whitney Rank Sum Test Ran 
APPENDIX VII 
CRYO Preparation Protocol 
1. Thaw 2 litres of plasma. 
2. Filter through a damp cotton cloth. 
3. Add 4 units/ml heparin. 
4. Aliquot into 45ml volumes. 
5. Add 4.5ml of cooled ethanol to each aliquot. 
6. Precipitate on ice for 30 minutes. 
7. Centrifuge at 30OOrpm at 5"C for 10 minutes. 
8. Collect concentrate and pool. 
9. Re-spin pooled fraction at 30OOrpm at 51'C for 5 minutes. 
I O. Combine precipitates and heat to 37"C or until in solution. 
I l. Assay the concentration of the pooled fraction. 
12. Thaw plasma required to produce a resulting combination of pooled fraction and 
normal plasma at 6mg/ml (the concentration which is often used in device studies). 
B. Treated thawed normal plasma as in steps 2 and 3 above before addition of 
concentrated pooled fraction. 
14. Assay spiked plasma for fibrinogen concentration. 
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Treatment Post Percentage PSAs Fibrotic Tissue Generation Damage Zone Peritoneal Fibrin Cell 
Surgical Incidence Reduction Peritoneal Uterine Free Total Peritoneal Uterine Reaction Sealant conc, 
Adbesion Horn Floating Horn Zone Remaining 
Control Mean 73.93 100.00 N/A 48.71 12.42 1.01 136.07 44.29 20.26 108.62 0.00 1.61 
STD 45.18 13.13 18.17 1.80 64.61 20.99 18.69 28.42 0.00 2.54 
SEM 12.53 3.64 5.04 0.50 17.92 5.82 5.18 7.88 0.00 0.70 
CV% 16.95 7.48 40.59 49.45 13.17 13.14 25.58 7.26 #DIV/O! 43.73 
Vivostat Mean 11.30 15.28 84.72 68.75 6.69 2.37 89-11 18.02 2.50 79.58 21.20 29.62 
(Needle) STD 11.32 37.93 6.93 2.37 41.10 16.40 3.19 19.83 26.06 24.74 
SEM 3.27 10.95 2.00 0.68 11.87 4.73 0.92 5.72 7.52 7.14 
CV% 28.91 15.93 29.92 28.90 13.32 26.27 36.84 7.19 35.48 24.11 
CRYO Mean 21.06 28.49 71.51 111.20 13.95 1.49 147.70 48.78 8.89 88-18 13.64 22.87 
4 Units STD 21.45 26.43 15.35 1.13 39.36 24.06 8.51 26.93 11.51 18.85 
Thrombin SEM 8.76 10.79 6.27 0.46 16.07 9.82 3.47 11.00 4.70 7.70 
CV% 41.58 9.70 44.91 31.09 10.88 20.13 39.08 12.47 34.46 33.66 
CRYO Mean 179.98 243.46 -143.46 136.24 33.95 0.76 350.94 46.13 37.38 174.90 97.07 79.16 
500 Units STD 185.72 53.23 23.78 0.95 231.12 14.06 45.46 14.30 51.20 27.44 
Thrombin SEM 75.82 21.73 9.71 0.39 94.36 5.74 18.56 5.84 20.90 11.20 
CV% 42.13 15,95 28.59 50.61 26.89 12.44 49.65 3.34 21.53 14.15 
Tissucol Mean 106.12 143.55 43.55 82.34 14.45 1.32 204.23 50.62 18.08 122.09 42.47 35.33 
4 Units STD 107.71 56.61 12.12 1.52 169.56 19.82 6.31 38.22 46.20 36.97 
Thrombin SEM 48.17 25.32 5.42 0.68 75.83 8.86 2.82 17.09 20.66 16.54 
CV% 45.39 - 30.75 37.53 51.57 37.13 17.51 15.62 14.00 48.65 46.81 
Tissucol Mean 69.42 93.90 6.10 137.09 28.26 3.27 238.04 35-20 2.71 137.72 110.70 72.48 
500 Units STD 91.45 - 40.86 15.59 2.61 99.89 15-86 3.66 43.35 63.47 27.03 
Thrombin SEM 37.33 16.68 6.36 1.06 40.78 6.47 1.49 17.70 25.91 11.04 
CV% 53.78 12.17 22.52 32.57 17.13 18.39 55.15 12.85 23.41 15.23 
Table 7.2: Quantitative volumetric results. 
P VALUE 
post Fibrotic, rissue Generation DamageZone Puritoneal Fibrin Cell 
Surgical Peritonea] Uterine Free T`otal Peritoneal Lkerine Reaction Sealant Cone" 
Adhesion Horn Floating I lorn Zone Remaining 
Controls vs 0.3840** 0.9350* 0.1080* N/A 
Vivostat (Needle) 
Controls vs CRYO 01ý2 01 WO 1 0.630* 0.2350* 0.6911 0.6838 0.1722 0.1574 N/A 1W I 
4 Units Thrombin 
Controls vs CRYO 0.3130** 000 11 0 () i 16, 0.5670* -wii, 0.8490 0.8260* ()01)11)11 N/A ()Oý 
500 Units 
Thrombin 
Controls vs 0.3717 0.3240** 0.2370* 0.5850* 0.2205 0.5694 0.8041 0.4233 N/A 00M, 
Tissucol 4 Units 
Thrombin 
Controls vs 0.8854 00001* 0.0,41%'4* 0,0421)* 0M;, 1 0.3607 0,0159" 0.0964 N/A ()0(,, 
Tissucol 500 Units 
Thrombin 
CRYO 4 Units 0.0640 0.3624 0.1141 0.2582 0.0597 0.8203 0.1623 1 0 0() 10 0 00'ý, 
'Mrombin vs 500 
Units Thrombin 
Tissucol 4 Units 0.5555 0.0951 0.1414 0.1764 0.6896 0.1846 0.5461 0.0770 0.3605 
Thrombin vs 500 
Units'Mrombm 
Table 7.3: T Test analysis between controls and treated groups. 
Normality Test Failed. Mann-Whitnev Rank Sum Test Ran. 
Equal Variance Test Failed; Mann-Whitney Rank Sum Test Ran. 
One Way Anova, with multiple comparison via Dunn's Method showed significant 
differences (P<0.05) between fibrin sealant remaining for: 
Vivostat vs CRYO 500 Units Thrombin 
Vivostat vs Tissucol 500 Units Thrombin. 
APPENDIX VIII 
Volume of Percentage Volume Volume of 
Post Surgical Post Surgical of Fibrin Sealant 
Treatment Injury Adhesion Adhesion Inflammation Remaining 
Site (mm') Incidence Reduction (m[w) (mm') 
Control Colon MEAN 207.25 100.00 0.00 45.54 N/A 
SD 157.01 56.97 N/A 
SEM 78.40 28.48 N/A 
it Caecurn MEAN 31.33 100.00 0.00 0.00 N/A 
SD 10.19 - 0.00 N/A 
SEM 7.21 0.00 N/A 
it Stomach MEAN 248.11 100.00 0.00 9.01 N/A 
SD 36.29 8.42 N/A 
SEM 20.95 4.86 N/A 
Overall MEAN 181.78 100.00 0.00 23.24 N/A 
SD 131.22 41.16 N/A 
SEM 43.74 - - 13.72 N/A 
Human Colon MEAN 42.83 20.67 79.33 280.20 128.87 
Fibrin SD 21.39 84.82 50.11 
Sealant SEM 10.69 - 42.41 25.06 
it Caecum MEAN 8.96 28.60 71.40 375.02 162.82 
SD 12.67 4.02 39.92 
SEM 8.96 - - 2.84 28.23 
to Stomach MEAN 204.47 82.41 17.59 429.27 174.12 
SD 159.23 - - 259.56 14.22 
SEM 112.59 - 183.54 10.05 
Overall MEAN 74.77 41.10 58.90 341.17 148.67 
SD 102.31 131.83 42.42 
SEM 36.17 - - 46.61 15.00 
Porcine Colon MEAN 0.00 0.00 100.00 9.17 100.45 
Fibrin SD 0.00 - 9.72 16.75 
Sealant SEM 0.00 - 6.88 11.84 
it Caecurn MEAN 0.00 0.00 100.00 16.28 132.38 
SD 0.00 23.02 56.47 
SEM 0.00 - 16.28 39.93 
Stomach MEAN 6.35 2.56 97.44 55.24 139.23 
SD 0.00 - 0.00 0.00 
SEM 0.00 0.00 0.00 
Overall MEAN 1.27 0.70 99.30 21.23 120.98 
SD 2.84 - 23.03 35.02 
SEM 1.27 10.30 15.66 
Table 8.1: Quantitative results for each experimental site. 
APPENDIX IX 
Animal Injury Post % Post Tissue Generation Damage Novel 
No: Site Surgical Surgical Adhesions Peritonea 
I 
Colonl Total Peritonea 
I 
Colon/ Inflamm. Fibrin 
(PPSA) Adhesion Incidence Reductio I Stomacjh Stomach ation Sealant 
I - I 
n 
Control Group 
10 Colon 689.06 234.67 ý 83.79 1007.52 56.84 14.36 3.52 N/A 11 814.45 93.02 45.04 952.51 20.87 26.73 5.13 N/A 
12 937.89 0.00 0.00 937-89 36.91 17.09 4.10 N/A 
13 583.98 0.00 0.00 583.98 19.04 14.16 5.37 NIA 
17 342.11 0.00 0.00 342.11 23.41 11.71 0.00 N/A 
Mean 673.50 100.00 0.00 65.54 25.77 764.80 31.42 16.81 3.62 N/A 
STI) 227.95 102.77 37.85 289.60 15.85 5.87 2.16 N/A 
SEM 101.94 45.96 16.93 129.51 7.09 2.62 0.97 N/A 
%CV 15.14 70-13 65.69 16.93 22.56 15.61 26.68 N/A 
10 Stomach 1064.08 128.28 38.69 1231.05 61.90 21.58 6.92 N/A 
13 1400.94 0.00 58.86 1459.80 13.33 28.62 10.73 N/A 
14 627.54 48.14 0.00 675.68 24.07 37.35 5.40 N/A 
16 1345.01 0.00 0.00 1345.01 37.40 32.84 1.95 N/A 
20 675.00 0.00 0.00 675.00 34.28 11.72 0.59 N/A 
Mean 1022.51 100.00 0.00 35.28 19.51 1077.31 34.20 26.42 5.12 N/A 
STD 362.53 56.01 27.65 375.75 18.13 10.06 4.04 N/A 
SEM 162.13 25.05 12.37 168.04 8.11 4.50 1.81 N/A 
%CV 15.86 70.99 63.38 15.60 23.72 17.03 35.34 N/A 
Novel Fibrin Sealant Gr up 
14 Colon 0.00 186.04 219.73 405.76 3.66 19.78 127.44 9.89 
16 0.00 374.70 171.09 545.79 23.95 2.99 90.68 0.00 
18 0.00 197.86 67.92 265.78 12.92 7.01 134.37 0.00 
19 0.00 224.30 101.84 326.13 14.18 6.12 148.24 0,00 
20 0.00 109.85 49.82 159.67 12.13 2.87 24.27 0.00 
21 77.50 239.77 130.78 448.05 18.47 14.23 231.29 31.18 
Mean 12.92 1.92 98.08 222-08 123.53 358.53 14.22 8.83 126-05 6.84 
STD 31.64 87.28 64.13 137.48 6.79 6.77 68.19 12.56 
SEM 12.92 35.63 26.18 56.13 2.77 2.76 27.84 5.13 
%CV 100.00 16.04 21.20 15.65 19.48 31.28 22.09 74.92 
11 Stomach 982.08 0.00 0,00 982.08 6.42 25.24 855.47 107.79 
12 720.63 75.45 41.63 837.70 25.69 13.98 299.18 5.85 
17 199.32 0.00 0.00 199.32 4.13 6.67 96.48 48.24 
18 297.50 471.48 33.20 802.19 18.93 4.98 276.25 32.87 
19 34.28 455.76 214.55 704-59 16.50 17.14 302.15 6.67 
21 87.02 526.55 213.70 827.27 22.86 54.25 295.22 18.18 
Mean 386.80 37.83 62.20 254.87 83.85 725.52 15.75 20.38 354.13 36.60 
STI) 380.28 254.24 102.33 272.75 8.74 18.15 258.06 38.47 
SEM 155.25 103.79 41.77 111.35 3.57 7.41 105.35 15.70 
%CV 40.14 40.72 49.82 15.35 22.66 36.37 29.75 42.91 
Table 9.1: Mean volumes (mm) for each tissue zone for control and novel fibrin sealant groups, together 
with SDs, SEMs and %CV. 
P VALUES 
Post Tissue Generation Damage 
Injury Surgical Peritoncal Colon/ Total Peritoneal Colon/ Inflammation 
Site Adhesion Stomach Stomach 
Colon 1) t ý(4 , 1) () Iý" () 111 4 0.0691 11,14 
Stomach 0.0201 0.247 0.2087 0.1053 0.0538 0.525 004 
Overall Mean -)4 1 0.1998 
Table 9.2: T test analysis comparing control and novel fibrin sealant groups for volumes of each tissue 
zones. 
P VALUES I 
Post Tissue Generation Damage Fibrin 
Injury 
Site 
Surgical 
Adhesion 
Peritoneal Colon/ 
Stomach 
Total Peritoneal Colon/ 
Stomach 
Inflammation Sealant 
Remaining 
Controls 
Treated 
1 0.1059 
11 I, f i. ý " 
0.8410* 
1.0000 
0.8410* 
0.4396 
0.2220* 
1ý f) 14 - 
0.8029 
0.7413 
0.1022 
0.1752 
0.4869 
() (C 6 
N/A 
0.1019 
Table 9.3: T test analysis comparing colon and stomach experimental sites of control and novel fibrin 
sealant groups for volumes of each tissue zones. 
*= Normality test failed-, Mann-Whitney Rank sum test ran. 
APPENDIX X 
Variable Authors 
Animal Species 
Rat Chandy & Rhoads, 1946; Grosfeld et al., 1973; Lindenberg & Lauritsen, 
1984; de Virgilio et al., 1990; Dulchavsky et al, 199 1; Bothin & Hallberg, 
1992; Evans et al., 1993; Sheppard et al., 1993; Sahin & Saglam, 1994; 
Alponat et al., 1997. 
Rabbit Neuwirth and Khalaf, 1975; Nishimura et al., 1983; Diamond et al, 1987; 
De Laco et al., 1994; Takeuchi et al., 1997; Marana et al., 1997; Rodgers 
et al., 1997; De Laco et al., 1998. 
Pig Fowler et al., 1994; Christoforoni et al., 1996; Reissman et al., 1996. 
Dog Replogle et al., 1966; Stevens, 1968; Yournons et al, 1968; Buckman et 
al., 1975; Vander Salm et al., 1986; Shimanuki et al., 1987; Duncan et al., 
19 8 8; McCabe Fowler et al., 199 1; Mitchell et al., 1994. 
Monkey Larsson et al., 1986; Kapur et al., 1969; Liao et al., 1973. 
Cow (calf) Baker et al., 1989. 
Chicken Bums et al., 1997. 
Human Adhesion Study Group, 1983; Krinsky et al., 1984; Jansen, 1985; Rein & 
Hill, 1989; Jansen, 1985; Larsson et al., 1986; Kram et al., 1988; Malinak, 
1990; Longaker et al., 199 1; Beck, 1997. 
Induction Methods 
Rubbing of caecal Conolly & Stephens FO, 1968; Milligan & Raftery, 1974. 
surface 
Chemical trauma Chandy & Rhoads, 1946. 
Crushing caecal wall Chandy & Rhoads, 1946. 
Mesentric division Ellis, 1962. 
Polythene/ omental wrap Ellis, 1962. 
around devascularised 
intestine 
Liver lobe scraping with Milligan & Raftery, 1974. 
scalpel blade 
Severity of Techniques 
Rubbing Conolly & Stephens FO, 1968; Milligan & Raftery, 1974. 
Crushing Chandy & Rhoads, 1946. 
Scalpel scraping Milligan & Raftery, 1974. 
Site of PSA Induction 
Caecum Chandy & Rhoads, 1946; Conolly & Stephens FO, 1968; Milligan & 
Raftery, 1974. 
Intestine Ellis, 1962. 
Liver Milligan & Raftery, 1974. 
Uterine hom Neuwirth and Khalaf, 1975; Nishimura et al., 1983; Diamond et al., 1987; 
De Laco et aL, 1994; Takeuchi et aL, 1997; Marana et al., 1997; Rodgers 
et al., 1997; De Laco et aL, 1998. 
End Point 
Incidence Ellis, 1962. 
Length of adhesion O'Leary & Coakley, 1992. 
attachment 
Type of adhesion ShimanukietaL, 1987. 
Macromorphological Dargenio et al., 1986; Sheppard et al., 1993. 
adhesion grading 
Table 10.1: PSA experimental model variations. 
PSA 
Volume 
(mm3) 
% PSA Fibrin Sealant 
Associated 
Reaction Volume 
Fibrin Sealant 
Remaining 
Volume 
Incidence Reduction (mm3) (mm3) 
Control Cases 
Mean 89.91 100.00 
SD 52.11 
SEM 18.42 
CV% 20.49 - - 
Treated Cases 
Mean 17.82 19.82 80.18 2.75 0.97 
SD 23.76 3.06 1.05 
SEM 8.40 1.08 0.37 
CV% 47.16 39.34 38.33 
Table 10.2: Rat caecal abrasion study quantitative results. 
Wet tissue g -') 
Protein 
mg 
Activity 
CTA U 
Tissue 
I 
16.9 412.0 Pancreas 
32.3 70.0 Ovary 
53.8 69.9 Oesophagus 
58.6 69.2 Vena cava 
40.5 67.6 Pleura 
10.8 63.8 Testes 
37.5 63.0 Bladder 
38.8 60.3 Uterus 
26.9 56.0 Duodenum 
6.4 55.7 Liver 
27.9 49.3 Prostate 
26.7 49.1 Colon 
48.0 49.0 Aorta 
21.6 43.2 Adrenal 
21.7 41.2 Pituitary 
34.6 33.5 Lung 
32.2 31.1 Gall-bladder 
44.7 27.6 Ureter 
3.2 22.7 Cerebrum 
51.4 21.4 id 
28.3 21.0 Peritoneum 
2.2 19.4 Cerebellum 
21.5 18.3 Heart 
14.2 16.3 Omentum 
26.7 13.9 Trachea 
15.3 13.3 Breast 
16.1 10.8 Kidney 
9.7 9.7 Muscle 
18.3 7.5 Stomach 
25.9 <5.4 Spleen 
21.6 0.0 Placenta 
D tissue (g I 
Tissue Activity 
CTA U 
Protein 
mg 
Pancreas 956.0 39.1 
Testes 356.4 60.3 
Ovary 303.0 139.8 
Oesophagus 284.1 218.7 
Uterus 266.8 171.7 
Pituitary 265.8 140.0 
Duodenum 235.3 113.0 
Bladder 198.1 117.6 
Liver 197.5 22.7 
Vcna cava 194.9 165.1 
Prostate 181.2 102.6 
Lung 176.3 182.1 
Colon 147.9 80.4 
Aorta 142.0 139.1 
Gall-bladder 116.5 120.6 
Cerebrum 115.2 16.2 
Pleura 112.1 67.2 
Cerebellum 91.9 10.4 
Heart 78.9 92.7 
Ureter 74.8 121.1 
Adrenal 71.9 35.9 
Thyroid 71.8 172.5 
Kidney 43.7 65.2 
Trachea 42.6 81.9 
Peritoneum 40.0 53.9 
Muscle 36.5 36. 
Stomach 30.0 73.2 
Omentum 19.5 16.9 
Breast 17.1 19.6 
1 Spleen <25.1 1 120.5 
1 Placenta 0.0 1 108.5 
Table 10.3: Comparison of the extractable fibrinolytic activity and protein per gram wet and dry weight 
of tissue, based on the 40 000 xg tissue extract supernatants (taken directly from Marshall, 
1985). 
Legend: 
Protein and activity values per gram of dry tissue were calculated from the wet weight 
values by correcting for the water content estimated for each tissue (Section 6.2.1.2. ). 
Generally, tissues with a large water content have a higher relative fibrinolytic activity 
ranking when expressed per gram dry weight compared with their position on a wet 
weight basis, the converse being true for tissues of low water content. 
Injury Animal Length Density Length 
Time x -5 um2) (xlO-5um) 
No: Actual Mean 
I 
Actual I Mean 
Control Cases 
16 Hours 105 0 0 0 0 
107 0 0 
1 Day 97 5.096 3.716 435.87 290.29 
99 2.335 144.71 
3 Days 101 7.59 9.635 478.33 1002.9 
103 11.68 1527.46 
5 Days 112 12.1 9.553 2286.65 2016.4 
115 7.006 1746.15 
7 Days 123 3.503 3.854 796.08 641.58 
125 4.204 487.08 
14 Days 117 4.671 6.54 2523.56 1822.6 
126 8.408 1121.65 
28 Days 119 5.839 5.372 448.54 1683.21 
121 4.904 2917.88 
42 Days 109 7.643 6.391 998.76 1193.82 
1 
114 5.138 
1 1 
1388.87 
1 
Injury Animal Length Density Length 
Time (xlO-5/um2 5um) 
_4xlL No: Actual I Meaqn 
y 
- 
ctua Mean 
Treated Cases 
16 Hours 170 0 0 0 0 
172 0 0 
1 Day 150 0.876 0.438 45 22.5 
152 0 0 
3 Days 154 3.503 6.131 77.89 174.47 
156 8.758 271.05 
5 Days 138 12.84 12.725 296.55 897.15 
140 12.61 1497.75 
7 Days 142 7.785 9.898 543.11 599.11 
144 12.01 655.12 
14 Days 131 4.204 6.306 304.22 361.49 
134 8.408 418.76 
28 Days 146 5.255 6.715 302.81 312.3 
148 8.174 321.8 
42 Days 130 7.006 5.255 143.09 186.04 
1 
135 
1 
3.503 
1 
228.986 
Table 10A Length density and total length of vessels within PSAs and tissue generation for control and 
novel fibrin sealant treated cases. 
Time Animal I Volume (cm) % 
Point Number Wax I Resin Wax Mean Difference 
Control Cases 
4 Hours FIB 87 LHS PTG 8.00 12.00 10.00 20.00 
8 Hours FIB 93 RHS U. Horn width 15.00 17.00 - 16.00 6.25 
U. Horn height 7.00 10.00 - 8.50 17.65 
Peritoneum height 5.00 6.00 5.50 9.09 
PSA 7.50 14.50 11.00 31.82 
PTG 1.50 5.50 3.50 57.14 
PSA 0.50 4.50 2.50 80.00 
16 Hours FIB 106 RHS U. Horn width 16.00 17.00 16.50 3.03 
U. Horn height 16.00 15.00 15.50 3.23 
PSA 21.00 23.00 22.00 4.55 
1 Day FIB 99 RHS U. Horn width 13.00 13.00 15.00 13.67 6.50 
U. Horn height 8.00 9.00 7.00 8.00 0.00 
Peritoneum height 7.00 8.00 6.00 7.00 9.52 
PSA 6.50 6.50 8.00 7.00 9.52 
3 Days FIB 101 LHS U. Horn width 21.00 19.00 21.00 20.33 4.37 
PSA 2.50 15.00 12.00 9.83 49.72 
5 Days FIB 112 RHS U. Horn height 8.00 8.00 9.00 8.33 5.33 
PSA 22.00 13.00 16.00 17.00 19.61 
7 Days FIB 129 RHS U. Hom width 6.00 6.00 7.00 6.33 7.02 
U. Horn height 6.00 6.00 6.00 6.00 0.00 
Peritoneum height 6.00 7.00 6.00 6.33 7.02 
PSA 44.00 53.00 48.00 48.33 5.98 
14 Days FIB 119 LHS U. Horn width 16.00 16.00 20.00 17.33 10.26 
U. Horn height 16.00 18.00 15-00 16.33 6.80 
Peritoneum height 4.00 5.00 5.00 4.67 9.52 
PSA 5.00 8.00 8.00 7.00 19.05 
42Days FIBI16LHS, PSA 1 29.00 1 38.00 1 49.00 1 38.67 1 17.82 
Treated Cases 
I Hour : FIB 166 LHS U. Horn width 9.00 10.00 8.00 9.00 7.41 
U. Horn height 8.00 9.00 8.00 8.33 5.33 
Peritoneum height 8.00 8.00 8.00 8.00 0.00 
Fibrin Sealant 21.00 35.00 19.00 25.00 26.67 
PTG 3.00 4.00 3.00 3.33 13.33 
16 Hours FIB 171 RHS U. Horn width 9.00 13.00 11-00 11-00 12.12 
U. Horn height 10.00 10.00 8.00 9.33 9.52 
Peritoneum height 8.00 9.00 8.00 8.33 5.33 
Fibrin Sealant 16.00 28.00 20.00 21.33 20.83 
PTG 5.00 16.00 7.00 9.33 47.62 
7 Days FIB 144 LHS U. Horn width 15.00 15.00 - 15.00 0.00 
Peritoneum height 10.00 9.00 9.50 5.26 
Fibrin Sealant 13.00 16.00 - 14.50 10.34 
PTG 4.00 4.00 - 4.00 0.00 
42 Days FIB 132 LHS U. Horn width 11.00 13.00 12.00 12.00 5.56 
Peritoneum height 7.00 5.00 5.00 5.67 15.69 
PTG 1 7.00 1 5.00 4.00 1 5.33 2 .8 
Mean 14.24 
TG Mean 27.40 
Table 10.5: Comparison of tissue zone volumes for wax and resin processed sections. 
